{"27f14f7db4b016c6558fe0efdb416fc194b291a7": [["IntroductionCoronaviruses (family Coronaviridae, subfamily Coronavirinae) circulate in a diverse array of mammalian and avian reservoirs, including humans, bats, pigs, cats, dogs, rodents, and birds (Perlman & Netland, 2009 ).", [["Coronavirinae", "GENE_OR_GENE_PRODUCT", 59, 72], ["avian", "ORGANISM", 120, 125], ["humans", "ORGANISM", 148, 154], ["pigs", "ORGANISM", 162, 166], ["cats", "ORGANISM", 168, 172], ["dogs", "ORGANISM", 174, 178], ["birds", "ORGANISM", 193, 198], ["humans", "SPECIES", 148, 154], ["pigs", "SPECIES", 162, 166], ["cats", "SPECIES", 168, 172], ["dogs", "SPECIES", 174, 178], ["humans", "SPECIES", 148, 154], ["pigs", "SPECIES", 162, 166], ["avian reservoirs", "OBSERVATION", 120, 136]]], ["Coronaviruses (CoV) are classified into four genera (Alpha-, Beta-, Gamma-, and Deltacoronavirus) and are enveloped, positive-strand RNA viruses between 70 and 120 nm in size (Masters, 2006; de Groot, 2012) .", [["Coronaviruses", "GENE_OR_GENE_PRODUCT", 0, 13], ["CoV", "ORGANISM", 15, 18], ["Alpha", "GENE_OR_GENE_PRODUCT", 53, 58], ["Beta-", "GENE_OR_GENE_PRODUCT", 61, 66], ["Gamma-", "GENE_OR_GENE_PRODUCT", 68, 74], ["Deltacoronavirus", "GENE_OR_GENE_PRODUCT", 80, 96], ["CoV", "SPECIES", 15, 18], ["Coronaviruses", "PROBLEM", 0, 13], ["four genera", "TEST", 40, 51], ["Alpha", "TEST", 53, 58], ["Beta-", "TEST", 61, 66], ["Gamma-", "TEST", 68, 74], ["Deltacoronavirus", "TEST", 80, 96], ["strand RNA viruses", "PROBLEM", 126, 144], ["strand RNA viruses", "OBSERVATION", 126, 144], ["size", "OBSERVATION_MODIFIER", 170, 174]]], ["The spike glycoproteins that radiate from the virus envelope of the spherical particles are responsible for the characteristic crown-like appearance of coronaviruses (Fig. 1) .IntroductionFour coronaviruses continuously circulate in the human population, all of which cause generally mild respiratory disease: HCoV-229E, HCoV-NL63 (Alphacoronavirus), HCoV-OC43, and HKU1 (Betacoronavirus; Hamre & Procknow, 1966; McIntosh et al., 1967; Fouchier et al., 2004; van der Hoek et al., 2004; Woo et al., 2005) .", [["respiratory", "ANATOMY", 289, 300], ["respiratory disease", "DISEASE", 289, 308], ["coronaviruses", "ORGANISM", 152, 165], ["coronaviruses", "ORGANISM", 193, 206], ["human", "ORGANISM", 237, 242], ["HCoV-229E", "ORGANISM", 310, 319], ["HCoV-NL63", "ORGANISM", 321, 330], ["Alphacoronavirus", "GENE_OR_GENE_PRODUCT", 332, 348], ["HCoV-OC43", "CELL", 351, 360], ["HKU1", "GENE_OR_GENE_PRODUCT", 366, 370], ["spike glycoproteins", "PROTEIN", 4, 23], ["human", "SPECIES", 237, 242], ["human", "SPECIES", 237, 242], ["HCoV-229E", "SPECIES", 310, 319], ["The spike glycoproteins", "PROBLEM", 0, 23], ["the characteristic crown-like appearance of coronaviruses", "PROBLEM", 108, 165], ["generally mild respiratory disease", "PROBLEM", 274, 308], ["HCoV", "TEST", 310, 314], ["HCoV", "TEST", 321, 325], ["Alphacoronavirus", "TEST", 332, 348], ["HCoV", "TEST", 351, 355], ["virus", "OBSERVATION", 46, 51], ["spherical particles", "OBSERVATION", 68, 87], ["crown", "OBSERVATION_MODIFIER", 127, 132], ["coronaviruses", "OBSERVATION", 152, 165], ["mild", "OBSERVATION_MODIFIER", 284, 288], ["respiratory disease", "OBSERVATION", 289, 308]]], ["In addition, there have been two zoonotic introductions of coronaviruses into the human population over the last decade, both associated with acute respiratory distress syndrome (ARDS) and high case fatality rates: severe acute respiratory syndrome CoV (SARS-CoV; Drosten et al., 2003; Kuiken et al., 2003) and Middle East respiratory syndrome CoV (MERS-CoV; Zaki et al., 2012) .", [["respiratory", "ANATOMY", 148, 159], ["acute respiratory distress syndrome", "DISEASE", 142, 177], ["ARDS", "DISEASE", 179, 183], ["acute respiratory syndrome CoV", "DISEASE", 222, 252], ["SARS-CoV", "DISEASE", 254, 262], ["Middle East respiratory syndrome CoV", "DISEASE", 311, 347], ["coronaviruses", "ORGANISM", 59, 72], ["human", "ORGANISM", 82, 87], ["Middle East respiratory syndrome CoV", "ORGANISM", 311, 347], ["human", "SPECIES", 82, 87], ["human", "SPECIES", 82, 87], ["severe acute respiratory syndrome CoV", "SPECIES", 215, 252], ["SARS-CoV", "SPECIES", 254, 262], ["Middle East respiratory syndrome CoV (MERS-CoV", "SPECIES", 311, 357], ["acute respiratory distress syndrome", "PROBLEM", 142, 177], ["ARDS", "PROBLEM", 179, 183], ["severe acute respiratory syndrome CoV", "PROBLEM", 215, 252], ["SARS", "TEST", 254, 258], ["Middle East respiratory syndrome CoV", "PROBLEM", 311, 347], ["two", "OBSERVATION_MODIFIER", 29, 32], ["zoonotic", "OBSERVATION_MODIFIER", 33, 41], ["associated with", "UNCERTAINTY", 126, 141], ["acute", "OBSERVATION_MODIFIER", 142, 147], ["respiratory", "ANATOMY", 148, 159], ["distress syndrome", "OBSERVATION", 160, 177], ["severe", "OBSERVATION_MODIFIER", 215, 221], ["acute", "OBSERVATION_MODIFIER", 222, 227], ["respiratory syndrome", "OBSERVATION", 228, 248], ["Middle", "ANATOMY_MODIFIER", 311, 317], ["respiratory syndrome", "OBSERVATION", 323, 343]]], ["SARS-CoV caused the first pandemic of the 21st century, resulting in c.", [["SARS-CoV", "DISEASE", 0, 8], ["SARS-CoV", "ORGANISM", 0, 8], ["SARS-CoV", "SPECIES", 0, 8]]], ["8400 human cases and an 11% case fatality rate (SARS Epidemiology Working Group, 2003) .", [["SARS", "DISEASE", 48, 52], ["human", "ORGANISM", 5, 10], ["human", "SPECIES", 5, 10], ["human", "SPECIES", 5, 10]]], ["In addition to the impact of SARS-CoV on infected individuals and the global public health community, the economic cost of the SARS-CoV outbreak event was estimated at $16 billion (Brahmbhatt & Dutta, 2008) .", [["SARS-CoV on infected", "DISEASE", 29, 49], ["SARS", "DISEASE", 127, 131], ["SARS-CoV", "ORGANISM", 29, 37], ["SARS-CoV", "ORGANISM", 127, 135], ["SARS-CoV", "SPECIES", 29, 37], ["SARS-CoV", "SPECIES", 127, 135], ["SARS", "PROBLEM", 29, 33], ["infected individuals", "PROBLEM", 41, 61], ["the SARS", "PROBLEM", 123, 131]]], ["Although only 163 laboratory-confirmed cases of MERS-CoV are currently reported, the high case fatality rate and travel-related spread across multiple countries are reminiscent of the SARS-CoV pandemic.Epidemiology of MERS-CoVVirus detection and case definitionEpidemiology of MERS-CoVThe first human case of MERS-CoV was identified using a pancoronavirus reverse-transcriptase polymerase chain reaction (RT-PCR) assay (Zaki et al., 2012) .", [["SARS-CoV pandemic", "DISEASE", 184, 201], ["MERS-CoV", "ORGANISM", 48, 56], ["SARS-CoV", "ORGANISM", 184, 192], ["human", "ORGANISM", 295, 300], ["MERS-CoV", "ORGANISM", 309, 317], ["human", "SPECIES", 295, 300], ["MERS-CoV", "SPECIES", 48, 56], ["SARS-CoV", "SPECIES", 184, 192], ["human", "SPECIES", 295, 300], ["MERS-CoV", "SPECIES", 309, 317], ["the SARS", "PROBLEM", 180, 188], ["CoV pandemic", "PROBLEM", 189, 201], ["MERS", "PROBLEM", 309, 313], ["CoV", "PROBLEM", 314, 317], ["a pancoronavirus reverse", "TREATMENT", 339, 363], ["transcriptase polymerase chain reaction", "PROBLEM", 364, 403]]], ["MERS -CoV-specific quantitative RT-PCRs (qRT-PCR), targeting the region upstream of the E protein gene and the open reading frame 1b, were rapidly developed and have become standards in the laboratory testing and diagnosis of MERS-CoV (Corman et al., 2012a) .", [["MERS -CoV", "GENE_OR_GENE_PRODUCT", 0, 9], ["E protein", "GENE_OR_GENE_PRODUCT", 88, 97], ["MERS-CoV", "ORGANISM", 226, 234], ["MERS -CoV", "DNA", 0, 9], ["E protein gene", "DNA", 88, 102], ["open reading frame 1b", "DNA", 111, 132], ["MERS-CoV", "SPECIES", 226, 234], ["MERS", "TEST", 0, 4], ["PCRs", "TEST", 35, 39], ["qRT", "TEST", 41, 44], ["PCR", "TEST", 45, 48], ["the laboratory testing", "TEST", 186, 208]]], ["Additional qRT-PCRs targeting the RNA-dependent RNA polymerase (RdRp) and nucleocapsid (N) genes have been developed as confirmatory assays (Corman et al., 2012b) .", [["RNA-dependent RNA polymerase", "GENE_OR_GENE_PRODUCT", 34, 62], ["nucleocapsid (N)", "GENE_OR_GENE_PRODUCT", 74, 90], ["RNA-dependent RNA polymerase (RdRp) and nucleocapsid (N) genes", "DNA", 34, 96], ["Additional qRT-PCRs", "TEST", 0, 19], ["the RNA", "TEST", 30, 37], ["dependent RNA polymerase", "PROBLEM", 38, 62], ["nucleocapsid (N) genes", "PROBLEM", 74, 96]]], ["The World Health Organization (WHO) case definition for MERS-CoV focuses on patients suffering febrile acute respiratory disease who have a direct epidemiological link to another confirmed case or are residents of or travelers to MERS-CoV-source countries (WHO, 2013c) .", [["respiratory", "ANATOMY", 109, 120], ["febrile acute respiratory disease", "DISEASE", 95, 128], ["MERS-CoV", "ORGANISM", 56, 64], ["patients", "ORGANISM", 76, 84], ["patients", "SPECIES", 76, 84], ["MERS-CoV", "SPECIES", 56, 64], ["MERS", "PROBLEM", 56, 60], ["febrile acute respiratory disease", "PROBLEM", 95, 128], ["respiratory", "ANATOMY", 109, 120], ["disease", "OBSERVATION", 121, 128]]], ["Confirmatory laboratory testing requires a positive qRT-PCR of at least two specific genomic targets or a single positive target by qRT-PCR combined with sequencing of a second target (Centers for Disease Control and Prevention, 2013) .", [["genomic targets", "DNA", 85, 100], ["Confirmatory laboratory testing", "TEST", 0, 31], ["a positive qRT-PCR", "PROBLEM", 41, 59], ["PCR", "TEST", 136, 139], ["Disease Control", "TREATMENT", 197, 212]]], ["In instances of inadequate testing or negative tests, a patient with a direct epidemiologic link to a confirmed MERS-CoV case is determined to be a probable case of MERS-CoV infection if they present with acute febrile respiratory illness.Spatial distribution and demographicsWhile primary cases of MERS-CoV have been confined to six countries in the Middle East -Saudi Arabia, United Arab Emirates, Qatar, Jordan, Oman and Kuwaittravel-related cases have been identified in Tunisia the United Kingdom, France, Germany, and Italy ( Fig. 2 ; Bermingham et al., 2012; Buchholz et al., 2013; Gulland, 2013a, b; Health Protection Agency, 2013; Hijawi et al., 2013; Mailles et al., 2013; Memish et al., 2013b; Puzelli et al., 2013) .", [["respiratory", "ANATOMY", 219, 230], ["MERS-CoV infection", "DISEASE", 165, 183], ["febrile respiratory illness", "DISEASE", 211, 238], ["patient", "ORGANISM", 56, 63], ["MERS-CoV", "ORGANISM", 112, 120], ["MERS-CoV", "ORGANISM", 165, 173], ["MERS-CoV", "ORGANISM", 299, 307], ["patient", "SPECIES", 56, 63], ["MERS-CoV", "SPECIES", 112, 120], ["MERS-CoV", "SPECIES", 165, 173], ["MERS-CoV", "SPECIES", 299, 307], ["inadequate testing", "TEST", 16, 34], ["MERS", "PROBLEM", 165, 169], ["CoV infection", "PROBLEM", 170, 183], ["acute febrile respiratory illness", "PROBLEM", 205, 238], ["CoV", "PROBLEM", 304, 307], ["infection", "OBSERVATION", 174, 183], ["acute", "OBSERVATION_MODIFIER", 205, 210], ["febrile", "OBSERVATION_MODIFIER", 211, 218], ["respiratory illness", "OBSERVATION", 219, 238]]], ["Limited secondary transmission occurred after MERS-CoV introduction in Tunisia, France, and the United Kingdom, while imported cases of MERS-CoV infection in Germany and Italy did not lead to subsequent confirmed infections (Buchholz et al., 2013; Gulland, 2013a, b; Health Protection Agency, 2013; Puzelli et al., 2013) .", [["MERS-CoV infection", "DISEASE", 136, 154], ["infections", "DISEASE", 213, 223], ["MERS-CoV", "ORGANISM", 136, 144], ["MERS-CoV", "SPECIES", 136, 144], ["MERS", "PROBLEM", 136, 140], ["CoV infection", "PROBLEM", 141, 154], ["infections", "PROBLEM", 213, 223], ["infection", "OBSERVATION", 145, 154], ["infections", "OBSERVATION", 213, 223]]], ["Over 80% of cases of MERS-CoV have occurred in Saudi Arabia, largely within the Riyadh and Eastern provinces (Centers for Disease Control and Prevention, 2013) .Spatial distribution and demographicsAs of January 20, 2014, there were 178 confirmed cases of MERS-CoV, 76 (43%) of which were fatal (Fig. 3) .", [["MERS-CoV", "ORGANISM", 21, 29], ["MERS-CoV", "ORGANISM", 256, 264], ["MERS-CoV", "SPECIES", 21, 29], ["MERS-CoV", "SPECIES", 256, 264], ["MERS", "PROBLEM", 21, 25], ["CoV", "PROBLEM", 26, 29], ["Disease Control", "TREATMENT", 122, 137], ["MERS", "TEST", 256, 260], ["CoV", "TEST", 261, 264], ["distribution", "OBSERVATION_MODIFIER", 169, 181]]], ["Although most cases have been clinically severe, contact surveillance has uncovered at least 27 subclinical or mild infections (Centers for Disease Control and Prevention, 2013).", [["infections", "DISEASE", 116, 126], ["mild infections", "PROBLEM", 111, 126], ["Disease Control", "TREATMENT", 140, 155], ["mild", "OBSERVATION_MODIFIER", 111, 115], ["infections", "OBSERVATION", 116, 126]]], ["The case fatality ratio of MERS-CoV (43%) is much higher than that of SARS-CoV (CFR 11%) (SARS Epidemiology Working Group, 2003) .", [["SARS", "DISEASE", 70, 74], ["SARS", "DISEASE", 90, 94], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 27, 35], ["SARS-CoV", "ORGANISM", 70, 78], ["MERS-CoV", "SPECIES", 27, 35], ["SARS-CoV", "SPECIES", 70, 78], ["MERS", "TEST", 27, 31], ["CoV", "TEST", 32, 35], ["SARS", "TEST", 70, 74], ["CFR", "TEST", 80, 83]]], ["The average age of Fig. 1 False-color MERS-CoV particle visualized by electron microscopy.", [["electron microscopy", "TEST", 70, 89], ["average", "OBSERVATION_MODIFIER", 4, 11], ["color MERS", "OBSERVATION", 32, 42]]], ["A MERS-CoV particle (yellow) attached to the surface of a cell (red).", [["surface", "ANATOMY", 45, 52], ["cell", "ANATOMY", 58, 62], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 2, 10], ["surface", "CELLULAR_COMPONENT", 45, 52], ["cell", "CELL", 58, 62], ["A MERS-CoV particle (yellow)", "TREATMENT", 0, 28], ["CoV particle", "OBSERVATION_MODIFIER", 7, 19], ["surface", "OBSERVATION_MODIFIER", 45, 52], ["cell", "ANATOMY", 58, 62]]], ["The characteristic MERS-CoV spike glycoproteins are clearly visible on the surface of the MERS-CoV particle.", [["surface", "ANATOMY", 75, 82], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 19, 27], ["surface", "CELLULAR_COMPONENT", 75, 82], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 90, 98], ["MERS-CoV spike glycoproteins", "PROTEIN", 19, 47], ["MERS-CoV", "SPECIES", 19, 27], ["MERS-CoV", "SPECIES", 90, 98], ["The characteristic MERS", "PROBLEM", 0, 23], ["CoV spike glycoproteins", "PROBLEM", 24, 47], ["MERS", "OBSERVATION", 19, 23], ["CoV spike", "OBSERVATION", 24, 33], ["visible", "OBSERVATION_MODIFIER", 60, 67], ["CoV particle", "OBSERVATION", 95, 107]]], ["MERS-CoV cases is 52 years, with a male-to-female ratio of 1.6-1 (The WHO MERS-CoV Research Group, 2013) .", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 0, 8], ["MERS-CoV", "SPECIES", 0, 8]]], ["Both the case fatality ratio and the male-to-female ratio have decreased as the incidence of MERS-CoV has increased, changes that may be attributed to improved case surveillance (Penttinen et al., 2013) .", [["female", "ORGANISM", 45, 51], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 93, 101], ["MERS-CoV", "SPECIES", 93, 101], ["CoV", "PROBLEM", 98, 101], ["decreased", "OBSERVATION_MODIFIER", 63, 72], ["increased", "OBSERVATION_MODIFIER", 106, 115]]], ["Interestingly, over three quarters of MERS-CoV cases have occurred in patients with comorbidities (The WHO MERS-CoV Research Group, 2013) .", [["MERS-CoV", "ORGANISM", 38, 46], ["patients", "ORGANISM", 70, 78], ["patients", "SPECIES", 70, 78], ["MERS-CoV", "SPECIES", 38, 46]]], ["The most common comorbidities for MERS-CoV cases have been diabetes, hypertension, obesity, cancer, and chronic kidney, heart, and lung disease .", [["cancer", "ANATOMY", 92, 98], ["kidney", "ANATOMY", 112, 118], ["heart", "ANATOMY", 120, 125], ["lung", "ANATOMY", 131, 135], ["diabetes", "DISEASE", 59, 67], ["hypertension", "DISEASE", 69, 81], ["obesity", "DISEASE", 83, 90], ["cancer", "DISEASE", 92, 98], ["chronic kidney, heart, and lung disease", "DISEASE", 104, 143], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 34, 42], ["cancer", "CANCER", 92, 98], ["kidney", "ORGAN", 112, 118], ["heart", "ORGAN", 120, 125], ["lung", "ORGAN", 131, 135], ["MERS-CoV", "SPECIES", 34, 42], ["diabetes", "PROBLEM", 59, 67], ["hypertension", "PROBLEM", 69, 81], ["obesity", "PROBLEM", 83, 90], ["cancer", "PROBLEM", 92, 98], ["chronic kidney, heart", "PROBLEM", 104, 125], ["lung disease", "PROBLEM", 131, 143], ["diabetes", "OBSERVATION", 59, 67], ["hypertension", "OBSERVATION", 69, 81], ["obesity", "OBSERVATION", 83, 90], ["cancer", "OBSERVATION", 92, 98], ["chronic", "OBSERVATION_MODIFIER", 104, 111], ["kidney", "ANATOMY", 112, 118], ["heart", "ANATOMY", 120, 125], ["lung", "ANATOMY", 131, 135], ["disease", "OBSERVATION", 136, 143]]], ["While these comorbidities likely affect disease progression and outcome, the strong correlation of chronic disease and MERS-CoV may be biased by the high rate of these risk factors in the populations of the affected countries.", [["chronic disease", "DISEASE", 99, 114], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 119, 127], ["MERS-CoV", "SPECIES", 119, 127], ["disease progression", "PROBLEM", 40, 59], ["chronic disease", "PROBLEM", 99, 114], ["chronic", "OBSERVATION_MODIFIER", 99, 106], ["disease", "OBSERVATION", 107, 114]]], ["In the Kingdom of Saudi Arabia, for instance, the prevalence of type-II diabetes across ages is 31.6%, the prevalence of obesity is 31.1% (Al-Daghri et al., 2011) , and one quarter of adult males smoke (WHO, 2013a).", [["type-II diabetes", "DISEASE", 64, 80], ["obesity", "DISEASE", 121, 128], ["type-II diabetes", "PROBLEM", 64, 80], ["obesity", "PROBLEM", 121, 128], ["obesity", "OBSERVATION", 121, 128]]], ["Epidemiologic and pathogenesis studies will be necessary to discern how comorbidities impact susceptibility to, and progression of, MERS-CoV infection.MERS-CoV clinical featuresThe clinical manifestations of MERS-CoV range from subclinical infection to severe respiratory disease.", [["respiratory", "ANATOMY", 260, 271], ["MERS-CoV infection", "DISEASE", 132, 150], ["infection", "DISEASE", 240, 249], ["respiratory disease", "DISEASE", 260, 279], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 132, 140], ["MERS-CoV", "ORGANISM", 208, 216], ["MERS-CoV", "SPECIES", 132, 140], ["MERS-CoV", "SPECIES", 208, 216], ["Epidemiologic and pathogenesis studies", "TEST", 0, 38], ["CoV infection", "PROBLEM", 137, 150], ["subclinical infection", "PROBLEM", 228, 249], ["severe respiratory disease", "PROBLEM", 253, 279], ["CoV", "OBSERVATION_MODIFIER", 137, 140], ["infection", "OBSERVATION", 141, 150], ["subclinical", "OBSERVATION_MODIFIER", 228, 239], ["infection", "OBSERVATION", 240, 249], ["severe", "OBSERVATION_MODIFIER", 253, 259], ["respiratory disease", "OBSERVATION", 260, 279]]], ["Symptomatic patients often present with fever, myalgia, sore throat, shortness of breath, cough, and occasionally hemoptysis (Albarrak et al., 2012; Assiri et al., 2013a; Drosten et al., 2013; Guberina et al., 2013; Guery et al., 2013; Health Protection Agency, 2013; Memish et al., 2013b, c;MERS-CoV Cases by DateCrystal structure for MERS-CoV bound to its receptor is determined (Lu et al. 2013 (Bermingham et al. 2012 , Corman et al. 2012a MERS-CoV infection in rhesus macaques fullfills Koch's postulates.", [["fever", "DISEASE", 40, 45], ["myalgia", "DISEASE", 47, 54], ["sore throat", "DISEASE", 56, 67], ["shortness of breath", "DISEASE", 69, 88], ["cough", "DISEASE", 90, 95], ["hemoptysis", "DISEASE", 114, 124], ["infection", "DISEASE", 452, 461], ["patients", "ORGANISM", 12, 20], ["throat", "ORGANISM_SUBDIVISION", 61, 67], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 336, 344], ["MERS-CoV", "ORGANISM", 443, 451], ["rhesus", "ORGANISM", 465, 471], ["macaques", "ORGANISM", 472, 480], ["MERS", "PROTEIN", 336, 340], ["CoV", "PROTEIN", 341, 344], ["patients", "SPECIES", 12, 20], ["rhesus macaques", "SPECIES", 465, 480], ["rhesus macaques", "SPECIES", 465, 480], ["fever", "PROBLEM", 40, 45], ["myalgia", "PROBLEM", 47, 54], ["sore throat", "PROBLEM", 56, 67], ["shortness of breath", "PROBLEM", 69, 88], ["cough", "PROBLEM", 90, 95], ["occasionally hemoptysis", "PROBLEM", 101, 124], ["MERS", "PROBLEM", 336, 340], ["CoV bound", "PROBLEM", 341, 350], ["CoV infection", "PROBLEM", 448, 461], ["myalgia", "OBSERVATION", 47, 54], ["sore throat", "ANATOMY", 56, 67], ["cough", "OBSERVATION", 90, 95], ["occasionally", "OBSERVATION_MODIFIER", 101, 113], ["hemoptysis", "OBSERVATION", 114, 124], ["CoV", "OBSERVATION_MODIFIER", 448, 451], ["infection", "OBSERVATION", 452, 461]]], ["Treatment with interferon-a2b and ribavirin improves outcome in MERS-CoV-infected rhesus macaques A phylogenetic analysis of 21 MERS-CoV genomes suggests multiple zoonotic introductions.", [["interferon-a2b", "CHEMICAL", 15, 29], ["ribavirin", "CHEMICAL", 34, 43], ["MERS-CoV-infected", "DISEASE", 64, 81], ["ribavirin", "CHEMICAL", 34, 43], ["interferon-a2b", "GENE_OR_GENE_PRODUCT", 15, 29], ["ribavirin", "SIMPLE_CHEMICAL", 34, 43], ["MERS-CoV", "ORGANISM", 64, 72], ["rhesus", "ORGANISM", 82, 88], ["macaques", "ORGANISM", 89, 97], ["MERS-CoV", "ORGANISM", 128, 136], ["interferon", "PROTEIN", 15, 25], ["21 MERS-CoV genomes", "DNA", 125, 144], ["rhesus macaques", "SPECIES", 82, 97], ["MERS-CoV", "SPECIES", 64, 72], ["rhesus macaques", "SPECIES", 82, 97], ["MERS-CoV", "SPECIES", 128, 136], ["interferon", "TREATMENT", 15, 25], ["a2b", "TREATMENT", 26, 29], ["ribavirin", "TREATMENT", 34, 43], ["CoV", "TEST", 69, 72], ["infected rhesus macaques", "TREATMENT", 73, 97], ["A phylogenetic analysis", "TEST", 98, 121], ["CoV genomes", "PROBLEM", 133, 144], ["multiple zoonotic introductions", "PROBLEM", 154, 185], ["multiple", "OBSERVATION_MODIFIER", 154, 162], ["zoonotic introductions", "OBSERVATION", 163, 185]]], ["(Cotten et al. 2013b) MERS-CoV neutralizing antibodies are found in Omani camels (Reusken et al. 2013b) An RNA fragment identical to MERS-CoV is recovered from an Egyptian tomb bat in Saudi Arabia (Memish et al. 2013c) A hospital outbreak of MERS-CoV in Saudi Arabia forms the largest cluster to date.", [["MERS-CoV", "ORGANISM", 22, 30], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 133, 141], ["MERS-CoV", "ORGANISM", 242, 250], ["MERS-CoV neutralizing antibodies", "PROTEIN", 22, 54], ["MERS-CoV", "DNA", 133, 141], ["MERS-CoV", "SPECIES", 133, 141], ["MERS-CoV", "SPECIES", 242, 250], ["CoV neutralizing antibodies", "TEST", 27, 54], ["An RNA fragment", "PROBLEM", 104, 119], ["RNA fragment", "OBSERVATION", 107, 119], ["largest", "OBSERVATION_MODIFIER", 277, 284]]], ["Gastrointestinal symptoms such as diarrhea and vomiting are also common Guery et al., 2013; Memish et al., 2013b) .", [["Gastrointestinal", "ANATOMY", 0, 16], ["diarrhea", "DISEASE", 34, 42], ["vomiting", "DISEASE", 47, 55], ["Gastrointestinal", "ORGAN", 0, 16], ["Gastrointestinal symptoms", "PROBLEM", 0, 25], ["diarrhea", "PROBLEM", 34, 42], ["vomiting", "PROBLEM", 47, 55]]], ["Although coinfections have been limited, MERS-CoV coinfection with Klebsiella pneumoniae, Staphylococcus aureus, Candida species, and influenza A virus (H1N1), rhinovirus, and herpes simplex virus type-1 has been reported (Zaki et al., 2012; Assiri et al., 2013a; Drosten et al., 2013; Guery et al., 2013; Health Protection Agency, 2013; Omrani et al., 2013) .", [["coinfections", "DISEASE", 9, 21], ["coinfection", "DISEASE", 50, 61], ["Klebsiella pneumoniae", "DISEASE", 67, 88], ["Staphylococcus aureus", "DISEASE", 90, 111], ["influenza A virus", "DISEASE", 134, 151], ["rhinovirus", "DISEASE", 160, 170], ["herpes simplex virus", "DISEASE", 176, 196], ["MERS-CoV", "ORGANISM", 41, 49], ["Klebsiella pneumoniae", "ORGANISM", 67, 88], ["Staphylococcus aureus", "ORGANISM", 90, 111], ["Candida species", "ORGANISM", 113, 128], ["influenza A virus", "ORGANISM", 134, 151], ["H1N1", "ORGANISM", 153, 157], ["rhinovirus", "ORGANISM", 160, 170], ["herpes simplex virus type-1", "ORGANISM", 176, 203], ["Klebsiella pneumoniae", "SPECIES", 67, 88], ["Staphylococcus aureus", "SPECIES", 90, 111], ["influenza A virus (H1N1", "SPECIES", 134, 157], ["rhinovirus", "SPECIES", 160, 170], ["herpes simplex virus", "SPECIES", 176, 196], ["MERS-CoV", "SPECIES", 41, 49], ["Klebsiella pneumoniae", "SPECIES", 67, 88], ["Staphylococcus aureus", "SPECIES", 90, 111], ["influenza A virus", "SPECIES", 134, 151], ["herpes simplex virus type-1", "SPECIES", 176, 203], ["coinfections", "PROBLEM", 9, 21], ["MERS", "PROBLEM", 41, 45], ["CoV coinfection", "PROBLEM", 46, 61], ["Klebsiella pneumoniae", "PROBLEM", 67, 88], ["Staphylococcus aureus", "PROBLEM", 90, 111], ["Candida species", "PROBLEM", 113, 128], ["influenza A virus (H1N1)", "PROBLEM", 134, 158], ["rhinovirus", "PROBLEM", 160, 170], ["herpes simplex virus type", "PROBLEM", 176, 201], ["coinfections", "OBSERVATION", 9, 21], ["Klebsiella pneumoniae", "OBSERVATION", 67, 88], ["Staphylococcus aureus", "OBSERVATION", 90, 111], ["Candida species", "OBSERVATION", 113, 128]]], ["All clinically described patients have shown abnormal chest radiographs with a spectrum of lower pulmonary infiltrates and consolidation consistent with viral pneumonia (Albarrak et al., 2012; Zaki et al., 2012; Assiri et al., 2013a; Drosten et al., 2013; Guberina et al., 2013; Guery et al., 2013; Memish et al., 2013b) .", [["chest", "ANATOMY", 54, 59], ["pulmonary", "ANATOMY", 97, 106], ["viral pneumonia", "DISEASE", 153, 168], ["patients", "ORGANISM", 25, 33], ["pulmonary", "ORGAN", 97, 106], ["patients", "SPECIES", 25, 33], ["abnormal chest radiographs", "PROBLEM", 45, 71], ["lower pulmonary infiltrates", "PROBLEM", 91, 118], ["consolidation", "PROBLEM", 123, 136], ["viral pneumonia", "PROBLEM", 153, 168], ["chest", "ANATOMY", 54, 59], ["lower", "ANATOMY_MODIFIER", 91, 96], ["pulmonary", "ANATOMY", 97, 106], ["infiltrates", "OBSERVATION", 107, 118], ["consolidation", "OBSERVATION", 123, 136], ["consistent with", "UNCERTAINTY", 137, 152], ["viral", "OBSERVATION_MODIFIER", 153, 158], ["pneumonia", "OBSERVATION", 159, 168]]], ["Over 60% of the first 144 MERS-CoV patients suffered severe disease, requiring intensive care such as mechanical ventilation and extracorporeal membrane oxygenation (The WHO MERS-CoV Research Group, 2013) .", [["extracorporeal membrane", "ANATOMY", 129, 152], ["MERS-CoV", "ORGANISM", 26, 34], ["patients", "ORGANISM", 35, 43], ["extracorporeal membrane", "MULTI-TISSUE_STRUCTURE", 129, 152], ["patients", "SPECIES", 35, 43], ["MERS-CoV", "SPECIES", 26, 34], ["severe disease", "PROBLEM", 53, 67], ["intensive care", "TREATMENT", 79, 93], ["mechanical ventilation", "TREATMENT", 102, 124], ["extracorporeal membrane oxygenation", "TREATMENT", 129, 164], ["severe", "OBSERVATION_MODIFIER", 53, 59], ["disease", "OBSERVATION", 60, 67], ["mechanical ventilation", "OBSERVATION", 102, 124], ["extracorporeal membrane oxygenation", "OBSERVATION", 129, 164]]], ["Hematological abnormalities reported for clinical cases include thrombocytopenia (36%), lymphopenia (34%), lymphocytosis (11%), and neutrophilia (8%) .MERS-CoV Cases by DateWhile kidney failure necessitating renal replacement therapy has been reported for a number of MERS-CoV cases (Albarrak et al., 2012; Zaki et al., 2012; Drosten et al., 2013; Guberina et al., 2013; Guery et al., 2013; Memish et al., 2013b; Omrani et al., 2013) , in the absence of postmortem examinations, there is no direct evidence of MERS-CoV replication in renal tissue.", [["kidney", "ANATOMY", 179, 185], ["renal", "ANATOMY", 208, 213], ["renal tissue", "ANATOMY", 534, 546], ["Hematological abnormalities", "DISEASE", 0, 27], ["thrombocytopenia", "DISEASE", 64, 80], ["lymphopenia", "DISEASE", 88, 99], ["lymphocytosis", "DISEASE", 107, 120], ["neutrophilia", "DISEASE", 132, 144], ["kidney failure", "DISEASE", 179, 193], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 151, 159], ["kidney", "ORGAN", 179, 185], ["renal", "ORGAN", 208, 213], ["MERS-CoV", "ORGANISM", 268, 276], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 510, 518], ["renal tissue", "TISSUE", 534, 546], ["MERS-CoV", "SPECIES", 268, 276], ["MERS-CoV", "SPECIES", 510, 518], ["Hematological abnormalities", "PROBLEM", 0, 27], ["clinical cases", "PROBLEM", 41, 55], ["thrombocytopenia", "PROBLEM", 64, 80], ["lymphopenia", "PROBLEM", 88, 99], ["lymphocytosis", "TEST", 107, 120], ["neutrophilia", "TEST", 132, 144], ["kidney failure", "PROBLEM", 179, 193], ["renal replacement therapy", "TREATMENT", 208, 233], ["postmortem examinations", "TEST", 454, 477], ["MERS", "PROBLEM", 510, 514], ["CoV replication in renal tissue", "PROBLEM", 515, 546], ["thrombocytopenia", "OBSERVATION", 64, 80], ["lymphopenia", "OBSERVATION", 88, 99], ["lymphocytosis", "OBSERVATION", 107, 120], ["neutrophilia", "OBSERVATION", 132, 144], ["kidney", "ANATOMY", 179, 185], ["failure", "OBSERVATION", 186, 193], ["renal", "ANATOMY", 208, 213], ["replacement", "OBSERVATION", 214, 225], ["no direct evidence of", "UNCERTAINTY", 488, 509], ["MERS", "OBSERVATION", 510, 514], ["renal tissue", "ANATOMY", 534, 546]]], ["In many cases, renal involvement can be explained by pre-existing conditions, hemorrhagic complications, and organ stress due to extreme hypoxemia (Albarrak et al., 2012; Drosten et al., 2013; Guery et al., 2013) .", [["renal", "ANATOMY", 15, 20], ["organ", "ANATOMY", 109, 114], ["hemorrhagic complications", "DISEASE", 78, 103], ["hypoxemia", "DISEASE", 137, 146], ["renal", "ORGAN", 15, 20], ["organ", "ORGAN", 109, 114], ["pre-existing conditions", "PROBLEM", 53, 76], ["hemorrhagic complications", "PROBLEM", 78, 103], ["organ stress", "PROBLEM", 109, 121], ["extreme hypoxemia", "PROBLEM", 129, 146], ["renal", "ANATOMY", 15, 20], ["hemorrhagic", "OBSERVATION_MODIFIER", 78, 89], ["complications", "OBSERVATION", 90, 103], ["hypoxemia", "OBSERVATION", 137, 146]]], ["Long-term sequelae of acute MERS-CoV have not yet been described.Patient careClinical treatment for MERS-CoV patients has centered on intensive care.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 28, 36], ["MERS-CoV", "ORGANISM", 100, 108], ["patients", "ORGANISM", 109, 117], ["Patient", "SPECIES", 65, 72], ["patients", "SPECIES", 109, 117], ["MERS-CoV", "SPECIES", 28, 36], ["MERS-CoV", "SPECIES", 100, 108], ["acute MERS", "PROBLEM", 22, 32], ["CoV", "PROBLEM", 33, 36], ["Patient careClinical treatment", "TREATMENT", 65, 95], ["intensive care", "TREATMENT", 134, 148], ["-term", "OBSERVATION_MODIFIER", 4, 9], ["sequelae", "OBSERVATION_MODIFIER", 10, 18], ["acute", "OBSERVATION_MODIFIER", 22, 27], ["MERS", "OBSERVATION", 28, 32]]], ["Drug treatment has consisted of broad-spectrum antibiotics and often oseltamivir, a drug targeting influenza A virus (Albarrak et al., 2012; Zaki et al., 2012; Assiri et al., 2013a; Drosten et al., 2013; Guery et al., 2013; Memish et al., 2013b; Omrani et al., 2013) .", [["oseltamivir", "CHEMICAL", 69, 80], ["influenza A virus", "DISEASE", 99, 116], ["oseltamivir", "CHEMICAL", 69, 80], ["oseltamivir", "SIMPLE_CHEMICAL", 69, 80], ["influenza A virus", "ORGANISM", 99, 116], ["influenza A virus", "SPECIES", 99, 116], ["influenza A virus", "SPECIES", 99, 116], ["Drug treatment", "TREATMENT", 0, 14], ["broad-spectrum antibiotics", "TREATMENT", 32, 58], ["oseltamivir", "TREATMENT", 69, 80]]], ["Corticosteroids have been used for some patients, and antifungals were administered when necessary (Zaki et al., 2012; Assiri et al., 2013a; Drosten et al., 2013; Guery et al., 2013; Memish et al., 2013b; Omrani et al., 2013) .", [["patients", "ORGANISM", 40, 48], ["patients", "SPECIES", 40, 48], ["Corticosteroids", "TREATMENT", 0, 15], ["antifungals", "TREATMENT", 54, 65]]], ["Patients that progressed to severe acute respiratory distress were provided oxygen therapy, mechanical ventilation, or extracorporeal membrane oxygenation (Assiri et al., 2013b; Drosten et al., 2013; Guery et al., 2013; Health Protection Agency, 2013; Memish et al., 2013b; Omrani et al., 2013) .", [["respiratory", "ANATOMY", 41, 52], ["extracorporeal membrane", "ANATOMY", 119, 142], ["acute respiratory distress", "DISEASE", 35, 61], ["oxygen", "CHEMICAL", 76, 82], ["oxygen", "CHEMICAL", 76, 82], ["Patients", "ORGANISM", 0, 8], ["oxygen", "SIMPLE_CHEMICAL", 76, 82], ["Patients", "SPECIES", 0, 8], ["severe acute respiratory distress", "PROBLEM", 28, 61], ["oxygen therapy", "TREATMENT", 76, 90], ["mechanical ventilation", "TREATMENT", 92, 114], ["extracorporeal membrane oxygenation", "TREATMENT", 119, 154], ["severe", "OBSERVATION_MODIFIER", 28, 34], ["acute", "OBSERVATION_MODIFIER", 35, 40], ["respiratory distress", "OBSERVATION", 41, 61], ["oxygen therapy", "OBSERVATION", 76, 90], ["mechanical ventilation", "OBSERVATION", 92, 114]]], ["Five of the 47 clinically described Saudi patients were treated with ribavirin, and one was given interferon-a (IFN-a); a few patients have also been infused with intravenous immunoglobulin .", [["intravenous", "ANATOMY", 163, 174], ["ribavirin", "CHEMICAL", 69, 78], ["interferon-a", "CHEMICAL", 98, 110], ["ribavirin", "CHEMICAL", 69, 78], ["patients", "ORGANISM", 42, 50], ["ribavirin", "SIMPLE_CHEMICAL", 69, 78], ["interferon-a", "SIMPLE_CHEMICAL", 98, 110], ["IFN-a", "SIMPLE_CHEMICAL", 112, 117], ["patients", "ORGANISM", 126, 134], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 175, 189], ["interferon", "PROTEIN", 98, 108], ["IFN", "PROTEIN", 112, 115], ["intravenous immunoglobulin", "PROTEIN", 163, 189], ["patients", "SPECIES", 42, 50], ["patients", "SPECIES", 126, 134], ["ribavirin", "TREATMENT", 69, 78], ["interferon", "TREATMENT", 98, 108], ["intravenous immunoglobulin", "TREATMENT", 163, 189]]], ["Few clinical case studies and no analyses of MERS-CoV patients receiving treatments such as ribavirin and immunoglobulin have been published.Natural reservoirRapid full-genome sequencing provided the first insight into the origin of MERS-CoV (van Boheemen et al., 2012; Cotten et al., 2013a) .", [["ribavirin", "CHEMICAL", 92, 101], ["ribavirin", "CHEMICAL", 92, 101], ["MERS-CoV", "ORGANISM", 45, 53], ["patients", "ORGANISM", 54, 62], ["ribavirin", "SIMPLE_CHEMICAL", 92, 101], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 106, 120], ["MERS-CoV", "ORGANISM", 233, 241], ["immunoglobulin", "PROTEIN", 106, 120], ["patients", "SPECIES", 54, 62], ["MERS-CoV", "SPECIES", 45, 53], ["MERS-CoV", "SPECIES", 233, 241], ["Few clinical case studies", "TEST", 0, 25], ["MERS", "PROBLEM", 45, 49], ["treatments", "TREATMENT", 73, 83], ["ribavirin", "TREATMENT", 92, 101], ["immunoglobulin", "TREATMENT", 106, 120], ["Natural reservoirRapid full-genome sequencing", "TREATMENT", 141, 186]]], ["Phylogenetic analysis shows a close genetic relatedness between MERS-CoV and the group C BetacoronavirusesNatural reservoirBtCoV-HKU4 and BtCoV-HKU5 detected in insectivorous bats (Woo et al., 2012) , although molecular clock analyses suggest they are unlikely to be direct ancestors of MERS-CoV ( Fig. 4 ; Lau et al., 2013) .", [["MERS-CoV", "ORGANISM", 64, 72], ["reservoirBtCoV-HKU4", "GENE_OR_GENE_PRODUCT", 114, 133], ["BtCoV-HKU5", "GENE_OR_GENE_PRODUCT", 138, 148], ["MERS-CoV", "ORGANISM", 287, 295], ["MERS-CoV", "DNA", 64, 72], ["HKU4", "DNA", 129, 133], ["BtCoV", "DNA", 138, 143], ["HKU5", "DNA", 144, 148], ["MERS-CoV", "SPECIES", 64, 72], ["MERS-CoV", "SPECIES", 287, 295], ["Phylogenetic analysis", "TEST", 0, 21], ["a close genetic relatedness", "PROBLEM", 28, 55], ["Betacoronaviruses", "TEST", 89, 106], ["Natural reservoirBtCoV", "TEST", 106, 128], ["BtCoV", "TEST", 138, 143], ["molecular clock analyses", "TEST", 210, 234]]], ["Since MERS-CoV's identification in 2012, closely related coronavirus sequences have been detected in bats in Africa, Asia, the Americas, and Eurasia, suggesting a widespread circulation of MERS-CoV-related viruses in the order ChiropteraIntermediate hostDirect contact between humans and bats is limited, and an intermediate species often plays a role in the transmission of emerging viruses from bats to humans (Field et al., 2001; Luo et al., 2003; Mahalingam et al., 2012; Nel, 2013) .", [["MERS-CoV", "ORGANISM", 6, 14], ["coronavirus", "ORGANISM", 57, 68], ["MERS-CoV", "ORGANISM", 189, 197], ["humans", "ORGANISM", 277, 283], ["humans", "ORGANISM", 405, 411], ["coronavirus sequences", "DNA", 57, 78], ["humans", "SPECIES", 277, 283], ["humans", "SPECIES", 405, 411], ["MERS-CoV", "SPECIES", 6, 14], ["MERS-CoV", "SPECIES", 189, 197], ["humans", "SPECIES", 277, 283], ["humans", "SPECIES", 405, 411], ["CoV's identification", "TEST", 11, 31], ["coronavirus sequences", "PROBLEM", 57, 78], ["a widespread circulation of MERS", "PROBLEM", 161, 193], ["CoV", "PROBLEM", 194, 197], ["related viruses", "PROBLEM", 198, 213]]], ["Anecdotal evidence of MERS-CoV patient contact with farm animals has been reported in a few cases (Albarrak et al., 2012; Buchholz et al., 2013; Drosten et al., 2013; The WHO MERS-CoV Research Group, 2013) , and so suspicions about the potential source of MERS-CoV have focused on livestock common to the Arabian Peninsula, such as goats, sheep, dromedary camels, and cows.", [["MERS-CoV", "ORGANISM", 22, 30], ["patient", "ORGANISM", 31, 38], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 256, 264], ["sheep", "ORGANISM", 339, 344], ["cows", "ORGANISM_SUBDIVISION", 368, 372], ["patient", "SPECIES", 31, 38], ["goats", "SPECIES", 332, 337], ["sheep", "SPECIES", 339, 344], ["cows", "SPECIES", 368, 372], ["MERS-CoV", "SPECIES", 22, 30], ["MERS-CoV", "SPECIES", 256, 264], ["goats", "SPECIES", 332, 337], ["sheep", "SPECIES", 339, 344], ["MERS", "OBSERVATION", 22, 26], ["Arabian Peninsula", "ANATOMY", 305, 322]]], ["The first evidence for the existence of an intermediate animal reservoir was the detection of MERS-CoV neutralizing antibodies in dromedary camels from Oman and the Canary Islands (Spain) (Reusken et al., 2013b) .", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 94, 102], ["MERS-CoV neutralizing antibodies", "PROTEIN", 94, 126], ["MERS-CoV", "SPECIES", 94, 102], ["an intermediate animal reservoir", "TREATMENT", 40, 72], ["MERS", "PROBLEM", 94, 98], ["CoV neutralizing antibodies", "PROBLEM", 99, 126], ["intermediate", "OBSERVATION_MODIFIER", 43, 55], ["Canary", "OBSERVATION_MODIFIER", 165, 171], ["Islands", "OBSERVATION_MODIFIER", 172, 179]]], ["Subsequent studies have detected MERS-CoV neutralizing antibodies in dromedary camels from Egypt, Jordan, Saudi Arabia, and importantly, in camel serum collected in 2003 from the United Arab Emirates (Hemida et al., 2013; Perera et al., 2013; Reusken et al., 2013a; Meyer et al., 2014) .", [["serum", "ANATOMY", 146, 151], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 33, 41], ["camel", "ORGANISM", 140, 145], ["serum", "ORGANISM_SUBSTANCE", 146, 151], ["MERS-CoV neutralizing antibodies", "PROTEIN", 33, 65], ["MERS-CoV", "SPECIES", 33, 41], ["camel", "SPECIES", 140, 145], ["Subsequent studies", "TEST", 0, 18], ["MERS", "TEST", 33, 37], ["CoV neutralizing antibodies", "TREATMENT", 38, 65]]], ["While MERS-CoV neutralizing antibodies were not detected in any other species of livestock tested, including chickens, goats, sheep, and cattle, seropositivity among camels passed 90% in every location, even in 2003 (Hemida et al., 2013; Perera et al., 2013; Reusken et al., 2013a, b; Meyer et al., 2014) .", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 6, 14], ["chickens", "ORGANISM", 109, 117], ["goats", "ORGANISM", 119, 124], ["sheep", "ORGANISM", 126, 131], ["cattle", "ORGANISM", 137, 143], ["MERS-CoV neutralizing antibodies", "PROTEIN", 6, 38], ["chickens", "SPECIES", 109, 117], ["goats", "SPECIES", 119, 124], ["sheep", "SPECIES", 126, 131], ["cattle", "SPECIES", 137, 143], ["MERS-CoV", "SPECIES", 6, 14], ["chickens", "SPECIES", 109, 117], ["goats", "SPECIES", 119, 124], ["sheep", "SPECIES", 126, 131], ["cattle", "SPECIES", 137, 143], ["CoV neutralizing antibodies", "TEST", 11, 38]]], ["The high prevalence of neutralizing antibodies across age grades suggests pervasive and early infection of camels with MERS-CoV or a MERS-CoV-like virus.", [["infection", "DISEASE", 94, 103], ["camels", "ORGANISM", 107, 113], ["MERS-CoV", "ORGANISM", 119, 127], ["MERS-CoV-like virus", "ORGANISM", 133, 152], ["neutralizing antibodies", "PROTEIN", 23, 46], ["MERS-CoV", "SPECIES", 119, 127], ["MERS-CoV-like virus", "SPECIES", 133, 152], ["neutralizing antibodies", "PROBLEM", 23, 46], ["pervasive and early infection of camels", "PROBLEM", 74, 113], ["MERS", "PROBLEM", 119, 123], ["CoV", "PROBLEM", 124, 127], ["a MERS", "PROBLEM", 131, 137], ["CoV-like virus", "PROBLEM", 138, 152], ["high", "OBSERVATION_MODIFIER", 4, 8], ["pervasive", "OBSERVATION_MODIFIER", 74, 83], ["early", "OBSERVATION_MODIFIER", 88, 93], ["infection", "OBSERVATION", 94, 103]]], ["Recently, MERS-CoV virus was detected by RT-PCR in nose swabs from three camels in Qatar .", [["nose swabs", "ANATOMY", 51, 61], ["MERS-CoV virus", "ORGANISM", 10, 24], ["nose swabs", "MULTI-TISSUE_STRUCTURE", 51, 61], ["CoV virus", "SPECIES", 15, 24], ["MERS-CoV virus", "SPECIES", 10, 24], ["CoV virus", "PROBLEM", 15, 24], ["PCR", "TEST", 44, 47], ["nose swabs", "TEST", 51, 61]]], ["The camels were epidemiologically linked to two human cases of MERS-CoV, and viral fragments sequenced from the camels showed high similarity to sequences from the human cases .", [["camels", "ORGANISM", 4, 10], ["human", "ORGANISM", 48, 53], ["MERS-CoV", "ORGANISM", 63, 71], ["human", "ORGANISM", 164, 169], ["viral fragments", "DNA", 77, 92], ["human", "SPECIES", 48, 53], ["human", "SPECIES", 164, 169], ["human", "SPECIES", 48, 53], ["MERS-CoV", "SPECIES", 63, 71], ["human", "SPECIES", 164, 169], ["CoV", "PROBLEM", 68, 71], ["viral fragments", "PROBLEM", 77, 92], ["the camels", "TEST", 108, 118], ["viral fragments", "OBSERVATION", 77, 92]]], ["While this datum provides more conclusive evidence that dromedary camels form part of the MERS-CoV outbreak picture, the direction of transmission is still unclear (Fig. 5 ).", [["camels", "ORGANISM_SUBDIVISION", 66, 72], ["MERS-CoV", "SPECIES", 90, 98], ["dromedary camels", "PROBLEM", 56, 72]]], ["Transmission could have occurred from camels to humans, humans to camels, or concurrently from a third source to both humans and camels .", [["humans", "ORGANISM", 48, 54], ["humans", "ORGANISM", 56, 62], ["humans", "ORGANISM", 118, 124], ["camels", "ORGANISM_SUBDIVISION", 129, 135], ["humans", "SPECIES", 48, 54], ["humans", "SPECIES", 56, 62], ["humans", "SPECIES", 118, 124], ["humans", "SPECIES", 48, 54], ["humans", "SPECIES", 56, 62], ["humans", "SPECIES", 118, 124]]], ["Furthermore, the detection of MERS-CoV neutralizing antibodies in dromedary camels in regions with no reported human cases, such as Egypt and the Canary Islands, raises questions about the extent of MERS-CoV or MERS-CoV-like virus circulation in Africa, the Arabic peninsula, and minor Asia Reusken et al., 2013b) .", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 30, 38], ["human", "ORGANISM", 111, 116], ["MERS-CoV", "ORGANISM", 199, 207], ["MERS-CoV-like virus", "ORGANISM", 211, 230], ["MERS-CoV neutralizing antibodies", "PROTEIN", 30, 62], ["human", "SPECIES", 111, 116], ["MERS-CoV", "SPECIES", 30, 38], ["human", "SPECIES", 111, 116], ["MERS-CoV", "SPECIES", 199, 207], ["MERS-CoV", "SPECIES", 211, 219], ["the detection", "TEST", 13, 26], ["MERS", "PROBLEM", 30, 34], ["CoV neutralizing antibodies", "PROBLEM", 35, 62], ["MERS", "PROBLEM", 199, 203], ["CoV", "PROBLEM", 204, 207], ["MERS", "PROBLEM", 211, 215], ["CoV", "PROBLEM", 216, 219], ["like virus circulation", "PROBLEM", 220, 242], ["Arabic peninsula", "ANATOMY", 258, 274]]], ["Movement of camels between Africa and the Arabian Peninsula is common and could contribute to the spread of MERS-CoV between regions (Mukasa-Mugerwa, 1981; Perera et al., 2013) .Transmission of MERS-CoVThe respective roles of human-to-human and zoonotic transmission in the current MERS-CoV outbreak are not well understood (Fig. 5 ).", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 108, 116], ["MERS-CoVThe", "GENE_OR_GENE_PRODUCT", 194, 205], ["human", "ORGANISM", 226, 231], ["human", "ORGANISM", 235, 240], ["MERS-CoV", "ORGANISM", 282, 290], ["human", "SPECIES", 226, 231], ["human", "SPECIES", 235, 240], ["MERS-CoV", "SPECIES", 108, 116], ["human", "SPECIES", 226, 231], ["human", "SPECIES", 235, 240], ["MERS-CoV", "SPECIES", 282, 290], ["zoonotic transmission", "TREATMENT", 245, 266], ["Arabian Peninsula", "ANATOMY", 42, 59]]], ["Conclusive evidence of humanto-human transmission of MERS-CoV was first reported in a cluster of MERS-CoV cases in the United Kingdom, when an adult male who had travelled to Saudi Arabia transmitted the virus to two of his family members (Health Protection Agency, 2013).", [["human", "ORGANISM", 31, 36], ["MERS-CoV", "ORGANISM", 53, 61], ["MERS-CoV", "ORGANISM", 97, 105], ["human", "SPECIES", 31, 36], ["human", "SPECIES", 31, 36], ["MERS-CoV", "SPECIES", 53, 61], ["MERS-CoV", "SPECIES", 97, 105]]], ["Overall, MERS-CoV human-to-human transmission chains have been self-limiting and irregular, and more than half of secondary MERS-CoV cases have originated in a healthcare setting (WHO, 2014).", [["MERS-CoV human", "ORGANISM", 9, 23], ["human", "ORGANISM", 27, 32], ["MERS-CoV", "ORGANISM", 124, 132], ["human", "SPECIES", 18, 23], ["human", "SPECIES", 27, 32], ["MERS-CoV human", "SPECIES", 9, 23], ["human", "SPECIES", 27, 32], ["MERS-CoV", "SPECIES", 124, 132], ["irregular", "OBSERVATION_MODIFIER", 81, 90]]], ["The largest cluster of MERS-CoV to date has involved 23 patients at three different healthcare facilities in the Eastern Province of Saudi Arabia, highlighting the potential of nosocomial transmission (Assiri et al., 2013b) .", [["nosocomial transmission", "DISEASE", 177, 200], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 23, 31], ["patients", "ORGANISM", 56, 64], ["patients", "SPECIES", 56, 64], ["MERS-CoV", "SPECIES", 23, 31], ["largest", "OBSERVATION_MODIFIER", 4, 11], ["cluster", "OBSERVATION_MODIFIER", 12, 19], ["MERS", "OBSERVATION", 23, 27]]], ["On the other hand, an early MERS-CoV patient transferred from Qatar to a specialist lung hospital in Germany was given intensive treatment for almost a month before the hospital learned of his MERS-CoV diagnosis.", [["lung", "ANATOMY", 84, 88], ["MERS-CoV", "ORGANISM", 28, 36], ["patient", "ORGANISM", 37, 44], ["lung", "ORGAN", 84, 88], ["patient", "SPECIES", 37, 44], ["MERS-CoV", "SPECIES", 28, 36], ["intensive treatment", "TREATMENT", 119, 138], ["lung", "ANATOMY", 84, 88]]], ["Extensive contact investigation and serological analysis of those potentially exposed to the patient revealed no secondary infections (Buchholz et al., 2013) .", [["infections", "DISEASE", 123, 133], ["patient", "ORGANISM", 93, 100], ["patient", "SPECIES", 93, 100], ["Extensive contact investigation", "TEST", 0, 31], ["serological analysis", "TEST", 36, 56], ["secondary infections", "PROBLEM", 113, 133], ["no", "UNCERTAINTY", 110, 112], ["secondary", "OBSERVATION_MODIFIER", 113, 122], ["infections", "OBSERVATION", 123, 133]]], ["Screening of MERS-CoV patient contacts has uncovered at least 18 instances of asymptomatic MERS-CoV infection in healthcare workers and other contacts, although the role these subclinical cases can play in the transmission of infection is unclear (Memish et al., 2013a; The WHO MERS-CoV Research Group, 2013) .", [["MERS-CoV infection", "DISEASE", 91, 109], ["infection", "DISEASE", 226, 235], ["MERS-CoV", "ORGANISM", 13, 21], ["patient", "ORGANISM", 22, 29], ["MERS-CoV", "ORGANISM", 91, 99], ["patient", "SPECIES", 22, 29], ["MERS-CoV", "SPECIES", 13, 21], ["MERS-CoV", "SPECIES", 91, 99], ["asymptomatic MERS", "PROBLEM", 78, 95], ["CoV infection", "PROBLEM", 96, 109], ["infection", "PROBLEM", 226, 235], ["infection", "OBSERVATION", 100, 109], ["infection", "OBSERVATION", 226, 235]]], ["Transmission of respiratory viruses is often directly associated with the amount of virus shed.", [["respiratory viruses", "DISEASE", 16, 35], ["respiratory viruses", "PROBLEM", 16, 35], ["respiratory viruses", "OBSERVATION", 16, 35], ["virus", "OBSERVATION", 84, 89]]], ["The dynamics of MERS-CoV shedding throughout the course of disease have not been well characterized, but high viral loads detected in bronchoalveolar lavage samples from infected patients suggests that coughing and exudates from the lower respiratory tract could be important mechanisms of MERS-CoV human-to-human transmission de Sousa et al., 2013) .Transmission of MERS-CoVThe zoonotic source of MERS-CoV continues to play a role in outbreak epidemiology through repeated introductions of virus into the human population (Cotten et al., 2013a, b) .", [["bronchoalveolar lavage samples", "ANATOMY", 134, 164], ["lower respiratory tract", "ANATOMY", 233, 256], ["coughing", "DISEASE", 202, 210], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 16, 24], ["bronchoalveolar lavage samples", "ORGANISM_SUBSTANCE", 134, 164], ["patients", "ORGANISM", 179, 187], ["lower", "ORGANISM_SUBDIVISION", 233, 238], ["respiratory tract", "ORGANISM_SUBDIVISION", 239, 256], ["MERS-CoV", "ORGANISM", 290, 298], ["human", "ORGANISM", 299, 304], ["human", "ORGANISM", 308, 313], ["MERS-CoV", "ORGANISM", 398, 406], ["human", "ORGANISM", 506, 511], ["patients", "SPECIES", 179, 187], ["human", "SPECIES", 299, 304], ["human", "SPECIES", 308, 313], ["human", "SPECIES", 506, 511], ["MERS-CoV", "SPECIES", 16, 24], ["MERS-CoV human", "SPECIES", 290, 304], ["human", "SPECIES", 308, 313], ["MERS-CoV", "SPECIES", 398, 406], ["human", "SPECIES", 506, 511], ["CoV shedding", "PROBLEM", 21, 33], ["disease", "PROBLEM", 59, 66], ["high viral loads", "PROBLEM", 105, 121], ["bronchoalveolar lavage samples", "TEST", 134, 164], ["coughing", "PROBLEM", 202, 210], ["exudates", "PROBLEM", 215, 223], ["the lower respiratory tract", "PROBLEM", 229, 256], ["MERS", "PROBLEM", 367, 371], ["bronchoalveolar lavage", "OBSERVATION", 134, 156], ["coughing", "OBSERVATION", 202, 210], ["lower", "ANATOMY_MODIFIER", 233, 238], ["respiratory tract", "ANATOMY", 239, 256]]], ["The WHO has identified 62 sporadic cases of MERS-CoV, defined as having occurred with no known human exposure (The WHO MERS-CoV Research Group, 2013; WHO, 2014) .", [["MERS-CoV", "ORGANISM", 44, 52], ["human", "ORGANISM", 95, 100], ["human", "SPECIES", 95, 100], ["MERS-CoV", "SPECIES", 44, 52], ["human", "SPECIES", 95, 100]]], ["Interestingly, the rate of severe disease and death is higher for primary MERS-CoV patients than for secondary cases, despite a similar prevalence of comorbidities (The WHO MERS-CoV Research Group, 2013) .", [["death", "DISEASE", 46, 51], ["MERS-CoV", "ORGANISM", 74, 82], ["patients", "ORGANISM", 83, 91], ["patients", "SPECIES", 83, 91], ["MERS-CoV", "SPECIES", 74, 82], ["severe disease", "PROBLEM", 27, 41], ["death", "PROBLEM", 46, 51], ["secondary cases", "PROBLEM", 101, 116], ["severe", "OBSERVATION_MODIFIER", 27, 33], ["disease", "OBSERVATION", 34, 41]]], ["This could be the result of higher doses of virus exposure among primary patients.Transmission dynamics of MERS-CoVBecause of the epidemiologic dynamics described above, the basic reproduction number (R 0 ) of MERS-CoV is uncertain.", [["patients", "ORGANISM", 73, 81], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 210, 218], ["patients", "SPECIES", 73, 81], ["MERS-CoV", "SPECIES", 210, 218], ["virus exposure", "TREATMENT", 44, 58], ["the epidemiologic dynamics", "PROBLEM", 126, 152]]], ["R 0 is a measure of the number of secondary cases generated by one case of disease in a na\u20ac \u0131ve populationan R 0 of < 1 is self-limiting within a population.", [["disease", "PROBLEM", 75, 82], ["a na\u20ac", "TEST", 86, 91], ["disease", "OBSERVATION", 75, 82]]], ["Using the epidemiological information from 62 probable cases of MERS-CoV infection, two different transmission scenarios were used to estimate the R 0 for MERS-CoV (Breban et al., 2013) .", [["MERS-CoV infection", "DISEASE", 64, 82], ["MERS-CoV", "ORGANISM", 64, 72], ["MERS-CoV", "SPECIES", 64, 72], ["MERS-CoV", "SPECIES", 155, 163], ["MERS", "PROBLEM", 64, 68], ["CoV infection", "PROBLEM", 69, 82], ["infection", "OBSERVATION", 73, 82]]], ["One scenario was modeled on a large number of index patients per cluster, each generating a small transmission tree, reflecting the possibility that two epidemiologically linked cases could have been exposed to the same nonhuman source of MERS-CoV.", [["patients", "ORGANISM", 52, 60], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 239, 247], ["patients", "SPECIES", 52, 60], ["MERS-CoV", "SPECIES", 239, 247], ["large", "OBSERVATION_MODIFIER", 30, 35]]], ["This scenario yielded an R 0 of 0.60 and a yearly MERS-CoV introduction rate of 22.3 (Breban et al., 2013) .", [["This scenario", "TEST", 0, 13], ["CoV introduction rate", "TEST", 55, 76]]], ["The second scenario, which used a lower rate of introduction with higher human-to-human transmission, predicted an R 0 of 0.67 and a yearly introduction rate of 17.1 (Breban et al., 2013) .", [["human", "ORGANISM", 73, 78], ["human", "ORGANISM", 82, 87], ["human", "SPECIES", 73, 78], ["human", "SPECIES", 82, 87], ["human", "SPECIES", 73, 78], ["human", "SPECIES", 82, 87], ["a yearly introduction rate", "TEST", 131, 157]]], ["A large-scale analysis of full-genome sequences of MERS-CoV has identified multiple zoonotic introductions of the virus and distinct genomes circulating in the same geographic spaces, providing evidence for multiple zoonotic introductions and transmission dynamics in agreement with a lower R 0 (Cotten et al., 2013b) .", [["MERS-CoV", "ORGANISM", 51, 59], ["full-genome sequences", "DNA", 26, 47], ["MERS-CoV", "SPECIES", 51, 59], ["A large-scale analysis", "TEST", 0, 22], ["CoV", "PROBLEM", 56, 59], ["the virus", "PROBLEM", 110, 119], ["multiple zoonotic introductions", "PROBLEM", 207, 238], ["large", "OBSERVATION_MODIFIER", 2, 7], ["multiple", "OBSERVATION_MODIFIER", 75, 83], ["zoonotic", "OBSERVATION_MODIFIER", 84, 92], ["distinct", "OBSERVATION_MODIFIER", 124, 132], ["genomes", "OBSERVATION_MODIFIER", 133, 140], ["circulating", "OBSERVATION_MODIFIER", 141, 152], ["providing evidence for", "UNCERTAINTY", 184, 206], ["multiple", "OBSERVATION_MODIFIER", 207, 215], ["zoonotic", "OBSERVATION_MODIFIER", 216, 224], ["introductions", "OBSERVATION", 225, 238]]], ["Furthermore, a comparison of the R 0 s predicted for MERS-CoV and prepandemic SARS-CoV (R 0 of 0.8) suggests MERS-CoV has low pandemic potential (Breban et al., 2013) .", [["SARS", "DISEASE", 78, 82], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 53, 61], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 109, 117], ["MERS-CoV", "SPECIES", 53, 61], ["SARS-CoV", "SPECIES", 78, 86], ["MERS-CoV", "SPECIES", 109, 117], ["MERS", "TEST", 53, 57], ["CoV", "TEST", 58, 61], ["prepandemic SARS", "TEST", 66, 82], ["CoV", "TEST", 83, 86]]], ["Another transmission model of 111 MERS-CoV cases predicted a similar R 0 (0.63), but warned that in the absence of control measures, the R 0 could range between 0.8 and 1.3 and allow for self-sustaining transmission (Cauchemez et al., 2013) .", [["MERS-CoV", "SPECIES", 34, 42], ["Another transmission model", "TEST", 0, 26], ["CoV cases", "TEST", 39, 48]]], ["Based on extrapolations of the incidence of disease in travelers returning from MERS-CoV-source countries, it was predicted that as many as 940 symptomatic cases of MERS-CoV may have occurred before August 8, 2013 (Cauchemez et al., 2013) .", [["MERS-CoV", "ORGANISM", 165, 173], ["MERS-CoV", "SPECIES", 165, 173], ["disease", "PROBLEM", 44, 51], ["disease", "OBSERVATION", 44, 51]]], ["Epidemiologic studies will be necessary to assess the prevalence and circulation of MERS-CoV infection in the human population.MERS-CoV biologyThe 30 119-base pair genome of MERS-CoV consists of at least ten polycistronic open reading frames (ORFs), the organization of which follows that of coronaviruses in general (Masters, 2006; van Boheemen et al., 2012) .", [["MERS-CoV infection", "DISEASE", 84, 102], ["MERS-CoV", "ORGANISM", 84, 92], ["human", "ORGANISM", 110, 115], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 127, 135], ["MERS-CoV", "ORGANISM", 174, 182], ["30 119-base pair genome", "DNA", 147, 170], ["MERS-CoV", "DNA", 174, 182], ["polycistronic open reading frames", "DNA", 208, 241], ["ORFs", "DNA", 243, 247], ["human", "SPECIES", 110, 115], ["MERS-CoV", "SPECIES", 84, 92], ["human", "SPECIES", 110, 115], ["MERS-CoV", "SPECIES", 174, 182], ["Epidemiologic studies", "TEST", 0, 21], ["MERS", "PROBLEM", 84, 88], ["CoV infection", "PROBLEM", 89, 102], ["CoV", "OBSERVATION_MODIFIER", 89, 92], ["infection", "OBSERVATION", 93, 102]]], ["Over two-thirds of the 5 0 end of the coronavirus genome is composed of the replicase open reading frames ORF1a and ORF1b (Masters, 2006) .", [["coronavirus", "ORGANISM", 38, 49], ["ORF1a", "GENE_OR_GENE_PRODUCT", 106, 111], ["ORF1b", "GENE_OR_GENE_PRODUCT", 116, 121], ["5 0 end", "DNA", 23, 30], ["coronavirus genome", "DNA", 38, 56], ["replicase open reading frames", "DNA", 76, 105], ["ORF1a", "DNA", 106, 111], ["ORF1b", "DNA", 116, 121], ["the coronavirus genome", "PROBLEM", 34, 56], ["coronavirus genome", "OBSERVATION", 38, 56]]], ["In MERS-CoV, these ORFs are translated into two polyproteins, one requiring a ribosomal frame shift, which are eventually cleaved into 16 putative nonstructural proteins (nsps; Sawicki et al., 2007; van Boheemen et al., 2012) .", [["ribosomal", "ANATOMY", 78, 87], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 3, 11], ["ribosomal", "CELLULAR_COMPONENT", 78, 87], ["MERS-CoV", "DNA", 3, 11], ["ORFs", "DNA", 19, 23], ["16 putative nonstructural proteins", "PROTEIN", 135, 169], ["MERS-CoV", "SPECIES", 3, 11], ["these ORFs", "TEST", 13, 23], ["two polyproteins", "PROBLEM", 44, 60]]], ["The role of these nsps has not been empirically determined for MERS-CoV, but some function can be predicted based on conserved domains characterized in other coronaviruses.", [["nsps", "GENE_OR_GENE_PRODUCT", 18, 22], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 63, 71], ["coronaviruses", "ORGANISM", 158, 171], ["nsps", "DNA", 18, 22], ["MERS-CoV", "SPECIES", 63, 71], ["MERS", "PROBLEM", 63, 67], ["CoV", "PROBLEM", 68, 71], ["other coronaviruses", "PROBLEM", 152, 171]]], ["For instance, nsp12 putatively serves as the RdRp, and nsp14 is thought to function as the proofreading exoribonuclease (ExoN; van .", [["nsp12", "GENE_OR_GENE_PRODUCT", 14, 19], ["RdRp", "GENE_OR_GENE_PRODUCT", 45, 49], ["nsp14", "GENE_OR_GENE_PRODUCT", 55, 60], ["nsp12", "PROTEIN", 14, 19], ["RdRp", "PROTEIN", 45, 49], ["nsp14", "PROTEIN", 55, 60], ["proofreading exoribonuclease", "PROTEIN", 91, 119], ["ExoN", "PROTEIN", 121, 125]]], ["Interestingly, coronaviruses are the only RNA viruses known to use a specific proofreading enzyme for the maintenance of high-fidelity viral RNA replication (Smith et al., 2013) .", [["coronaviruses", "ORGANISM", 15, 28], ["proofreading enzyme", "PROTEIN", 78, 97], ["coronaviruses", "PROBLEM", 15, 28], ["RNA viruses", "PROBLEM", 42, 53], ["a specific proofreading enzyme", "TEST", 67, 97], ["coronaviruses", "OBSERVATION", 15, 28], ["viral RNA", "OBSERVATION", 135, 144]]], ["Downstream of the two large ORFs are at least nine ORFs encoding the structural proteinsspike, envelope, membrane, and nucleocapsidand some accessory proteins .", [["membrane", "ANATOMY", 105, 113], ["membrane", "CELLULAR_COMPONENT", 105, 113], ["ORFs", "DNA", 28, 32], ["ORFs", "DNA", 51, 55], ["structural proteinsspike, envelope, membrane, and nucleocapsidand some accessory proteins", "PROTEIN", 69, 158], ["the two large ORFs", "PROBLEM", 14, 32], ["two", "OBSERVATION_MODIFIER", 18, 21], ["large", "OBSERVATION_MODIFIER", 22, 27], ["ORFs", "OBSERVATION", 28, 32], ["accessory proteins", "OBSERVATION", 140, 158]]], ["The translation of the downstream ORFs occurs via subgenomic mRNAs, a salient feature of the order to which coronaviruses belong: Nidovirales (Sawicki et al., 2007) .Receptor binding of MERS-CoVBy granting binding of the virus to the host cell, cellular receptors play an important role in determining the species and tissue tropism of coronaviruses (Thackray & Holmes, 2004; Masters, 2006; Tusell et al., 2007) .", [["cell", "ANATOMY", 239, 243], ["cellular", "ANATOMY", 245, 253], ["tissue", "ANATOMY", 318, 324], ["coronaviruses", "ORGANISM", 108, 121], ["MERS-CoVBy", "GENE_OR_GENE_PRODUCT", 186, 196], ["host cell", "CELL", 234, 243], ["cellular", "CELL", 245, 253], ["tissue", "TISSUE", 318, 324], ["coronaviruses", "ORGANISM", 336, 349], ["downstream ORFs", "DNA", 23, 38], ["subgenomic mRNAs", "RNA", 50, 66], ["MERS", "PROTEIN", 186, 190], ["CoVBy", "PROTEIN", 191, 196], ["cellular receptors", "PROTEIN", 245, 263], ["the downstream ORFs", "PROBLEM", 19, 38], ["Receptor binding of MERS", "PROBLEM", 166, 190], ["the virus", "PROBLEM", 217, 226], ["subgenomic mRNAs", "OBSERVATION", 50, 66], ["host cell", "OBSERVATION", 234, 243]]], ["The MERS-CoV spike protein is a 1353 amino acid type-I transmembrane glycoprotein presented as a trimer on the surface of the enveloped virus.", [["surface", "ANATOMY", 111, 118], ["amino acid", "CHEMICAL", 37, 47], ["amino acid", "CHEMICAL", 37, 47], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 4, 12], ["surface", "CELLULAR_COMPONENT", 111, 118], ["enveloped virus", "ORGANISM", 126, 141], ["MERS-CoV spike protein", "PROTEIN", 4, 26], ["1353 amino acid type-I transmembrane glycoprotein", "PROTEIN", 32, 81], ["MERS-CoV", "SPECIES", 4, 12], ["The MERS", "TEST", 0, 8], ["CoV spike protein", "TEST", 9, 26], ["transmembrane glycoprotein", "PROBLEM", 55, 81], ["the enveloped virus", "PROBLEM", 122, 141], ["virus", "OBSERVATION", 136, 141]]], ["After translation, the spike protein is cleaved into two domains: the S1 subunit responsible for receptor binding and the S2 unit that mediates membrane fusion (Ohnuma et al., 2013; Raj et al., 2013) .", [["membrane", "ANATOMY", 144, 152], ["membrane", "CELLULAR_COMPONENT", 144, 152], ["spike protein", "PROTEIN", 23, 36], ["S1 subunit", "PROTEIN", 70, 80], ["S2 unit", "PROTEIN", 122, 129], ["the spike protein", "TEST", 19, 36], ["receptor binding", "PROBLEM", 97, 113], ["membrane fusion", "TREATMENT", 144, 159], ["membrane fusion", "OBSERVATION", 144, 159]]], ["The S1 spike glycoprotein binds to the surface enzyme dipeptidyl peptidase 4 (DPP4, also known as CD26).", [["surface", "ANATOMY", 39, 46], ["dipeptidyl peptidase 4", "GENE_OR_GENE_PRODUCT", 54, 76], ["DPP4", "GENE_OR_GENE_PRODUCT", 78, 82], ["CD26", "GENE_OR_GENE_PRODUCT", 98, 102], ["S1 spike glycoprotein", "PROTEIN", 4, 25], ["surface enzyme", "PROTEIN", 39, 53], ["dipeptidyl peptidase 4", "PROTEIN", 54, 76], ["DPP4", "PROTEIN", 78, 82], ["CD26", "PROTEIN", 98, 102], ["The S1 spike glycoprotein binds", "PROBLEM", 0, 31], ["the surface enzyme dipeptidyl peptidase", "TEST", 35, 74], ["DPP4", "TEST", 78, 82]]], ["DPP4 is a type-II transmembrane glycoprotein that catalyzes the cleavage of N-terminal proline-containing dipeptides and aids glucose metabolism by proteolytic inactivation of incretins (Engel et al., 2003; Hiramatsu et al., 2003; Lambeir et al., 2003) .", [["proline", "CHEMICAL", 87, 94], ["glucose", "CHEMICAL", 126, 133], ["N-", "CHEMICAL", 76, 78], ["proline", "CHEMICAL", 87, 94], ["dipeptides", "CHEMICAL", 106, 116], ["glucose", "CHEMICAL", 126, 133], ["DPP4", "GENE_OR_GENE_PRODUCT", 0, 4], ["type-II", "GENE_OR_GENE_PRODUCT", 10, 17], ["N-terminal proline-containing dipeptides", "SIMPLE_CHEMICAL", 76, 116], ["glucose", "SIMPLE_CHEMICAL", 126, 133], ["incretins", "SIMPLE_CHEMICAL", 176, 185], ["DPP4", "PROTEIN", 0, 4], ["type-II transmembrane glycoprotein", "PROTEIN", 10, 44], ["DPP4", "TEST", 0, 4], ["a type-II transmembrane glycoprotein", "TREATMENT", 8, 44], ["N-terminal proline", "TREATMENT", 76, 94], ["dipeptides", "TREATMENT", 106, 116], ["aids glucose metabolism", "PROBLEM", 121, 144]]], ["DPP4 is the third exopeptidase found to act as a receptor for coronaviruses .", [["DPP4", "GENE_OR_GENE_PRODUCT", 0, 4], ["coronaviruses", "ORGANISM", 62, 75], ["DPP4", "PROTEIN", 0, 4], ["exopeptidase", "PROTEIN", 18, 30], ["DPP4", "TREATMENT", 0, 4], ["coronaviruses", "PROBLEM", 62, 75]]], ["Blocking the enzymatic activity of DPP4 does not affect MERS-CoV susceptibility, and so the significance of these enzymes as receptors for coronaviruses is thought to lie in their widespread expression on endothelial and epithelial tissues .", [["endothelial", "ANATOMY", 205, 216], ["epithelial tissues", "ANATOMY", 221, 239], ["DPP4", "GENE_OR_GENE_PRODUCT", 35, 39], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 56, 64], ["coronaviruses", "ORGANISM", 139, 152], ["endothelial", "CELL", 205, 216], ["epithelial tissues", "TISSUE", 221, 239], ["DPP4", "PROTEIN", 35, 39], ["enzymes", "PROTEIN", 114, 121], ["MERS-CoV", "SPECIES", 56, 64], ["CoV susceptibility", "PROBLEM", 61, 79], ["these enzymes", "TEST", 108, 121], ["coronaviruses", "PROBLEM", 139, 152], ["enzymatic activity", "OBSERVATION", 13, 31], ["widespread", "OBSERVATION_MODIFIER", 180, 190], ["expression", "OBSERVATION", 191, 201], ["endothelial", "ANATOMY", 205, 216], ["epithelial tissues", "ANATOMY", 221, 239]]], ["DPP4 is relatively conserved between mammalian species, allowing MERS-CoV to bind to species as diverse as bats and humans Raj et al., 2013) .", [["DPP4", "GENE_OR_GENE_PRODUCT", 0, 4], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 65, 73], ["humans", "ORGANISM", 116, 122], ["DPP4", "PROTEIN", 0, 4], ["humans", "SPECIES", 116, 122], ["MERS-CoV", "SPECIES", 65, 73], ["DPP4", "TEST", 0, 4], ["mammalian species", "PROBLEM", 37, 54]]], ["The receptor-binding domain (RBD) of MERS-CoV, the region of the spike protein that attaches to the DPP4 receptor, has been mapped to 240 amino acid residues in the S1 region of the spike protein (Chen et al., 2013; Lu et al., 2013; Mou et al., 2013; Wang et al., 2013) .", [["amino acid", "CHEMICAL", 138, 148], ["amino acid", "CHEMICAL", 138, 148], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 37, 45], ["DPP4", "GENE_OR_GENE_PRODUCT", 100, 104], ["amino acid", "AMINO_ACID", 138, 148], ["receptor-binding domain", "PROTEIN", 4, 27], ["RBD", "PROTEIN", 29, 32], ["MERS", "PROTEIN", 37, 41], ["CoV", "PROTEIN", 42, 45], ["spike protein", "PROTEIN", 65, 78], ["DPP4 receptor", "PROTEIN", 100, 113], ["S1 region", "PROTEIN", 165, 174], ["spike protein", "PROTEIN", 182, 195], ["MERS-CoV", "SPECIES", 37, 45], ["CoV", "PROBLEM", 42, 45], ["the spike protein", "PROBLEM", 61, 78], ["the DPP4 receptor", "TREATMENT", 96, 113], ["amino acid residues", "TEST", 138, 157], ["S1", "ANATOMY", 165, 167], ["region", "ANATOMY_MODIFIER", 168, 174]]], ["Co-crystallization of MERS-CoV spike protein and DPP4 revealed an interaction between the beta-propeller blades 4 and 5 of DPP4 and beta-strands 5, 6, 7, and 8 of the MERS-CoV RBD, also known as the receptor-binding motif (RBM; Fig. 6 ; Lu et al., 2013; Wang et al., 2013) .", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 22, 30], ["DPP4", "GENE_OR_GENE_PRODUCT", 49, 53], ["DPP4", "GENE_OR_GENE_PRODUCT", 123, 127], ["beta-strands 5", "GENE_OR_GENE_PRODUCT", 132, 146], ["7", "GENE_OR_GENE_PRODUCT", 151, 152], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 167, 175], ["MERS-CoV spike protein", "PROTEIN", 22, 44], ["DPP4", "PROTEIN", 49, 53], ["beta-propeller blades 4 and 5", "PROTEIN", 90, 119], ["DPP4", "PROTEIN", 123, 127], ["beta-strands 5, 6, 7, and 8", "PROTEIN", 132, 159], ["MERS-CoV RBD", "PROTEIN", 167, 179], ["receptor-binding motif", "PROTEIN", 199, 221], ["MERS-CoV", "SPECIES", 167, 175], ["Co-crystallization of MERS", "PROBLEM", 0, 26], ["CoV spike protein", "TEST", 27, 44], ["DPP4", "TEST", 49, 53], ["DPP4", "TEST", 123, 127], ["beta-strands", "TEST", 132, 144], ["the MERS", "TEST", 163, 171], ["CoV RBD", "PROBLEM", 172, 179], ["the receptor-binding motif (RBM", "TREATMENT", 195, 226]]], ["The RBD of the spike protein induces neutralizing antibodies, making it an important target for the development of prophylactics and therapeutics (Agnihothram et al., 2013; Du et al., 2013a, b, c; Gierer et al., 2013; Song et al., 2013) .Host interaction of MERS-CoVPreliminary investigations of MERS-CoV host interactions and innate immune responses have been performed in vitro, ex vivo, and in vivo in a nonhuman primate model.", [["MERS-CoV", "ORGANISM", 296, 304], ["primate", "ORGANISM", 416, 423], ["RBD", "PROTEIN", 4, 7], ["spike protein", "PROTEIN", 15, 28], ["neutralizing antibodies", "PROTEIN", 37, 60], ["MERS", "PROTEIN", 258, 262], ["MERS-CoV", "SPECIES", 296, 304], ["the spike protein", "PROBLEM", 11, 28], ["neutralizing antibodies", "PROBLEM", 37, 60], ["prophylactics", "TREATMENT", 115, 128], ["MERS", "PROBLEM", 296, 300], ["RBD", "OBSERVATION", 4, 7], ["neutralizing antibodies", "OBSERVATION", 37, 60]]], ["MERS-CoV has been shown to replicate in vitro in human, bat, and porcine-derived cell lines, whereas cow, hamster, murine, rat, and canine cell lines were not susceptible Chan et al., 2013b; Dijkman et al., 2013; Kindler et al., 2013; Raj et al., 2013; Scobey et al., 2013) .", [["cell lines", "ANATOMY", 81, 91], ["hamster", "ANATOMY", 106, 113], ["cell lines", "ANATOMY", 139, 149], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 0, 8], ["human", "ORGANISM", 49, 54], ["bat", "ORGANISM", 56, 59], ["porcine", "ORGANISM", 65, 72], ["cell lines", "CELL", 81, 91], ["cow", "ORGANISM", 101, 104], ["hamster", "ORGANISM", 106, 113], ["murine", "ORGANISM", 115, 121], ["rat", "ORGANISM", 123, 126], ["canine", "ORGANISM", 132, 138], ["cell lines", "CELL", 139, 149], ["MERS-CoV", "DNA", 0, 8], ["human, bat, and porcine-derived cell lines", "CELL_LINE", 49, 91], ["cow, hamster, murine, rat, and canine cell lines", "CELL_LINE", 101, 149], ["human", "SPECIES", 49, 54], ["porcine", "SPECIES", 65, 72], ["cow", "SPECIES", 101, 104], ["hamster", "SPECIES", 106, 113], ["murine", "SPECIES", 115, 121], ["rat", "SPECIES", 123, 126], ["canine", "SPECIES", 132, 138], ["MERS-CoV", "SPECIES", 0, 8], ["human", "SPECIES", 49, 54], ["cow", "SPECIES", 101, 104], ["hamster", "SPECIES", 106, 113], ["rat", "SPECIES", 123, 126], ["canine", "SPECIES", 132, 138], ["porcine-derived cell lines", "TREATMENT", 65, 91], ["cell lines", "OBSERVATION", 81, 91]]], ["While in vitro modeling holds some predictive value for MERS-CoV susceptibility in vivo, a more complete characterization of the mechanisms of cellular entry is necessary to understand host susceptibility (Leow, 2013) .", [["cellular", "ANATOMY", 143, 151], ["MERS-CoV", "ORGANISM", 56, 64], ["cellular", "CELL", 143, 151], ["MERS-CoV", "SPECIES", 56, 64], ["MERS", "PROBLEM", 56, 60]]], ["For instance, the species tropism of MERS-CoV appears to be restricted by variability in the cellular receptor.", [["cellular", "ANATOMY", 93, 101], ["MERS-CoV", "ORGANISM", 37, 45], ["cellular", "CELL", 93, 101], ["cellular receptor", "PROTEIN", 93, 110], ["MERS-CoV", "SPECIES", 37, 45], ["the species tropism", "TEST", 14, 33], ["CoV", "PROBLEM", 42, 45], ["cellular receptor", "OBSERVATION", 93, 110]]], ["MERS-CoV is unable to replicate in mice, hamsters, or ferretscommon small animal modelsand the MERS-CoV spike glycoprotein is unable to bind ferret-specific DPP4 (Coleman et al., 2013; de Wit et al., 2013a; Raj et al., 2014) . (a) The linear organization of the S1 subunit of MERS-CoV spike glycoprotein with the variable RBD located at amino acid residues 367-607, with a RBM containing the critical amino acid residues for binding at residues 484-567. (b) The crystal structure of the MERS-CoV RBD coupled with the receptor dipeptidyl peptidase IV (DPP4).", [["amino acid residues 367-607", "CHEMICAL", 337, 364], ["amino acid", "CHEMICAL", 401, 411], ["amino acid", "CHEMICAL", 337, 347], ["amino acid", "CHEMICAL", 401, 411], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 0, 8], ["mice", "ORGANISM", 35, 39], ["hamsters", "ORGANISM", 41, 49], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 95, 103], ["DPP4", "GENE_OR_GENE_PRODUCT", 157, 161], ["MERS-CoV spike glycoprotein", "GENE_OR_GENE_PRODUCT", 276, 303], ["amino acid", "AMINO_ACID", 337, 347], ["residues 367-607", "AMINO_ACID", 348, 364], ["amino acid", "AMINO_ACID", 401, 411], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 487, 495], ["dipeptidyl peptidase IV", "GENE_OR_GENE_PRODUCT", 526, 549], ["DPP4", "GENE_OR_GENE_PRODUCT", 551, 555], ["MERS-CoV", "DNA", 0, 8], ["MERS-CoV spike glycoprotein", "PROTEIN", 95, 122], ["DPP4", "PROTEIN", 157, 161], ["S1 subunit", "PROTEIN", 262, 272], ["MERS-CoV spike glycoprotein", "PROTEIN", 276, 303], ["RBD", "PROTEIN", 322, 325], ["RBM", "PROTEIN", 373, 376], ["MERS-CoV RBD", "PROTEIN", 487, 499], ["receptor dipeptidyl peptidase IV", "PROTEIN", 517, 549], ["DPP4", "PROTEIN", 551, 555], ["mice", "SPECIES", 35, 39], ["MERS-CoV", "SPECIES", 0, 8], ["mice", "SPECIES", 35, 39], ["hamsters", "SPECIES", 41, 49], ["MERS-CoV", "SPECIES", 95, 103], ["MERS-CoV", "SPECIES", 276, 284], ["MERS-CoV", "SPECIES", 487, 495], ["small animal modelsand the MERS", "PROBLEM", 68, 99], ["CoV spike glycoprotein", "PROBLEM", 100, 122], ["MERS", "PROBLEM", 276, 280], ["CoV spike glycoprotein", "PROBLEM", 281, 303], ["the variable RBD", "PROBLEM", 309, 325], ["amino acid residues", "TEST", 337, 356], ["a RBM", "TREATMENT", 371, 376], ["the critical amino acid residues", "TREATMENT", 388, 420], ["CoV RBD", "PROBLEM", 492, 499], ["the receptor dipeptidyl peptidase IV (DPP4)", "TREATMENT", 513, 556], ["S1", "ANATOMY", 262, 264], ["amino acid residues", "OBSERVATION", 401, 420]]], ["DPP4 is structurally divided into an alpha-and beta-hydrolase domain, and a beta-propeller domain.", [["DPP4", "GENE_OR_GENE_PRODUCT", 0, 4], ["DPP4", "PROTEIN", 0, 4], ["alpha-and beta-hydrolase domain", "PROTEIN", 37, 68], ["beta-propeller domain", "PROTEIN", 76, 97], ["DPP4", "TEST", 0, 4], ["an alpha", "TEST", 34, 42]]], ["The beta-propeller domain of DPP4 (pink) interacts with the RBM region (light blue) of the MERS-CoV spike protein RBD.", [["DPP4", "GENE_OR_GENE_PRODUCT", 29, 33], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 91, 99], ["beta-propeller domain", "PROTEIN", 4, 25], ["DPP4", "PROTEIN", 29, 33], ["pink", "PROTEIN", 35, 39], ["RBM region", "PROTEIN", 60, 70], ["MERS-CoV spike protein", "PROTEIN", 91, 113], ["RBD", "PROTEIN", 114, 117], ["MERS-CoV", "SPECIES", 91, 99], ["DPP4", "TEST", 29, 33], ["light blue", "TEST", 72, 82], ["the MERS", "TEST", 87, 95], ["CoV spike protein RBD", "PROBLEM", 96, 117], ["RBD", "OBSERVATION", 114, 117]]], ["The schematic representation of the DPP4 -MERS-CoV spike protein RBD structure was generated using chimera and protein accession number 4KR0 (Lu et al., 2013) .", [["DPP4", "GENE_OR_GENE_PRODUCT", 36, 40], ["DPP4", "PROTEIN", 36, 40], ["MERS-CoV spike protein RBD structure", "PROTEIN", 42, 78], ["chimera", "PROTEIN", 99, 106], ["the DPP4", "TEST", 32, 40], ["CoV spike protein RBD structure", "PROBLEM", 47, 78]]], ["Yet consistent with observations of SARS-CoV infection, MERS-CoV infection of human respiratory cells does not lead to a pronounced type-I IFN response (Kopecky-Bromberg et al., 2007; Kindler et al., 2013; Zielecki et al., 2013) .", [["respiratory cells", "ANATOMY", 84, 101], ["SARS-CoV infection", "DISEASE", 36, 54], ["infection", "DISEASE", 65, 74], ["SARS-CoV", "ORGANISM", 36, 44], ["MERS-CoV", "ORGANISM", 56, 64], ["human", "ORGANISM", 78, 83], ["respiratory cells", "CELL", 84, 101], ["type-I IFN", "GENE_OR_GENE_PRODUCT", 132, 142], ["human respiratory cells", "CELL_TYPE", 78, 101], ["IFN", "PROTEIN", 139, 142], ["human", "SPECIES", 78, 83], ["SARS-CoV", "SPECIES", 36, 44], ["MERS-CoV", "SPECIES", 56, 64], ["human", "SPECIES", 78, 83], ["SARS", "PROBLEM", 36, 40], ["CoV infection", "PROBLEM", 41, 54], ["MERS", "PROBLEM", 56, 60], ["CoV infection of human respiratory cells", "PROBLEM", 61, 101], ["a pronounced type-I IFN response", "PROBLEM", 119, 151], ["Kopecky", "TEST", 153, 160], ["consistent with", "UNCERTAINTY", 4, 19], ["SARS", "OBSERVATION", 36, 40], ["CoV", "OBSERVATION_MODIFIER", 41, 44], ["infection", "OBSERVATION", 45, 54], ["respiratory cells", "OBSERVATION", 84, 101]]], ["Type-I IFNs play a key role in viral immunity, and pathogenic viruses often evade innate immunity through antagonist proteins that disrupt the IFN reaction (Garc \u0131a-Sastre & Biron, 2006; Randall & Goodbourn, 2008; Taylor & Mossman, 2013) .", [["Type-I IFNs", "GENE_OR_GENE_PRODUCT", 0, 11], ["Type-I IFNs", "PROTEIN", 0, 11], ["antagonist proteins", "PROTEIN", 106, 125], ["IFN", "PROTEIN", 143, 146], ["Garc \u0131a-Sastre & Biron, 2006; Randall & Goodbourn, 2008; Taylor & Mossman, 2013)", "SPECIES", 157, 237], ["Type-I IFNs", "PROBLEM", 0, 11], ["viral immunity", "PROBLEM", 31, 45], ["pathogenic viruses", "PROBLEM", 51, 69], ["antagonist proteins", "TREATMENT", 106, 125], ["the IFN reaction", "PROBLEM", 139, 155]]], ["In MERS-CoV, inhibition of type-I IFNs has been demonstrated by the structural M protein and the accessory proteins encoded by ORF 4a, ORF 4b, and ORF 5 .", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 3, 11], ["type-I IFNs", "GENE_OR_GENE_PRODUCT", 27, 38], ["ORF 4a", "GENE_OR_GENE_PRODUCT", 127, 133], ["ORF 4b", "GENE_OR_GENE_PRODUCT", 135, 141], ["type-I IFNs", "PROTEIN", 27, 38], ["structural M protein", "PROTEIN", 68, 88], ["accessory proteins", "PROTEIN", 97, 115], ["ORF 4a", "DNA", 127, 133], ["ORF 4b", "DNA", 135, 141], ["ORF 5", "DNA", 147, 152], ["MERS-CoV", "SPECIES", 3, 11], ["type-I IFNs", "PROBLEM", 27, 38], ["the structural M protein", "TEST", 64, 88], ["the accessory proteins", "PROBLEM", 93, 115], ["ORF", "TEST", 135, 138]]], ["The most potent inhibitor, ORF 4a, has been shown to inhibit type-I IFN activation by blocking the interaction between the RNA helicase sensor MDA5 and viral double-stranded RNA, a mechanism distinct from that employed by SARS-CoV (Kopecky-Bromberg et al., 2007; Niemeyer et al., 2013; Yang et al., 2013) .Infection experiments in human airway epithelial cells have shown that the global transcriptional host response is earlier and more robust after MERS-CoV infection than after SARS-CoV infectionEfficient MERS-CoV replication has also been demonstrated in nonciliated bronchial epithelium, alveolar epithelial cells, endothelial cells, and macrophages in human ex vivo organ cultures (Chan et al., 2013c; Zhou et al., 2013) .", [["airway epithelial cells", "ANATOMY", 337, 360], ["bronchial epithelium", "ANATOMY", 572, 592], ["alveolar epithelial cells", "ANATOMY", 594, 619], ["endothelial cells", "ANATOMY", 621, 638], ["macrophages", "ANATOMY", 644, 655], ["organ cultures", "ANATOMY", 673, 687], ["ORF 4a", "CHEMICAL", 27, 33], ["SARS", "DISEASE", 222, 226], ["infection", "DISEASE", 460, 469], ["ORF 4a", "GENE_OR_GENE_PRODUCT", 27, 33], ["type-I IFN", "GENE_OR_GENE_PRODUCT", 61, 71], ["MDA5", "GENE_OR_GENE_PRODUCT", 143, 147], ["SARS-CoV", "ORGANISM", 222, 230], ["human", "ORGANISM", 331, 336], ["airway epithelial cells", "CELL", 337, 360], ["MERS-CoV", "ORGANISM", 451, 459], ["SARS-CoV", "ORGANISM", 481, 489], ["MERS-CoV", "ORGANISM", 509, 517], ["bronchial epithelium", "CELL", 572, 592], ["alveolar epithelial cells", "CELL", 594, 619], ["endothelial cells", "CELL", 621, 638], ["macrophages", "CELL", 644, 655], ["human", "ORGANISM", 659, 664], ["organ cultures", "CELL", 673, 687], ["ORF 4a", "DNA", 27, 33], ["IFN", "PROTEIN", 68, 71], ["RNA helicase", "PROTEIN", 123, 135], ["MDA5", "PROTEIN", 143, 147], ["viral double-stranded RNA", "RNA", 152, 177], ["human airway epithelial cells", "CELL_TYPE", 331, 360], ["alveolar epithelial cells", "CELL_TYPE", 594, 619], ["endothelial cells", "CELL_TYPE", 621, 638], ["macrophages", "CELL_TYPE", 644, 655], ["human", "SPECIES", 331, 336], ["human", "SPECIES", 659, 664], ["SARS-CoV", "SPECIES", 222, 230], ["human", "SPECIES", 331, 336], ["MERS-CoV", "SPECIES", 451, 459], ["SARS-CoV infectionEfficient MERS-CoV", "SPECIES", 481, 517], ["human", "SPECIES", 659, 664], ["The most potent inhibitor", "TREATMENT", 0, 25], ["type-I IFN activation", "PROBLEM", 61, 82], ["viral double-stranded RNA", "TREATMENT", 152, 177], ["Infection experiments in human airway epithelial cells", "PROBLEM", 306, 360], ["CoV infection", "PROBLEM", 456, 469], ["SARS", "PROBLEM", 481, 485], ["CoV infectionEfficient MERS", "PROBLEM", 486, 513], ["CoV replication", "TREATMENT", 514, 529], ["nonciliated bronchial epithelium", "PROBLEM", 560, 592], ["alveolar epithelial cells", "PROBLEM", 594, 619], ["endothelial cells", "TEST", 621, 638], ["macrophages in human ex vivo organ cultures", "TEST", 644, 687], ["stranded RNA", "OBSERVATION_MODIFIER", 165, 177], ["airway", "ANATOMY", 337, 343], ["epithelial cells", "OBSERVATION", 344, 360], ["host response", "OBSERVATION", 404, 417], ["nonciliated", "ANATOMY_MODIFIER", 560, 571], ["bronchial epithelium", "ANATOMY", 572, 592], ["alveolar", "ANATOMY_MODIFIER", 594, 602], ["epithelial cells", "OBSERVATION", 603, 619], ["endothelial cells", "OBSERVATION", 621, 638]]], ["Consistent with the results obtained from human respiratory cell lines, MERS-CoV infection ex vivo does not lead to a strong type-I IFN response in these cultures (Chan et al., 2013c; Zhou et al., 2013) .", [["respiratory cell lines", "ANATOMY", 48, 70], ["infection", "DISEASE", 81, 90], ["human", "ORGANISM", 42, 47], ["respiratory cell lines", "CELL", 48, 70], ["MERS-CoV", "ORGANISM", 72, 80], ["type-I IFN", "GENE_OR_GENE_PRODUCT", 125, 135], ["human respiratory cell lines", "CELL_LINE", 42, 70], ["IFN", "PROTEIN", 132, 135], ["human", "SPECIES", 42, 47], ["human", "SPECIES", 42, 47], ["MERS-CoV", "SPECIES", 72, 80], ["human respiratory cell lines", "TREATMENT", 42, 70], ["MERS", "PROBLEM", 72, 76], ["CoV infection", "PROBLEM", 77, 90], ["a strong type-I IFN response", "PROBLEM", 116, 144], ["these cultures", "TEST", 148, 162], ["respiratory cell lines", "OBSERVATION", 48, 70]]], ["The combined in vitro and ex vivo data suggest that MERS-CoV actively interacts with and evades innate immune recognition pathways by the host (Kindler et al., 2013) .Infection experiments in human airway epithelial cells have shown that the global transcriptional host response is earlier and more robust after MERS-CoV infection than after SARS-CoV infectionEx vivo data support the results of viral dissemination and pathology, and cellular tropism established in the rhesus macaque model .", [["airway epithelial cells", "ANATOMY", 198, 221], ["cellular", "ANATOMY", 435, 443], ["infection", "DISEASE", 321, 330], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 52, 60], ["human", "ORGANISM", 192, 197], ["airway epithelial cells", "CELL", 198, 221], ["MERS-CoV", "ORGANISM", 312, 320], ["SARS-CoV", "ORGANISM", 342, 350], ["cellular", "CELL", 435, 443], ["rhesus", "ORGANISM", 471, 477], ["macaque", "ORGANISM", 478, 485], ["MERS", "PROTEIN", 52, 56], ["human airway epithelial cells", "CELL_TYPE", 192, 221], ["human", "SPECIES", 192, 197], ["rhesus macaque", "SPECIES", 471, 485], ["MERS-CoV", "SPECIES", 52, 60], ["human", "SPECIES", 192, 197], ["MERS-CoV", "SPECIES", 312, 320], ["SARS-CoV", "SPECIES", 342, 350], ["rhesus macaque", "SPECIES", 471, 485], ["Infection experiments in human airway epithelial cells", "PROBLEM", 167, 221], ["CoV infection", "PROBLEM", 317, 330], ["SARS", "PROBLEM", 342, 346], ["viral dissemination", "PROBLEM", 396, 415], ["pathology", "TEST", 420, 429], ["cellular tropism", "TEST", 435, 451], ["airway", "ANATOMY", 198, 204], ["epithelial cells", "OBSERVATION", 205, 221], ["host response", "OBSERVATION", 265, 278], ["viral dissemination", "OBSERVATION", 396, 415], ["cellular tropism", "OBSERVATION", 435, 451]]], ["Gene expression analysis in experimentally infected rhesus macaques showed differentially expressed genes in infected lung tissue associated with antiviral immunity, inflammation, and chemotaxis, including IL-6, chemokine C-X-C ligand 1, and matrix metalloproteinase.", [["lung tissue", "ANATOMY", 118, 129], ["inflammation", "DISEASE", 166, 178], ["rhesus", "ORGANISM", 52, 58], ["macaques", "ORGANISM", 59, 67], ["lung tissue", "TISSUE", 118, 129], ["IL-6", "GENE_OR_GENE_PRODUCT", 206, 210], ["chemokine C-X-C ligand 1", "GENE_OR_GENE_PRODUCT", 212, 236], ["matrix metalloproteinase", "GENE_OR_GENE_PRODUCT", 242, 266], ["IL-6", "PROTEIN", 206, 210], ["chemokine C-X-C ligand 1", "PROTEIN", 212, 236], ["matrix metalloproteinase", "PROTEIN", 242, 266], ["rhesus macaques", "SPECIES", 52, 67], ["rhesus macaques", "SPECIES", 52, 67], ["Gene expression analysis", "TEST", 0, 24], ["experimentally infected rhesus macaques", "PROBLEM", 28, 67], ["infected lung tissue", "PROBLEM", 109, 129], ["antiviral immunity", "PROBLEM", 146, 164], ["inflammation", "PROBLEM", 166, 178], ["chemotaxis", "TEST", 184, 194], ["IL", "TEST", 206, 208], ["chemokine C", "TEST", 212, 223], ["matrix metalloproteinase", "TREATMENT", 242, 266], ["infected lung tissue", "OBSERVATION", 109, 129], ["antiviral immunity", "OBSERVATION", 146, 164], ["inflammation", "OBSERVATION", 166, 178]]], ["As expected, type-I IFNs were not activated (de Wit et al., 2013b).", [["type-I IFNs", "GENE_OR_GENE_PRODUCT", 13, 24], ["type-I IFNs", "PROTEIN", 13, 24]]], ["The chemokine IL-8, a strong recruiter of neutrophils and other granulocytes, was induced in the macaques, perhaps explaining the increased numbers of neutrophils recorded in the blood of infected macaques and some human patients (Zaki et al., 2012; Assiri et al., 2013a; Guery et al., 2013; de Wit et al., 2013b) .Public health measuresMathematical transmission models highlight two important ways MERS-CoV can be controlled: reducing the rate of MERS-CoV introductions into the human population and breaking chains of human-to-human transmission.", [["neutrophils", "ANATOMY", 42, 53], ["granulocytes", "ANATOMY", 64, 76], ["neutrophils", "ANATOMY", 151, 162], ["blood", "ANATOMY", 179, 184], ["IL-8", "GENE_OR_GENE_PRODUCT", 14, 18], ["neutrophils", "CELL", 42, 53], ["granulocytes", "CELL", 64, 76], ["macaques", "ORGANISM", 97, 105], ["neutrophils", "CELL", 151, 162], ["blood", "ORGANISM_SUBSTANCE", 179, 184], ["macaques", "ORGANISM", 197, 205], ["human", "ORGANISM", 215, 220], ["patients", "ORGANISM", 221, 229], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 399, 407], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 448, 456], ["human", "ORGANISM", 480, 485], ["human", "ORGANISM", 520, 525], ["human", "ORGANISM", 529, 534], ["chemokine IL-8", "PROTEIN", 4, 18], ["neutrophils", "CELL_TYPE", 42, 53], ["granulocytes", "CELL_TYPE", 64, 76], ["neutrophils", "CELL_TYPE", 151, 162], ["macaques", "SPECIES", 97, 105], ["macaques", "SPECIES", 197, 205], ["human", "SPECIES", 215, 220], ["patients", "SPECIES", 221, 229], ["human", "SPECIES", 480, 485], ["human", "SPECIES", 520, 525], ["human", "SPECIES", 529, 534], ["human", "SPECIES", 215, 220], ["MERS-CoV", "SPECIES", 448, 456], ["human", "SPECIES", 480, 485], ["human", "SPECIES", 520, 525], ["human", "SPECIES", 529, 534], ["The chemokine IL", "TEST", 0, 16], ["other granulocytes", "PROBLEM", 58, 76], ["the increased numbers of neutrophils", "PROBLEM", 126, 162], ["Public health measures", "TREATMENT", 315, 337], ["CoV introductions", "TREATMENT", 453, 470], ["granulocytes", "OBSERVATION", 64, 76], ["increased", "OBSERVATION_MODIFIER", 130, 139], ["numbers", "OBSERVATION_MODIFIER", 140, 147], ["infected macaques", "OBSERVATION", 188, 205]]], ["The reduction in the rate of MERS-CoV introductions in the human population requires a comprehensive understanding of the nonhuman source of MERS-CoV and the spatial and temporal dynamics of MERS-CoV circulation in this source.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 29, 37], ["human", "ORGANISM", 59, 64], ["nonhuman", "ORGANISM", 122, 130], ["MERS-CoV", "ORGANISM", 141, 149], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 191, 199], ["human", "SPECIES", 59, 64], ["human", "SPECIES", 59, 64], ["MERS-CoV", "SPECIES", 141, 149], ["MERS-CoV", "SPECIES", 191, 199], ["The reduction", "TREATMENT", 0, 13], ["CoV introductions", "TREATMENT", 34, 51], ["CoV", "PROBLEM", 146, 149], ["CoV circulation", "PROBLEM", 196, 211], ["reduction", "OBSERVATION_MODIFIER", 4, 13]]], ["On the other hand, interrupting the human-to-human transmission cycle of MERS-CoV calls for an understanding of the parameters involved in transmission, such as virus shedding, stability, and routes of transmission.", [["human", "ORGANISM", 36, 41], ["human", "ORGANISM", 45, 50], ["MERS-CoV", "ORGANISM", 73, 81], ["human", "SPECIES", 36, 41], ["human", "SPECIES", 45, 50], ["human", "SPECIES", 36, 41], ["human", "SPECIES", 45, 50], ["MERS-CoV", "SPECIES", 73, 81], ["stability", "OBSERVATION_MODIFIER", 177, 186]]], ["Although routes of transmission for MERS-CoV are not well understood, the spread of MERS-CoV between people in close contact settings suggests that direct contact and fomite transmission routes are likely to be involved.", [["MERS-CoV", "ORGANISM", 36, 44], ["MERS-CoV", "ORGANISM", 84, 92], ["people", "ORGANISM", 101, 107], ["people", "SPECIES", 101, 107], ["MERS-CoV", "SPECIES", 36, 44], ["MERS-CoV", "SPECIES", 84, 92]]], ["As stated above, the localization of MERS-CoV infection in the lower respiratory tract implicates coughing and other exudates as important sources of virus shedding.", [["lower respiratory tract", "ANATOMY", 63, 86], ["infection", "DISEASE", 46, 55], ["MERS-CoV", "ORGANISM", 37, 45], ["lower", "ORGANISM_SUBDIVISION", 63, 68], ["respiratory tract", "ORGANISM_SUBDIVISION", 69, 86], ["MERS-CoV", "SPECIES", 37, 45], ["MERS", "PROBLEM", 37, 41], ["CoV infection", "PROBLEM", 42, 55], ["the lower respiratory tract", "PROBLEM", 59, 86], ["coughing", "PROBLEM", 98, 106], ["other exudates", "PROBLEM", 111, 125], ["virus shedding", "PROBLEM", 150, 164], ["CoV", "OBSERVATION_MODIFIER", 42, 45], ["infection", "OBSERVATION", 46, 55], ["lower", "ANATOMY_MODIFIER", 63, 68], ["respiratory tract", "ANATOMY", 69, 86], ["coughing", "OBSERVATION", 98, 106], ["exudates", "OBSERVATION", 117, 125], ["virus", "OBSERVATION", 150, 155]]], ["In addition, the environmental stability of MERS-CoV provides some information on the potential for fomite transmission.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 44, 52], ["MERS", "PROTEIN", 44, 48], ["MERS-CoV", "SPECIES", 44, 52]]], ["At low temperatures and humidity, both MERS-CoV and SARS-CoV virions retain viability on smooth surfaces much longer than many other respiratory viruses, including influenza virus H1N1, HCoV-229E, and HCoV-OC43 (Sizun et al., 2000; Chan et al., 2011; van Doremalen et al., 2013) .", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 39, 47], ["SARS-CoV virions", "ORGANISM", 52, 68], ["influenza virus H1N1", "ORGANISM", 164, 184], ["HCoV-229E", "CELL", 186, 195], ["HCoV-OC43", "CELL", 201, 210], ["influenza virus H1N1", "SPECIES", 164, 184], ["MERS-CoV", "SPECIES", 39, 47], ["SARS-CoV", "SPECIES", 52, 60], ["influenza virus H1N1", "SPECIES", 164, 184], ["HCoV-229E", "SPECIES", 186, 195], ["HCoV-OC43", "SPECIES", 201, 210], ["humidity", "TREATMENT", 24, 32], ["CoV", "PROBLEM", 44, 47], ["SARS", "PROBLEM", 52, 56], ["CoV virions", "TREATMENT", 57, 68], ["many other respiratory viruses", "PROBLEM", 122, 152], ["influenza virus H1N1", "PROBLEM", 164, 184], ["HCoV", "TEST", 186, 190], ["HCoV", "TEST", 201, 205], ["low temperatures", "OBSERVATION_MODIFIER", 3, 19], ["respiratory", "ANATOMY", 133, 144], ["viruses", "OBSERVATION", 145, 152]]], ["Thus, temperature-controlled settings such as hospitals may be of particular risk for fomite transmission of MERS-CoV.", [["MERS-CoV", "ORGANISM", 109, 117], ["MERS-CoV", "SPECIES", 109, 117]]], ["Performing high-risk patient care procedures such as intubation and manual ventilation, along with inconsistent use of surgical masks, was associated with nosocomial transmission of SARS-CoV to healthcare workers (Ofner-Agostini et al., 2006; Nishiyama et al., 2008) .", [["SARS", "DISEASE", 182, 186], ["patient", "ORGANISM", 21, 28], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 182, 190], ["patient", "SPECIES", 21, 28], ["SARS-CoV", "SPECIES", 182, 190], ["care procedures", "TREATMENT", 29, 44], ["intubation", "TREATMENT", 53, 63], ["manual ventilation", "TREATMENT", 68, 86], ["surgical masks", "TREATMENT", 119, 133]]], ["Healthcare workers are a growing cohort of MERS-CoV cases, but while routes of exposure may be similar for both viruses, the MERS-CoV outbreak has not been characterized by the hospital-based super-spreader events which defined the epidemiology of SARS-CoV (Lipsitch et al., 2003) .Public health measuresDuring infection with SARS-CoV, viral load in upper respiratory tract secretions remained low for the first 5 days of illness, not peaking in nasopharyngeal aspirates until about 10 days after onset of symptoms (Peiris et al., 2003; Cheng et al., 2004) .", [["upper respiratory tract secretions", "ANATOMY", 350, 384], ["nasopharyngeal aspirates", "ANATOMY", 446, 470], ["SARS", "DISEASE", 248, 252], ["infection", "DISEASE", 311, 320], ["SARS", "DISEASE", 326, 330], ["illness", "DISEASE", 422, 429], ["MERS-CoV", "ORGANISM", 43, 51], ["MERS-CoV", "ORGANISM", 125, 133], ["SARS-CoV", "ORGANISM", 248, 256], ["SARS-CoV", "ORGANISM", 326, 334], ["upper", "ORGANISM_SUBDIVISION", 350, 355], ["respiratory tract", "ORGANISM_SUBDIVISION", 356, 373], ["nasopharyngeal aspirates", "MULTI-TISSUE_STRUCTURE", 446, 470], ["MERS-CoV", "SPECIES", 43, 51], ["MERS-CoV", "SPECIES", 125, 133], ["SARS-CoV", "SPECIES", 248, 256], ["SARS-CoV", "SPECIES", 326, 334], ["both viruses", "PROBLEM", 107, 119], ["CoV outbreak", "PROBLEM", 130, 142], ["SARS", "PROBLEM", 248, 252], ["Public health measures", "TREATMENT", 282, 304], ["infection", "PROBLEM", 311, 320], ["SARS", "PROBLEM", 326, 330], ["CoV", "PROBLEM", 331, 334], ["viral load", "TEST", 336, 346], ["upper respiratory tract secretions", "PROBLEM", 350, 384], ["illness", "PROBLEM", 422, 429], ["nasopharyngeal aspirates", "PROBLEM", 446, 470], ["symptoms", "PROBLEM", 506, 514], ["viruses", "OBSERVATION", 112, 119], ["infection", "OBSERVATION", 311, 320], ["viral load", "OBSERVATION", 336, 346], ["upper", "ANATOMY_MODIFIER", 350, 355], ["respiratory tract", "ANATOMY", 356, 373], ["nasopharyngeal", "ANATOMY", 446, 460], ["aspirates", "OBSERVATION", 461, 470]]], ["Thus, SARS-CoV transmission could be prevented in the general population by basic public health and infection control measures, such as the isolation of patients in negative-pressure rooms, active surveillance and quarantine of contacts, and the provision of education and protective equipment for healthcare workers (Twu et al., 2003; Svoboda et al., 2004) .", [["SARS", "DISEASE", 6, 10], ["infection", "DISEASE", 100, 109], ["SARS-CoV", "ORGANISM", 6, 14], ["patients", "ORGANISM", 153, 161], ["patients", "SPECIES", 153, 161], ["SARS-CoV", "SPECIES", 6, 14], ["SARS", "PROBLEM", 6, 10], ["infection control measures", "TREATMENT", 100, 126]]], ["Estimates of the serial interval of MERS-CoV infection in the largest cluster of MERS-CoV to date -23 cases in a hospital settingare slightly shorter than those for SARS-CoV (median 7.6 vs. 8.4 days), suggesting that transmission may occur earlier in the course of illness (Assiri et al., 2013b) .", [["MERS-CoV infection", "DISEASE", 36, 54], ["SARS", "DISEASE", 165, 169], ["illness", "DISEASE", 265, 272], ["MERS-CoV", "ORGANISM", 36, 44], ["MERS-CoV", "ORGANISM", 81, 89], ["SARS-CoV", "ORGANISM", 165, 173], ["MERS-CoV", "SPECIES", 36, 44], ["MERS-CoV", "SPECIES", 81, 89], ["SARS-CoV", "SPECIES", 165, 173], ["MERS", "PROBLEM", 36, 40], ["CoV infection", "PROBLEM", 41, 54], ["SARS", "PROBLEM", 165, 169], ["CoV", "OBSERVATION_MODIFIER", 41, 44], ["infection", "OBSERVATION", 45, 54], ["largest", "OBSERVATION_MODIFIER", 62, 69]]], ["Effective implementation of public health measures against the current MERS-CoV outbreak must integrate knowledge of shedding dynamics, exposure mechanisms, and virus viability.TherapeuticsAntiviral treatment specific to human coronaviruses has not been developed, and during the short-lived 2002-2003 SARS-CoV outbreak, supportive treatment regimens were not optimized (Stockman et al., 2006; Cheng et al., 2013) .TherapeuticsCommercially available drugs, such as type-I IFNs, lopinavir, and, at very high concentrations, ribavirin, were shown to inhibit cytopathic effect of SARS-CoV in in vitro studies, with a synergistic antiviral effect described for type-I IFNs and ribavirin (Chen et al., 2004; Tan et al., 2004; Birgit et al., 2005) .", [["SARS-CoV outbreak", "DISEASE", 302, 319], ["type-I IFNs", "CHEMICAL", 465, 476], ["lopinavir", "CHEMICAL", 478, 487], ["ribavirin", "CHEMICAL", 523, 532], ["SARS", "DISEASE", 577, 581], ["type-I IFNs", "CHEMICAL", 657, 668], ["ribavirin", "CHEMICAL", 673, 682], ["lopinavir", "CHEMICAL", 478, 487], ["ribavirin", "CHEMICAL", 523, 532], ["ribavirin", "CHEMICAL", 673, 682], ["MERS-CoV", "ORGANISM", 71, 79], ["human", "ORGANISM", 221, 226], ["coronaviruses", "ORGANISM", 227, 240], ["-CoV", "ORGANISM", 306, 310], ["type-I IFNs", "GENE_OR_GENE_PRODUCT", 465, 476], ["lopinavir", "SIMPLE_CHEMICAL", 478, 487], ["ribavirin", "SIMPLE_CHEMICAL", 523, 532], ["SARS-CoV", "ORGANISM", 577, 585], ["type-I IFNs", "GENE_OR_GENE_PRODUCT", 657, 668], ["ribavirin", "SIMPLE_CHEMICAL", 673, 682], ["type-I IFNs", "PROTEIN", 465, 476], ["IFNs", "PROTEIN", 664, 668], ["human", "SPECIES", 221, 226], ["MERS-CoV", "SPECIES", 71, 79], ["human coronaviruses", "SPECIES", 221, 240], ["SARS-CoV", "SPECIES", 302, 310], ["SARS-CoV", "SPECIES", 577, 585], ["public health measures", "TREATMENT", 28, 50], ["CoV outbreak", "PROBLEM", 76, 88], ["shedding dynamics", "PROBLEM", 117, 134], ["virus viability", "PROBLEM", 161, 176], ["TherapeuticsAntiviral treatment", "TREATMENT", 177, 208], ["human coronaviruses", "PROBLEM", 221, 240], ["supportive treatment regimens", "TREATMENT", 321, 350], ["drugs", "TREATMENT", 450, 455], ["type-I IFNs", "TREATMENT", 465, 476], ["lopinavir", "TREATMENT", 478, 487], ["ribavirin", "TREATMENT", 523, 532], ["SARS", "PROBLEM", 577, 581], ["vitro studies", "TEST", 592, 605], ["a synergistic antiviral effect", "TREATMENT", 612, 642], ["type-I IFNs", "TREATMENT", 657, 668], ["ribavirin", "TREATMENT", 673, 682], ["virus viability", "OBSERVATION", 161, 176]]], ["These drugs were used to varying extents on SARS-CoV patients, often in combination with corticosteroids (Stockman et al., 2006; Cheng et al., 2013) .", [["SARS-CoV", "DISEASE", 44, 52], ["corticosteroids", "CHEMICAL", 89, 104], ["SARS-CoV", "ORGANISM", 44, 52], ["patients", "ORGANISM", 53, 61], ["patients", "SPECIES", 53, 61], ["SARS-CoV", "SPECIES", 44, 52], ["These drugs", "TREATMENT", 0, 11], ["corticosteroids", "TREATMENT", 89, 104]]], ["Ribavirin is a structural analog of guanosine with broad-spectrum mutagenic effects on viruses.", [["Ribavirin", "CHEMICAL", 0, 9], ["guanosine", "CHEMICAL", 36, 45], ["Ribavirin", "CHEMICAL", 0, 9], ["guanosine", "CHEMICAL", 36, 45], ["Ribavirin", "SIMPLE_CHEMICAL", 0, 9], ["guanosine", "SIMPLE_CHEMICAL", 36, 45], ["Ribavirin", "TREATMENT", 0, 9], ["a structural analog of guanosine", "TREATMENT", 13, 45], ["broad-spectrum mutagenic effects", "TREATMENT", 51, 83], ["mutagenic effects", "OBSERVATION", 66, 83]]], ["Despite its frequent use on SARS-CoV patients, ribavirin was not shown to be effective for patients, and adverse effects such as hemolytic anemia were common (Stockman et al., 2006; Cheng et al., 2013) .", [["SARS-CoV", "DISEASE", 28, 36], ["ribavirin", "CHEMICAL", 47, 56], ["hemolytic anemia", "DISEASE", 129, 145], ["ribavirin", "CHEMICAL", 47, 56], ["SARS-CoV", "ORGANISM", 28, 36], ["patients", "ORGANISM", 37, 45], ["ribavirin", "SIMPLE_CHEMICAL", 47, 56], ["patients", "ORGANISM", 91, 99], ["patients", "SPECIES", 37, 45], ["patients", "SPECIES", 91, 99], ["SARS-CoV", "SPECIES", 28, 36], ["ribavirin", "TREATMENT", 47, 56], ["adverse effects", "PROBLEM", 105, 120], ["hemolytic anemia", "PROBLEM", 129, 145]]], ["Type-I IFN regimens for SARS-CoV patients were sometimes used as part of a multi-drug regimen, and one study of 22 SARS-CoV patients reported more rapid improvement of radiographic lung pathologies and better oxygenation in patients treated with IFN-a1 (Loutfy et al., 2003; Stockman et al., 2006; Cheng et al., 2013) .", [["lung", "ANATOMY", 181, 185], ["SARS-CoV", "DISEASE", 24, 32], ["SARS", "DISEASE", 115, 119], ["Type-I IFN", "GENE_OR_GENE_PRODUCT", 0, 10], ["SARS-CoV", "ORGANISM", 24, 32], ["patients", "ORGANISM", 33, 41], ["SARS-CoV", "ORGANISM", 115, 123], ["patients", "ORGANISM", 124, 132], ["lung", "ORGAN", 181, 185], ["patients", "ORGANISM", 224, 232], ["IFN-a1", "GENE_OR_GENE_PRODUCT", 246, 252], ["IFN", "PROTEIN", 7, 10], ["IFN", "PROTEIN", 246, 249], ["patients", "SPECIES", 33, 41], ["patients", "SPECIES", 124, 132], ["patients", "SPECIES", 224, 232], ["SARS-CoV", "SPECIES", 24, 32], ["SARS-CoV", "SPECIES", 115, 123], ["Type-I IFN regimens", "TREATMENT", 0, 19], ["SARS", "PROBLEM", 24, 28], ["a multi-drug regimen", "TREATMENT", 73, 93], ["one study", "TEST", 99, 108], ["radiographic lung pathologies", "PROBLEM", 168, 197], ["lung", "ANATOMY", 181, 185], ["pathologies", "OBSERVATION", 186, 197]]], ["Speculations that immunopathology rather than uncontrolled viral replication contributed to lung deterioration during advanced SARS-CoV infection favored the widespread use of corticosteroids in its treatment (Nicholls et al., 2003; Peiris et al., 2003; Hui & Sung, 2004; Cheng et al., 2013) .", [["lung", "ANATOMY", 92, 96], ["immunopathology", "DISEASE", 18, 33], ["lung deterioration", "DISEASE", 92, 110], ["SARS-CoV infection", "DISEASE", 127, 145], ["corticosteroids", "CHEMICAL", 176, 191], ["corticosteroids", "CHEMICAL", 176, 191], ["lung", "ORGAN", 92, 96], ["SARS-CoV", "ORGANISM", 127, 135], ["corticosteroids", "SIMPLE_CHEMICAL", 176, 191], ["SARS-CoV", "SPECIES", 127, 135], ["immunopathology", "PROBLEM", 18, 33], ["uncontrolled viral replication", "PROBLEM", 46, 76], ["lung deterioration", "PROBLEM", 92, 110], ["advanced SARS", "PROBLEM", 118, 131], ["CoV infection", "PROBLEM", 132, 145], ["corticosteroids", "TREATMENT", 176, 191], ["its treatment", "TREATMENT", 195, 208], ["viral replication", "OBSERVATION", 59, 76], ["lung", "ANATOMY", 92, 96], ["deterioration", "OBSERVATION", 97, 110], ["widespread", "OBSERVATION_MODIFIER", 158, 168]]], ["Retrospective analysis of SARS-CoV patients showed no benefit of corticosteroid administration except when critical cases were analyzed alone and death-related variables were adjusted.", [["SARS", "DISEASE", 26, 30], ["death", "DISEASE", 146, 151], ["SARS-CoV", "ORGANISM", 26, 34], ["patients", "ORGANISM", 35, 43], ["corticosteroid", "SIMPLE_CHEMICAL", 65, 79], ["patients", "SPECIES", 35, 43], ["SARS-CoV", "SPECIES", 26, 34], ["Retrospective analysis", "TEST", 0, 22], ["SARS", "TEST", 26, 30], ["corticosteroid administration", "TREATMENT", 65, 94], ["death", "PROBLEM", 146, 151], ["no", "UNCERTAINTY", 51, 53]]], ["Among these critical patients, corticosteroid therapy did significantly reduce case fatality (Chen, 2006) .", [["patients", "ORGANISM", 21, 29], ["corticosteroid", "SIMPLE_CHEMICAL", 31, 45], ["patients", "SPECIES", 21, 29], ["corticosteroid therapy", "TREATMENT", 31, 53]]], ["Similarly, corticosteroids have been used in some MERS-CoV patients with severe disease Guberina et al., 2013; Memish et al., 2013b; Omrani et al., 2013) .", [["corticosteroids", "CHEMICAL", 11, 26], ["corticosteroids", "CHEMICAL", 11, 26], ["corticosteroids", "SIMPLE_CHEMICAL", 11, 26], ["MERS-CoV", "ORGANISM", 50, 58], ["patients", "ORGANISM", 59, 67], ["patients", "SPECIES", 59, 67], ["MERS-CoV", "SPECIES", 50, 58], ["corticosteroids", "TREATMENT", 11, 26], ["severe disease", "PROBLEM", 73, 87], ["corticosteroids", "OBSERVATION", 11, 26], ["severe", "OBSERVATION_MODIFIER", 73, 79], ["disease", "OBSERVATION", 80, 87]]], ["One previously healthy MERS-CoV patient who suffered ARDS, multidrug-resistant Pseudomonas aeruginosa, and suspected concomitant allergic bronchopulmonary aspergillosis improved rapidly when treated with the corticosteroid prednisolone (Guberina et al., 2013) .", [["bronchopulmonary", "ANATOMY", 138, 154], ["ARDS", "DISEASE", 53, 57], ["multidrug-resistant Pseudomonas aeruginosa", "DISEASE", 59, 101], ["allergic bronchopulmonary aspergillosis", "DISEASE", 129, 168], ["prednisolone", "CHEMICAL", 223, 235], ["prednisolone", "CHEMICAL", 223, 235], ["MERS-CoV", "ORGANISM", 23, 31], ["patient", "ORGANISM", 32, 39], ["Pseudomonas aeruginosa", "ORGANISM", 79, 101], ["bronchopulmonary aspergillosis", "PATHOLOGICAL_FORMATION", 138, 168], ["prednisolone", "SIMPLE_CHEMICAL", 223, 235], ["patient", "SPECIES", 32, 39], ["Pseudomonas aeruginosa", "SPECIES", 79, 101], ["MERS-CoV", "SPECIES", 23, 31], ["Pseudomonas aeruginosa", "SPECIES", 79, 101], ["ARDS", "PROBLEM", 53, 57], ["multidrug-resistant Pseudomonas aeruginosa", "PROBLEM", 59, 101], ["concomitant allergic bronchopulmonary aspergillosis", "PROBLEM", 117, 168], ["the corticosteroid prednisolone", "TREATMENT", 204, 235], ["ARDS", "OBSERVATION", 53, 57], ["Pseudomonas aeruginosa", "OBSERVATION", 79, 101], ["suspected", "UNCERTAINTY", 107, 116], ["concomitant", "OBSERVATION_MODIFIER", 117, 128], ["allergic", "OBSERVATION_MODIFIER", 129, 137], ["bronchopulmonary", "ANATOMY", 138, 154], ["aspergillosis", "OBSERVATION", 155, 168]]], ["The efficacy of corticosteroid treatment for other MERS-CoV patients with ARDS has not been reported.TherapeuticsTherapies used during the SARS-CoV outbreak have shaped investigations of treatment regimens for MERS--CoV.", [["ARDS", "DISEASE", 74, 78], ["SARS-CoV outbreak", "DISEASE", 139, 156], ["corticosteroid", "SIMPLE_CHEMICAL", 16, 30], ["MERS-CoV", "ORGANISM", 51, 59], ["patients", "ORGANISM", 60, 68], ["MERS--CoV", "ORGANISM", 210, 219], ["patients", "SPECIES", 60, 68], ["MERS-CoV", "SPECIES", 51, 59], ["SARS-CoV", "SPECIES", 139, 147], ["corticosteroid treatment", "TREATMENT", 16, 40], ["ARDS", "PROBLEM", 74, 78], ["TherapeuticsTherapies", "TREATMENT", 101, 122], ["the SARS", "PROBLEM", 135, 143], ["treatment regimens", "TREATMENT", 187, 205], ["MERS", "PROBLEM", 210, 214], ["CoV", "PROBLEM", 216, 219], ["ARDS", "OBSERVATION", 74, 78]]], ["MERS-CoV shows greater sensitivity than SARS-CoV to the antiviral effects of type-I and type-III IFNs in vitro and ex vivo (Kindler et al., 2013; Wilde et al., 2013; Zielecki et al., 2013) .", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 0, 8], ["SARS-CoV", "ORGANISM", 40, 48], ["type-I", "GENE_OR_GENE_PRODUCT", 77, 83], ["type-III IFNs", "GENE_OR_GENE_PRODUCT", 88, 101], ["MERS-CoV", "PROTEIN", 0, 8], ["type-I and type-III IFNs", "PROTEIN", 77, 101], ["MERS-CoV", "SPECIES", 0, 8], ["SARS-CoV", "SPECIES", 40, 48], ["greater sensitivity", "PROBLEM", 15, 34], ["SARS", "PROBLEM", 40, 44], ["the antiviral effects", "TREATMENT", 52, 73]]], ["This greater sensitivity could be explained by mechanistic differences of IFN antagonist accessory proteins between the viruses.", [["IFN antagonist", "GENE_OR_GENE_PRODUCT", 74, 88], ["IFN antagonist accessory proteins", "PROTEIN", 74, 107], ["IFN antagonist accessory proteins", "TREATMENT", 74, 107], ["could be explained", "UNCERTAINTY", 25, 43], ["viruses", "OBSERVATION", 120, 127]]], ["For instance, MERS-CoV lacks a homologue of the SARS-CoV ORF6 protein, which blocks the STAT1-activating effects of IFNs and ultimately the transcriptional activation of downstream antiviral genes (Wilde et al., 2013) .", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 14, 22], ["SARS-CoV ORF6", "GENE_OR_GENE_PRODUCT", 48, 61], ["STAT1", "GENE_OR_GENE_PRODUCT", 88, 93], ["IFNs", "GENE_OR_GENE_PRODUCT", 116, 120], ["MERS", "PROTEIN", 14, 18], ["SARS-CoV ORF6 protein", "PROTEIN", 48, 69], ["STAT1", "PROTEIN", 88, 93], ["IFNs", "PROTEIN", 116, 120], ["downstream antiviral genes", "DNA", 170, 196], ["MERS-CoV", "SPECIES", 14, 22], ["SARS-CoV", "SPECIES", 48, 56], ["the SARS", "TEST", 44, 52], ["CoV ORF6 protein", "TEST", 53, 69], ["IFNs", "TREATMENT", 116, 120]]], ["A comparison of five different IFNs has shown IFN-b to be the most potent inhibitor of MERS-CoV (Hart et al., 2013) .", [["IFNs", "GENE_OR_GENE_PRODUCT", 31, 35], ["IFN-b", "GENE_OR_GENE_PRODUCT", 46, 51], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 87, 95], ["IFNs", "PROTEIN", 31, 35], ["IFN", "PROTEIN", 46, 49], ["MERS-CoV", "SPECIES", 87, 95], ["IFN", "PROBLEM", 46, 49]]], ["Although high concentrations of ribavirin were effective in vitro in one study , another study found no inhibitory effects of ribavirin at a dose translatable to current drug regiments in humans (Hart et al., 2013) .", [["ribavirin", "CHEMICAL", 32, 41], ["ribavirin", "CHEMICAL", 126, 135], ["ribavirin", "CHEMICAL", 32, 41], ["ribavirin", "CHEMICAL", 126, 135], ["ribavirin", "SIMPLE_CHEMICAL", 32, 41], ["ribavirin", "SIMPLE_CHEMICAL", 126, 135], ["humans", "ORGANISM", 188, 194], ["humans", "SPECIES", 188, 194], ["humans", "SPECIES", 188, 194], ["ribavirin", "TREATMENT", 32, 41], ["another study", "TEST", 81, 94], ["ribavirin", "TREATMENT", 126, 135], ["ribavirin", "OBSERVATION", 32, 41]]], ["When IFN-a2b and ribavirin were used in combination against MERS-CoV, however, the 50% effective concentrations (EC 50 ) of the drugs in combination were much lower than for the individual drugs.", [["IFN-a2b", "CHEMICAL", 5, 12], ["ribavirin", "CHEMICAL", 17, 26], ["ribavirin", "CHEMICAL", 17, 26], ["IFN-a2b", "GENE_OR_GENE_PRODUCT", 5, 12], ["ribavirin", "SIMPLE_CHEMICAL", 17, 26], ["MERS-CoV", "ORGANISM", 60, 68], ["IFN", "PROTEIN", 5, 8], ["MERS-CoV", "SPECIES", 60, 68], ["IFN", "TREATMENT", 5, 8], ["a2b", "TREATMENT", 9, 12], ["ribavirin", "TREATMENT", 17, 26], ["the drugs", "TREATMENT", 124, 133]]], ["This additive effect decreased the drug requirements to concentrations potentially achievable in humans .", [["humans", "ORGANISM", 97, 103], ["humans", "SPECIES", 97, 103], ["humans", "SPECIES", 97, 103], ["the drug requirements", "TREATMENT", 31, 52], ["effect", "OBSERVATION_MODIFIER", 14, 20], ["decreased", "OBSERVATION_MODIFIER", 21, 30]]], ["Interestingly, ribavirin is significantly more effective when the ExoN activity of coronaviruses is knocked out (Smith et al., 2013) .", [["ribavirin", "CHEMICAL", 15, 24], ["ribavirin", "CHEMICAL", 15, 24], ["ribavirin", "SIMPLE_CHEMICAL", 15, 24], ["ExoN", "GENE_OR_GENE_PRODUCT", 66, 70], ["coronaviruses", "ORGANISM", 83, 96], ["ExoN", "PROTEIN", 66, 70], ["ribavirin", "TREATMENT", 15, 24], ["the ExoN activity of coronaviruses", "PROBLEM", 62, 96], ["ribavirin", "OBSERVATION", 15, 24], ["significantly more effective", "OBSERVATION_MODIFIER", 28, 56]]], ["Data indicate that in these knockout viruses, ribavirin has a greater ability to inhibit viral RNA synthesis and inosine monophosphate dehydrogenase (IMPDH), and enzyme necessary for the de novo synthesis of guanine nucleotides, which would explain the relatively high ribavirin dose needed to achieve inhibition of viral replication with MERS-CoV (Smith et al., 2013) .TherapeuticsIn a study to identify compounds that inhibit MERS-CoV, mycophenolic acid demonstrated a particularly high efficacy against MERS-CoV, with an EC 50 of < 10 lM (Chan et al., 2013a, b, c) .", [["ribavirin", "CHEMICAL", 46, 55], ["inosine monophosphate", "CHEMICAL", 113, 134], ["guanine", "CHEMICAL", 208, 215], ["ribavirin", "CHEMICAL", 269, 278], ["mycophenolic acid", "CHEMICAL", 438, 455], ["ribavirin", "CHEMICAL", 46, 55], ["inosine monophosphate", "CHEMICAL", 113, 134], ["guanine nucleotides", "CHEMICAL", 208, 227], ["ribavirin", "CHEMICAL", 269, 278], ["mycophenolic acid", "CHEMICAL", 438, 455], ["ribavirin", "SIMPLE_CHEMICAL", 46, 55], ["inosine monophosphate dehydrogenase", "GENE_OR_GENE_PRODUCT", 113, 148], ["IMPDH", "GENE_OR_GENE_PRODUCT", 150, 155], ["guanine nucleotides", "SIMPLE_CHEMICAL", 208, 227], ["ribavirin", "SIMPLE_CHEMICAL", 269, 278], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 339, 347], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 428, 436], ["mycophenolic acid", "SIMPLE_CHEMICAL", 438, 455], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 506, 514], ["EC", "CELL", 524, 526], ["viral RNA", "RNA", 89, 98], ["inosine monophosphate dehydrogenase", "PROTEIN", 113, 148], ["IMPDH", "PROTEIN", 150, 155], ["MERS-CoV", "SPECIES", 339, 347], ["MERS-CoV", "SPECIES", 428, 436], ["MERS-CoV", "SPECIES", 506, 514], ["these knockout viruses", "PROBLEM", 22, 44], ["ribavirin", "TREATMENT", 46, 55], ["viral RNA synthesis", "PROBLEM", 89, 108], ["inosine monophosphate dehydrogenase (IMPDH)", "PROBLEM", 113, 156], ["enzyme", "TEST", 162, 168], ["the de novo synthesis of guanine nucleotides", "PROBLEM", 183, 227], ["high ribavirin dose", "TREATMENT", 264, 283], ["viral replication", "TREATMENT", 316, 333], ["a study", "TEST", 385, 392], ["MERS", "TEST", 428, 432], ["mycophenolic acid", "TEST", 438, 455], ["an EC", "TEST", 521, 526], ["guanine nucleotides", "OBSERVATION", 208, 227], ["viral replication", "OBSERVATION", 316, 333]]], ["Mycophenolic acid is an approved drug and, like ribavirin, acts by inhibiting IMPDH.", [["Mycophenolic acid", "CHEMICAL", 0, 17], ["ribavirin", "CHEMICAL", 48, 57], ["Mycophenolic acid", "CHEMICAL", 0, 17], ["ribavirin", "CHEMICAL", 48, 57], ["Mycophenolic acid", "SIMPLE_CHEMICAL", 0, 17], ["ribavirin", "SIMPLE_CHEMICAL", 48, 57], ["IMPDH", "GENE_OR_GENE_PRODUCT", 78, 83], ["IMPDH", "PROTEIN", 78, 83], ["Mycophenolic acid", "TREATMENT", 0, 17], ["an approved drug", "TREATMENT", 21, 37], ["ribavirin", "TREATMENT", 48, 57]]], ["While typically used as an immunosuppressant after tissue transplants, its antiviral activity has been attributed to an inhibition of viral RNA replication (Diamond et al., 2002) .TherapeuticsPreliminary in vitro comparisons suggest that mycophenolic acid is a more potent inhibitor of MERS-CoV than ribavirin (Chan et al., 2013a Hart et al., 2013) .", [["tissue", "ANATOMY", 51, 57], ["mycophenolic acid", "CHEMICAL", 238, 255], ["ribavirin", "CHEMICAL", 300, 309], ["mycophenolic acid", "CHEMICAL", 238, 255], ["ribavirin", "CHEMICAL", 300, 309], ["tissue", "TISSUE", 51, 57], ["mycophenolic acid", "SIMPLE_CHEMICAL", 238, 255], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 286, 294], ["ribavirin", "SIMPLE_CHEMICAL", 300, 309], ["MERS-CoV", "SPECIES", 286, 294], ["an immunosuppressant", "TREATMENT", 24, 44], ["tissue transplants", "TREATMENT", 51, 69], ["viral RNA replication", "TREATMENT", 134, 155], ["mycophenolic acid", "TREATMENT", 238, 255], ["ribavirin", "TREATMENT", 300, 309], ["antiviral activity", "OBSERVATION", 75, 93], ["viral RNA", "OBSERVATION", 134, 143], ["mycophenolic acid", "OBSERVATION", 238, 255]]], ["Because of this, effective plasma drug levels may be better achievable for intravenous doses of mycophenolic acid than ribavirin (Chan et al., 2013a) .", [["plasma", "ANATOMY", 27, 33], ["intravenous", "ANATOMY", 75, 86], ["mycophenolic acid", "CHEMICAL", 96, 113], ["ribavirin", "CHEMICAL", 119, 128], ["mycophenolic acid", "CHEMICAL", 96, 113], ["ribavirin", "CHEMICAL", 119, 128], ["plasma", "ORGANISM_SUBSTANCE", 27, 33], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 75, 86], ["mycophenolic acid", "SIMPLE_CHEMICAL", 96, 113], ["ribavirin", "SIMPLE_CHEMICAL", 119, 128], ["effective plasma drug levels", "TEST", 17, 45], ["mycophenolic acid", "TREATMENT", 96, 113], ["ribavirin", "TREATMENT", 119, 128]]], ["Assumptions about the in vivo usefulness of drugs effective in vitro need to be made with care.", [["drugs", "TREATMENT", 44, 49]]], ["Mycophenolic acid, for instance, is a potent inhibitor of T and B lymphocytes and dendritic cell maturation, effectively suppressing antigen presentation and immunoglobulin production (Villarroel et al., 2009) .", [["T", "ANATOMY", 58, 59], ["B lymphocytes", "ANATOMY", 64, 77], ["dendritic cell", "ANATOMY", 82, 96], ["Mycophenolic acid", "CHEMICAL", 0, 17], ["Mycophenolic acid", "CHEMICAL", 0, 17], ["Mycophenolic acid", "SIMPLE_CHEMICAL", 0, 17], ["T", "CELL", 58, 59], ["B lymphocytes", "CELL", 64, 77], ["dendritic cell", "CELL", 82, 96], ["immunoglobulin", "GENE_OR_GENE_PRODUCT", 158, 172], ["T and B lymphocytes", "CELL_TYPE", 58, 77], ["immunoglobulin", "PROTEIN", 158, 172], ["Mycophenolic acid", "TREATMENT", 0, 17], ["T and B lymphocytes", "PROBLEM", 58, 77], ["dendritic cell maturation", "PROBLEM", 82, 107], ["immunoglobulin production", "PROBLEM", 158, 183], ["lymphocytes", "ANATOMY", 66, 77], ["dendritic cell maturation", "OBSERVATION", 82, 107]]], ["In a well-characterized animal model, the adverse immunomodulatory effects of the drug may outweigh any reduction in MERS-CoV virulence.Animals model for MERS-CoVAttempts to establish a small animal model for MERS-CoV Syrian hamsters, mice, and ferrets have been unsuccessful (Coleman et al., 2013; Raj et al., 2013a, b; de Wit et al., 2013a) .", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 117, 125], ["MERS-CoV Syrian hamsters", "ORGANISM", 209, 233], ["mice", "ORGANISM", 235, 239], ["ferrets", "ORGANISM", 245, 252], ["CoV Syrian hamsters", "SPECIES", 214, 233], ["mice", "SPECIES", 235, 239], ["ferrets", "SPECIES", 245, 252], ["MERS-CoV", "SPECIES", 117, 125], ["MERS-CoV", "SPECIES", 209, 217], ["Syrian hamsters", "SPECIES", 218, 233], ["mice", "SPECIES", 235, 239], ["ferrets", "SPECIES", 245, 252], ["the drug", "TREATMENT", 78, 86], ["CoV virulence", "PROBLEM", 122, 135], ["CoV virulence", "OBSERVATION", 122, 135]]], ["However, experimental infection studies in rhesus macaques showed that this animal species was susceptible to MERS-CoV .", [["infection", "DISEASE", 22, 31], ["rhesus", "ORGANISM", 43, 49], ["macaques", "ORGANISM", 50, 58], ["MERS-CoV", "ORGANISM", 110, 118], ["rhesus macaques", "SPECIES", 43, 58], ["rhesus macaques", "SPECIES", 43, 58], ["MERS-CoV", "SPECIES", 110, 118], ["experimental infection studies in rhesus macaques", "PROBLEM", 9, 58], ["this animal species", "PROBLEM", 71, 90], ["infection", "OBSERVATION", 22, 31]]], ["In rhesus macaques, MERS-CoV causes a lower respiratory tract infection reminiscent of mild to moderate human cases .", [["lower respiratory tract", "ANATOMY", 38, 61], ["respiratory tract infection", "DISEASE", 44, 71], ["rhesus", "ORGANISM", 3, 9], ["macaques", "ORGANISM", 10, 18], ["MERS-CoV", "ORGANISM", 20, 28], ["respiratory tract", "ORGANISM_SUBDIVISION", 44, 61], ["human", "ORGANISM", 104, 109], ["rhesus macaques", "SPECIES", 3, 18], ["human", "SPECIES", 104, 109], ["rhesus macaques", "SPECIES", 3, 18], ["MERS-CoV", "SPECIES", 20, 28], ["human", "SPECIES", 104, 109], ["a lower respiratory tract infection", "PROBLEM", 36, 71], ["mild to moderate human cases", "PROBLEM", 87, 115], ["rhesus macaques", "OBSERVATION", 3, 18], ["lower", "ANATOMY_MODIFIER", 38, 43], ["respiratory tract", "ANATOMY", 44, 61], ["infection", "OBSERVATION", 62, 71], ["mild", "OBSERVATION_MODIFIER", 87, 91], ["moderate", "OBSERVATION_MODIFIER", 95, 103]]], ["Clinical signs of MERS-CoV-infected macaques included cough and increased respiration rate, and lung samples showed lesions characteristic of mild to marked pneumonia de Wit et al., 2013b) .", [["lung samples", "ANATOMY", 96, 108], ["lesions", "ANATOMY", 116, 123], ["MERS-CoV-infected", "DISEASE", 18, 35], ["cough", "DISEASE", 54, 59], ["pneumonia", "DISEASE", 157, 166], ["MERS-CoV", "ORGANISM", 18, 26], ["macaques", "ORGANISM", 36, 44], ["lung samples", "CANCER", 96, 108], ["lesions", "PATHOLOGICAL_FORMATION", 116, 123], ["CoV-infected macaques", "SPECIES", 23, 44], ["MERS-CoV", "SPECIES", 18, 26], ["MERS", "PROBLEM", 18, 22], ["CoV", "PROBLEM", 23, 26], ["infected macaques", "PROBLEM", 27, 44], ["cough", "PROBLEM", 54, 59], ["increased respiration rate", "PROBLEM", 64, 90], ["lung samples", "TEST", 96, 108], ["lesions", "PROBLEM", 116, 123], ["mild to marked pneumonia", "PROBLEM", 142, 166], ["lung", "ANATOMY", 96, 100], ["lesions", "OBSERVATION", 116, 123], ["mild", "OBSERVATION_MODIFIER", 142, 146], ["marked", "OBSERVATION_MODIFIER", 150, 156], ["pneumonia", "OBSERVATION", 157, 166]]], ["Virus was detected throughout the respiratory tract and mediastinal lymph nodes, with viral loads higher earlier during infection.", [["respiratory tract", "ANATOMY", 34, 51], ["mediastinal lymph nodes", "ANATOMY", 56, 79], ["infection", "DISEASE", 120, 129], ["Virus", "ORGANISM", 0, 5], ["respiratory tract", "ORGAN", 34, 51], ["lymph nodes", "MULTI-TISSUE_STRUCTURE", 68, 79], ["Virus", "PROBLEM", 0, 5], ["mediastinal lymph nodes", "PROBLEM", 56, 79], ["viral loads", "PROBLEM", 86, 97], ["infection", "PROBLEM", 120, 129], ["respiratory tract", "ANATOMY", 34, 51], ["mediastinal", "ANATOMY", 56, 67], ["lymph nodes", "OBSERVATION", 68, 79], ["viral", "OBSERVATION_MODIFIER", 86, 91], ["loads", "OBSERVATION_MODIFIER", 92, 97], ["higher", "OBSERVATION_MODIFIER", 98, 104], ["infection", "OBSERVATION", 120, 129]]], ["The primary sites of virus replication were type-I and type-II pneumocytes, main components of the alveolar architecture.", [["pneumocytes", "ANATOMY", 63, 74], ["alveolar", "ANATOMY", 99, 107], ["type-I", "GENE_OR_GENE_PRODUCT", 44, 50], ["type-II pneumocytes", "GENE_OR_GENE_PRODUCT", 55, 74], ["alveolar architecture", "MULTI-TISSUE_STRUCTURE", 99, 120], ["virus replication", "TREATMENT", 21, 38], ["type-II pneumocytes", "PROBLEM", 55, 74], ["virus replication", "OBSERVATION", 21, 38], ["pneumocytes", "OBSERVATION", 63, 74], ["main", "OBSERVATION_MODIFIER", 76, 80], ["components", "OBSERVATION_MODIFIER", 81, 91], ["alveolar architecture", "OBSERVATION", 99, 120]]], ["Replication of MERS-CoV deep in the macaque lower respiratory tract may explain the low potential for transmission of MERS-CoV.", [["lower respiratory tract", "ANATOMY", 44, 67], ["MERS-CoV", "ORGANISM", 15, 23], ["macaque", "ORGANISM", 36, 43], ["lower", "ORGANISM_SUBDIVISION", 44, 49], ["respiratory tract", "ORGANISM_SUBDIVISION", 50, 67], ["MERS-CoV", "ORGANISM", 118, 126], ["MERS-CoV", "SPECIES", 15, 23], ["MERS-CoV", "SPECIES", 118, 126], ["CoV deep in the macaque lower respiratory tract", "TREATMENT", 20, 67], ["macaque", "ANATOMY_MODIFIER", 36, 43], ["lower", "ANATOMY_MODIFIER", 44, 49], ["respiratory tract", "ANATOMY", 50, 67]]], ["Despite renal failure in some human patients, virus was absent from the kidney tissue of all macaques .", [["renal", "ANATOMY", 8, 13], ["kidney tissue", "ANATOMY", 72, 85], ["renal failure", "DISEASE", 8, 21], ["renal", "ORGAN", 8, 13], ["human", "ORGANISM", 30, 35], ["patients", "ORGANISM", 36, 44], ["kidney tissue", "TISSUE", 72, 85], ["macaques", "ORGANISM", 93, 101], ["human", "SPECIES", 30, 35], ["patients", "SPECIES", 36, 44], ["macaques", "SPECIES", 93, 101], ["human", "SPECIES", 30, 35], ["renal failure", "PROBLEM", 8, 21], ["virus", "PROBLEM", 46, 51], ["renal", "ANATOMY", 8, 13], ["failure", "OBSERVATION", 14, 21], ["virus", "OBSERVATION", 46, 51], ["kidney", "ANATOMY", 72, 78], ["tissue", "ANATOMY_MODIFIER", 79, 85], ["all macaques", "OBSERVATION", 89, 101]]], ["A more recent characterization of MERS-CoV in rhesus macaques reported transient fever in infected monkeys and demonstrated a MERS-CoV-specific antibody response in the macaques starting at 7 days postinfection (Yao et al., 2013) .", [["transient fever", "DISEASE", 71, 86], ["MERS-CoV", "ORGANISM", 34, 42], ["rhesus macaques", "ORGANISM", 46, 61], ["monkeys", "ORGANISM", 99, 106], ["MERS-CoV", "ORGANISM", 126, 134], ["macaques", "ORGANISM", 169, 177], ["MERS-CoV", "PROTEIN", 34, 42], ["rhesus macaques", "SPECIES", 46, 61], ["monkeys", "SPECIES", 99, 106], ["MERS-CoV", "SPECIES", 34, 42], ["rhesus macaques", "SPECIES", 46, 61], ["MERS", "PROBLEM", 34, 38], ["CoV in rhesus macaques", "PROBLEM", 39, 61], ["transient fever in infected monkeys", "PROBLEM", 71, 106], ["a MERS-CoV", "TEST", 124, 134], ["transient", "OBSERVATION_MODIFIER", 71, 80], ["fever", "OBSERVATION", 81, 86]]], ["The rhesus macaque model of MERS-CoV infection is the only in vivo model established to date, and development of a small animal model is essential to conduct widespread research on pathogenesis and prophylactic and therapeutic countermeasures.In vivo testing of antiviralsOf the antiviral and immune modulatory compounds shown effective against MERS-CoV in vitro, only one treatment option has been examined in vivo.", [["MERS-CoV infection", "DISEASE", 28, 46], ["macaque", "ORGANISM", 11, 18], ["MERS-CoV", "ORGANISM", 28, 36], ["MERS-CoV", "ORGANISM", 345, 353], ["rhesus macaque", "SPECIES", 4, 18], ["rhesus macaque", "SPECIES", 4, 18], ["MERS-CoV", "SPECIES", 28, 36], ["MERS-CoV", "SPECIES", 345, 353], ["MERS", "PROBLEM", 28, 32], ["CoV infection", "PROBLEM", 33, 46], ["a small animal model", "PROBLEM", 113, 133], ["pathogenesis", "PROBLEM", 181, 193], ["prophylactic", "TREATMENT", 198, 210], ["therapeutic countermeasures", "TREATMENT", 215, 242], ["antivirals", "TREATMENT", 262, 272], ["the antiviral", "TREATMENT", 275, 288], ["immune modulatory compounds", "TREATMENT", 293, 320], ["one treatment option", "TREATMENT", 369, 389], ["CoV", "OBSERVATION_MODIFIER", 33, 36], ["infection", "OBSERVATION", 37, 46], ["small", "OBSERVATION_MODIFIER", 115, 120]]], ["The efficacy of a combination IFN-a2b and ribavirin treatment regimen was tested in MERS-CoV-infected rhesus macaques .", [["IFN-a2b", "CHEMICAL", 30, 37], ["ribavirin", "CHEMICAL", 42, 51], ["ribavirin", "CHEMICAL", 42, 51], ["IFN-a2b", "SIMPLE_CHEMICAL", 30, 37], ["ribavirin", "SIMPLE_CHEMICAL", 42, 51], ["MERS-CoV", "ORGANISM", 84, 92], ["rhesus", "ORGANISM", 102, 108], ["macaques", "ORGANISM", 109, 117], ["IFN", "PROTEIN", 30, 33], ["rhesus macaques", "SPECIES", 102, 117], ["MERS-CoV", "SPECIES", 84, 92], ["rhesus macaques", "SPECIES", 102, 117], ["a combination IFN", "TREATMENT", 16, 33], ["a2b", "TREATMENT", 34, 37], ["ribavirin treatment regimen", "TREATMENT", 42, 69], ["infected rhesus macaques", "TREATMENT", 93, 117], ["infected", "OBSERVATION_MODIFIER", 93, 101], ["rhesus macaques", "OBSERVATION", 102, 117]]], ["Doses were designed to achieve serum concentrations at or above the EC 50 values determined in vitro.", [["serum", "ANATOMY", 31, 36], ["EC", "ANATOMY", 68, 70], ["serum", "ORGANISM_SUBSTANCE", 31, 36], ["EC", "CELL", 68, 70], ["serum concentrations", "TEST", 31, 51]]], ["Treated animals did not show the clinical signs or hematological changes that developed in the untreated animals, such as breathing difficulties, decreased oxygen saturation levels, and increased neutrophil counts .", [["neutrophil", "ANATOMY", 196, 206], ["oxygen", "CHEMICAL", 156, 162], ["oxygen", "CHEMICAL", 156, 162], ["oxygen", "SIMPLE_CHEMICAL", 156, 162], ["neutrophil", "CELL", 196, 206], ["the clinical signs", "PROBLEM", 29, 47], ["hematological changes", "PROBLEM", 51, 72], ["breathing difficulties", "PROBLEM", 122, 144], ["decreased oxygen saturation levels", "PROBLEM", 146, 180], ["increased neutrophil counts", "PROBLEM", 186, 213], ["oxygen saturation", "OBSERVATION", 156, 173], ["increased", "OBSERVATION_MODIFIER", 186, 195], ["neutrophil counts", "OBSERVATION", 196, 213]]], ["Gross pathology of lungs from treated animals was normal, while untreated animals displayed visible lesions.", [["lungs", "ANATOMY", 19, 24], ["lesions", "ANATOMY", 100, 107], ["lungs", "ORGAN", 19, 24], ["lesions", "PATHOLOGICAL_FORMATION", 100, 107], ["Gross pathology of lungs", "PROBLEM", 0, 24], ["visible lesions", "PROBLEM", 92, 107], ["pathology", "OBSERVATION", 6, 15], ["lungs", "ANATOMY", 19, 24], ["normal", "OBSERVATION", 50, 56], ["visible", "OBSERVATION_MODIFIER", 92, 99], ["lesions", "OBSERVATION", 100, 107]]], ["Histopathology revealed mild signs of bronchointerstitial pneumonia in the treated animals, with more abundant alveolar edema and severe lesions seen in the untreated animals.", [["bronchointerstitial", "ANATOMY", 38, 57], ["alveolar edema", "ANATOMY", 111, 125], ["lesions", "ANATOMY", 137, 144], ["bronchointerstitial pneumonia", "DISEASE", 38, 67], ["alveolar edema", "DISEASE", 111, 125], ["alveolar edema", "PATHOLOGICAL_FORMATION", 111, 125], ["lesions", "PATHOLOGICAL_FORMATION", 137, 144], ["Histopathology", "TEST", 0, 14], ["bronchointerstitial pneumonia", "PROBLEM", 38, 67], ["abundant alveolar edema", "PROBLEM", 102, 125], ["severe lesions", "PROBLEM", 130, 144], ["mild", "OBSERVATION_MODIFIER", 24, 28], ["bronchointerstitial", "OBSERVATION_MODIFIER", 38, 57], ["pneumonia", "OBSERVATION", 58, 67], ["more", "OBSERVATION_MODIFIER", 97, 101], ["abundant", "OBSERVATION_MODIFIER", 102, 110], ["alveolar", "ANATOMY_MODIFIER", 111, 119], ["edema", "OBSERVATION", 120, 125], ["severe", "OBSERVATION_MODIFIER", 130, 136], ["lesions", "OBSERVATION", 137, 144]]], ["The MERS-CoV viral load in lung samples was 0.81 log lower for treated animals compared to untreated animals.", [["lung samples", "ANATOMY", 27, 39], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 4, 12], ["lung samples", "CANCER", 27, 39], ["MERS-CoV", "SPECIES", 4, 12], ["The MERS", "TEST", 0, 8], ["CoV viral load in lung samples", "TEST", 9, 39], ["lung", "ANATOMY", 27, 31]]], ["Furthermore, a lung-specific host response occurred in untreated macaques but not in treated animals, with increased levels of the cytokines and chemokines IL-6, IFN-y, and MCP-1.", [["lung", "ANATOMY", 15, 19], ["lung", "ORGAN", 15, 19], ["macaques", "ORGANISM", 65, 73], ["IL-6", "GENE_OR_GENE_PRODUCT", 156, 160], ["IFN", "GENE_OR_GENE_PRODUCT", 162, 165], ["MCP-1", "GENE_OR_GENE_PRODUCT", 173, 178], ["cytokines", "PROTEIN", 131, 140], ["chemokines", "PROTEIN", 145, 155], ["IL-6", "PROTEIN", 156, 160], ["IFN", "PROTEIN", 162, 165], ["MCP", "PROTEIN", 173, 176], ["the cytokines", "TEST", 127, 140], ["chemokines IL", "TEST", 145, 158], ["MCP", "TEST", 173, 176], ["lung", "ANATOMY", 15, 19], ["host response", "OBSERVATION", 29, 42], ["untreated macaques", "OBSERVATION", 55, 73]]], ["Reduced expression of inflammatory genes was observed in the lungs of treated animals .", [["lungs", "ANATOMY", 61, 66], ["lungs", "ORGAN", 61, 66], ["inflammatory genes", "DNA", 22, 40], ["inflammatory genes", "PROBLEM", 22, 40], ["inflammatory genes", "OBSERVATION", 22, 40], ["lungs", "ANATOMY", 61, 66]]], ["The significant improvement in clinical score for treated animals despite relatively similar viral loads between the groups suggests that immunopathology may be a factor in the severity of MERS-CoV infection.", [["immunopathology", "DISEASE", 138, 153], ["MERS-CoV infection", "DISEASE", 189, 207], ["MERS-CoV", "ORGANISM", 189, 197], ["MERS-CoV", "SPECIES", 189, 197], ["immunopathology", "PROBLEM", 138, 153], ["MERS", "PROBLEM", 189, 193], ["CoV infection", "PROBLEM", 194, 207], ["significant", "OBSERVATION_MODIFIER", 4, 15], ["improvement", "OBSERVATION_MODIFIER", 16, 27], ["viral loads", "OBSERVATION", 93, 104], ["CoV", "OBSERVATION_MODIFIER", 194, 197], ["infection", "OBSERVATION", 198, 207]]], ["However, because the rhesus macaque model only recapitulates mild to moderate disease in humans, the effectiveness of these drugs against MERS-CoV-induced ARDS is unclear.", [["MERS-CoV", "CHEMICAL", 138, 146], ["ARDS", "DISEASE", 155, 159], ["macaque", "ORGANISM", 28, 35], ["humans", "ORGANISM", 89, 95], ["MERS-CoV", "ORGANISM", 138, 146], ["rhesus macaque", "SPECIES", 21, 35], ["humans", "SPECIES", 89, 95], ["rhesus macaque", "SPECIES", 21, 35], ["humans", "SPECIES", 89, 95], ["MERS-CoV", "SPECIES", 138, 146], ["mild to moderate disease in humans", "PROBLEM", 61, 95], ["these drugs", "TREATMENT", 118, 129], ["MERS", "PROBLEM", 138, 142], ["CoV", "PROBLEM", 143, 146], ["ARDS", "PROBLEM", 155, 159], ["mild", "OBSERVATION_MODIFIER", 61, 65], ["moderate", "OBSERVATION_MODIFIER", 69, 77], ["disease", "OBSERVATION", 78, 85], ["ARDS", "OBSERVATION", 155, 159]]], ["Timing is also critical to the efficacy of treatment; most patients do not begin treatment until they are quite ill, whereas drug regimens in the macaques began only 8 h postinoculation.", [["patients", "ORGANISM", 59, 67], ["macaques", "ORGANISM", 146, 154], ["patients", "SPECIES", 59, 67], ["treatment", "TREATMENT", 43, 52], ["treatment", "TREATMENT", 81, 90], ["drug regimens", "TREATMENT", 125, 138]]], ["The translation of drug regimens from the laboratory to the clinic must address such discrepancies.ProphylacticsIn the years since the SARS-CoV outbreak, attempts have been made to prepare for reemergence by establishing vaccines, and the advent of MERS-CoV has only heightened the need for effective coronavirus vaccines.", [["SARS-CoV", "DISEASE", 135, 143], ["MERS-CoV", "ORGANISM", 249, 257], ["coronavirus", "ORGANISM", 301, 312], ["SARS-CoV", "SPECIES", 135, 143], ["MERS-CoV", "SPECIES", 249, 257], ["coronavirus", "SPECIES", 301, 312], ["drug regimens", "TREATMENT", 19, 32], ["the SARS", "PROBLEM", 131, 139], ["vaccines", "TREATMENT", 221, 229], ["effective coronavirus vaccines", "TREATMENT", 291, 321]]], ["Inactivated viruses, live-attenuated viruses, DNA vaccines, virus-like particles, and viral vector-based vaccines have all been shown to produce neutralizing antibodies to SARS-CoV (Chen et al., 2005; Zhao et al., 2005; Graham et al., 2012; Tseng et al., 2012) .", [["SARS", "DISEASE", 172, 176], ["DNA", "CELLULAR_COMPONENT", 46, 49], ["virus-like particles", "ORGANISM", 60, 80], ["SARS-CoV", "ORGANISM", 172, 180], ["neutralizing antibodies", "PROTEIN", 145, 168], ["SARS-CoV", "SPECIES", 172, 180], ["Inactivated viruses", "PROBLEM", 0, 19], ["live-attenuated viruses", "TREATMENT", 21, 44], ["DNA vaccines", "TREATMENT", 46, 58], ["virus-like particles", "TREATMENT", 60, 80], ["viral vector-based vaccines", "TREATMENT", 86, 113], ["viruses", "OBSERVATION", 12, 19]]], ["Unfortunately, SARS-CoV causes pulmonary immunopathology upon challenge after vaccination in animal models, presumably because they induce an immune response skewed toward T helper 2 (T H 2) cell responses (Tseng et al., 2012) .", [["pulmonary", "ANATOMY", 31, 40], ["T helper 2 (T H 2) cell", "ANATOMY", 172, 195], ["SARS", "DISEASE", 15, 19], ["pulmonary immunopathology", "DISEASE", 31, 56], ["SARS-CoV", "ORGANISM", 15, 23], ["pulmonary", "ORGAN", 31, 40], ["T helper 2", "CELL", 172, 182], ["T H 2) cell", "CELL", 184, 195], ["SARS-CoV", "SPECIES", 15, 23], ["SARS", "PROBLEM", 15, 19], ["pulmonary immunopathology", "PROBLEM", 31, 56], ["vaccination", "TREATMENT", 78, 89], ["an immune response", "PROBLEM", 139, 157], ["cell responses", "TEST", 191, 205], ["pulmonary", "ANATOMY", 31, 40], ["immunopathology", "OBSERVATION", 41, 56]]], ["While inactivated virus vaccines are particularly prone to inducing this type of T H 2-related hypersensitivity, immunopathology upon challenge has been observed with SARS-CoV-based viral vector vaccines (Deming et al., 2006) , virus-like particle vaccines (Tseng et al., 2012) , and DNA vaccines (Zhao et al., 2005) .ProphylacticsInvestigations of the antigenic and serologic relationships of MERS-CoV to other coronaviruses have confirmed that neutralizing antibodies target the spike protein of MERS-CoV and are specific to MERS-CoV, while the N protein induces antibodies cross-reactive within its coronavirus subgroup (Agnihothram et al., 2013) .", [["hypersensitivity", "DISEASE", 95, 111], ["immunopathology", "DISEASE", 113, 128], ["T H 2", "CELL", 81, 86], ["SARS-CoV", "ORGANISM", 167, 175], ["DNA", "CELLULAR_COMPONENT", 284, 287], ["MERS-CoV", "ORGANISM", 394, 402], ["coronaviruses", "ORGANISM", 412, 425], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 498, 506], ["MERS-CoV", "ORGANISM", 527, 535], ["coronavirus", "ORGANISM", 602, 613], ["neutralizing antibodies", "PROTEIN", 446, 469], ["spike protein", "PROTEIN", 481, 494], ["MERS", "PROTEIN", 498, 502], ["N protein", "PROTEIN", 547, 556], ["antibodies", "PROTEIN", 565, 575], ["coronavirus", "SPECIES", 602, 613], ["T H", "SPECIES", 81, 84], ["SARS-CoV", "SPECIES", 167, 175], ["MERS-CoV", "SPECIES", 394, 402], ["MERS-CoV", "SPECIES", 498, 506], ["MERS-CoV", "SPECIES", 527, 535], ["inactivated virus vaccines", "TREATMENT", 6, 32], ["T H 2", "PROBLEM", 81, 86], ["hypersensitivity", "PROBLEM", 95, 111], ["SARS", "PROBLEM", 167, 171], ["CoV", "TEST", 172, 175], ["viral vector vaccines", "TREATMENT", 182, 203], ["virus", "PROBLEM", 228, 233], ["DNA vaccines", "TREATMENT", 284, 296], ["ProphylacticsInvestigations", "TEST", 318, 345], ["the antigenic and serologic relationships of MERS", "PROBLEM", 349, 398], ["CoV to other coronaviruses", "PROBLEM", 399, 425], ["neutralizing antibodies", "TEST", 446, 469], ["CoV", "TEST", 532, 535], ["the N protein", "TEST", 543, 556], ["antibodies cross-reactive", "PROBLEM", 565, 590]]], ["The spike protein, and especially its RBD, is considered a key component in coronavirus vaccine design (Du et al., 2009 (Du et al., , 2013b .", [["RBD", "GENE_OR_GENE_PRODUCT", 38, 41], ["coronavirus", "ORGANISM", 76, 87], ["spike protein", "PROTEIN", 4, 17], ["RBD", "PROTEIN", 38, 41], ["The spike protein", "TEST", 0, 17], ["its RBD", "PROBLEM", 34, 41]]], ["A replication-defective vaccinia virus-based vaccine expressing the full-length spike protein of MERS-CoV has been shown to produce high levels of neutralizing antibodies in mice, but virus challenge cannot be applied to the mouse model (Song et al., 2013) .Vaccination with recombinant protein containing a truncated RBD of the spike protein (amino acids 377-588) and the Fc of human IgG also induced high titers of neutralizing antibodies.", [["amino acids 377-588", "CHEMICAL", 344, 363], ["amino acids", "CHEMICAL", 344, 355], ["vaccinia virus", "ORGANISM", 24, 38], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 97, 105], ["mice", "ORGANISM", 174, 178], ["mouse", "ORGANISM", 225, 230], ["amino acids", "AMINO_ACID", 344, 355], ["377-588", "AMINO_ACID", 356, 363], ["Fc", "GENE_OR_GENE_PRODUCT", 373, 375], ["human", "ORGANISM", 379, 384], ["IgG", "GENE_OR_GENE_PRODUCT", 385, 388], ["full-length spike protein", "PROTEIN", 68, 93], ["MERS", "PROTEIN", 97, 101], ["CoV", "PROTEIN", 102, 105], ["neutralizing antibodies", "PROTEIN", 147, 170], ["recombinant protein", "PROTEIN", 275, 294], ["truncated RBD", "PROTEIN", 308, 321], ["spike protein", "PROTEIN", 329, 342], ["amino acids 377-588", "PROTEIN", 344, 363], ["Fc", "PROTEIN", 373, 375], ["human IgG", "PROTEIN", 379, 388], ["neutralizing antibodies", "PROTEIN", 417, 440], ["vaccinia virus", "SPECIES", 24, 38], ["mice", "SPECIES", 174, 178], ["mouse", "SPECIES", 225, 230], ["human", "SPECIES", 379, 384], ["vaccinia virus", "SPECIES", 24, 38], ["MERS-CoV", "SPECIES", 97, 105], ["mice", "SPECIES", 174, 178], ["mouse", "SPECIES", 225, 230], ["human", "SPECIES", 379, 384], ["A replication", "TREATMENT", 0, 13], ["defective vaccinia virus", "TREATMENT", 14, 38], ["based vaccine", "TREATMENT", 39, 52], ["MERS", "PROBLEM", 97, 101], ["CoV", "PROBLEM", 102, 105], ["neutralizing antibodies", "TREATMENT", 147, 170], ["virus challenge", "TREATMENT", 184, 199], ["Vaccination", "TREATMENT", 258, 269], ["recombinant protein", "TREATMENT", 275, 294], ["a truncated RBD", "PROBLEM", 306, 321], ["the spike protein", "TEST", 325, 342], ["amino acids", "TEST", 344, 355], ["the Fc", "TEST", 369, 375], ["human IgG", "TEST", 379, 388], ["high titers of neutralizing antibodies", "PROBLEM", 402, 440], ["vaccinia virus", "OBSERVATION", 24, 38], ["neutralizing antibodies", "OBSERVATION", 417, 440]]], ["The truncated RBD elicited higher levels of neutralizing antibodies than vaccination with a recombinant protein containing a larger fragment of the spike protein (amino acids 377-662).", [["amino acids 377-662", "CHEMICAL", 163, 182], ["amino acids", "CHEMICAL", 163, 174], ["RBD", "GENE_OR_GENE_PRODUCT", 14, 17], ["amino acids 377-662", "AMINO_ACID", 163, 182], ["RBD", "PROTEIN", 14, 17], ["neutralizing antibodies", "PROTEIN", 44, 67], ["recombinant protein", "PROTEIN", 92, 111], ["spike protein", "PROTEIN", 148, 161], ["amino acids 377-662", "PROTEIN", 163, 182], ["The truncated RBD", "PROBLEM", 0, 17], ["neutralizing antibodies", "PROBLEM", 44, 67], ["vaccination", "TREATMENT", 73, 84], ["a recombinant protein", "PROBLEM", 90, 111], ["a larger fragment", "PROBLEM", 123, 140], ["the spike protein", "TEST", 144, 161], ["amino acids", "TEST", 163, 174], ["truncated", "OBSERVATION_MODIFIER", 4, 13], ["RBD", "OBSERVATION", 14, 17], ["higher", "OBSERVATION_MODIFIER", 27, 33], ["neutralizing antibodies", "OBSERVATION", 44, 67], ["larger", "OBSERVATION_MODIFIER", 125, 131], ["fragment", "OBSERVATION", 132, 140]]], ["The authors suggest that non-neutralizing epitopes within the 588-662 region of the polypeptide may compete with neutralizing epitopes or destabilize the formation of the RBD (Du et al., 2013b) .", [["RBD", "DISEASE", 171, 174], ["non-neutralizing epitopes", "PROTEIN", 25, 50], ["588-662 region", "DNA", 62, 76], ["neutralizing epitopes", "PROTEIN", 113, 134], ["RBD", "PROTEIN", 171, 174], ["non-neutralizing epitopes", "PROBLEM", 25, 50], ["the polypeptide", "TREATMENT", 80, 95], ["neutralizing epitopes", "TREATMENT", 113, 134], ["the RBD", "PROBLEM", 167, 174]]], ["To maximize the protectiveness of neutralizing antibodies across MERS-CoV strains, the natural variation of MERS-CoV spike proteins needs to be characterized and considered in the design of vaccines (Graham et al., 2013) .", [["MERS-CoV strains", "ORGANISM", 65, 81], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 108, 116], ["neutralizing antibodies", "PROTEIN", 34, 57], ["MERS-CoV spike proteins", "PROTEIN", 108, 131], ["MERS-CoV", "SPECIES", 65, 73], ["MERS-CoV", "SPECIES", 108, 116], ["neutralizing antibodies", "PROBLEM", 34, 57], ["CoV strains", "PROBLEM", 70, 81], ["MERS", "PROBLEM", 108, 112], ["CoV spike proteins", "PROBLEM", 113, 131]]], ["Live-attenuated viruses are another approach to MERS-CoV vaccine development.", [["MERS-CoV", "ORGANISM", 48, 56], ["MERS-CoV", "SPECIES", 48, 56], ["attenuated viruses", "PROBLEM", 5, 23], ["CoV vaccine development", "TREATMENT", 53, 76], ["viruses", "OBSERVATION", 16, 23]]], ["A MERS-CoV mutant lacking the structural E protein has been shown to be replication-competent but propagation-defective (Almaz an et al., 2013) .", [["MERS-CoV mutant", "ORGANISM", 2, 17], ["MERS-CoV mutant", "PROTEIN", 2, 17], ["structural E protein", "PROTEIN", 30, 50], ["MERS-CoV", "SPECIES", 2, 10]]], ["Development of safe and effective MERS-CoV vaccines must potentially overcome the challenges that arose for SARS-CoV.", [["SARS-CoV", "DISEASE", 108, 116], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 34, 42], ["SARS-CoV", "ORGANISM", 108, 116], ["MERS-CoV", "SPECIES", 34, 42], ["SARS-CoV", "SPECIES", 108, 116], ["safe and effective MERS", "TREATMENT", 15, 38], ["CoV vaccines", "TREATMENT", 39, 51], ["SARS", "PROBLEM", 108, 112]]], ["No in vivo testing of vaccines has been performed to date; it remains therefore unclear whether challenge with MERS-CoV would illicit pulmonary immunopathology upon challenge.", [["pulmonary", "ANATOMY", 134, 143], ["pulmonary immunopathology", "DISEASE", 134, 159], ["MERS-CoV", "ORGANISM", 111, 119], ["pulmonary", "ORGAN", 134, 143], ["MERS-CoV", "SPECIES", 111, 119], ["vaccines", "TREATMENT", 22, 30], ["pulmonary", "ANATOMY", 134, 143], ["immunopathology", "OBSERVATION", 144, 159]]], ["Creative approaches, such as the use of adjuvants that promote T H 1 cell responses, need to be pursued, and potential vaccines must be rigorously evaluated in animal models (Graham et al., 2013) .Global responseIn the year since its identification, MERS-CoV has not only spread across the Arabic Peninsula, but has been transported to the United Kingdom, France, Germany, Italy, Tunisia, and Spain (Bermingham et al., 2012; Buchholz et al., 2013; Gulland, 2013a, b; Health Protection Agency, 2013; Hijawi et al., 2013; Mailles et al., 2013; Memish et al., 2013b; Puzelli et al., 2013) .", [["T H 1 cell", "ANATOMY", 63, 73], ["T H 1 cell", "CELL", 63, 73], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 250, 258], ["MERS-CoV", "SPECIES", 250, 258], ["adjuvants", "TREATMENT", 40, 49], ["vaccines", "TREATMENT", 119, 127], ["its identification", "TEST", 230, 248], ["MERS-CoV", "PROBLEM", 250, 258], ["Arabic Peninsula", "ANATOMY", 290, 306]]], ["The initial detection of MERS-CoV was followed by the rapid development of MERS-CoV molecular and serological diagnostics (Corman et al., 2012a, b) .", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 25, 33], ["MERS-CoV", "SPECIES", 25, 33], ["MERS-CoV", "SPECIES", 75, 83], ["serological diagnostics", "TEST", 98, 121]]], ["The emergence of MERS-CoV reminded the infectious disease community of the emergence of SARS-CoV and called for immediate public health preparedness and response.", [["infectious disease", "DISEASE", 39, 57], ["SARS-CoV", "DISEASE", 88, 96], ["MERS-CoV", "ORGANISM", 17, 25], ["SARS-CoV", "ORGANISM", 88, 96], ["MERS-CoV", "SPECIES", 17, 25], ["SARS-CoV", "SPECIES", 88, 96]]], ["Research efforts have largely focused on the epidemiology of the outbreak and identification of putative natural and intermediate reservoirs and potential therapeutics.", [["intermediate reservoirs", "OBSERVATION", 117, 140]]], ["Some controversy has surrounded the identification and sharing of MERS-CoV isolatesthe initial isolate was shared without the consent of the Saudi Arabian government, and material transfer agreements (MTA) of some isolates were said to be unnecessarily restrictive (Butler, 2013) .", [["MERS-CoV", "ORGANISM", 66, 74], ["MERS-CoV", "SPECIES", 66, 74], ["some isolates", "PROBLEM", 209, 222]]], ["An MTA has several purposes: it defines not only the material to be transferred, but who can use the materials and what the purpose of the transfer is.", [["MTA", "CHEMICAL", 3, 6]]], ["Lastly, it designates liability of each party and ensures that the receiving party will use the material in a safe way (for instance, at the proper biosafety level).", [["the material", "TREATMENT", 92, 104]]], ["The controversies surrounding the initial detection of MERS-CoV highlight the importance of creating an international framework for rapid global sharing of virus strains and biologic materials during outbreaks.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 55, 63], ["MERS-CoV", "SPECIES", 55, 63], ["virus strains", "PROBLEM", 156, 169], ["virus strains", "OBSERVATION", 156, 169]]], ["Similar controversies over ownership have arisen with H5N1 avian influenza (Fidler, 2008) .", [["H5N1 avian influenza", "DISEASE", 54, 74], ["H5N1", "ORGANISM", 54, 58], ["avian influenza", "ORGANISM", 59, 74], ["H5N1 avian influenza", "SPECIES", 54, 74]]], ["Both the avian flu virus and the MERS-CoV cases strongly point to the need not only for prenegotiated transfer agreements but also for standardized 'best practices' guidelines for highly virulent emerging disease materials where expedited sharing of material and data is of paramount importance.Future perspectivesDespite many advances in our understanding of the MERS-CoV outbreak, major questions remain.", [["avian flu virus", "ORGANISM", 9, 24], ["MERS-CoV", "ORGANISM", 33, 41], ["MERS-CoV", "ORGANISM", 364, 372], ["avian flu virus", "SPECIES", 9, 24], ["avian flu virus", "SPECIES", 9, 24], ["MERS-CoV", "SPECIES", 33, 41], ["MERS-CoV", "SPECIES", 364, 372], ["highly virulent emerging disease materials", "PROBLEM", 180, 222], ["flu virus", "OBSERVATION", 15, 24]]], ["The epidemiology of MERS-CoV is still poorly understood.", [["MERS-CoV", "ORGANISM", 20, 28], ["MERS-CoV", "SPECIES", 20, 28]]], ["Although dromedary camels have been implicated as the most likely intermediate reservoir, more details on the genetic variation of MERS-CoV viruses circulating in camels and humans are necessary to identify camels as the definitive source of human MERS-CoV infections.", [["MERS-CoV infections", "DISEASE", 248, 267], ["dromedary camels", "ORGANISM", 9, 25], ["MERS-CoV viruses", "ORGANISM", 131, 147], ["camels", "ORGANISM_SUBDIVISION", 163, 169], ["humans", "ORGANISM", 174, 180], ["camels", "ORGANISM", 207, 213], ["human", "ORGANISM", 242, 247], ["MERS-CoV", "ORGANISM", 248, 256], ["humans", "SPECIES", 174, 180], ["human", "SPECIES", 242, 247], ["MERS-CoV", "SPECIES", 131, 139], ["humans", "SPECIES", 174, 180], ["human MERS-CoV", "SPECIES", 242, 256], ["CoV viruses", "PROBLEM", 136, 147], ["human MERS", "PROBLEM", 242, 252], ["CoV infections", "PROBLEM", 253, 267], ["infections", "OBSERVATION", 257, 267]]], ["The widespread distribution of dromedary camels across Africa, the Arabic peninsula, and South-West Asia highlights their potential to facilitate the outbreak's spread (Fig. 7) , but information on the spatial and temporal patterns of MERS-CoV circulation in this species is needed.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 235, 243], ["MERS-CoV", "SPECIES", 235, 243], ["dromedary camels", "PROBLEM", 31, 47], ["MERS", "PROBLEM", 235, 239], ["CoV circulation", "PROBLEM", 240, 255], ["widespread", "OBSERVATION_MODIFIER", 4, 14], ["distribution", "OBSERVATION_MODIFIER", 15, 27], ["dromedary camels", "OBSERVATION", 31, 47], ["Arabic peninsula", "ANATOMY", 67, 83]]], ["Because zoonotic introductions continue to play a role in the epidemiology of MERS-CoV in humans (Cotten et al., 2013b) , an elucidation of the mechanisms of zoonotic transmission is essential and intervention strategies should focus on controlling these events.Future perspectivesOur clinical understanding of MERS-CoV infection is based on limited reports (Albarrak et al., 2012; Bermingham et al., 2012; Assiri et al., 2013a; Drosten et al., 2013; Guery et al., 2013; Memish et al., 2013a; Omrani et al., 2013) .", [["zoonotic transmission", "DISEASE", 158, 179], ["MERS-CoV infection", "DISEASE", 311, 329], ["MERS-CoV", "ORGANISM", 78, 86], ["humans", "ORGANISM", 90, 96], ["MERS-CoV", "ORGANISM", 311, 319], ["humans", "SPECIES", 90, 96], ["MERS-CoV", "SPECIES", 78, 86], ["humans", "SPECIES", 90, 96], ["MERS-CoV", "SPECIES", 311, 319], ["zoonotic transmission", "TREATMENT", 158, 179], ["intervention strategies", "TREATMENT", 197, 220], ["CoV infection", "PROBLEM", 316, 329], ["infection", "OBSERVATION", 320, 329]]], ["Of particular interest is the effect of comorbidities on MERS-CoV pathogenesis and patient outcomes.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 57, 65], ["patient", "ORGANISM", 83, 90], ["patient", "SPECIES", 83, 90], ["MERS-CoV", "SPECIES", 57, 65], ["comorbidities", "PROBLEM", 40, 53]]], ["Preliminary evidence shows a direct relation between underlying comorbidities and disease severity .", [["underlying comorbidities", "PROBLEM", 53, 77], ["disease severity", "PROBLEM", 82, 98], ["comorbidities", "OBSERVATION", 64, 77], ["disease", "OBSERVATION", 82, 89]]], ["The observation that primary cases have been more severe Fig. 7 Geographic distribution of dromedary camels.", [["camels", "ORGANISM", 101, 107], ["severe Fig", "PROBLEM", 50, 60], ["dromedary camels", "PROBLEM", 91, 107], ["more severe", "OBSERVATION_MODIFIER", 45, 56], ["Geographic", "OBSERVATION_MODIFIER", 64, 74], ["distribution", "OBSERVATION_MODIFIER", 75, 87], ["dromedary camels", "OBSERVATION", 91, 107]]], ["The global distribution of dromedary camels is indicated by yellow shading (Mukasa-Mugerwa, 1981 ). than secondary cases, even when controlling for underlying conditions, might suggest that these primary cases were exposed to higher virus doses than secondary cases (The WHO MERS-CoV Research Group, 2013) .", [["dromedary camels", "PROBLEM", 27, 43], ["yellow shading", "PROBLEM", 60, 74], ["underlying conditions", "PROBLEM", 148, 169], ["higher virus doses", "TREATMENT", 226, 244], ["global", "OBSERVATION_MODIFIER", 4, 10], ["distribution", "OBSERVATION_MODIFIER", 11, 23], ["dromedary camels", "OBSERVATION", 27, 43], ["yellow shading", "OBSERVATION", 60, 74]]], ["This could also indicate that MERS-CoV is more readily transmissible from the intermediate reservoir to humans than from human-to-human and that milder MERS-CoV cases would be less likely to efficiently transmit MERS-CoV.", [["MERS-CoV", "ORGANISM", 30, 38], ["humans", "ORGANISM", 104, 110], ["human", "ORGANISM", 121, 126], ["human", "ORGANISM", 130, 135], ["MERS-CoV", "ORGANISM", 152, 160], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 212, 220], ["humans", "SPECIES", 104, 110], ["human", "SPECIES", 121, 126], ["human", "SPECIES", 130, 135], ["MERS-CoV", "SPECIES", 30, 38], ["humans", "SPECIES", 104, 110], ["human", "SPECIES", 121, 126], ["human", "SPECIES", 130, 135], ["MERS-CoV", "SPECIES", 152, 160], ["MERS-CoV", "SPECIES", 212, 220], ["CoV", "PROBLEM", 35, 38], ["CoV cases", "PROBLEM", 157, 166]]], ["Human-to-human transmission could increase if MERS-CoV becomes better adapted to humans.", [["Human", "ORGANISM", 0, 5], ["human", "ORGANISM", 9, 14], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 46, 54], ["humans", "ORGANISM", 81, 87], ["Human", "SPECIES", 0, 5], ["human", "SPECIES", 9, 14], ["humans", "SPECIES", 81, 87], ["human", "SPECIES", 9, 14], ["MERS-CoV", "SPECIES", 46, 54], ["humans", "SPECIES", 81, 87], ["CoV", "PROBLEM", 51, 54]]], ["Prolonged MERS-CoV replication in immune-compromised patients could increase opportunity for the virus to acquire mutations enabling efficient transmission.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 10, 18], ["patients", "ORGANISM", 53, 61], ["patients", "SPECIES", 53, 61], ["MERS-CoV", "SPECIES", 10, 18], ["Prolonged MERS", "PROBLEM", 0, 14], ["CoV replication", "TREATMENT", 15, 30], ["the virus", "PROBLEM", 93, 102]]], ["The development and testing of MERS-CoV therapeutics is currently hindered by the absence of small animal models.", [["MERS-CoV", "GENE_OR_GENE_PRODUCT", 31, 39], ["MERS-CoV", "SPECIES", 31, 39], ["CoV therapeutics", "TREATMENT", 36, 52], ["small animal models", "PROBLEM", 93, 112], ["small", "OBSERVATION_MODIFIER", 93, 98]]], ["In addition, phase I-III clinical trials need to be conducted before experimental vaccines and treatment options can be available to humans.", [["humans", "ORGANISM", 133, 139], ["humans", "SPECIES", 133, 139], ["humans", "SPECIES", 133, 139], ["experimental vaccines", "TREATMENT", 69, 90], ["treatment options", "TREATMENT", 95, 112]]], ["Accordingly, research focusing on already-approved drugs for the treatment of MERS-CoV with result in faster implementation and wider availability of therapeutics in the clinic.Future perspectivesThe increase in emerging infectious disease events over the last decades has made it apparent that a more complete understanding of the ecology, biology, and political economy of infectious disease emergence is necessary.", [["infectious disease", "DISEASE", 375, 393], ["MERS-CoV", "ORGANISM", 78, 86], ["MERS-CoV", "SPECIES", 78, 86], ["drugs", "TREATMENT", 51, 56], ["emerging infectious disease events", "PROBLEM", 212, 246], ["infectious disease emergence", "PROBLEM", 375, 403], ["increase", "OBSERVATION_MODIFIER", 200, 208], ["infectious", "OBSERVATION_MODIFIER", 221, 231], ["infectious", "OBSERVATION", 375, 385]]], ["Globalization, climate change, habitat alteration, and wildlife encroachment likely contribute to novel interactions between pathogens and hosts.", [["habitat alteration", "PROBLEM", 31, 49], ["wildlife encroachment", "PROBLEM", 55, 76], ["novel interactions between pathogens and hosts", "PROBLEM", 98, 144], ["habitat alteration", "OBSERVATION", 31, 49]]], ["Adequate preparation for future infectious disease outbreaks requires strong international relationships in research, monitoring and surveillance, and public health response.", [["infectious disease", "DISEASE", 32, 50], ["future infectious disease outbreaks", "PROBLEM", 25, 60], ["surveillance", "TEST", 133, 145], ["infectious", "OBSERVATION_MODIFIER", 32, 42]]], ["In 2005, after facing the emergence of SARS-CoV and avian influenza H5N1, the WHO (2013b) developed International Health Regulations for the coordination of global responses to emerging health threats.", [["SARS-CoV", "DISEASE", 39, 47], ["avian influenza H5N1", "DISEASE", 52, 72], ["SARS-CoV", "ORGANISM", 39, 47], ["avian influenza H5N1", "ORGANISM", 52, 72], ["avian influenza H5N1", "SPECIES", 52, 72], ["SARS-CoV", "SPECIES", 39, 47], ["SARS", "PROBLEM", 39, 43]]], ["The WHO has structured its MERS-CoV response according to these regulations, forming an emergency committee on MERS-CoV, creating case definitions of infection, and providing frequent updates of the MERS-CoV outbreak through the IHR's global alert and response function.", [["infection", "DISEASE", 150, 159], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 111, 119], ["MERS-CoV", "SPECIES", 111, 119], ["MERS-CoV", "SPECIES", 199, 207], ["infection", "PROBLEM", 150, 159], ["infection", "OBSERVATION", 150, 159]]], ["The Program for Monitoring of Emerging Diseases (ProMED-mail), which communicated the first report of MERS-CoV infection in a human, has also continued to provide the global health and research communities with updates of epidemiological reports and scientific findings.", [["MERS-CoV infection", "DISEASE", 102, 120], ["MERS-CoV", "ORGANISM", 102, 110], ["human", "ORGANISM", 126, 131], ["human", "SPECIES", 126, 131], ["MERS-CoV", "SPECIES", 102, 110], ["human", "SPECIES", 126, 131], ["Emerging Diseases", "PROBLEM", 30, 47], ["MERS", "PROBLEM", 102, 106], ["CoV infection", "PROBLEM", 107, 120], ["infection", "OBSERVATION", 111, 120]]], ["Capacity building, knowledge transfer, and training of the future generation of scientists are key factors in forming multidisciplinary preparedness for future infectious disease outbreaks.", [["infectious disease outbreaks", "DISEASE", 160, 188], ["future infectious disease outbreaks", "PROBLEM", 153, 188]]], ["In this regard, special attention should be given to prevention and control of emerging infectious diseases in the developing world, the origin of the majority of infectious disease outbreaks.", [["infectious diseases", "DISEASE", 88, 107], ["infectious disease", "DISEASE", 163, 181], ["emerging infectious diseases", "PROBLEM", 79, 107], ["infectious disease outbreaks", "PROBLEM", 163, 191], ["infectious", "OBSERVATION", 88, 98], ["majority", "OBSERVATION_MODIFIER", 151, 159], ["infectious", "OBSERVATION", 163, 173]]]], "38df3b1f635f3643d1a818ea62ac60915d71e92c": [["BackgroundTo control outbreaks of (emerging) diseases at an early stage, effective collaboration between human and veterinary healthcare professionals is essential [1] .", [["human", "ORGANISM", 105, 110], ["human", "SPECIES", 105, 110], ["human", "SPECIES", 105, 110], ["diseases", "PROBLEM", 45, 53]]], ["However, to date, collaboration has taken place only on a very limited scale [1] [2] [3] [4] [5] [6] .", [["[1] [2] [3] [4] [5] [6]", "SIMPLE_CHEMICAL", 77, 100]]], ["For this reason, One Health, an interdisciplinary approach addressing the connections between health care for humans, animals and the environment and focused on the elements biomedical research, enhanced public health efficacy, an expanded scientific knowledge base and improved medical educational and clinical care in which human and veterinary healthcare and other stakeholders work together [7] , is placed high on the agendas of organizations such as the WHO, the European Commission's Directorate-General for Health and Consumers, USA Centers for Disease Control and Prevention [CDCP] and Worldbank [1, [8] [9] [10] .BackgroundBecause more than three-quarters of all the infections seen in humans originate in animals [1] , there is great and widespread interest in the effective collaboration between human and veterinary healthcare professionals as a means to halt outbreaks of infections at an early stage.", [["infections", "DISEASE", 677, 687], ["infections", "DISEASE", 886, 896], ["humans", "ORGANISM", 110, 116], ["human", "ORGANISM", 326, 331], ["humans", "ORGANISM", 696, 702], ["human", "ORGANISM", 808, 813], ["humans", "SPECIES", 110, 116], ["human", "SPECIES", 326, 331], ["humans", "SPECIES", 696, 702], ["human", "SPECIES", 808, 813], ["humans", "SPECIES", 110, 116], ["human", "SPECIES", 326, 331], ["humans", "SPECIES", 696, 702], ["human", "SPECIES", 808, 813], ["Disease Control", "TREATMENT", 553, 568], ["Prevention [CDCP] and Worldbank", "TREATMENT", 573, 604], ["all the infections", "PROBLEM", 669, 687], ["infections", "PROBLEM", 886, 896], ["infections", "OBSERVATION", 677, 687], ["great", "OBSERVATION_MODIFIER", 739, 744], ["widespread", "OBSERVATION_MODIFIER", 749, 759], ["interest", "OBSERVATION_MODIFIER", 760, 768], ["infections", "OBSERVATION", 886, 896]]], ["The outbreak of Severe Acute Respiratory Syndrome (SARS), for instance, which was not even known to be an animal-transmitted infection when it first occurred, is estimated to have caused a loss of as much as US$40 billion in terms of Gross Domestic Product (GDP) worldwide [11] .", [["Acute Respiratory Syndrome", "DISEASE", 23, 49], ["SARS", "DISEASE", 51, 55], ["animal-transmitted infection", "DISEASE", 106, 134], ["Severe Acute Respiratory Syndrome (SARS)", "SPECIES", 16, 56], ["Severe Acute Respiratory Syndrome", "PROBLEM", 16, 49], ["transmitted infection", "PROBLEM", 113, 134], ["Severe", "OBSERVATION_MODIFIER", 16, 22], ["Acute", "OBSERVATION_MODIFIER", 23, 28], ["Respiratory Syndrome", "OBSERVATION", 29, 49], ["infection", "OBSERVATION", 125, 134]]], ["Other examples include the recent outbreaks of avian influenza and Q fever in the Netherlands, which have shown that serious outbreaks can have major consequences for human and animal health [12] .", [["avian influenza and Q fever", "DISEASE", 47, 74], ["avian influenza", "ORGANISM", 47, 62], ["human", "ORGANISM", 167, 172], ["avian influenza", "SPECIES", 47, 62], ["human", "SPECIES", 167, 172], ["human", "SPECIES", 167, 172], ["avian influenza", "PROBLEM", 47, 62], ["Q fever", "PROBLEM", 67, 74]]], ["Areas where close cooperation would be fruitful because they share the same goals include combatting and controlling zoonoses and emerging zoonoses; here, the interdependence of the two fields requires an integrated approach.", [["zoonoses", "DISEASE", 117, 125], ["zoonoses", "DISEASE", 139, 147], ["an integrated approach", "TREATMENT", 202, 224]]], ["In efforts to reach mutual goals, an interdisciplinary exchange of knowledge between the two professional groups can lead to a sharing of domainspecific expertise and experience, thus enabling experts to identify possible zoonotic infections and to fight them with the help of appropriate control measures at earlier stages [2] .", [["zoonotic infections", "DISEASE", 222, 241], ["zoonotic infections", "PROBLEM", 222, 241], ["appropriate control measures", "TREATMENT", 277, 305]]], ["Another advantage of collaboration between these two groups of healthcare professionals, besides the more adequate fight against infectious diseases, is the exchange of knowledge on the treatment of diseases [2] leading to major healthcare cost savings [6, 11] and to new scientific insights [7] .", [["infectious diseases", "DISEASE", 129, 148], ["infectious diseases", "PROBLEM", 129, 148], ["diseases", "PROBLEM", 199, 207]]], ["In order to better understand the mental motivation of health care professionals with respect to the One Health approach, this study used psychosocial concepts such as social dilemma, (group) identification and category thinking.Collaboration as a social dilemmaCollaboration can be defined as \"any action which is intended to benefit others, regardless of whether the actor also benefits in the process\" [13] .", [["this study", "TEST", 122, 132]]], ["However, collaboration can also fail to take place: in human and veterinary healthcare, cooperation between professionals can fail to materialize because there is a social dilemma, for instance.", [["human", "ORGANISM", 55, 60], ["human", "SPECIES", 55, 60], ["human", "SPECIES", 55, 60]]], ["For example, it is commonly accepted that professionals have a constant and permanent responsibility for their patients, who expect care and action in the short term.", [["patients", "ORGANISM", 111, 119], ["patients", "SPECIES", 111, 119]]], ["But if everyone pursues this non-cooperative course of action, then everyone will ultimately be worse off (often in the longer term) than would have been the case if everyone had collaborated.Collaboration as a social dilemmaCollaboration between human and veterinary healthcare professionals can be characterized as a social dilemma.", [["human", "ORGANISM", 247, 252], ["human", "SPECIES", 247, 252], ["human", "SPECIES", 247, 252]]], ["Fleuren, Wieferink and Paulussen [14] , however, show that healthcare professionals actually have other reasons than time; what lies at the heart of their limited cooperation is a lack of clarity as to why collaboration should be organized in the first place.", [["heart", "ANATOMY", 140, 145], ["heart", "ORGAN", 140, 145], ["heart", "ANATOMY", 140, 145]]], ["This type of calculation, or dilemma, can lead to cooperation 'for the public good'.", [["dilemma", "PROBLEM", 29, 36]]], ["Considering its objectives, One Health can be seen as a public good dilemma, because \"public good dilemmas require individuals to make an active contribution to establish or maintain a collective good, such as building a local bridge or joining a social movement\" [13] .", [["a local bridge", "TREATMENT", 219, 233]]], ["However, in terms of making room for the bigger collective goal alongside their responsibilities related to the day-to-day care of their own patients, human and veterinary healthcare professionals often see insufficient added value [14] , even though a greater awareness of the added value associated with collaboration would ultimately result in improved care [5, 15, 16] .Collaboration as a social dilemmaGreater awareness of the added value brought about by collaboration on the part of healthcare professionals is consistent with the social desire for more intensive collaboration between human and veterinary healthcare [1, [8] [9] [10] 12] .", [["patients", "ORGANISM", 141, 149], ["human", "ORGANISM", 151, 156], ["human", "ORGANISM", 593, 598], ["patients", "SPECIES", 141, 149], ["human", "SPECIES", 151, 156], ["human", "SPECIES", 593, 598], ["human", "SPECIES", 151, 156], ["human", "SPECIES", 593, 598]]], ["In addition, a clear focus on common goals is lacking, and collaboration between human and veterinary healthcare professionals remains limited at present [5, 6, 20] .", [["human", "ORGANISM", 81, 86], ["human", "SPECIES", 81, 86], ["human", "SPECIES", 81, 86], ["clear", "OBSERVATION", 15, 20]]], ["Closer examinations have revealed that the limited scale of collaboration is due, among other things, to mutual prejudices [2] and psychological barriers between the parties concerned [5] .", [["Closer examinations", "TEST", 0, 19]]], ["The present study is aimed to help fill that gap.Common ingroup identity theoryIn order to gain a better understanding of what stimulates cooperation among healthcare professionals, we used the Common Ingroup Identity Model developed by Gaertner and Dovidio [17] .", [["The present study", "TEST", 0, 17]]], ["According to the Common Ingroup Identity Model, sharing a common goal affects the degree of collaboration, but this relationship is also influenced by the perception of this degree and the means of categorization [17, 21] .", [["degree", "OBSERVATION_MODIFIER", 82, 88], ["collaboration", "OBSERVATION", 92, 105]]], ["In essence, the model states that members who see themselves as belonging to a larger, common whole consciously classify themselves within that larger whole, as a result of which prejudices between groups or communities decrease.Common ingroup identity theoryAccording to Gaertner and Dovidio, collaboration is influenced by characteristics (in this study qualified as the common goal) which play a role in the individual perception of the situation: does the individual perceive the existence of a single overarching group, several groups or subgroups, or no group at all?", [["this study", "TEST", 345, 355]]], ["As explained above, when group members see themselves as part of a larger whole and when they classify themselves within this structure, prejudice between groups or communities is reduced.", [["reduced", "OBSERVATION_MODIFIER", 180, 187]]], ["According to Kramer and Brewer [22] , people within a group or an overarching whole are prepared to share communal resources and other supplies, but they will develop resistance if these have to be shared with others outside the group.", [["people", "ORGANISM", 38, 44], ["people", "SPECIES", 38, 44]]], ["The realization that there is in fact a larger whole means that the positive thoughts, feelings and behaviours (such as the sharing of resources and information) which would normally be reserved for the individual's own familiar group are extended to members of other communities who also belong to the larger overarching whole.", [["larger", "OBSERVATION_MODIFIER", 40, 46]]], ["Common endeavour and classifying thus go hand in hand, leading to feelings of 'us' rather than feelings of 'us versus them'.", [["hand", "ANATOMY", 41, 45], ["hand", "ANATOMY", 49, 53], ["hand", "ORGANISM_SUBDIVISION", 41, 45], ["hand", "ORGANISM_SUBDIVISION", 49, 53]]], ["In other words, it depends on how an individual sees his group or subgroup within a larger whole [17] .Common ingroup identity theoryUsing the Common Ingroup Identity Model, we quantitatively assessed healthcare group interrelationships in order to gain insight into the contributions towards cooperation that can be made by means of a common goal for healthcare professionals formulated via their perception of group formation.", [["healthcare professionals", "TREATMENT", 352, 376]]], ["In the past, the Common Ingroup Identity Model was researched primarily in experimental studies, with a main focus on perceived group formation [23] .", [["experimental studies", "TEST", 75, 95], ["main", "OBSERVATION_MODIFIER", 104, 108]]], ["A limitation of the model is that the duration of the effect of an intervention is unclear, as is the reduction of bias [24] .", [["an intervention", "TREATMENT", 64, 79]]], ["The current study will not only indicate whether the Common Ingroup Identity Model is useful for the respective groups of healthcare professionals, but it will also quantitatively assess the relationships between the common goal and collaboration in combination with associated mediating factors.", [["mediating factors", "PROTEIN", 278, 295], ["The current study", "TEST", 0, 17], ["associated mediating factors", "PROBLEM", 267, 295]]], ["In this way, the study will contribute to further theoretical development in terms of validation as well as to the quantitative usefulness of the Common Ingroup Identity Model.", [["the study", "TEST", 13, 22]]], ["It will also examine whether the exchange of knowledge is an additional trigger for collaboration once healthcare professionals have become aware of the common goal.Collaboration and common goalIn the social dilemma referred to earlier, where there is insufficient awareness of the possible advantages of collaboration, and in this case human and veterinary collaboration, crucial factors include the reasons why healthcare professionals place themselves in a particular category and identify with their 'own' professional group [2, 3, 5] .", [["human", "ORGANISM", 337, 342], ["human", "SPECIES", 337, 342], ["human", "SPECIES", 337, 342]]], ["It is 'natural' for people to engage in social categorization: the brain is hard-wired to think in terms of categories, and categories form the basis for standard judgements and prejudices [25] .", [["brain", "ANATOMY", 67, 72], ["people", "ORGANISM", 20, 26], ["brain", "ORGAN", 67, 72], ["people", "SPECIES", 20, 26], ["brain", "ANATOMY", 67, 72]]], ["The same is true of human and veterinary healthcare professionals, although a certain distance is maintained between them [2, 5] .", [["human", "ORGANISM", 20, 25], ["human", "SPECIES", 20, 25], ["human", "SPECIES", 20, 25], ["true", "OBSERVATION_MODIFIER", 12, 16]]], ["After all, what is qualified by the terms 'human' and 'animal' is placed in different categories.", [["human", "ORGANISM", 43, 48], ["human", "SPECIES", 43, 48], ["human", "SPECIES", 43, 48]]], ["This is illustrated by the dichotomy between the two professional groups, established on the basis of typical activities, with 'human patient' being contrasted with 'animal patient' , and hence on the basis of categorybased thinking [2] .", [["human", "ORGANISM", 128, 133], ["patient", "ORGANISM", 134, 141], ["patient", "ORGANISM", 173, 180], ["human", "SPECIES", 128, 133], ["patient", "SPECIES", 134, 141], ["patient", "SPECIES", 173, 180], ["human", "SPECIES", 128, 133]]], ["According to the Common Ingroup Identity Theory, the awareness of a larger whole or a common ingroup, in this case a joint responsibility for improving care, will lead to the extension of positive thoughts, feelings and behaviours (such as the sharing of resources and information) that were traditionally reserved for the individual's own familiar group to members of other communities who also belong to the larger overarching whole.Collaboration and common goalIn the case of common goals and interests, a clear interdependence can be seen: after all, the aim is to achieve a result which requires contributions from both groups.", [["positive thoughts", "PROBLEM", 188, 205], ["joint", "ANATOMY", 117, 122]]], ["In this respect, collaboration between human and veterinary healthcare professionals is the result of addressing common goals and interests [2, 3, 6, 11, 16] .", [["human", "ORGANISM", 39, 44], ["human", "SPECIES", 39, 44], ["human", "SPECIES", 39, 44]]], ["This is in line with the social interdependence theory which argues that interdependence results from a common goal [27] [28] [29] [30] [31] .", [["[27] [28] [29] [30] [31]", "SIMPLE_CHEMICAL", 116, 140]]], ["Mutatis mutandis, this altruistic goal was recently incorporated in the One Health initiative (16) .", [["Mutatis mutandis", "SPECIES", 0, 16]]], ["This brings us to our first hypothesis:Collaboration and common goalOne Health as a common goal has a positive effect on collaboration between human and veterinary healthcare professionals.Collaboration and common goalThe process of classifying concerns the individual's perception of the connection betweenin this casetwo groups of healthcare professionals: how an individual sees his group or subgroup within a larger whole and whether the individual perceives the existence of a single overarching group, multiple groups or subgroups, or no group at all [17] .", [["human", "ORGANISM", 143, 148], ["human", "SPECIES", 143, 148], ["human", "SPECIES", 143, 148], ["positive effect", "OBSERVATION_MODIFIER", 102, 117]]], ["As described earlier, One Health can affect how people see themselves as part of a larger, common whole and how they classify themselves within that larger whole.", [["people", "ORGANISM", 48, 54], ["people", "SPECIES", 48, 54]]], ["The Common Ingroup Identity theory distinguishes the following types of perception and reclassification: recategorization, decategorization and mutual differentiation [21] .", [["recategorization", "TREATMENT", 105, 121]]], ["That being said, the feeling of 'us' is not by definition limited to a single group: a person can possess multiple identities because he or she can be a member of multiple groups [33] .", [["person", "SPECIES", 87, 93]]], ["This brings us to our second hypothesis:RecategorizationThe positive relation between common goal and collaboration is mediated by the partial effect of recategorization.DecategorizationAccording to Gaertner and Dovidio [17] , a common goal causes perceptions to be reclassified into changed perceptions, thus leading to greater collaboration.", [["recategorization", "TREATMENT", 153, 169], ["partial effect", "OBSERVATION", 135, 149]]], ["If a certain situation is perceived as a form of decategorization, the emotional group connections become less important, so that there will be room for individuals to recognize shared identities.", [["decategorization", "TREATMENT", 49, 65]]], ["In turn, this will lead individuals to have more extensive contacts with other individuals, as a result of which prejudices will decrease and positive attitudes towards people in a different group can be developed [17] .", [["people", "ORGANISM", 169, 175], ["people", "SPECIES", 169, 175]]], ["This brings us to our third hypothesis:DecategorizationThe positive relation between common goal and collaboration is mediated by the partial effect of decategorization.Mutual differentiationBrown and Wade [35] and Molleman, Broekhuis, Stoffels and Jaspers [36] conclude that if one wishes to stimulate collaboration, both groups must be able to retain their old identity.", [["Decategorization", "TREATMENT", 39, 55], ["decategorization", "TREATMENT", 152, 168], ["partial effect", "OBSERVATION", 134, 148]]], ["Such a structure, with interdependence and individual space for each group, will ultimately reduce prejudice and tension on either side [21, 37, 38] .", [["prejudice", "OBSERVATION", 99, 108], ["tension", "OBSERVATION_MODIFIER", 113, 120]]], ["According to Gaertner and Dovidio [17] , 'there is a winwin situation which produces positive feelings and stereotyping towards the other group, while the individual's own group can define its own profile'.", [["positive feelings", "PROBLEM", 85, 102]]], ["Both groups will then be able to retain some autonomy within a common whole and they will not stray too far into each other's territory [36] .Mutual differentiationWhere the common goal (in casu One Health) is perceived as collaboration by mutual differentiation, a special focus lies on the importance of each of the groups with respect to their different qualities and expertise.", [["differentiation", "OBSERVATION_MODIFIER", 149, 164]]], ["Hewstone and Brown [40] state that collaboration should be focused on complementary knowledge and expertise.", [["Hewstone", "CHEMICAL", 0, 8]]], ["This brings us to our fourth hypothesis:Mutual differentiationThe positive relation between common goal and collaboration is mediated by the partial effect of mutual differentiation.Knowledge sharingIves, Torrey and Gordon [41] argue that having a clear common interest leads to situations in which an exchange of knowledge can take place.", [["positive", "OBSERVATION", 66, 74], ["partial effect", "OBSERVATION", 141, 155], ["mutual differentiation", "OBSERVATION", 159, 181]]], ["Kramer and Brewer [22] showed that individuals were particularly inclined to share knowledge with others within their own group, but also that they can be more reticent with more distant contacts.", [["individuals", "ORGANISM", 35, 46]]], ["Finally, Holmes [50] demonstrates a positive connection between (continuing) knowledge sharing and mutual ties, trust within a group and collaboration [22, 32, 51] .", [["a positive connection", "PROBLEM", 34, 55]]], ["This brings us to our fifth hypothesis:Knowledge sharingThe positive relation between common goal and collaboration is mediated by the partial effect of knowledge sharing.SampleOur study sample consisted of 368 respondents.", [["SampleOur study sample", "TEST", 171, 193], ["positive", "OBSERVATION", 60, 68]]], ["By means of a digital newsletter from the professional organizationsthe Royal Dutch Veterinary Association (KNMvD) and the Royal Dutch Medical Association (KNMG)human and veterinary healthcare professionals were invited on a one-off basis to complete the questionnaire.", [["human", "ORGANISM", 161, 166], ["human", "SPECIES", 161, 166], ["human", "SPECIES", 161, 166]]], ["The questionnaire was sent to 40,000 human and 5000 veterinary healthcare professionals.", [["human", "ORGANISM", 37, 42], ["human", "SPECIES", 37, 42], ["human", "SPECIES", 37, 42]]], ["In addition to these professional associations, human and veterinary healthcare professionals were contacted via social media such as LinkedIn and Twitter.SampleA total of 595 healthcare professionals responded, 368 of whom completed the survey in full.", [["human", "ORGANISM", 48, 53], ["human", "SPECIES", 48, 53], ["human", "SPECIES", 48, 53]]], ["Of the 368 respondents, 58 (16%) were human healthcare professionals; 310 (84%) were veterinary healthcare professionals.", [["human", "ORGANISM", 38, 43], ["human", "SPECIES", 38, 43], ["human", "SPECIES", 38, 43]]], ["The low response rate demonstrated by the group of human healthcare professionals could be explained by their limited interest in the One Health topic [5] .", [["human", "ORGANISM", 51, 56], ["human", "SPECIES", 51, 56], ["human", "SPECIES", 51, 56], ["low response", "OBSERVATION_MODIFIER", 4, 16]]], ["An illustration of this can be found in the difference in attention paid to the topic in the professional body's journals.", [["body", "ANATOMY", 106, 110], ["body", "ORGANISM_SUBDIVISION", 106, 110]]], ["During the last five years, One Health was mentioned only nine times in the weekly Dutch journal of Human healthcare professionals; in contrast, every monthly issue of the veterinary journal elaborated on the topic.", [["Human", "ORGANISM", 100, 105], ["Human", "SPECIES", 100, 105]]], ["The average age of the respondents was 44, and respondents had been working in the profession for an average of approximately 16 years.", [["average", "OBSERVATION_MODIFIER", 4, 11]]], ["87% of respondents were still active in clinical practice and 10% were working outside clinical practice.", [["active", "OBSERVATION_MODIFIER", 30, 36]]], ["Of the healthcare professionals, 289 respondents (79%) had completed their studies in Utrecht.", [["their studies", "TEST", 69, 82]]], ["Of the 58 human healthcare professionals, 90% had a specialization listed in the Dutch healthcare professions register (BIG).", [["human", "ORGANISM", 10, 15], ["human", "SPECIES", 10, 15], ["human", "SPECIES", 10, 15]]], ["In the veterinary sector, the 310 respondents included 179 domestic animal veterinarians, 27 equine veterinarians, 76 farm veterinarians and 6 special animal veterinarians.", [["equine", "ORGANISM", 93, 99], ["equine", "SPECIES", 93, 99]]], ["These general figures tally with the figures obtained from the professional associations; there are no indications of bias.MeasuresThe variables were measured with a series of questions that had been compiled from various existing validated questionnaires.", [["bias", "PROBLEM", 118, 122], ["no indications of", "UNCERTAINTY", 100, 117]]], ["Many original items were adapted to the specific situation of human and veterinary healthcare professionals in order to ensure that the items were meaningful to them.", [["human", "ORGANISM", 62, 67], ["human", "SPECIES", 62, 67], ["human", "SPECIES", 62, 67]]], ["The questionnaire took approximately 15 min to complete.MeasuresApart from a number of open questions (related to age or the number of working years), all items were based on a Likert scale (1-7) and can be interpreted as continuous variables, thus following the fundamental Ordinary Least Square (OLS) principles.", [["a Likert scale", "TEST", 175, 189]]], ["The sevenpoint scale was used to obtain greater dispersion and hence more nuance in the data [52] .", [["The sevenpoint scale", "TREATMENT", 0, 20]]], ["Table 1 reports the general descriptives of the variables (mean, SD, alpha and correlations).MeasuresThe dependent variable, collaboration, was based on Bock, Zmud, Kim and Lee [53] with a construct reliability score of 0.90, to which the one-item question on the perceived degree of overlap formulated by Schubert and Otten [54] was added (the OSIO -Overlap of Self Ingroup and Outgroup).", [["a construct reliability score", "TEST", 187, 216], ["dependent", "OBSERVATION_MODIFIER", 105, 114], ["variable", "OBSERVATION_MODIFIER", 115, 123]]], ["An example of an item is 'I collaborate when the opportunity arises'.MeasuresCommon goal was based on Fisman and Laupland [2] and Kahn [3] and has a construct reliability score of 0.89.", [["Fisman", "TEST", 102, 108], ["a construct reliability score", "TEST", 147, 176]]], ["Participants were asked the following:Measures\"Thinking of possible collaboration between physicians and veterinarians, to what extent do you agree with the following statements?\".", [["Participants", "SPECIES", 0, 12]]], ["An example of an item is 'I think more could be done to stimulate innovation in healthcare'.MeasuresRecategorization was measured with questions based on Edmondson [55] with a construct reliability of 0.85.", [["a construct reliability", "TEST", 174, 197]]], ["An example of an item is 'In the collaboration between physicians and veterinarians in general, it is possible to raise problems and difficult subjects in the collaboration'.MeasuresDecategorization was measured with a combination of items based on the instruments developed by Doosje, Ellemers and Spears [56] and Shamir, Zakay, Breinin and Popper [57] .", [["Breinin", "SIMPLE_CHEMICAL", 330, 337], ["Decategorization", "TREATMENT", 182, 198], ["a combination of items", "TREATMENT", 217, 239]]], ["An example of an item is 'In the collaboration between physicians and veterinarians in general, it is considered important to make a lasting contribution to the collaboration'.MeasuresMutual differentiation was measured with questions based on Berendsen, Benneker, Groenier, Schuling, Grol and Meyboom-de Jong [58] with a construct reliability of 0.94.", [["a construct reliability", "TEST", 320, 343]]], ["An example of an item is 'In the collaboration between physicians and veterinarians in general, there is appreciation of the expertise of the other professional group and a readiness to pursue contact on it'.MeasuresKnowledge sharing was based on Connolly and Kellaway's study [59] with a construct reliability of 0.82.", [["Kellaway's study", "TEST", 260, 276], ["a construct reliability", "TEST", 287, 310]]], ["An example of an item is 'In the collaboration between physicians and veterinarians in general, I am prepared to share specific professional knowledge (expertise) with the other professional group'.Analysis strategyThe study sample consisted of 368 respondents.", [["Analysis strategy", "TEST", 198, 215], ["The study sample", "TEST", 215, 231]]], ["This size is acceptable in view of the rule of thumb provided by Barclay, Higgins and Thompson [60] , which suggests using ten times the maximum number of paths aiming at any construct in the outer model (this is not applicable as no formative constructs were used) and the inner model.", [["thumb", "ORGANISM_SUBDIVISION", 47, 52], ["inner", "TISSUE", 274, 279], ["formative constructs", "TREATMENT", 234, 254], ["size", "OBSERVATION_MODIFIER", 5, 9], ["acceptable", "OBSERVATION_MODIFIER", 13, 23], ["thumb", "ANATOMY", 47, 52]]], ["All construct variables (Collaboration, Common Goal, Recategorization, Decategorization, Mutual Differentiation, and Knowledge Sharing) are reflective constructs.Analysis strategyFor the outer model evaluation, internal consistency reliability and convergent validity were examined.", [["Analysis strategy", "TEST", 162, 179], ["the outer model evaluation", "TEST", 183, 209], ["internal consistency reliability", "TEST", 211, 243], ["convergent validity", "TEST", 248, 267]]], ["The construct reliability scores ranged between 0.82 and 0.94, which was acceptable [61] , and for the convergent validity the Average Variance Extracted (AVEs) of the constructs was also good [62] ; this is included in Table 1 .", [["The construct reliability scores", "TEST", 0, 32]]], ["Secondly, indicator reliability was examined and all factor loadings were found to be higher than 0.6 and as such acceptable [63] .", [["all factor loadings", "TEST", 49, 68]]], ["The construct and the factor loadings proved to be satisfactory for use in the analysis, although it can be said that the coefficients of the determinants are lowand that they are negligible in the case of Mutual Differentiation and Decategorization for collaboration.", [["the factor loadings", "TEST", 18, 37], ["the analysis", "TEST", 75, 87]]], ["Finally, discriminant validity was checked, comparing the AVEs of the constructs with the inter-construct correlations [62] .", [["discriminant validity", "TEST", 9, 30]]], ["Additionally, cross-loadings were checked.", [["cross-loadings", "TEST", 14, 28]]], ["Evidence was found to exclude three items from Mutual Differentiation due to cross-factor loadings.Analysis strategyPartial Least Squares Path Modelling (PLS-SEM) was conducted with SmartPLS version 2.0 [64] .", [["cross-factor loadings", "PROBLEM", 77, 98], ["Analysis strategy", "TEST", 99, 116], ["PLS", "TEST", 154, 157], ["SmartPLS version", "TEST", 182, 198]]], ["A uniform value of 1 was used as an initial value for each of the outer weights [65] .", [["A uniform value", "TEST", 0, 15], ["the outer weights", "TEST", 62, 79], ["uniform", "OBSERVATION_MODIFIER", 2, 9]]], ["Reliability and convergent validity of the measurement model was also confirmed by computing standardized loadings for indicators ( Table 2) and Bootstrap t-statistics for their significance [66] , see Table 3 .", [["the measurement model", "TEST", 39, 60]]], ["For this bootstrapping, 5000 subsamples were used with a bias-corrected bootstrap testing for a two-tailed significance of 95%.", [["this bootstrapping", "TREATMENT", 4, 22], ["a bias", "TEST", 55, 61], ["bootstrap testing", "TEST", 72, 89]]], ["The coefficient of determination was found to be moderate for Collaboration (R 2 = 0.42).", [["moderate", "OBSERVATION_MODIFIER", 49, 57]]], ["The effect size of Common Goal on Collaboration (f 2 = 0.12), Recategorization on Collaboration (f 2 = 0.03) and Knowledge Sharing on Collaboration (f 2 = 0.04) can be considered small [67] .", [["effect", "OBSERVATION_MODIFIER", 4, 10], ["size", "OBSERVATION_MODIFIER", 11, 15], ["Common", "OBSERVATION_MODIFIER", 19, 25], ["small", "OBSERVATION_MODIFIER", 179, 184]]], ["The effect sizes of Decategorization on Collaboration (f 2 = 0.00) and Mutual Differentiation on Collaboration (f 2 = 0.00) were negligible.Results and discussionTo obtain the Q 2 values as an indicator of the model's predictive relevance, the blindfolding procedure was used, resulting in small predictive relevance for Collaboration (Q 2 = 0.24), Knowledge Sharing (Q 2 = 0.19), and Mutual Differentiation (Q 2 = 0.11).", [["the blindfolding procedure", "TREATMENT", 240, 266], ["Knowledge Sharing (Q 2", "TEST", 349, 371], ["effect", "OBSERVATION_MODIFIER", 4, 10], ["sizes", "OBSERVATION_MODIFIER", 11, 16], ["small", "OBSERVATION_MODIFIER", 290, 295]]], ["The effect size for the predictive relevance of Common Goal on Collaboration was very small (q 2 = 0.05), as was Knowledge Sharing on Collaboration (q 2 = 0.02).", [["effect", "OBSERVATION_MODIFIER", 4, 10], ["size", "OBSERVATION_MODIFIER", 11, 15], ["small", "OBSERVATION_MODIFIER", 86, 91]]], ["The mediation effects are a 1 b 1 = .051 (through Recategorization), a 2 b 2 = .037 (through Decategorization), a 3 b 3 = .024 (through Mutual Differentiation), and a 4 b 4 = .167 (through Knowledge Sharing).", [["Decategorization", "TEST", 93, 109]]], ["All paths show a significant relation.", [["significant", "OBSERVATION_MODIFIER", 17, 28]]], ["This makes the Common Ingroup Identity Model an effective model to provide a plausible explanation why human and veterinary healthcare professionals do or do not collaborate.", [["human", "ORGANISM", 103, 108], ["human", "SPECIES", 103, 108], ["human", "SPECIES", 103, 108]]], ["However, for Decategorization and Mutual Differentiation, there is a significant relation with Common Goal and with Collaboration; Decategorization and Mutual Differentiation have a direct relation with Collaboration that is not a mediating relation.Results and discussionThe PLS analysis confirms that a common goal promotes collaboration.", [["Decategorization", "TREATMENT", 13, 29], ["Decategorization", "TREATMENT", 131, 147], ["The PLS analysis", "TEST", 272, 288]]], ["Bootstrapping the indirect effects of Common Goal on Collaboration, we found that Recategorization (0,051) and Knowledge Sharing (0,167) are significant mediators, thus supporting hypotheses 2 and 5.", [["Recategorization", "TEST", 82, 98]]], ["The specific indirect effect through Knowledge Sharing is larger than through Recategorization (effect Recategorization is significantly smaller; see contrasts) [68] .Results and discussionSignificant relations were found between Common Goal via Decategorization with Collaboration and for Mutual Differentiation with collaboration.", [["larger", "OBSERVATION_MODIFIER", 58, 64]]], ["No evidence was found to support hypotheses 2 (mediating effect of decategorization) and 3 (mediating effect of mutual differentiation).", [["decategorization)", "TREATMENT", 67, 84]]], ["Nevertheless, the results indicate an intervening effect for Decategorization and Mutual Differentiation, resulting in a satisfactory explanation why human and veterinary healthcare professionals do or do not collaborate.", [["human", "ORGANISM", 150, 155], ["human", "SPECIES", 150, 155], ["human", "SPECIES", 150, 155], ["Decategorization", "TREATMENT", 61, 77]]], ["All four elements (Recategorization, Decategorization, Mutual Differentiation and Knowledge Sharing) are relevant; Recategorization and Knowledge Sharing are mediating variables.Results and discussionCommon Goal proved to be an important factor for promoting collaboration between human and veterinary healthcare professionals.", [["human", "ORGANISM", 281, 286], ["human", "SPECIES", 281, 286], ["human", "SPECIES", 281, 286]]], ["This relationship is partly explained by the mediating role of recategorizing and knowledge sharing, but also partly by the intervening Having a common goal (in casu One Health) produces altered perceptions in the form of an overarching identity.", [["overarching identity", "OBSERVATION", 225, 245]]], ["Upon recognizing their interdependence, human and veterinary healthcare professionals will initiate collaboration [27] .", [["human", "ORGANISM", 40, 45], ["human", "SPECIES", 40, 45], ["human", "SPECIES", 40, 45]]], ["Collaboration, if there is a common goal, must therefore be seen to a greater extent as interdependence, as described earlier by Mohr and Spekman [69] , in which there is still scope to retain individual identity, as argued by Brown and Wade [35] and Molleman et al. [36] .", [["greater extent", "OBSERVATION_MODIFIER", 70, 84]]], ["Gaertner and Dovidio [17] showed that a common goal leads to a reduction of prejudice and resistance between groups (thus influencing the perception of the situation), which in turn has an influence on collaboration.", [["a reduction of prejudice", "TREATMENT", 61, 85], ["prejudice", "OBSERVATION", 76, 85]]], ["This study shows that in addition to recategorization, knowledge sharing also has a mediating role with respect to the influence of a common goal (One Health) on cooperation.", [["This study", "TEST", 0, 10]]], ["Findings indicate that One Health stimulates knowledge sharing and in this way enhances collaboration between human and veterinary healthcare professionals.", [["human", "ORGANISM", 110, 115], ["human", "SPECIES", 110, 115], ["human", "SPECIES", 110, 115]]], ["It may therefore be concluded that knowledge sharing is a promoting factor for human and veterinary healthcare professionals to use each other's expertise [42] [43] [44] .", [["human", "ORGANISM", 79, 84], ["human", "SPECIES", 79, 84], ["human", "SPECIES", 79, 84]]], ["This study has shown that knowledge sharing is in fact stimulated if the common goal of One Health is perceived as an invitation to work together on the basis of mutual interdependence.", [["This study", "TEST", 0, 10]]], ["Seen in this way, continuous knowledge sharing will ultimately improve the ties and the forms of collaboration between the two groups of healthcare professionals [50] .Results and discussionThis study has also shown that Decategorization has a significant effect in the relation between Common Goal and Collaboration, although this is not a mediating but an intervening effect.", [["This study", "TEST", 190, 200]]], ["Our analyses show that this path, which has also been described by Gaertner and Dovidio [17] , also applies to the human and veterinary healthcare professionals.", [["human", "ORGANISM", 115, 120], ["human", "SPECIES", 115, 120], ["human", "SPECIES", 115, 120], ["Our analyses", "TEST", 0, 12]]], ["Many healthcare professionals will be of the opinion that decategorization is not sufficiently concrete; they will therefore give it little importance, which might explain why we did not find a mediating effect.Results and discussionThis study has also revealed that Mutual Differentiation expresses a significant relation between Common Goal and Collaboration.", [["This study", "TEST", 233, 243], ["significant", "OBSERVATION_MODIFIER", 302, 313]]], ["However, as with Decategorization, there is no mediating effect between Collaboration and Common Goal for Mutual Differentiation.", [["no mediating", "UNCERTAINTY", 44, 56]]], ["It may therefore be concluded that Mutual Differentiation helps to explain the collaboration between human and veterinary healthcare professionals.", [["human", "ORGANISM", 101, 106], ["human", "SPECIES", 101, 106], ["human", "SPECIES", 101, 106]]], ["A possible explanation for the fact that no mediating effect was found for Mutual Differentiation may be limited insight in each other's sectors and expertise, and any untapped added value still to be discovered [2] .Practical implicationsThe current study's findings indicate that in order to achieve greater collaboration between human and veterinary healthcare professionals, it is first and foremost necessary to define a common goal.", [["human", "ORGANISM", 332, 337], ["human", "SPECIES", 332, 337], ["human", "SPECIES", 332, 337], ["The current study", "TEST", 239, 256], ["possible explanation for", "UNCERTAINTY", 2, 26]]], ["A common goal (as investigated in this study) only comes into existence as a result of this concreteness, and this will trigger the mechanisms required to create an overarching identity [21] .Practical implicationsFurthermore, it is of importance for both groups of healthcare professionals to know each other and to realize that they have a shared responsibility, not only in terms of combatting infectious diseases, but also in terms of providing optimum care for patients.", [["infectious diseases", "DISEASE", 397, 416], ["patients", "ORGANISM", 466, 474], ["patients", "SPECIES", 466, 474], ["this study", "TEST", 34, 44], ["infectious diseases", "PROBLEM", 397, 416]]], ["As respondents in the current study reported, fewer than 25% read a professional journal related to the other sector.", [["the current study", "TEST", 18, 35]]], ["In addition to the publication of articles in each other's professional journals, professional associations could offer joint interdisciplinary training programmes and refresher courses.Practical implicationsIt has become increasingly clear that greater awareness of the added value of the common goal results in more extensive cooperation [21, 37, 38] .", [["joint interdisciplinary training programmes", "TREATMENT", 120, 163], ["refresher courses", "TREATMENT", 168, 185], ["increasingly", "OBSERVATION_MODIFIER", 222, 234], ["clear", "OBSERVATION", 235, 240], ["greater", "OBSERVATION_MODIFIER", 246, 253]]], ["This awareness reveals not only what both groups of healthcare professionals have in common, but also that human and veterinary healthcare professionals have more in common than they themselves realize.", [["human", "ORGANISM", 107, 112], ["human", "SPECIES", 107, 112], ["human", "SPECIES", 107, 112]]], ["This awareness among both groups of healthcare professionals could be further improved via the communications issued by their professional groups.Limitations and future researchAs the current study was a cross-sectional study, it has certain limitations concerning long-term effects or relations.", [["the current study", "TEST", 180, 197], ["a cross-sectional study", "TEST", 202, 225], ["long-term effects", "PROBLEM", 265, 282], ["long-term effects", "OBSERVATION_MODIFIER", 265, 282]]], ["In addition, an international study is needed to compare the different worlds.", [["an international study", "TEST", 13, 35]]], ["For instance, to the best of our knowledge, in the Western world veterinarians generally are greater all-rounders than physicians, but in the developing countries we see that physicians are also allrounders; one would expect that the psychological barrier will be lower between these health care professionals.", [["the psychological barrier", "TREATMENT", 230, 255]]], ["We expect this to have an influence on their cooperation.ConclusionTo the best of our knowledge, this study is the first research project in which the Common Ingroup Identity Model is quantitatively researched with the help of questionnaires.", [["this study", "TEST", 97, 107]]], ["The healthcare sector, and specifically the interaction between the human and veterinary fields, offers untapped potential, such as the development of treatments which could improve the healthcare as a whole.ConclusionEvery study that analyzes the interaction between the two fields and addresses the healthcare professional's social dilemma will be of immense value to society and can possibly give indications how to improve the quality of life.", [["human", "ORGANISM", 68, 73], ["human", "SPECIES", 68, 73], ["human", "SPECIES", 68, 73], ["treatments", "TREATMENT", 151, 161], ["ConclusionEvery study", "TEST", 208, 229]]], ["This study has shown that the Common Ingroup Identity Model helps to explain why human and veterinary healthcare professionals do or do not collaborate.", [["human", "ORGANISM", 81, 86], ["human", "SPECIES", 81, 86], ["human", "SPECIES", 81, 86], ["This study", "TEST", 0, 10]]]], "PMC7486051": [["IntroductionOld age, obesity, BAME (Black, Asian, and minority ethnicity) and male gender are all associated with higher IL6 levels [1], [2], [3], [4].", [["obesity", "DISEASE", 21, 28], ["IL6", "GENE_OR_GENE_PRODUCT", 121, 124], ["IL6", "PROTEIN", 121, 124], ["obesity", "PROBLEM", 21, 28], ["BAME (Black, Asian, and minority ethnicity", "PROBLEM", 30, 72], ["higher IL6 levels", "TEST", 114, 131], ["obesity", "OBSERVATION", 21, 28]]], ["Observationally, interleukin-6 (IL-6) elevation has been associated with poorer outcomes in severe covid-19 infection [5], [6].", [["infection", "DISEASE", 108, 117], ["interleukin-6", "GENE_OR_GENE_PRODUCT", 17, 30], ["IL-6", "GENE_OR_GENE_PRODUCT", 32, 36], ["interleukin-6", "PROTEIN", 17, 30], ["interleukin", "TEST", 17, 28], ["elevation", "PROBLEM", 38, 47], ["severe covid-19 infection", "PROBLEM", 92, 117]]], ["It is possible that constitutive (premorbid) IL-6 elevation may also increase the likelihood of Covid-19 infection through the following mechanisms: COVID-19 requires cathepsin L to infect pulmonary epithelial cells [7], with cathepsin L production upregulated by IL-6 [8].", [["pulmonary epithelial cells", "ANATOMY", 189, 215], ["infection", "DISEASE", 105, 114], ["IL-6", "GENE_OR_GENE_PRODUCT", 45, 49], ["Covid-19", "GENE_OR_GENE_PRODUCT", 96, 104], ["COVID-19", "GENE_OR_GENE_PRODUCT", 149, 157], ["cathepsin L", "GENE_OR_GENE_PRODUCT", 167, 178], ["pulmonary epithelial cells", "CELL", 189, 215], ["cathepsin L", "GENE_OR_GENE_PRODUCT", 226, 237], ["IL-6", "GENE_OR_GENE_PRODUCT", 264, 268], ["cathepsin L", "PROTEIN", 167, 178], ["pulmonary epithelial cells", "CELL_TYPE", 189, 215], ["cathepsin L", "PROTEIN", 226, 237], ["IL", "PROTEIN", 264, 266], ["constitutive (premorbid) IL-6 elevation", "PROBLEM", 20, 59], ["Covid-19 infection", "PROBLEM", 96, 114], ["COVID", "TEST", 149, 154], ["cathepsin", "TREATMENT", 167, 176], ["pulmonary epithelial cells", "PROBLEM", 189, 215], ["cathepsin L production", "TREATMENT", 226, 248], ["infection", "OBSERVATION", 105, 114], ["pulmonary", "ANATOMY", 189, 198], ["epithelial cells", "OBSERVATION", 199, 215]]], ["This interleukin also likely upregulates expression of the ACE2 receptor which the virus utilizes for cellular entry - see Table S2 of the article by Schouten, et al [9].IntroductionLow vitamin D levels are common in older adults, the obese and those with darkly pigmented skin [10].", [["cellular", "ANATOMY", 102, 110], ["skin", "ANATOMY", 273, 277], ["vitamin D", "CHEMICAL", 186, 195], ["vitamin D", "CHEMICAL", 186, 195], ["interleukin", "GENE_OR_GENE_PRODUCT", 5, 16], ["ACE2", "GENE_OR_GENE_PRODUCT", 59, 63], ["cellular", "CELL", 102, 110], ["vitamin D", "SIMPLE_CHEMICAL", 186, 195], ["skin", "ORGAN", 273, 277], ["interleukin", "PROTEIN", 5, 16], ["ACE2 receptor", "PROTEIN", 59, 72], ["the ACE2 receptor", "TREATMENT", 55, 72], ["the virus", "PROBLEM", 79, 88], ["cellular entry", "TEST", 102, 116], ["IntroductionLow vitamin D levels", "TEST", 170, 202], ["obese", "OBSERVATION", 235, 240], ["skin", "ANATOMY", 273, 277]]], ["These constituencies have also experienced disproportionately high morbidity and mortality from Covid-19 [11], [12].IntroductionThis paper proposes that IL6 elevation lies at the nexus between low vitamin D status and higher risk of Covid-19 infection, severe morbidity and death in these vulnerable populations.", [["vitamin D", "CHEMICAL", 197, 206], ["infection", "DISEASE", 242, 251], ["death", "DISEASE", 274, 279], ["vitamin D", "CHEMICAL", 197, 206], ["IL6", "GENE_OR_GENE_PRODUCT", 153, 156], ["vitamin D", "SIMPLE_CHEMICAL", 197, 206], ["Covid-19", "ORGANISM", 233, 241], ["IL6", "PROTEIN", 153, 156], ["Covid-19", "SPECIES", 233, 241], ["high morbidity", "PROBLEM", 62, 76], ["Covid-", "TEST", 96, 102], ["IL6 elevation", "PROBLEM", 153, 166], ["low vitamin D status", "PROBLEM", 193, 213], ["Covid-19 infection", "PROBLEM", 233, 251], ["severe morbidity", "PROBLEM", 253, 269], ["death", "PROBLEM", 274, 279], ["infection", "OBSERVATION", 242, 251], ["severe", "OBSERVATION_MODIFIER", 253, 259], ["morbidity", "OBSERVATION", 260, 269], ["vulnerable", "OBSERVATION_MODIFIER", 289, 299]]], ["It further proposes that these IL6-mediated risks can be ameliorated by vitamin D supplementation appears to inhibit IL6 expression [13].IntroductionThe primary objective of this study was to determine whether IL-6 levels in healthy individuals from a similar demographic to patients infected with COVID-19 correlate with severity of clinical manifestations.", [["vitamin D", "CHEMICAL", 72, 81], ["vitamin D", "CHEMICAL", 72, 81], ["COVID-19", "CHEMICAL", 298, 306], ["IL6", "GENE_OR_GENE_PRODUCT", 31, 34], ["vitamin D", "SIMPLE_CHEMICAL", 72, 81], ["IL6", "GENE_OR_GENE_PRODUCT", 117, 120], ["IL-6", "GENE_OR_GENE_PRODUCT", 210, 214], ["patients", "ORGANISM", 275, 283], ["IL6", "PROTEIN", 31, 34], ["IL6", "PROTEIN", 117, 120], ["IL-6", "PROTEIN", 210, 214], ["patients", "SPECIES", 275, 283], ["these IL6-mediated risks", "TREATMENT", 25, 49], ["vitamin D supplementation", "TREATMENT", 72, 97], ["this study", "TEST", 174, 184], ["IL", "TEST", 210, 212], ["COVID", "TEST", 298, 303], ["clinical manifestations", "PROBLEM", 334, 357]]], ["A secondary objective was to review evidence from recent clinical trials supporting the use of Vitamin D to lower IL-6 levels.IL-6 Levels and Severity of Clinical Manifestations ::: Materials and MethodsGiven the range of severity of clinical manifestations of COVID-19, analysis was limited to assessment of mortality.", [["Vitamin D", "CHEMICAL", 95, 104], ["Vitamin D", "CHEMICAL", 95, 104], ["Vitamin D", "SIMPLE_CHEMICAL", 95, 104], ["IL-6", "GENE_OR_GENE_PRODUCT", 114, 118], ["IL-6", "GENE_OR_GENE_PRODUCT", 126, 130], ["IL-6", "PROTEIN", 114, 118], ["IL", "PROTEIN", 126, 128], ["Vitamin D to lower IL", "TREATMENT", 95, 116], ["IL", "TEST", 126, 128], ["COVID", "TEST", 261, 266], ["analysis", "TEST", 271, 279], ["assessment", "TEST", 295, 305]]], ["To limit any potential confounding factors, the literature was searched for results of IL-6 determinations in healthy individuals with included age and sex data from specific geographical regions for which published mortality rates from COVID-19 were available.", [["IL-6", "GENE_OR_GENE_PRODUCT", 87, 91], ["IL-6", "PROTEIN", 87, 91], ["published mortality rates", "TEST", 206, 231], ["COVID", "TEST", 237, 242]]], ["The largest study, in terms of numbers of subjects, by Stowe and colleagues [3], did not include detailed demographic information broken down into age groups, so analysis was performed on data from an Italian study that examined IL-6 from the Tuscany region [14].", [["IL-6", "GENE_OR_GENE_PRODUCT", 229, 233], ["IL-6", "PROTEIN", 229, 233], ["The largest study", "TEST", 0, 17], ["an Italian study", "TEST", 198, 214], ["largest", "OBSERVATION_MODIFIER", 4, 11]]], ["Data on COVID-19 mortality from Italy broken down by age were sourced from statista.com [15] with a time point (to end of May 2020) chosen to correspond with the results of the study by Williamson, et al [11].", [["COVID", "TEST", 8, 13], ["the study", "TEST", 173, 182]]], ["Italian gender mortality data published as raw numbers [16] were converted to death rates/million derived from accepted sources [17].", [["death", "DISEASE", 78, 83], ["death rates", "PROBLEM", 78, 89]]], ["Statistical analysis on age data was carried out using the Pearson Correlation Coefficient Calculator.", [["Statistical analysis", "TEST", 0, 20], ["age data", "TEST", 24, 32]]], ["Data on sex, ethnic minority status and BMI were insufficient for statistical analysis, and these were assessed qualitatively.", [["BMI", "TEST", 40, 43], ["statistical analysis", "TEST", 66, 86]]], ["Age data were stratified slightly differently in each study, with the majority quoting in increments of 10 years from 20 years of age upwards.", [["each study", "TEST", 49, 59]]], ["Where included studies stratified age groups in different formats, ages were rounded to nearest multiple of 10.", [["studies", "TEST", 15, 22], ["rounded", "OBSERVATION_MODIFIER", 77, 84]]], ["For example, recently published UK data included a category of 18 to 40 years of age [6]; this category was rounded up to 20 to 40 in the analysis.", [["this category", "TEST", 90, 103], ["the analysis", "TEST", 134, 146], ["rounded", "OBSERVATION_MODIFIER", 108, 115]]], ["Other studies, including that by Ferruci and colleagues [14] included a category in the format \u201c20 to 39\u201d years of age, which was rounded up to 20 to 40.Vitamin D and IL-6 Levels ::: Materials and MethodsA limited narrative review of recent clinical trials supporting the use of Vitamin D administration to lower IL-6 levels was performed by searching PubMed and Google Scholar for adult human research studies published from January 1, 2015 that included key words \u201cvitamin D\u201d and/or \u201cinterleukin-6\u201d and/or \u201cIL-6\u201d.", [["Vitamin D", "CHEMICAL", 153, 162], ["Vitamin D", "CHEMICAL", 279, 288], ["vitamin D", "CHEMICAL", 467, 476], ["Vitamin D", "CHEMICAL", 153, 162], ["Vitamin D", "CHEMICAL", 279, 288], ["vitamin D", "CHEMICAL", 467, 476], ["Vitamin D", "SIMPLE_CHEMICAL", 153, 162], ["IL-6", "GENE_OR_GENE_PRODUCT", 167, 171], ["Vitamin D", "SIMPLE_CHEMICAL", 279, 288], ["IL-6", "GENE_OR_GENE_PRODUCT", 313, 317], ["human", "ORGANISM", 388, 393], ["vitamin D", "SIMPLE_CHEMICAL", 467, 476], ["interleukin-6", "GENE_OR_GENE_PRODUCT", 486, 499], ["IL-6", "GENE_OR_GENE_PRODUCT", 509, 513], ["IL", "PROTEIN", 313, 315], ["interleukin", "PROTEIN", 486, 497], ["IL", "PROTEIN", 509, 511], ["human", "SPECIES", 388, 393], ["human", "SPECIES", 388, 393], ["Other studies", "TEST", 0, 13], ["Vitamin D and IL", "TEST", 153, 169], ["Vitamin D administration", "TREATMENT", 279, 303], ["vitamin D\u201d", "TREATMENT", 467, 477], ["interleukin", "TREATMENT", 486, 497], ["rounded", "OBSERVATION_MODIFIER", 130, 137]]], ["As there was heterogeneity in the format of how results were published, analysis was limited to whether administration of Vitamin D resulted in a statistically significant reduction in IL-6 level.Premorbid IL-6 Levels Correlate Strongly with Age-Stratified Mortality ::: ResultsThe data on Italian mortality [15] provided raw numerical deaths by population groups but did not provide information on stratified mortality rates by age group.", [["Vitamin D", "CHEMICAL", 122, 131], ["deaths", "DISEASE", 336, 342], ["Vitamin D", "CHEMICAL", 122, 131], ["Vitamin D", "SIMPLE_CHEMICAL", 122, 131], ["IL-6", "GENE_OR_GENE_PRODUCT", 185, 189], ["IL-6", "GENE_OR_GENE_PRODUCT", 206, 210], ["IL-6", "PROTEIN", 185, 189], ["IL", "PROTEIN", 206, 208], ["analysis", "TEST", 72, 80], ["Vitamin D", "TREATMENT", 122, 131], ["a statistically significant reduction in IL", "TREATMENT", 144, 187], ["Premorbid IL", "TEST", 196, 208], ["significant", "OBSERVATION_MODIFIER", 160, 171], ["reduction", "OBSERVATION_MODIFIER", 172, 181]]], ["To assess the validity of using this data, these results were compared with stratified mortality rate data in a large UK study [6] (see Table 1).", [["this data", "TEST", 32, 41], ["a large UK study", "TEST", 110, 126]]], ["There was an extremely strong correlation between age stratified Italian raw numerical deaths and UK mortality rates (r(6) = 0.9837; 95% CI: 0.85 \u2013 1.0; p = 0.00396, see Figure 1).", [["deaths", "DISEASE", 87, 93], ["UK mortality rates", "TEST", 98, 116], ["CI", "TEST", 137, 139], ["p", "TEST", 153, 154]]], ["Given the likely validity of using the Italian data, these were compared with IL-6 levels derived from a healthy Italian population [14].", [["IL-6", "GENE_OR_GENE_PRODUCT", 78, 82], ["IL", "PROTEIN", 78, 80]]], ["There was an extremely strong correlation between age stratified Italian raw numerical deaths and IL-6 levels (r(6) = 0.9883; 95% CI: 0.89 \u2013 1.0; p = 0.00025, see Table 2and Figure 2).", [["deaths", "DISEASE", 87, 93], ["IL-6", "GENE_OR_GENE_PRODUCT", 98, 102], ["IL", "PROTEIN", 98, 100], ["IL", "TEST", 98, 100], ["CI", "TEST", 130, 132], ["p", "TEST", 146, 147]]], ["As a broad test to confirm this, UK death rates were also compared with historic UK data published by Wei and colleagues [1] on IL-6 levels in a similar population.", [["death", "DISEASE", 36, 41], ["IL-6", "GENE_OR_GENE_PRODUCT", 128, 132], ["IL", "PROTEIN", 128, 130], ["a broad test", "TEST", 3, 15], ["IL", "TEST", 128, 130]]], ["Mean death rates in patients over 60 were more than 10 times higher than in patients under 50; mean levels of IL-6 were higher in older patients, although only by 26%.Beneficial Effect of Vitamin D on Lowering IL-6 Levels ::: ResultsOf the 11 studies included in the analysis, 11 identified a significant effect of Vitamin D administration on IL-6 (p < 0.05) and the remaining 3 found no effect.", [["death", "DISEASE", 5, 10], ["Vitamin D", "CHEMICAL", 188, 197], ["Vitamin D", "CHEMICAL", 315, 324], ["Vitamin D", "CHEMICAL", 188, 197], ["Vitamin D", "CHEMICAL", 315, 324], ["patients", "ORGANISM", 20, 28], ["patients", "ORGANISM", 76, 84], ["IL-6", "GENE_OR_GENE_PRODUCT", 110, 114], ["patients", "ORGANISM", 136, 144], ["Vitamin D", "SIMPLE_CHEMICAL", 188, 197], ["IL-6", "GENE_OR_GENE_PRODUCT", 210, 214], ["Vitamin D", "SIMPLE_CHEMICAL", 315, 324], ["IL-6", "GENE_OR_GENE_PRODUCT", 343, 347], ["IL", "PROTEIN", 110, 112], ["IL", "PROTEIN", 343, 345], ["patients", "SPECIES", 20, 28], ["patients", "SPECIES", 76, 84], ["patients", "SPECIES", 136, 144], ["Mean death rates", "TEST", 0, 16], ["mean levels", "TEST", 95, 106], ["IL", "TEST", 110, 112], ["Vitamin D on Lowering IL", "TREATMENT", 188, 212], ["the 11 studies", "TEST", 236, 250], ["the analysis", "TEST", 263, 275], ["Vitamin D administration", "TREATMENT", 315, 339], ["IL", "TEST", 343, 345], ["significant", "OBSERVATION_MODIFIER", 293, 304], ["no", "UNCERTAINTY", 385, 387]]], ["The results of this analysis are displayed in Table 3.DiscussionThis is the first study to have demonstrated a significant correlation between IL-6 levels in matched healthy individuals and age-stratified mortality from COVID-19.", [["IL-6", "GENE_OR_GENE_PRODUCT", 143, 147], ["IL-6", "PROTEIN", 143, 147], ["this analysis", "TEST", 15, 28], ["the first study", "TEST", 72, 87], ["COVID", "TEST", 220, 225]]], ["The large analysis by Williamson, et al [11] also indicated other risk factors for increased mortality including sex, obesity and ethnicity.", [["obesity", "DISEASE", 118, 125], ["increased mortality", "PROBLEM", 83, 102], ["obesity", "PROBLEM", 118, 125], ["large", "OBSERVATION_MODIFIER", 4, 9], ["obesity", "OBSERVATION", 118, 125]]], ["Interestingly, UK male death rates were 72% higher than amongst females [11]; this compares with data published by Wei, et al in 1992 [1] in which mean UK IL-6 levels for males were 112% greater than mean female levels.", [["death", "DISEASE", 23, 28], ["IL-6", "GENE_OR_GENE_PRODUCT", 155, 159], ["IL", "PROTEIN", 155, 157], ["death rates", "TEST", 23, 34], ["mean UK IL", "TEST", 147, 157], ["males", "TEST", 171, 176]]], ["Italian death rates were 55% higher than amongst females [11]; this compares with data published by Ferruci and colleagues [14] in 2006 in which mean Italian IL-6 levels for males were 23% higher than mean female levels.", [["death", "DISEASE", 8, 13], ["IL-6", "GENE_OR_GENE_PRODUCT", 158, 162], ["IL", "PROTEIN", 158, 160], ["Italian death rates", "TEST", 0, 19], ["Italian IL", "TEST", 150, 160], ["males", "TEST", 174, 179]]], ["Similarly, death rates amongst UK patients of black ethnicity were 40% higher than amongst white patients [11], compared with 59% greater IL-6 levels amongst black patients derived from a US study [3].", [["death", "DISEASE", 11, 16], ["UK", "ORGANISM", 31, 33], ["patients", "ORGANISM", 34, 42], ["patients", "ORGANISM", 97, 105], ["IL-6", "GENE_OR_GENE_PRODUCT", 138, 142], ["patients", "ORGANISM", 164, 172], ["IL", "PROTEIN", 138, 140], ["patients", "SPECIES", 34, 42], ["patients", "SPECIES", 97, 105], ["patients", "SPECIES", 164, 172], ["black ethnicity", "PROBLEM", 46, 61], ["a US study", "TEST", 186, 196]]], ["Mean UK death rates in obese patients were 48% higher than in non-obese patients [11]; this compared with IL-6 levels more than 300 times greater in obese patients from a US study [2].", [["death", "DISEASE", 8, 13], ["non-obese", "DISEASE", 62, 71], ["UK", "GENE_OR_GENE_PRODUCT", 5, 7], ["patients", "ORGANISM", 29, 37], ["patients", "ORGANISM", 72, 80], ["IL-6", "GENE_OR_GENE_PRODUCT", 106, 110], ["patients", "ORGANISM", 155, 163], ["IL", "PROTEIN", 106, 108], ["patients", "SPECIES", 29, 37], ["patients", "SPECIES", 72, 80], ["patients", "SPECIES", 155, 163], ["Mean UK death rates", "TEST", 0, 19], ["IL", "TEST", 106, 108], ["a US study", "TEST", 169, 179]]], ["These findings on sex, obesity and ethnicity, together with the age data analysis herein reported, suggest that IL-6 may have a far more important role in the pathogenesis of viral infection than previously thought.", [["obesity", "DISEASE", 23, 30], ["viral infection", "DISEASE", 175, 190], ["IL-6", "GENE_OR_GENE_PRODUCT", 112, 116], ["IL-6", "PROTEIN", 112, 116], ["obesity", "PROBLEM", 23, 30], ["viral infection", "PROBLEM", 175, 190], ["obesity", "OBSERVATION", 23, 30], ["viral", "OBSERVATION_MODIFIER", 175, 180], ["infection", "OBSERVATION", 181, 190]]], ["IL-6 upregulates cathepsin L production [8], which then cleaves the virus, enabling it to infect pulmonary epithelial cells [7].", [["pulmonary epithelial cells", "ANATOMY", 97, 123], ["IL-6", "GENE_OR_GENE_PRODUCT", 0, 4], ["cathepsin L", "GENE_OR_GENE_PRODUCT", 17, 28], ["pulmonary epithelial cells", "CELL", 97, 123], ["IL-6", "PROTEIN", 0, 4], ["cathepsin L", "PROTEIN", 17, 28], ["pulmonary epithelial cells", "CELL_TYPE", 97, 123], ["IL", "TREATMENT", 0, 2], ["cathepsin L production", "TREATMENT", 17, 39], ["the virus", "PROBLEM", 64, 73], ["pulmonary", "ANATOMY", 97, 106], ["epithelial cells", "OBSERVATION", 107, 123]]], ["IL-6 also upregulates the Angiotensin II AT1 receptor [18], and likely upregulates pulmonary epithelial cell ACE2 receptors, with a positive correlation between IL-6 and ACE2 levels in bronchioalveolar lavage (BAL) in patients with severe acute pulmonary inflammation [9].", [["pulmonary epithelial cell", "ANATOMY", 83, 108], ["bronchioalveolar lavage", "ANATOMY", 185, 208], ["BAL", "ANATOMY", 210, 213], ["pulmonary", "ANATOMY", 245, 254], ["Angiotensin II", "CHEMICAL", 26, 40], ["acute pulmonary inflammation", "DISEASE", 239, 267], ["IL-6", "GENE_OR_GENE_PRODUCT", 0, 4], ["Angiotensin II AT1 receptor", "GENE_OR_GENE_PRODUCT", 26, 53], ["pulmonary epithelial cell", "CELL", 83, 108], ["ACE2", "GENE_OR_GENE_PRODUCT", 109, 113], ["IL-6", "GENE_OR_GENE_PRODUCT", 161, 165], ["ACE2", "GENE_OR_GENE_PRODUCT", 170, 174], ["bronchioalveolar lavage", "ORGANISM_SUBSTANCE", 185, 208], ["BAL", "MULTI-TISSUE_STRUCTURE", 210, 213], ["patients", "ORGANISM", 218, 226], ["pulmonary", "ORGAN", 245, 254], ["IL-6", "PROTEIN", 0, 4], ["Angiotensin II AT1 receptor", "PROTEIN", 26, 53], ["pulmonary epithelial cell ACE2 receptors", "PROTEIN", 83, 123], ["IL-6", "PROTEIN", 161, 165], ["ACE2", "PROTEIN", 170, 174], ["patients", "SPECIES", 218, 226], ["IL", "TREATMENT", 0, 2], ["the Angiotensin II AT1 receptor", "TREATMENT", 22, 53], ["upregulates pulmonary epithelial cell ACE2 receptors", "PROBLEM", 71, 123], ["IL", "TEST", 161, 163], ["ACE2 levels", "TEST", 170, 181], ["bronchioalveolar lavage", "TEST", 185, 208], ["severe acute pulmonary inflammation", "PROBLEM", 232, 267], ["pulmonary", "ANATOMY", 83, 92], ["epithelial cell", "OBSERVATION", 93, 108], ["ACE2 receptors", "OBSERVATION", 109, 123], ["bronchioalveolar", "ANATOMY", 185, 201], ["lavage", "OBSERVATION", 202, 208], ["severe", "OBSERVATION_MODIFIER", 232, 238], ["acute", "OBSERVATION_MODIFIER", 239, 244], ["pulmonary", "ANATOMY", 245, 254], ["inflammation", "OBSERVATION", 255, 267]]], ["Viral reproduction within pulmonary epithelial cells then recruits inflammatory cells which, in turn produce cytokines, as part of the \u201ccytokine storm\u201d phenomenon [19] including IL-6.", [["pulmonary epithelial cells", "ANATOMY", 26, 52], ["inflammatory cells", "ANATOMY", 67, 85], ["pulmonary epithelial cells", "CELL", 26, 52], ["inflammatory cells", "CELL", 67, 85], ["IL-6", "GENE_OR_GENE_PRODUCT", 178, 182], ["pulmonary epithelial cells", "CELL_TYPE", 26, 52], ["inflammatory cells", "CELL_TYPE", 67, 85], ["cytokines", "PROTEIN", 109, 118], ["cytokine", "PROTEIN", 136, 144], ["IL-6", "PROTEIN", 178, 182], ["Viral reproduction within pulmonary epithelial cells", "PROBLEM", 0, 52], ["inflammatory cells", "PROBLEM", 67, 85], ["pulmonary", "ANATOMY", 26, 35], ["epithelial cells", "OBSERVATION", 36, 52], ["inflammatory cells", "OBSERVATION", 67, 85]]], ["This could be expected to set up a noxious cycle between immune cells and pulmonary epithelium which the virus utilizes to enter cells and replicate (see Figure 3).", [["immune cells", "ANATOMY", 57, 69], ["pulmonary epithelium", "ANATOMY", 74, 94], ["cells", "ANATOMY", 129, 134], ["immune cells", "CELL", 57, 69], ["pulmonary epithelium", "TISSUE", 74, 94], ["cells", "CELL", 129, 134], ["immune cells", "CELL_TYPE", 57, 69], ["a noxious cycle", "TEST", 33, 48], ["immune cells", "PROBLEM", 57, 69], ["pulmonary epithelium", "PROBLEM", 74, 94], ["the virus", "PROBLEM", 101, 110], ["pulmonary", "ANATOMY", 74, 83], ["epithelium", "ANATOMY_MODIFIER", 84, 94]]], ["The principal predisposing factor could well be IL-6, with premorbid levels correlating with stratified mortality rates.", [["IL-6", "GENE_OR_GENE_PRODUCT", 48, 52], ["IL", "PROTEIN", 48, 50], ["premorbid levels", "TEST", 59, 75], ["stratified mortality rates", "TEST", 93, 119]]], ["There are other manifestations of this infection that could readily be attributed to IL-6.", [["infection", "DISEASE", 39, 48], ["IL-6", "GENE_OR_GENE_PRODUCT", 85, 89], ["IL-6", "PROTEIN", 85, 89], ["this infection", "PROBLEM", 34, 48], ["infection", "OBSERVATION", 39, 48]]], ["Levels of this interleukin are generally low in children, but there is a short spurt in early childhood [20], correlating with a recently described severe COVID-19 manifestation in young children, a Kawasaki-like condition [21].", [["Kawasaki-like condition", "DISEASE", 199, 222], ["interleukin", "GENE_OR_GENE_PRODUCT", 15, 26], ["children", "ORGANISM", 48, 56], ["children", "ORGANISM", 187, 195], ["interleukin", "PROTEIN", 15, 26], ["children", "SPECIES", 48, 56], ["children", "SPECIES", 187, 195], ["low", "OBSERVATION_MODIFIER", 41, 44], ["severe", "OBSERVATION_MODIFIER", 148, 154]]], ["IL-6 is also thrombogenic, which may well account for this significant cause of death from the virus [22].", [["death", "DISEASE", 80, 85], ["IL-6", "GENE_OR_GENE_PRODUCT", 0, 4], ["IL-6", "PROTEIN", 0, 4], ["thrombogenic", "PROBLEM", 13, 25], ["death", "PROBLEM", 80, 85], ["the virus", "PROBLEM", 91, 100], ["thrombogenic", "OBSERVATION", 13, 25], ["may well account for", "UNCERTAINTY", 33, 53]]], ["Intense exercise also produces large quantities of IL-6 [23], which may account for the more severe clinical manifestations of infection amongst athletes [24].", [["infection", "DISEASE", 127, 136], ["IL-6", "GENE_OR_GENE_PRODUCT", 51, 55], ["IL", "PROTEIN", 51, 53], ["the more severe clinical manifestations of infection", "PROBLEM", 84, 136], ["large", "OBSERVATION_MODIFIER", 31, 36], ["quantities", "OBSERVATION_MODIFIER", 37, 47], ["may account for", "UNCERTAINTY", 68, 83], ["infection", "OBSERVATION", 127, 136]]], ["Indeed, dexamethasone, which lowers production of IL-6 by human bronchial epithelium [25], has recently been successfully trialled in COVID-19 patients [26], and there is increasing evidence that tocilizumab, an IL-6 antagonist, can result in improved outcomes amongst severely affected patients [27].DiscussionCan these findings be utilized to offer a rationale for Vitamin D prescription for COVID-19?", [["bronchial epithelium", "ANATOMY", 64, 84], ["dexamethasone", "CHEMICAL", 8, 21], ["tocilizumab", "CHEMICAL", 196, 207], ["Vitamin D", "CHEMICAL", 367, 376], ["dexamethasone", "CHEMICAL", 8, 21], ["Vitamin D", "CHEMICAL", 367, 376], ["COVID-19", "CHEMICAL", 394, 402], ["dexamethasone", "SIMPLE_CHEMICAL", 8, 21], ["IL-6", "GENE_OR_GENE_PRODUCT", 50, 54], ["human", "ORGANISM", 58, 63], ["bronchial epithelium", "TISSUE", 64, 84], ["patients", "ORGANISM", 143, 151], ["tocilizumab", "SIMPLE_CHEMICAL", 196, 207], ["IL-6", "GENE_OR_GENE_PRODUCT", 212, 216], ["patients", "ORGANISM", 287, 295], ["Vitamin D", "SIMPLE_CHEMICAL", 367, 376], ["IL-6", "PROTEIN", 50, 54], ["human", "SPECIES", 58, 63], ["patients", "SPECIES", 143, 151], ["patients", "SPECIES", 287, 295], ["human", "SPECIES", 58, 63], ["dexamethasone", "TREATMENT", 8, 21], ["production of IL", "TREATMENT", 36, 52], ["tocilizumab", "TREATMENT", 196, 207], ["an IL-6 antagonist", "TREATMENT", 209, 227], ["Vitamin D prescription", "TREATMENT", 367, 389], ["COVID", "TEST", 394, 399], ["bronchial epithelium", "ANATOMY", 64, 84]]], ["The role of Vitamin D deficiency as a predictor for worse clinical outcomes remains the focus of investigation, although early results appear to support this contention [10].", [["Vitamin D", "CHEMICAL", 12, 21], ["Vitamin D", "CHEMICAL", 12, 21], ["Vitamin D", "SIMPLE_CHEMICAL", 12, 21], ["Vitamin D deficiency", "PROBLEM", 12, 32]]], ["What is unclear is whether Vitamin D exerts a general immune-enhancing effect, given that it appears to be protective in patients with acute respiratory tract infections [28], or whether it may have a specific role in prevention and treatment of COVID-19.", [["respiratory tract", "ANATOMY", 141, 158], ["Vitamin D", "CHEMICAL", 27, 36], ["acute respiratory tract infections", "DISEASE", 135, 169], ["Vitamin D", "CHEMICAL", 27, 36], ["COVID-19", "CHEMICAL", 246, 254], ["Vitamin D", "SIMPLE_CHEMICAL", 27, 36], ["patients", "ORGANISM", 121, 129], ["patients", "SPECIES", 121, 129], ["Vitamin D", "PROBLEM", 27, 36], ["acute respiratory tract infections", "PROBLEM", 135, 169], ["COVID", "TEST", 246, 251], ["acute", "OBSERVATION_MODIFIER", 135, 140], ["respiratory tract", "ANATOMY", 141, 158]]], ["Vitamin D lowers immune cell production of IL-6 in laboratory studies [13], but does it have a similar effect in human populations?", [["immune cell", "ANATOMY", 17, 28], ["Vitamin D", "CHEMICAL", 0, 9], ["Vitamin D", "CHEMICAL", 0, 9], ["Vitamin D", "SIMPLE_CHEMICAL", 0, 9], ["immune cell", "CELL", 17, 28], ["IL-6", "GENE_OR_GENE_PRODUCT", 43, 47], ["human", "ORGANISM", 113, 118], ["IL-6", "PROTEIN", 43, 47], ["human", "SPECIES", 113, 118], ["human", "SPECIES", 113, 118], ["Vitamin D lowers immune cell production of IL", "TREATMENT", 0, 45], ["laboratory studies", "TEST", 51, 69]]], ["Since Khoo, et al suggested that increased Vitamin D levels reduced cytokine production, including IL-6 in 2011 [29], there have been multiple studies of the relationship between Vitamin D and cytokines.", [["Vitamin D", "CHEMICAL", 43, 52], ["Vitamin D", "CHEMICAL", 179, 188], ["Vitamin D", "CHEMICAL", 43, 52], ["Vitamin D", "CHEMICAL", 179, 188], ["Vitamin D", "SIMPLE_CHEMICAL", 43, 52], ["IL-6", "GENE_OR_GENE_PRODUCT", 99, 103], ["Vitamin D", "SIMPLE_CHEMICAL", 179, 188], ["cytokine", "PROTEIN", 68, 76], ["cytokines", "PROTEIN", 193, 202], ["increased Vitamin D levels reduced cytokine production", "PROBLEM", 33, 87], ["multiple studies", "TEST", 134, 150], ["Vitamin D", "TREATMENT", 179, 188], ["cytokines", "TREATMENT", 193, 202]]], ["Cannell and colleagues reviewed the literature in 2015, and found that Vitamin D appeared to reduce production of certain cytokines, including IL-6, in patients with inflammatory medical conditions [30].", [["Vitamin D", "CHEMICAL", 71, 80], ["Vitamin D", "CHEMICAL", 71, 80], ["Vitamin D", "SIMPLE_CHEMICAL", 71, 80], ["IL-6", "GENE_OR_GENE_PRODUCT", 143, 147], ["patients", "ORGANISM", 152, 160], ["cytokines", "PROTEIN", 122, 131], ["IL-6", "PROTEIN", 143, 147], ["patients", "SPECIES", 152, 160], ["Vitamin D", "TREATMENT", 71, 80], ["production of certain cytokines", "PROBLEM", 100, 131], ["inflammatory medical conditions", "PROBLEM", 166, 197], ["inflammatory", "OBSERVATION_MODIFIER", 166, 178]]], ["Subsequently, Calton, et al completed a systematic review and meta-analysis of Vitamin D supplementation and IL-6 [31].", [["Vitamin D", "CHEMICAL", 79, 88], ["Vitamin D", "CHEMICAL", 79, 88], ["Vitamin D", "SIMPLE_CHEMICAL", 79, 88], ["IL-6", "GENE_OR_GENE_PRODUCT", 109, 113], ["Vitamin D supplementation", "TREATMENT", 79, 104], ["IL", "TREATMENT", 109, 111]]], ["Although they could not confirm a definite impact overall, they did find a significant Vitamin D-induced reduction in the elderly [31].", [["Vitamin D", "CHEMICAL", 87, 96], ["Vitamin D", "CHEMICAL", 87, 96], ["Vitamin D", "SIMPLE_CHEMICAL", 87, 96], ["a significant Vitamin D-induced reduction", "TREATMENT", 73, 114]]], ["In an analysis of 11 published studies since 2015, reported herein, 8 demonstrated a significant IL-6 lowering effect of Vitamin D supplementation including amongst fit and healthy individuals, as well as in patients with acute pneumonia and some chronic diseases including diabetes and multiple sclerosis.", [["Vitamin D", "CHEMICAL", 121, 130], ["pneumonia", "DISEASE", 228, 237], ["chronic diseases", "DISEASE", 247, 263], ["diabetes", "DISEASE", 274, 282], ["multiple sclerosis", "DISEASE", 287, 305], ["Vitamin D", "CHEMICAL", 121, 130], ["IL-6", "GENE_OR_GENE_PRODUCT", 97, 101], ["Vitamin D", "SIMPLE_CHEMICAL", 121, 130], ["patients", "ORGANISM", 208, 216], ["IL-6", "PROTEIN", 97, 101], ["patients", "SPECIES", 208, 216], ["a significant IL", "PROBLEM", 83, 99], ["Vitamin D supplementation", "TREATMENT", 121, 146], ["acute pneumonia", "PROBLEM", 222, 237], ["some chronic diseases", "PROBLEM", 242, 263], ["diabetes", "PROBLEM", 274, 282], ["multiple sclerosis", "PROBLEM", 287, 305], ["significant", "OBSERVATION_MODIFIER", 85, 96], ["acute", "OBSERVATION_MODIFIER", 222, 227], ["pneumonia", "OBSERVATION", 228, 237], ["chronic", "OBSERVATION_MODIFIER", 247, 254], ["diseases", "OBSERVATION", 255, 263], ["diabetes", "OBSERVATION", 274, 282], ["multiple", "OBSERVATION_MODIFIER", 287, 295], ["sclerosis", "OBSERVATION", 296, 305]]], ["Although there is a need for additional research on the relationship between Vitamin D supplementation, IL-6 and COVID-19 outcomes, and, in particular a meta-analysis, these findings support a role for Vitamin D prescription, both prophylactic, and, potentially as a specific therapy [19].", [["Vitamin D", "CHEMICAL", 77, 86], ["Vitamin D", "CHEMICAL", 202, 211], ["Vitamin D", "CHEMICAL", 77, 86], ["Vitamin D", "CHEMICAL", 202, 211], ["Vitamin D", "SIMPLE_CHEMICAL", 77, 86], ["IL-6", "GENE_OR_GENE_PRODUCT", 104, 108], ["Vitamin D", "SIMPLE_CHEMICAL", 202, 211], ["Vitamin D supplementation", "TREATMENT", 77, 102], ["IL", "TREATMENT", 104, 106], ["COVID", "TREATMENT", 113, 118], ["Vitamin D prescription", "TREATMENT", 202, 224], ["a specific therapy", "TREATMENT", 265, 283]]], ["There may well be other therapeutic strategies which could also be deployed, including nutritional supplementation with selenium [32], such as ingesting Brazil nuts [33], and administration of drugs which lower IL-6 production such as doxycycline [34] and budesonide/formoterol [35].DiscussionIt should also be noted that IL-6 depletion may, potentially, have deleterious effects.", [["selenium", "CHEMICAL", 120, 128], ["doxycycline", "CHEMICAL", 235, 246], ["budesonide", "CHEMICAL", 256, 266], ["formoterol", "CHEMICAL", 267, 277], ["selenium", "CHEMICAL", 120, 128], ["doxycycline", "CHEMICAL", 235, 246], ["budesonide", "CHEMICAL", 256, 266], ["formoterol", "CHEMICAL", 267, 277], ["selenium", "SIMPLE_CHEMICAL", 120, 128], ["IL-6", "GENE_OR_GENE_PRODUCT", 211, 215], ["doxycycline", "SIMPLE_CHEMICAL", 235, 246], ["budesonide", "SIMPLE_CHEMICAL", 256, 266], ["formoterol", "SIMPLE_CHEMICAL", 267, 277], ["IL-6", "GENE_OR_GENE_PRODUCT", 322, 326], ["IL", "PROTEIN", 322, 324], ["nutritional supplementation", "TREATMENT", 87, 114], ["drugs", "TREATMENT", 193, 198], ["doxycycline", "TREATMENT", 235, 246], ["budesonide", "TREATMENT", 256, 266], ["formoterol", "TREATMENT", 267, 277], ["IL-6 depletion", "TREATMENT", 322, 336]]], ["Potentiation of further immunosuppression is a recognised phenomenon in patients with Rheumatoid arthritis treated with tocilizumab [36].", [["Rheumatoid arthritis", "DISEASE", 86, 106], ["tocilizumab", "CHEMICAL", 120, 131], ["patients", "ORGANISM", 72, 80], ["tocilizumab", "SIMPLE_CHEMICAL", 120, 131], ["patients", "SPECIES", 72, 80], ["further immunosuppression", "TREATMENT", 16, 41], ["a recognised phenomenon", "PROBLEM", 45, 68], ["Rheumatoid arthritis", "PROBLEM", 86, 106], ["tocilizumab", "TREATMENT", 120, 131], ["immunosuppression", "OBSERVATION", 24, 41], ["Rheumatoid", "OBSERVATION_MODIFIER", 86, 96], ["arthritis", "OBSERVATION", 97, 106]]], ["Hence, prolonged duration of COVID-19 prophylaxis with, for example, Vitamin D may potentially worsen mortality in some patient groups.DiscussionWhile the results of this work offer a rationale for the diverse clinical manifestations of COVID-19 and a range of therapeutic options for trial, this must be tempered by the limitations of this analysis.", [["COVID-19", "CHEMICAL", 29, 37], ["Vitamin D", "CHEMICAL", 69, 78], ["COVID-19", "CHEMICAL", 29, 37], ["Vitamin D", "CHEMICAL", 69, 78], ["COVID-19", "CHEMICAL", 237, 245], ["Vitamin D", "SIMPLE_CHEMICAL", 69, 78], ["patient", "ORGANISM", 120, 127], ["patient", "SPECIES", 120, 127], ["COVID-19 prophylaxis", "TREATMENT", 29, 49], ["Vitamin D", "TREATMENT", 69, 78], ["COVID", "TEST", 237, 242], ["this analysis", "TEST", 336, 349]]], ["The data analysed were not strictly comparable, with premorbid data on IL-6 levels derived from different populations to those with mortality data.", [["IL-6", "GENE_OR_GENE_PRODUCT", 71, 75], ["IL", "PROTEIN", 71, 73], ["The data", "TEST", 0, 8], ["IL", "TEST", 71, 73], ["mortality data", "TEST", 132, 146]]], ["Further, only the age-stratified results are supported by statistical analysis as the other data on other factors including sex, ethnicity and obesity could not be assessed directly for statistical significance.", [["obesity", "DISEASE", 143, 150], ["statistical analysis", "TEST", 58, 78], ["obesity", "PROBLEM", 143, 150], ["obesity", "OBSERVATION", 143, 150]]], ["While the age-stratified data comprised only 6 groups, 95% Confidence Intervals for correlation coefficient were still very high [0.89 \u2013 1.0], supporting the conclusions drawn.", [["correlation coefficient", "TEST", 84, 107], ["the conclusions", "TEST", 154, 169]]], ["In addition, the IL-6 analysis was tailored to correspond with mortality data published by Williamson, et al [6]; mortality rates would be expected to have fallen subsequently as communities introduced additional measures to combat viral spread, such as obligatory mask-wearing and social distancing, potentially confounding later data analysis.", [["IL-6", "GENE_OR_GENE_PRODUCT", 17, 21], ["IL-6", "PROTEIN", 17, 21], ["the IL-6 analysis", "TREATMENT", 13, 30], ["mortality rates", "TREATMENT", 114, 129], ["additional measures", "TREATMENT", 202, 221], ["viral spread", "PROBLEM", 232, 244], ["obligatory mask", "TREATMENT", 254, 269]]], ["Nonetheless, the links drawn between the IL6 data and the Covid-19 incidence and severity data might be considered tenuous: data sets are separated by substantial time; IL6 levels presented were not taken from the same people; and there is no evidence that these IL6 levels or the individuals that they are taken from are a representative sample of the population under examination.", [["IL6", "GENE_OR_GENE_PRODUCT", 41, 44], ["IL6", "GENE_OR_GENE_PRODUCT", 169, 172], ["people", "ORGANISM", 219, 225], ["IL6", "GENE_OR_GENE_PRODUCT", 263, 266], ["IL6", "PROTEIN", 41, 44], ["IL6", "PROTEIN", 169, 172], ["IL6", "PROTEIN", 263, 266], ["people", "SPECIES", 219, 225], ["the IL6 data", "TEST", 37, 49], ["the Covid", "TEST", 54, 63], ["severity data", "TEST", 81, 94], ["data sets", "TEST", 124, 133], ["IL6 levels", "TEST", 169, 179], ["these IL6 levels", "TEST", 257, 273], ["examination", "TEST", 370, 381], ["no evidence", "UNCERTAINTY", 240, 251]]], ["Furthermore, no multivariate analysis was possible to adjust for other substantial confounding factors (including ethnicity, socioeconomic status, living conditions, lockdown and other social distancing measures) which could intercede in terms of causality: for instance, are the high IL-6 cohort also more obese than those with low IL6 levels?", [["IL-6", "GENE_OR_GENE_PRODUCT", 285, 289], ["IL6", "GENE_OR_GENE_PRODUCT", 333, 336], ["IL", "PROTEIN", 285, 287], ["IL6", "PROTEIN", 333, 336], ["multivariate analysis", "TEST", 16, 37], ["other substantial confounding factors", "PROBLEM", 65, 102], ["low IL6 levels", "PROBLEM", 329, 343]]], ["Finally, a number of cytokines are released following infection, and, as this analysis was limited to only IL-6, it is not possible to exclude other interleukins from having a role in predisposing to worse outcomes.", [["infection", "DISEASE", 54, 63], ["IL-6", "GENE_OR_GENE_PRODUCT", 107, 111], ["interleukins", "GENE_OR_GENE_PRODUCT", 149, 161], ["cytokines", "PROTEIN", 21, 30], ["IL-6", "PROTEIN", 107, 111], ["interleukins", "PROTEIN", 149, 161], ["infection", "PROBLEM", 54, 63], ["this analysis", "TEST", 73, 86], ["cytokines", "OBSERVATION", 21, 30], ["infection", "OBSERVATION", 54, 63], ["not possible", "UNCERTAINTY", 119, 131]]], ["While substantial premorbid data on IL-6 levels may never be obtainable in patients who die from COVID-19, prospective trials of therapeutic measures can and should be undertaken.", [["IL-6", "GENE_OR_GENE_PRODUCT", 36, 40], ["patients", "ORGANISM", 75, 83], ["IL", "PROTEIN", 36, 38], ["patients", "SPECIES", 75, 83], ["IL", "TEST", 36, 38], ["COVID", "TEST", 97, 102], ["therapeutic measures", "TREATMENT", 129, 149]]], ["However, given that Vitamin D causes little harm if administered under clinical supervision, the populations most vulnerable to this disease are likely vitamin D deficient [37], and this vitamin also likely modulates the oxidative stress occurring in severe COVID-19 [38] there is strong supports for its widespread prescription.DiscussionIn conclusion, this study has demonstrated a highly significant correlation between premorbid IL-6 levels and mortality rates from COVID-19, accounting for a range of previously described clinical predictors and, potentially directing future therapeutic strategies, including in relation to Vitamin D.Discussion", [["Vitamin D", "CHEMICAL", 20, 29], ["vitamin D", "CHEMICAL", 152, 161], ["vitamin", "CHEMICAL", 187, 194], ["Vitamin D.Discussion", "CHEMICAL", 630, 650], ["Vitamin D", "CHEMICAL", 20, 29], ["vitamin D", "CHEMICAL", 152, 161], ["vitamin", "CHEMICAL", 187, 194], ["COVID-19", "CHEMICAL", 258, 266], ["Vitamin D.Discussion", "CHEMICAL", 630, 650], ["Vitamin D", "SIMPLE_CHEMICAL", 20, 29], ["vitamin D", "SIMPLE_CHEMICAL", 152, 161], ["vitamin", "SIMPLE_CHEMICAL", 187, 194], ["IL-6", "GENE_OR_GENE_PRODUCT", 433, 437], ["Vitamin D.Discussion", "SIMPLE_CHEMICAL", 630, 650], ["IL", "PROTEIN", 433, 435], ["Vitamin D", "TREATMENT", 20, 29], ["this disease", "PROBLEM", 128, 140], ["vitamin D deficient", "PROBLEM", 152, 171], ["this vitamin", "TREATMENT", 182, 194], ["the oxidative stress", "PROBLEM", 217, 237], ["severe COVID", "PROBLEM", 251, 263], ["this study", "TEST", 354, 364], ["premorbid IL", "TEST", 423, 435], ["mortality rates", "TEST", 449, 464], ["COVID", "TEST", 470, 475], ["therapeutic strategies", "TREATMENT", 581, 603], ["Vitamin D.Discussion", "TREATMENT", 630, 650]]]], "PMC7088924": [["IntroductionIt is no secret that the health of the earth\u2019s ecosystems is in a downward spiral.", [["a downward spiral", "PROBLEM", 76, 93], ["no", "UNCERTAINTY", 18, 20], ["downward spiral", "OBSERVATION", 78, 93]]], ["All the recent global environmental assessments provide ample documentation for the rapid decline in the viability of life systems.", [["the rapid decline", "PROBLEM", 80, 97]]], ["This index measures the state of the world\u2019s biodiversity based on trends from 1970 to 2003 in 1,313 vertebrate species, comprising 695 terrestrial species, 274 marine species, and 344 freshwater species.", [["This index", "TEST", 0, 10], ["terrestrial species", "TEST", 136, 155], ["marine species", "TEST", 161, 175], ["terrestrial species", "OBSERVATION", 136, 155]]], ["The LPI shows an overall decline of 30% over the 33-year period\u2014reflecting declines in each of the major species groups.", [["The LPI", "TEST", 0, 7], ["LPI", "OBSERVATION_MODIFIER", 4, 7], ["overall", "OBSERVATION_MODIFIER", 17, 24], ["decline", "OBSERVATION_MODIFIER", 25, 32]]], ["During the same period, global satellite imagery records rapidly eroding seascapes and landscapes, including the eutrophication of semi-enclosed seas and coastal areas, deforestation particularly in tropical regions, the desertification of arid lands, the near total desiccation of the Aral Sea, the draining of the Mesopotamian marshlands\u2014and the list goes on (MEA 2005).", [["semi-enclosed seas and coastal areas", "PROBLEM", 131, 167], ["deforestation", "TREATMENT", 169, 182], ["the desertification of arid lands", "PROBLEM", 217, 250], ["eutrophication", "OBSERVATION_MODIFIER", 113, 127], ["seas", "OBSERVATION_MODIFIER", 145, 149], ["coastal", "OBSERVATION_MODIFIER", 154, 161], ["areas", "OBSERVATION_MODIFIER", 162, 167], ["deforestation", "OBSERVATION_MODIFIER", 169, 182], ["tropical", "ANATOMY_MODIFIER", 199, 207], ["desertification", "OBSERVATION_MODIFIER", 221, 236], ["arid lands", "OBSERVATION", 240, 250], ["total", "OBSERVATION_MODIFIER", 261, 266], ["desiccation", "OBSERVATION_MODIFIER", 267, 278], ["Aral Sea", "OBSERVATION", 286, 294], ["draining", "OBSERVATION", 300, 308]]], ["Add to these cases the rapid erosion of tropical coral reefs, the loss of boreal and coastal coniferous forests, the degradation and destruction of the world\u2019s grasslands and wetlands, marked deterioration of the world\u2019s lakes and rivers, the disappearance of coastal mangrove forests, and so forth, and an unequivocal picture emerges of many of the earth\u2019s major ecosystems in a state of imminent or present collapse.IntroductionThe catastrophic loss in the vitality of the world\u2019s ecosystems is a consequence of cumulative anthropogenic stress (Rapport and Friend 1979; Rapport et al. 1985; Rapport 2007a, 2007b).", [["tropical coral reefs", "TREATMENT", 40, 60], ["the loss of boreal and coastal coniferous forests", "PROBLEM", 62, 111], ["the degradation", "PROBLEM", 113, 128], ["present collapse", "PROBLEM", 401, 417], ["The catastrophic loss", "PROBLEM", 430, 451], ["rapid", "OBSERVATION_MODIFIER", 23, 28], ["erosion", "OBSERVATION", 29, 36], ["tropical", "OBSERVATION_MODIFIER", 40, 48], ["coral reefs", "OBSERVATION", 49, 60], ["loss", "OBSERVATION_MODIFIER", 66, 70], ["boreal", "OBSERVATION_MODIFIER", 74, 80], ["coastal", "OBSERVATION_MODIFIER", 85, 92], ["coniferous forests", "OBSERVATION", 93, 111], ["marked", "OBSERVATION_MODIFIER", 185, 191], ["deterioration", "OBSERVATION_MODIFIER", 192, 205], ["coastal", "OBSERVATION", 260, 267], ["mangrove forests", "OBSERVATION", 268, 284], ["collapse", "OBSERVATION", 409, 417], ["catastrophic", "OBSERVATION_MODIFIER", 434, 446], ["loss", "OBSERVATION_MODIFIER", 447, 451]]], ["This has now been documented in a number of case studies of freshwater, marine, and terrestrial ecosystems around the world.", [["terrestrial ecosystems", "OBSERVATION", 84, 106]]], ["These include the Laurentian Great Lakes (Regier and Hartman 1973; Rapport and Regier 1980), the Baltic Sea (Rapport 1989a; Hild\u00e9n and Rapport 1993), the desert grasslands of southern New Mexico (Schlesinger et al. 1990; Rapport and Whitford 1999), and the Aral Sea (Macklin 2007), among many others (Vitousek et al. 1997, MEA 2005).IntroductionLess well known, but of great significance, is the parallel loss in the viability of the world\u2019s cultures and languages\u2014which are vast repositories of knowledge and know-how in terms of sustaining human life within diverse ecosystems and landscapes (Maffi 2001, 2005, 2009; Harmon and Loh 2010; Maffi and Woodley 2010).", [["human", "ORGANISM", 542, 547], ["human", "SPECIES", 542, 547], ["human", "SPECIES", 542, 547], ["the parallel loss", "PROBLEM", 392, 409], ["cultures", "TEST", 442, 450]]], ["The dramatic losses in biological diversity over the past half century have been accompanied by equally dramatic losses in cultural diversity and in the vitality of the world\u2019s cultures and languages, due to many of the same pressures.", [["The dramatic losses in biological diversity", "PROBLEM", 0, 43], ["equally dramatic losses in cultural diversity", "PROBLEM", 96, 141], ["cultures", "TEST", 177, 185], ["dramatic", "OBSERVATION_MODIFIER", 4, 12], ["losses", "OBSERVATION_MODIFIER", 13, 19], ["biological", "OBSERVATION_MODIFIER", 23, 33], ["diversity", "OBSERVATION_MODIFIER", 34, 43], ["equally", "OBSERVATION_MODIFIER", 96, 103], ["dramatic", "OBSERVATION_MODIFIER", 104, 112], ["losses", "OBSERVATION_MODIFIER", 113, 119], ["cultural diversity", "OBSERVATION_MODIFIER", 123, 141]]], ["This configures a \u201cconverging extinction crisis\u201d of the diversity of life in nature and culture (Harmon 2002).IntroductionThese interrelated changes have profound implications for human futures in terms of public health and sustainability.", [["human", "ORGANISM", 180, 185], ["human", "SPECIES", 180, 185], ["human", "SPECIES", 180, 185], ["a \u201cconverging extinction crisis", "PROBLEM", 16, 47], ["culture", "TEST", 88, 95], ["extinction crisis", "OBSERVATION", 30, 47]]], ["Here, we explore these implications by first reviewing the ways in which human activities have led to the breakdown of ecosystems, and how we can identify dysfunction in ecosystems as a consequence of anthropogenic stress.", [["human", "ORGANISM", 73, 78], ["human", "SPECIES", 73, 78], ["human", "SPECIES", 73, 78], ["dysfunction in ecosystems", "PROBLEM", 155, 180], ["anthropogenic stress", "PROBLEM", 201, 221], ["anthropogenic stress", "OBSERVATION", 201, 221]]], ["We then turn to the flip side of this topic and define healthy ecosystems and their main characteristics, looking at how the loss of ecosystem health impacts human health and at the efforts underway to address global health issues from an ecosystem perspective.", [["human", "ORGANISM", 158, 163], ["human", "SPECIES", 158, 163], ["human", "SPECIES", 158, 163], ["global health issues", "PROBLEM", 210, 230]]], ["Building on this, we argue that attention to the cultural dimensions of ecosystem health and dysfunction calls for an even more integrative perspective, embodied in the concept of \u2018eco-cultural health\u2019.", [["dysfunction", "PROBLEM", 93, 104]]], ["By means of an illustrative example, we discuss how the breakdown of eco-cultural health impacts human health and well-being.", [["human", "ORGANISM", 97, 102], ["human", "SPECIES", 97, 102], ["human", "SPECIES", 97, 102]]], ["Lastly, we discuss the implications of this perspective for public policy and action.Signs and causes of ecosystem pathologyThe path-breaking work of Rachel Carson in the early 1960s (Carson 1962) was a profound wake-up call that human activities can inadvertently compromise the vitality of whole ecosystems.", [["human", "ORGANISM", 230, 235], ["human", "SPECIES", 230, 235], ["human", "SPECIES", 230, 235], ["public policy", "TREATMENT", 60, 73], ["ecosystem pathology", "PROBLEM", 105, 124], ["ecosystem pathology", "OBSERVATION", 105, 124]]], ["Carson focused on the production and use of man-made chemicals, particularly those substances that were long-lived in the environment.", [["man", "ORGANISM", 44, 47], ["man", "SPECIES", 44, 47]]], ["Carson drew attention to the fact that organic pollutants such as DDT, PCBs, and others bio-accumulate through the food web, with lethal effects on bird populations and other biota, including humans.Signs and causes of ecosystem pathologyRecognizing the growing relevance of environmental issues, statistical agencies began to seek ways and means of documenting changes in the environment in relation to human activities.", [["DDT", "CHEMICAL", 66, 69], ["PCBs", "CHEMICAL", 71, 75], ["DDT", "CHEMICAL", 66, 69], ["PCBs", "CHEMICAL", 71, 75], ["DDT", "SIMPLE_CHEMICAL", 66, 69], ["PCBs", "SIMPLE_CHEMICAL", 71, 75], ["humans", "ORGANISM", 192, 198], ["human", "ORGANISM", 404, 409], ["humans", "SPECIES", 192, 198], ["human", "SPECIES", 404, 409], ["humans", "SPECIES", 192, 198], ["human", "SPECIES", 404, 409], ["organic pollutants", "PROBLEM", 39, 57], ["DDT", "TREATMENT", 66, 69], ["PCBs", "TREATMENT", 71, 75], ["bird populations", "TREATMENT", 148, 164], ["ecosystem pathology", "PROBLEM", 219, 238], ["ecosystem pathology", "OBSERVATION", 219, 238]]], ["This framework, now known as the Pressure-State-Response system (PSR), was quickly adopted by the Organization for Economic Cooperation and Development (OECD) and many countries and international agencies, and has formed the conceptual basis for numerous regional and national state of environment reports and assessments (Rapport and Singh 2006).Signs and causes of ecosystem pathologyThe PSR system comprises a taxonomy of the major types of anthropogenic stress that impact the world\u2019s ecosystems.", [["ecosystem pathology", "PROBLEM", 367, 386], ["anthropogenic stress", "PROBLEM", 444, 464], ["ecosystem pathology", "OBSERVATION", 367, 386], ["anthropogenic stress", "OBSERVATION", 444, 464]]], ["These include: land-use change (physical restructuring), over-harvesting (resulting in over-exploitation of species and/or serious damage to habitat), introduction of non-native species (whether purposefully or accidentally), release of waste residuals (both nutrients and toxic substances) to air, water, and land, and extreme natural events (e.g., volcanic eruptions, weather and climatic events).1 The PSR system also incorporates a set of indicators of ecosystem dysfunction [e.g., loss of biodiversity, loss of soil fertility, increased presence of invasive (non-native) species, etc.], as well as indicators of societal actions (responses) that may be taken to prevent or mitigate damage to the environment.Signs and causes of ecosystem pathologyUtilizing the PSR framework, various assessments, including the Millennium Ecosystem Assessment (MEA 2005), the Helsinki Commission assessment of eutrophication of the Baltic Sea (HELCOM 2009) and various country- and regional-level assessments have documented ecosystem degradation induced by anthropogenic stress.", [["eruptions", "DISEASE", 359, 368], ["ecosystem dysfunction", "DISEASE", 457, 478], ["species", "PROBLEM", 108, 115], ["serious damage", "PROBLEM", 123, 137], ["non-native species", "PROBLEM", 167, 185], ["waste residuals", "PROBLEM", 237, 252], ["extreme natural events", "PROBLEM", 320, 342], ["volcanic eruptions", "PROBLEM", 350, 368], ["The PSR system", "TEST", 401, 415], ["ecosystem dysfunction", "PROBLEM", 457, 478], ["loss of biodiversity", "PROBLEM", 486, 506], ["loss of soil fertility", "PROBLEM", 508, 530], ["invasive (non-native) species", "PROBLEM", 554, 583], ["ecosystem pathology", "PROBLEM", 733, 752], ["various assessments", "TEST", 781, 800], ["regional-level assessments", "TEST", 970, 996], ["ecosystem degradation", "PROBLEM", 1013, 1034], ["anthropogenic stress", "PROBLEM", 1046, 1066], ["waste residuals", "OBSERVATION", 237, 252], ["ecosystem dysfunction", "OBSERVATION", 457, 478], ["invasive", "OBSERVATION_MODIFIER", 554, 562], ["ecosystem pathology", "OBSERVATION", 733, 752], ["eutrophication", "OBSERVATION", 898, 912], ["ecosystem degradation", "OBSERVATION", 1013, 1034], ["anthropogenic stress", "OBSERVATION", 1046, 1066]]], ["Among the many signs of ecosystem impairment are reduced biodiversity, altered primary and secondary productivity, leaching of soil nutrients, shifts in community composition to favor smaller life forms, reduced symbiotic relationships amongst biota, increased success of invasive species, loss of endemic species, increased presence of contaminants (particularly toxic substances that bio-accumulate in the food web), increased disease prevalence in various component species (including Homo sapiens), reduced efficiency in nutrient transport, and reduced ecosystem-level productivity/respiration ratios.Signs and causes of ecosystem pathologyThese signs, collectively, comprise what was identified early on as an \u2018ecosystem distress syndrome\u2019 (EDS) (Rapport et al. 1985).", [["community", "ANATOMY", 153, 162], ["ecosystem impairment", "DISEASE", 24, 44], ["\u2018ecosystem distress syndrome", "DISEASE", 715, 743], ["EDS", "DISEASE", 746, 749], ["Homo sapiens", "ORGANISM", 488, 500], ["Homo sapiens", "SPECIES", 488, 500], ["Homo sapiens", "SPECIES", 488, 500], ["ecosystem impairment", "PROBLEM", 24, 44], ["reduced biodiversity", "PROBLEM", 49, 69], ["altered primary", "PROBLEM", 71, 86], ["secondary productivity", "PROBLEM", 91, 113], ["smaller life forms", "PROBLEM", 184, 202], ["reduced symbiotic relationships", "PROBLEM", 204, 235], ["invasive species", "PROBLEM", 272, 288], ["endemic species", "PROBLEM", 298, 313], ["toxic substances", "PROBLEM", 364, 380], ["increased disease prevalence", "PROBLEM", 419, 447], ["various component species", "PROBLEM", 451, 476], ["Homo sapiens)", "PROBLEM", 488, 501], ["reduced efficiency in nutrient transport", "PROBLEM", 503, 543], ["reduced ecosystem-level productivity", "PROBLEM", 549, 585], ["respiration ratios", "TEST", 586, 604], ["ecosystem pathology", "PROBLEM", 625, 644], ["an \u2018ecosystem distress syndrome", "PROBLEM", 712, 743], ["ecosystem impairment", "OBSERVATION", 24, 44], ["reduced", "OBSERVATION_MODIFIER", 49, 56], ["biodiversity", "OBSERVATION_MODIFIER", 57, 69], ["altered", "OBSERVATION_MODIFIER", 71, 78], ["primary", "OBSERVATION_MODIFIER", 79, 86], ["secondary", "OBSERVATION_MODIFIER", 91, 100], ["productivity", "OBSERVATION_MODIFIER", 101, 113], ["invasive species", "OBSERVATION", 272, 288], ["endemic species", "OBSERVATION", 298, 313], ["increased", "OBSERVATION_MODIFIER", 419, 428], ["disease", "OBSERVATION", 429, 436], ["various component", "OBSERVATION_MODIFIER", 451, 468], ["species", "OBSERVATION_MODIFIER", 469, 476], ["reduced", "OBSERVATION_MODIFIER", 503, 510], ["efficiency", "OBSERVATION_MODIFIER", 511, 521], ["nutrient transport", "OBSERVATION", 525, 543], ["ecosystem pathology", "OBSERVATION", 625, 644]]], ["Initially, EDS was recognized on the basis of comparisons of ecosystem behavior under stress among a dozen or so documented case studies from the literature.", [["EDS", "DISEASE", 11, 14], ["EDS", "CHEMICAL", 11, 14]]], ["Subsequently, new case studies (e.g., Rapport 1989a, Hild\u00e9n and Rapport 1993, Rapport et al. 1998a, Rapport and Whitford 1999), as well as a plethora of government and international agency reports on the state of the environment, have confirmed that EDS is a widespread problem.", [["EDS", "DISEASE", 250, 253], ["EDS", "CHEMICAL", 250, 253], ["new case studies", "TEST", 14, 30], ["widespread", "OBSERVATION_MODIFIER", 259, 269]]], ["Interestingly, the signs of EDS were already observed in the early 1940s by the great American naturalist, Aldo Leopold, and recorded in his landmark (although rather obscurely published) essay on what he called \u2018land sickness\u2019 (Leopold 1941).", [["EDS", "DISEASE", 28, 31], ["sickness", "DISEASE", 218, 226], ["EDS", "CHEMICAL", 28, 31]]], ["Even back then, Leopold observed that in his rural Wisconsin countryside there was abundant evidence of soil erosion, nutrient depletion, reduced crop yield, loss of native species, increase in invasive species, and increases in plant and animal pathogens.Signs and causes of ecosystem pathologyToday, it is widely recognized that EDS2 is caused by anthropogenic stress (Rapport et al. 1985; Rapport and Whitford 1999; Vitousek et al. 1997), and that it characterizes many of the world\u2019s ecosystems, providing evidence of widespread and growing ecosystem pathology.", [["EDS2", "DISEASE", 331, 335], ["EDS2", "GENE_OR_GENE_PRODUCT", 331, 335], ["soil erosion", "PROBLEM", 104, 116], ["nutrient depletion", "PROBLEM", 118, 136], ["reduced crop yield", "PROBLEM", 138, 156], ["loss of native species", "PROBLEM", 158, 180], ["invasive species", "PROBLEM", 194, 210], ["animal pathogens", "PROBLEM", 239, 255], ["ecosystem pathology", "PROBLEM", 276, 295], ["widespread and growing ecosystem pathology", "PROBLEM", 522, 564], ["abundant evidence of", "UNCERTAINTY", 83, 103], ["soil erosion", "OBSERVATION", 104, 116], ["nutrient depletion", "OBSERVATION", 118, 136], ["native species", "OBSERVATION", 166, 180], ["increase", "OBSERVATION_MODIFIER", 182, 190], ["invasive species", "OBSERVATION", 194, 210], ["increases", "OBSERVATION_MODIFIER", 216, 225], ["ecosystem pathology", "OBSERVATION", 276, 295], ["evidence of", "UNCERTAINTY", 510, 521], ["widespread", "OBSERVATION_MODIFIER", 522, 532], ["growing", "OBSERVATION_MODIFIER", 537, 544], ["ecosystem pathology", "OBSERVATION", 545, 564]]], ["Regional examples of EDS are to be found in the cases of the Baltic Sea (Rapport 1989a, Hild\u00e9n and Rapport 1993; HELCOM 2009), the Laurentian Great Lakes (Rapport and Regier 1980; Bails et al. 2005), the Aral Sea (Macklin 2007), the Mesopotamian Marshlands (Lawler 2005), the Caribbean Coral Reefs (Hughes 1994), the grasslands of New Mexico (Schlesinger et al. 1990), among many others (Rapport et al. 1995; Rapport et al. 1998a, b, c).Signs and causes of ecosystem pathologyThe main three drivers of ecosystem degradation resulting in EDS\u2014habitat fragmentation and destruction (physical restructuring), over-exploitation of species (over-harvesting), and introduction of exotic species\u2014have been called the \u201cevil trio\u201d accounting for the worldwide loss of biodiversity (Aguirre 2009).", [["EDS", "DISEASE", 21, 24], ["EDS", "DISEASE", 537, 540], ["EDS", "CHEMICAL", 537, 540], ["the Mesopotamian Marshlands", "TREATMENT", 229, 256], ["ecosystem pathology", "PROBLEM", 457, 476], ["ecosystem degradation", "PROBLEM", 502, 523], ["EDS\u2014habitat fragmentation", "PROBLEM", 537, 562], ["destruction (physical restructuring)", "PROBLEM", 567, 603], ["species", "PROBLEM", 626, 633], ["Baltic Sea", "ANATOMY", 61, 71], ["ecosystem pathology", "OBSERVATION", 457, 476], ["main", "OBSERVATION_MODIFIER", 480, 484], ["ecosystem degradation", "OBSERVATION", 502, 523], ["destruction", "OBSERVATION_MODIFIER", 567, 578]]], ["Along with global toxification (release of waste residuals), pathogen pollution, and global warming, all these drivers comprise what Aguirre (2009) refers to as the expanded \u201csavage sextet\u201d accounting for biodiversity loss.Ecosystem healthGrowing awareness of widespread ecosystem pathology begs the question: what are \u2018healthy\u2019 ecosystems, and what constitutes ecosystem health?", [["biodiversity loss", "DISEASE", 205, 222], ["global toxification", "PROBLEM", 11, 30], ["waste residuals", "PROBLEM", 43, 58], ["pathogen pollution", "PROBLEM", 61, 79], ["global warming", "TREATMENT", 85, 99], ["biodiversity loss", "PROBLEM", 205, 222], ["global", "OBSERVATION_MODIFIER", 11, 17], ["toxification", "OBSERVATION", 18, 30], ["biodiversity loss", "OBSERVATION", 205, 222], ["widespread", "OBSERVATION_MODIFIER", 260, 270], ["ecosystem pathology", "OBSERVATION", 271, 290]]], ["The history of the development of the transdisciplinary field of ecosystem health is summarized in the Appendix.Ecosystem healthEarly debate on the validity of the concept of ecosystem health raised two key questions: (1) does the use of the term \u2018health\u2019 to describe the state of an ecosystem require resurrecting the much-discredited analogy between \u2018ecosystem\u2019 and \u2018organism\u2019? and (2) can \u2018ecosystem health\u2019 be objectively determined, or does it rest on the subjectivity of human goals and value judgments?", [["human", "ORGANISM", 477, 482], ["human", "SPECIES", 477, 482], ["human", "SPECIES", 477, 482], ["value judgments", "TEST", 493, 508], ["ecosystem health", "OBSERVATION", 65, 81], ["Appendix", "ANATOMY", 103, 111]]], ["From early on, it has been clear that the organizing principles for ecosystems are very different from those for organisms.", [["ecosystems", "PROBLEM", 68, 78], ["organisms", "PROBLEM", 113, 122], ["clear", "OBSERVATION", 27, 32]]], ["The behavior of organisms is a product of natural selection.", [["natural selection", "OBSERVATION", 42, 59]]], ["However, both systems can become dysfunctional under certain conditions.", [["dysfunctional under certain conditions", "PROBLEM", 33, 71], ["dysfunctional", "OBSERVATION", 33, 46]]], ["Thus, without the need to make an analogy between ecosystems and organisms, one can recognize that both systems can be described in terms of their state of health (proper functioning) or pathology (dysfunction).Ecosystem healthWith respect to the second question, as to whether ecosystem health depends on human goals, here too the short answer is \u2018no\u2019.", [["human", "ORGANISM", 306, 311], ["human", "SPECIES", 306, 311], ["human", "SPECIES", 306, 311], ["pathology (dysfunction)", "PROBLEM", 187, 210]]], ["It is unnecessary to bring human goals and values into the equation, when it is evident that ecosystem organization and functions can be objectively measured and compared with earlier states.", [["human", "ORGANISM", 27, 32], ["human", "SPECIES", 27, 32], ["human", "SPECIES", 27, 32], ["ecosystem", "OBSERVATION", 93, 102]]], ["Just as conservation biologists can assess biodiversity loss against situations that have prevailed in previous times, ecosystem health practitioners can assess the health of ecosystems by comparing metrics describing ecosystem properties (including biodiversity) under conditions prior to the onset of anthropogenic stress with conditions that prevail under stress.", [["biodiversity loss", "DISEASE", 43, 60], ["biodiversity loss against situations", "PROBLEM", 43, 79], ["anthropogenic stress with conditions", "PROBLEM", 303, 339], ["anthropogenic stress", "OBSERVATION", 303, 323]]], ["This can be done objectively without the need to invoke human values or goals (Rapport and Whitford 1999).Ecosystem healthEcosystem health can be assessed in terms of three general properties, each of which gives rise to a number of specific indicators or metrics (Rapport 1989a; Mageau et al. 1995, Rapport et al. 1998a, b, c).", [["human", "ORGANISM", 56, 61], ["human", "SPECIES", 56, 61], ["human", "SPECIES", 56, 61]]], ["These overriding properties of ecosystem health are:Organization (Structure): The capacity of ecosystems to maintain their biotic structure, their characteristic biological diversity, their interactions between species and with the abiotic environment;Vitality (Function): The capacity of ecosystems to maintain biological productivity; andResilience: The capacity of ecosystems to rebound from perturbations such as those caused by fire, flood, drought, and so forth.", [["biotic structure", "OBSERVATION", 123, 139]]]], "PMC7115785": [["IntroductionIn recent years, there has been increased interest in topic-focused multi-document summarization.", [["increased", "OBSERVATION_MODIFIER", 44, 53], ["interest", "OBSERVATION_MODIFIER", 54, 62]]], ["In response to this interest and to stimulate research in this area, the National Institute of Standards and Technology (NIST) conducted a series of workshops, the Document Understanding Conference2 (DUC), to provide large-scale common data sets for the evaluation of systems.", [["the evaluation of systems", "TEST", 250, 275]]], ["Participants in DUC2005 and DUC2006 were provided with a topic and a set of relevant documents (newswire articles), and the task was to produce an automatic summary of not more than 250 words in length.", [["Participants", "SPECIES", 0, 12]]], ["Consider the topic description for clusters D0652G and D0655A, for example:D0652G:Identify the world\u2019s top banana producers and their levels of production.", [["banana", "ORGANISM_SUBDIVISION", 107, 113]]], ["Describe the main markets for imports and relate any major issues in the industry.D0655A:Discuss the causes, effects, and treatment of childhood obesity.", [["D0655A", "CHEMICAL", 82, 88], ["obesity", "DISEASE", 145, 152], ["childhood obesity", "PROBLEM", 135, 152], ["obesity", "OBSERVATION", 145, 152]]]], "3c6bc6d24dcb9b075a4c230c1b8754769ae9bad9": [["Disease progression of mice infected with hRSV or UV-hRSV and mock-treated mice 307 were monitored by measuring the bodyweight of infected mice.", [["UV-hRSV", "CHEMICAL", 50, 57], ["mice", "ORGANISM", 23, 27], ["hRSV", "ORGANISM", 42, 46], ["UV-hRSV", "ORGANISM", 50, 57], ["mock", "ORGANISM", 62, 66], ["mice", "ORGANISM", 75, 79], ["mice", "ORGANISM", 139, 143], ["mice", "SPECIES", 23, 27], ["mice", "SPECIES", 75, 79], ["mice", "SPECIES", 139, 143], ["mice", "SPECIES", 23, 27], ["hRSV", "SPECIES", 42, 46], ["hRSV", "SPECIES", 53, 57], ["mice", "SPECIES", 75, 79], ["mice", "SPECIES", 139, 143], ["Disease progression", "PROBLEM", 0, 19], ["mice infected", "PROBLEM", 23, 36], ["hRSV", "PROBLEM", 42, 46], ["UV", "TREATMENT", 50, 52], ["hRSV", "PROBLEM", 53, 57], ["mice", "OBSERVATION_MODIFIER", 23, 27], ["infected", "OBSERVATION_MODIFIER", 28, 36]]], ["As expected, hRSV-infected 308 mice displayed significant weight loss at day 2, 3 and 4 p.i. as compared to mock-treated and 309 UV-hRSV challenged animals ( Figure 1A ).", [["weight loss", "DISEASE", 58, 69], ["hRSV", "ORGANISM", 13, 17], ["mice", "ORGANISM", 31, 35], ["mice", "SPECIES", 31, 35], ["hRSV", "SPECIES", 13, 17], ["mice", "SPECIES", 31, 35], ["hRSV", "TEST", 13, 17], ["significant weight loss", "PROBLEM", 46, 69], ["mock", "TEST", 108, 112], ["significant", "OBSERVATION_MODIFIER", 46, 57], ["weight loss", "OBSERVATION", 58, 69]]], ["Airway inflammation was also measured by339It has been previously shown that cytokines, such as IL-6, TNF-\u03b1, IL-1\u03b2, IL-4, IL-10, 340 and CD200 can affect the behavior, learning and memory of animals (46-51).", [["Airway", "ANATOMY", 0, 6], ["Airway", "MULTI-TISSUE_STRUCTURE", 0, 6], ["IL-6", "GENE_OR_GENE_PRODUCT", 96, 100], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 102, 107], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 109, 114], ["IL-4", "GENE_OR_GENE_PRODUCT", 116, 120], ["IL-10", "GENE_OR_GENE_PRODUCT", 122, 127], ["340", "GENE_OR_GENE_PRODUCT", 129, 132], ["CD200", "GENE_OR_GENE_PRODUCT", 137, 142], ["cytokines", "PROTEIN", 77, 86], ["IL-6", "PROTEIN", 96, 100], ["TNF", "PROTEIN", 102, 105], ["IL", "PROTEIN", 122, 124], ["CD200", "PROTEIN", 137, 142], ["Airway inflammation", "PROBLEM", 0, 19], ["cytokines", "TEST", 77, 86], ["IL", "TEST", 96, 98], ["TNF", "TEST", 102, 105], ["IL", "TEST", 109, 111], ["IL", "TEST", 116, 118], ["IL", "TEST", 122, 124], ["inflammation", "OBSERVATION", 7, 19]]], ["Moreover, the 341 high expression of GFAP by astrocytes has been related to astrocyte activation, inflammation 342 and neurodegenerative diseases (52-54).", [["astrocytes", "ANATOMY", 45, 55], ["astrocyte", "ANATOMY", 76, 85], ["inflammation", "DISEASE", 98, 110], ["neurodegenerative diseases", "DISEASE", 119, 145], ["GFAP", "GENE_OR_GENE_PRODUCT", 37, 41], ["astrocytes", "CELL", 45, 55], ["astrocyte", "CELL", 76, 85], ["GFAP", "PROTEIN", 37, 41], ["astrocytes", "CELL_TYPE", 45, 55], ["astrocyte activation", "PROBLEM", 76, 96], ["inflammation", "PROBLEM", 98, 110], ["neurodegenerative diseases", "PROBLEM", 119, 145], ["related to", "UNCERTAINTY", 65, 75], ["astrocyte activation", "OBSERVATION", 76, 96], ["neurodegenerative", "OBSERVATION_MODIFIER", 119, 136]]], ["We think that it is possible that the content of these 343 cytokines and GFAP could be altered in the brain of mice infected with hRSV.", [["brain", "ANATOMY", 102, 107], ["GFAP", "GENE_OR_GENE_PRODUCT", 73, 77], ["brain", "ORGAN", 102, 107], ["mice", "ORGANISM", 111, 115], ["hRSV", "GENE_OR_GENE_PRODUCT", 130, 134], ["cytokines", "PROTEIN", 59, 68], ["GFAP", "PROTEIN", 73, 77], ["mice", "SPECIES", 111, 115], ["mice", "SPECIES", 111, 115], ["hRSV", "SPECIES", 130, 134], ["these 343 cytokines", "TEST", 49, 68], ["GFAP", "TEST", 73, 77], ["hRSV", "PROBLEM", 130, 134], ["brain", "ANATOMY", 102, 107]]], ["Therefore, 344 the mRNA levels of IL-6, TNF-\u03b1, IL-1\u03b2, IL-4, IL-10, CD200 and GFAP were analyzed in 345 the brains from hRSV-infected mice 60 days p.i.", [["brains", "ANATOMY", 107, 113], ["IL-6", "GENE_OR_GENE_PRODUCT", 34, 38], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 40, 45], ["IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 47, 52], ["IL-4", "GENE_OR_GENE_PRODUCT", 54, 58], ["IL-10", "GENE_OR_GENE_PRODUCT", 60, 65], ["CD200", "GENE_OR_GENE_PRODUCT", 67, 72], ["GFAP", "GENE_OR_GENE_PRODUCT", 77, 81], ["brains", "ORGANISM", 107, 113], ["hRSV", "ORGANISM", 119, 123], ["mice", "ORGANISM", 133, 137], ["IL-6", "PROTEIN", 34, 38], ["TNF", "PROTEIN", 40, 43], ["IL-10", "PROTEIN", 60, 65], ["CD200", "PROTEIN", 67, 72], ["GFAP", "PROTEIN", 77, 81], ["mice", "SPECIES", 133, 137], ["hRSV", "SPECIES", 119, 123], ["mice", "SPECIES", 133, 137], ["the mRNA levels", "TEST", 15, 30], ["IL", "TEST", 34, 36], ["TNF", "TEST", 40, 43], ["IL", "TEST", 47, 49], ["IL", "TEST", 54, 56], ["IL", "TEST", 60, 62], ["CD200", "TEST", 67, 72], ["GFAP", "TEST", 77, 81], ["brains", "ANATOMY", 107, 113], ["hRSV", "ANATOMY", 119, 123]]], ["Similar levels of IL-6, TNF-\u03b1, CX3CL1,346IL-1\u03b2 and CD200 mRNAs were observed in the brains of hRSV-infected mice as compared 347 to mock-and UV-hRSV-treated mice ( Figure 3A ).", [["brains", "ANATOMY", 84, 90], ["IL-6", "GENE_OR_GENE_PRODUCT", 18, 22], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 24, 29], ["CX3CL1", "GENE_OR_GENE_PRODUCT", 31, 37], ["346IL-1\u03b2", "GENE_OR_GENE_PRODUCT", 38, 46], ["CD200", "GENE_OR_GENE_PRODUCT", 51, 56], ["brains", "ORGAN", 84, 90], ["hRSV", "ORGANISM", 94, 98], ["mice", "ORGANISM", 108, 112], ["UV-hRSV", "ORGANISM", 141, 148], ["mice", "ORGANISM", 157, 161], ["IL-6", "PROTEIN", 18, 22], ["TNF-\u03b1, CX3CL1,346IL-1\u03b2 and CD200 mRNAs", "RNA", 24, 62], ["mice", "SPECIES", 108, 112], ["mice", "SPECIES", 157, 161], ["hRSV", "SPECIES", 94, 98], ["mice", "SPECIES", 108, 112], ["mice", "SPECIES", 157, 161], ["IL", "TEST", 18, 20], ["TNF", "TEST", 24, 27], ["CX3CL1", "TEST", 31, 37], ["CD200 mRNAs", "TEST", 51, 62], ["hRSV", "PROBLEM", 94, 98], ["mock", "TEST", 132, 136], ["UV", "TEST", 141, 143], ["IL", "OBSERVATION_MODIFIER", 18, 20]]], ["Interestingly, 60 days p.i. a significant 348 increase was observed for IL-4, IL-10, CCL2 and GFAP mRNA levels in hRSV-infected 349 mice.", [["IL-4", "GENE_OR_GENE_PRODUCT", 72, 76], ["IL-10", "GENE_OR_GENE_PRODUCT", 78, 83], ["CCL2", "GENE_OR_GENE_PRODUCT", 85, 89], ["GFAP", "GENE_OR_GENE_PRODUCT", 94, 98], ["hRSV", "ORGANISM", 114, 118], ["mice", "ORGANISM", 132, 136], ["mice", "SPECIES", 132, 136], ["hRSV", "SPECIES", 114, 118], ["mice", "SPECIES", 132, 136], ["IL", "TEST", 72, 74], ["IL", "TEST", 78, 80], ["CCL2", "TEST", 85, 89], ["GFAP mRNA levels", "TEST", 94, 110], ["hRSV", "TEST", 114, 118]]], ["The expression of TNF-\u03b1 mRNA and protein content were alike among all 350 experimental groups ( Figure 3A and 3B, respectively).", [["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 18, 23], ["TNF-\u03b1 mRNA", "RNA", 18, 28], ["TNF", "TEST", 18, 21], ["protein content", "TEST", 33, 48], ["TNF", "ANATOMY", 18, 21]]], ["A significant increase in the protein 351 content of IL-4 ( Figure 3C ) and IL-10 ( Figure 3D ) and GFAP ( Figure 3E ) was observed in 352 hRSV infected mice as compared to UV-hRSV-and mock-treated mice.", [["IL-4", "GENE_OR_GENE_PRODUCT", 53, 57], ["Figure 3C", "GENE_OR_GENE_PRODUCT", 60, 69], ["IL-10", "GENE_OR_GENE_PRODUCT", 76, 81], ["Figure 3D", "GENE_OR_GENE_PRODUCT", 84, 93], ["GFAP ( Figure 3E", "GENE_OR_GENE_PRODUCT", 100, 116], ["mice", "ORGANISM", 153, 157], ["mock", "ORGANISM", 185, 189], ["mice", "ORGANISM", 198, 202], ["IL-4", "PROTEIN", 53, 57], ["IL-10", "PROTEIN", 76, 81], ["GFAP", "PROTEIN", 100, 104], ["mice", "SPECIES", 153, 157], ["mice", "SPECIES", 198, 202], ["hRSV", "SPECIES", 139, 143], ["mice", "SPECIES", 153, 157], ["mice", "SPECIES", 198, 202], ["A significant increase", "PROBLEM", 0, 22], ["the protein", "TEST", 26, 37], ["IL", "TEST", 53, 55], ["IL", "TEST", 76, 78], ["GFAP", "TEST", 100, 104], ["UV", "TEST", 173, 175], ["hRSV", "TEST", 176, 180], ["significant", "OBSERVATION_MODIFIER", 2, 13], ["increase", "OBSERVATION_MODIFIER", 14, 22]]], ["The protein levels 353 of these molecules were consistent with their mRNA levels.346354346Increased blood-brain barrier permeability and immune cell infiltration 355 into the brain of hRSV-infected mice356It has been observed an increase in the BBB permeability in mice infected with 357 influenza virus (55).", [["blood-brain barrier", "ANATOMY", 100, 119], ["immune cell", "ANATOMY", 137, 148], ["brain", "ANATOMY", 175, 180], ["BBB", "ANATOMY", 245, 248], ["346354346", "CHEMICAL", 81, 90], ["346354346", "CHEMICAL", 81, 90], ["blood", "ORGANISM_SUBSTANCE", 100, 105], ["brain barrier", "MULTI-TISSUE_STRUCTURE", 106, 119], ["immune cell", "CELL", 137, 148], ["brain", "ORGAN", 175, 180], ["hRSV", "GENE_OR_GENE_PRODUCT", 184, 188], ["mice", "ORGANISM", 198, 202], ["BBB", "TISSUE", 245, 248], ["mice", "ORGANISM", 265, 269], ["357 influenza virus", "ORGANISM", 284, 303], ["mice", "SPECIES", 198, 202], ["mice", "SPECIES", 265, 269], ["influenza virus", "SPECIES", 288, 303], ["346354346", "SPECIES", 81, 90], ["hRSV", "SPECIES", 184, 188], ["mice", "SPECIES", 198, 202], ["mice", "SPECIES", 265, 269], ["The protein levels", "TEST", 0, 18], ["these molecules", "TEST", 26, 41], ["Increased blood-brain barrier permeability", "PROBLEM", 90, 132], ["immune cell infiltration", "PROBLEM", 137, 161], ["influenza virus", "PROBLEM", 288, 303], ["consistent with", "UNCERTAINTY", 47, 62], ["blood", "ANATOMY", 100, 105], ["brain", "ANATOMY", 106, 111], ["barrier permeability", "OBSERVATION_MODIFIER", 112, 132], ["immune cell infiltration", "OBSERVATION", 137, 161], ["brain", "ANATOMY", 175, 180], ["hRSV", "ANATOMY", 184, 188], ["infected", "OBSERVATION", 189, 197], ["increase", "OBSERVATION_MODIFIER", 229, 237], ["BBB", "ANATOMY", 245, 248], ["permeability", "OBSERVATION_MODIFIER", 249, 261]]], ["Given that, we previously were able to identify hRSV in the brain cortex 358 (14) at 3 days p.i., we evaluated whether the hRSV infection promotes an alteration of the 359 BBB permeability and inflammatory cell infiltration.", [["brain cortex", "ANATOMY", 60, 72], ["BBB", "ANATOMY", 172, 175], ["inflammatory cell", "ANATOMY", 193, 210], ["infection", "DISEASE", 128, 137], ["hRSV", "GENE_OR_GENE_PRODUCT", 48, 52], ["brain cortex", "MULTI-TISSUE_STRUCTURE", 60, 72], ["hRSV", "ORGANISM", 123, 127], ["BBB", "MULTI-TISSUE_STRUCTURE", 172, 175], ["inflammatory cell", "CELL", 193, 210], ["hRSV", "PROTEIN", 48, 52], ["hRSV", "SPECIES", 48, 52], ["hRSV", "SPECIES", 123, 127], ["the hRSV infection", "PROBLEM", 119, 137], ["the 359 BBB permeability", "PROBLEM", 164, 188], ["inflammatory cell infiltration", "PROBLEM", 193, 223], ["brain", "ANATOMY", 60, 65], ["cortex", "ANATOMY_MODIFIER", 66, 72], ["hRSV", "OBSERVATION_MODIFIER", 123, 127], ["infection", "OBSERVATION", 128, 137], ["inflammatory cell infiltration", "OBSERVATION", 193, 223]]], ["For that BALB/c mice were either 360 intranasally (i.n.) infected with 1x10 6 PFUs of hRSV or inoculated with non-infectious 361 supernatant (i.e., mock) or UV-inactivated hRSV.", [["supernatant", "ANATOMY", 129, 140], ["hRSV", "CHEMICAL", 86, 90], ["BALB/c mice", "ORGANISM", 9, 20], ["hRSV", "ORGANISM", 86, 90], ["hRSV", "ORGANISM", 172, 176], ["mice", "SPECIES", 16, 20], ["mice", "SPECIES", 16, 20], ["hRSV", "SPECIES", 86, 90], ["hRSV", "SPECIES", 172, 176], ["BALB/c mice", "TREATMENT", 9, 20], ["hRSV", "PROBLEM", 86, 90], ["non-infectious", "PROBLEM", 110, 124], ["UV", "TEST", 157, 159], ["hRSV", "PROBLEM", 172, 176], ["non-infectious", "OBSERVATION_MODIFIER", 110, 124]]], ["After 3 or 7 days of infection BBB 362 permeability was measured by Evans blue extravasation into the brain (see materials and 363 methods).", [["brain", "ANATOMY", 102, 107], ["infection", "DISEASE", 21, 30], ["Evans blue", "CHEMICAL", 68, 78], ["Evans blue", "CHEMICAL", 68, 78], ["BBB 362", "SIMPLE_CHEMICAL", 31, 38], ["brain", "ORGAN", 102, 107], ["infection", "PROBLEM", 21, 30], ["Evans blue extravasation into the brain", "PROBLEM", 68, 107], ["infection", "OBSERVATION", 21, 30], ["brain", "ANATOMY", 102, 107]]], ["Evans blue is a cationic dye that binds to albumin in the serum and forms a 364 complex that under normal conditions is not able to trespass an intact BBB (56).", [["serum", "ANATOMY", 58, 63], ["Evans blue", "CHEMICAL", 0, 10], ["Evans blue", "CHEMICAL", 0, 10], ["Evans blue", "SIMPLE_CHEMICAL", 0, 10], ["cationic dye", "SIMPLE_CHEMICAL", 16, 28], ["albumin", "GENE_OR_GENE_PRODUCT", 43, 50], ["serum", "ORGANISM_SUBSTANCE", 58, 63], ["BBB", "MULTI-TISSUE_STRUCTURE", 151, 154], ["albumin", "PROTEIN", 43, 50], ["364 complex", "PROTEIN", 76, 87], ["a cationic dye", "TREATMENT", 14, 28], ["albumin in the serum", "TEST", 43, 63], ["intact", "OBSERVATION", 144, 150]]], ["Thus, 365 extravasation of the Evans blue-albumin complex into the brain is indicative of increased 366 BBB permeability to macromolecules (57).", [["brain", "ANATOMY", 67, 72], ["BBB", "ANATOMY", 104, 107], ["Evans blue-albumin", "GENE_OR_GENE_PRODUCT", 31, 49], ["brain", "ORGAN", 67, 72], ["BBB", "MULTI-TISSUE_STRUCTURE", 104, 107], ["Evans blue-albumin complex", "PROTEIN", 31, 57], ["the Evans blue-albumin complex", "TEST", 27, 57], ["brain", "ANATOMY", 67, 72], ["indicative of", "UNCERTAINTY", 76, 89], ["increased", "OBSERVATION_MODIFIER", 90, 99], ["366", "OBSERVATION", 100, 103]]], ["Mock-or UV-hRSV treated mice showed no 367 significant extravasation of Evans blue into the brain ( Figure 4A and B) .", [["brain", "ANATOMY", 92, 97], ["Evans blue", "CHEMICAL", 72, 82], ["mice", "ORGANISM", 24, 28], ["Evans blue", "GENE_OR_GENE_PRODUCT", 72, 82], ["brain", "ORGAN", 92, 97], ["mice", "SPECIES", 24, 28], ["mice", "SPECIES", 24, 28], ["Mock", "TEST", 0, 4], ["significant extravasation of Evans blue into the brain", "PROBLEM", 43, 97], ["no", "UNCERTAINTY", 36, 38], ["significant", "OBSERVATION_MODIFIER", 43, 54], ["extravasation", "OBSERVATION", 55, 68], ["brain", "ANATOMY", 92, 97]]], ["However, hRSV-368 infected mice showed a significantly increased of Evans blue extravasation into the brain at 369 3 days p.i.", [["brain", "ANATOMY", 102, 107], ["hRSV-368", "CHEMICAL", 9, 17], ["hRSV-368", "ORGANISM", 9, 17], ["mice", "ORGANISM", 27, 31], ["Evans blue", "GENE_OR_GENE_PRODUCT", 68, 78], ["brain", "ORGAN", 102, 107], ["mice", "SPECIES", 27, 31], ["hRSV-368", "SPECIES", 9, 17], ["mice", "SPECIES", 27, 31], ["hRSV", "TEST", 9, 13], ["Evans blue extravasation into the brain", "PROBLEM", 68, 107], ["significantly", "OBSERVATION_MODIFIER", 41, 54], ["increased", "OBSERVATION_MODIFIER", 55, 64], ["Evans blue extravasation", "OBSERVATION", 68, 92], ["brain", "ANATOMY", 102, 107]]], ["Even though, after seven days p.i. the amount of Evans Blue 370 detected at the CNS was reduced ( Figures 4B and 4D) , it is significantly high, suggesting 371 that the permeability of the BBB to macromolecules has increased in hRSV-infected mice.", [["CNS", "ANATOMY", 80, 83], ["BBB", "ANATOMY", 189, 192], ["Evans Blue 370", "CHEMICAL", 49, 63], ["Evans Blue 370", "CHEMICAL", 49, 63], ["Evans Blue 370", "GENE_OR_GENE_PRODUCT", 49, 63], ["CNS", "ANATOMICAL_SYSTEM", 80, 83], ["BBB", "MULTI-TISSUE_STRUCTURE", 189, 192], ["hRSV", "GENE_OR_GENE_PRODUCT", 228, 232], ["mice", "ORGANISM", 242, 246], ["mice", "SPECIES", 242, 246], ["hRSV", "SPECIES", 228, 232], ["mice", "SPECIES", 242, 246], ["Evans Blue", "TEST", 49, 59], ["hRSV", "PROBLEM", 228, 232], ["significantly", "OBSERVATION_MODIFIER", 125, 138], ["high", "OBSERVATION", 139, 143], ["increased", "OBSERVATION_MODIFIER", 215, 224], ["hRSV", "OBSERVATION", 228, 232], ["infected mice", "OBSERVATION", 233, 246]]], ["Moreover, it is possible that not only the BBB permeability has increased to 373 macromolecules but also the infiltration of inflammatory cells into the CNS.", [["BBB", "ANATOMY", 43, 46], ["inflammatory cells", "ANATOMY", 125, 143], ["CNS", "ANATOMY", 153, 156], ["BBB", "MULTI-TISSUE_STRUCTURE", 43, 46], ["inflammatory cells", "CELL", 125, 143], ["CNS", "ANATOMICAL_SYSTEM", 153, 156], ["inflammatory cells", "CELL_TYPE", 125, 143], ["the BBB permeability", "TEST", 39, 59], ["the infiltration of inflammatory cells into the CNS", "PROBLEM", 105, 156], ["increased", "OBSERVATION_MODIFIER", 64, 73], ["infiltration", "OBSERVATION", 109, 121], ["inflammatory cells", "OBSERVATION", 125, 143], ["CNS", "ANATOMY", 153, 156]]], ["We assessed the 374 presence of inflammatory cells into the brain parenchyma of hRSV-infected mice.", [["inflammatory cells", "ANATOMY", 32, 50], ["brain parenchyma", "ANATOMY", 60, 76], ["inflammatory cells", "CELL", 32, 50], ["brain parenchyma", "MULTI-TISSUE_STRUCTURE", 60, 76], ["hRSV", "GENE_OR_GENE_PRODUCT", 80, 84], ["mice", "ORGANISM", 94, 98], ["inflammatory cells", "CELL_TYPE", 32, 50], ["mice", "SPECIES", 94, 98], ["hRSV", "SPECIES", 80, 84], ["mice", "SPECIES", 94, 98], ["inflammatory cells", "PROBLEM", 32, 50], ["hRSV", "PROBLEM", 80, 84], ["inflammatory cells", "OBSERVATION", 32, 50], ["brain", "ANATOMY", 60, 65], ["parenchyma", "ANATOMY_MODIFIER", 66, 76], ["hRSV", "OBSERVATION", 80, 84], ["infected mice", "OBSERVATION", 85, 98]]], ["Immune 375 cell infiltration was evaluated by flow cytometry at days 3 and 7 p.i. with hRSV, UV-hRSV 376 or mock treatments ( Figure 5) .", [["Immune 375 cell", "ANATOMY", 0, 15], ["UV-hRSV 376", "CHEMICAL", 93, 104], ["Immune 375 cell", "CELL", 0, 15], ["hRSV", "SPECIES", 87, 91], ["Immune 375 cell infiltration", "PROBLEM", 0, 28], ["flow cytometry", "TEST", 46, 60], ["hRSV", "PROBLEM", 87, 91], ["mock treatments", "TREATMENT", 108, 123], ["375 cell infiltration", "OBSERVATION", 7, 28]]], ["A significant increase in neutrophils ( Figure 5A and 5D450It has been previously shown that hRSV can reach the brain at 3 days p.i.", [["neutrophils", "ANATOMY", 26, 37], ["brain", "ANATOMY", 112, 117], ["neutrophils", "CELL", 26, 37], ["hRSV", "GENE_OR_GENE_PRODUCT", 93, 97], ["brain", "ORGAN", 112, 117], ["neutrophils", "CELL_TYPE", 26, 37], ["5D450It", "PROTEIN", 54, 61], ["hRSV", "PROTEIN", 93, 97], ["hRSV", "SPECIES", 93, 97], ["A significant increase in neutrophils", "PROBLEM", 0, 37], ["hRSV", "PROBLEM", 93, 97], ["significant", "OBSERVATION_MODIFIER", 2, 13], ["increase", "OBSERVATION_MODIFIER", 14, 22], ["neutrophils", "OBSERVATION", 26, 37], ["hRSV", "OBSERVATION", 93, 97], ["brain", "ANATOMY", 112, 117]]], ["(14) and 451 enter the CNS utilizing a \"Trojan horse\" mechanism (66) However, whether hRSV can 452 infect and replicate in cells of the CNS remains unknown.", [["CNS", "ANATOMY", 23, 26], ["cells", "ANATOMY", 123, 128], ["CNS", "ANATOMY", 136, 139], ["CNS", "ANATOMICAL_SYSTEM", 23, 26], ["horse", "ORGANISM_SUBDIVISION", 47, 52], ["hRSV", "ORGANISM", 86, 90], ["cells", "CELL", 123, 128], ["CNS", "ANATOMICAL_SYSTEM", 136, 139], ["hRSV", "PROBLEM", 86, 90], ["CNS", "ANATOMY", 23, 26], ["CNS", "ANATOMY", 136, 139]]], ["Therefore, we evaluated whether 453 hRSV could infect astrocytes, neurons, microglia and endothelial cells at day 3 p.i. with 454 1x10 6 PFUs.", [["astrocytes", "ANATOMY", 54, 64], ["neurons", "ANATOMY", 66, 73], ["microglia", "ANATOMY", 75, 84], ["endothelial cells", "ANATOMY", 89, 106], ["hRSV", "GENE_OR_GENE_PRODUCT", 36, 40], ["astrocytes", "CELL", 54, 64], ["neurons", "CELL", 66, 73], ["microglia", "CELL", 75, 84], ["endothelial cells", "CELL", 89, 106], ["astrocytes", "CELL_TYPE", 54, 64], ["neurons", "CELL_TYPE", 66, 73], ["microglia", "CELL_TYPE", 75, 84], ["endothelial cells", "CELL_TYPE", 89, 106], ["hRSV", "SPECIES", 36, 40], ["endothelial", "ANATOMY", 89, 100]]], ["Figure 7 shows representative pictures of immunofluorescence colocalization 455 analyses in brain cortex for hRSV and various markers for CNS cells.", [["brain cortex", "ANATOMY", 92, 104], ["hRSV", "ANATOMY", 109, 113], ["CNS cells", "ANATOMY", 138, 147], ["brain cortex", "CANCER", 92, 104], ["hRSV", "CANCER", 109, 113], ["CNS cells", "CELL", 138, 147], ["hRSV", "PROTEIN", 109, 113], ["CNS cells", "CELL_TYPE", 138, 147], ["hRSV", "SPECIES", 109, 113], ["immunofluorescence colocalization", "TEST", 42, 75], ["brain cortex", "TEST", 92, 104], ["hRSV", "PROBLEM", 109, 113], ["various markers", "TEST", 118, 133], ["CNS cells", "PROBLEM", 138, 147], ["brain cortex", "ANATOMY", 92, 104], ["CNS cells", "OBSERVATION", 138, 147]]], ["F-hRSV colocalized 456 with 1% of endothelial cells ( Figure 7B ), 1% of neurons ( Figure 7C ) and 1% of microglia 457 ( Figure 7D ).", [["endothelial cells", "ANATOMY", 34, 51], ["neurons", "ANATOMY", 73, 80], ["F-hRSV", "GENE_OR_GENE_PRODUCT", 0, 6], ["endothelial cells", "CELL", 34, 51], ["neurons", "CELL", 73, 80], ["microglia", "CELL", 105, 114], ["hRSV", "DNA", 2, 6], ["endothelial cells", "CELL_TYPE", 34, 51], ["microglia 457", "PROTEIN", 105, 118], ["endothelial cells", "TEST", 34, 51], ["Figure 7B", "TEST", 54, 63], ["microglia", "TEST", 105, 114], ["endothelial cells", "ANATOMY", 34, 51]]], ["Whereas, F-hRSV colocalized with 5% of astrocytes ( Figure 7E ).", [["astrocytes", "ANATOMY", 39, 49], ["F-hRSV", "GENE_OR_GENE_PRODUCT", 9, 15], ["astrocytes", "CELL", 39, 49], ["F-hRSV", "PROTEIN", 9, 15], ["astrocytes", "CELL_TYPE", 39, 49]]], ["Moreover, we 458 also detected approximately 4% of F-hRSV + free, which means that the viral protein was not 465 According to this notion and because we found that the percentage of hRSV-infected 466 astrocytes was higher as compared to the other cell types (Figure 7) ,479To determine whether astrocytes can be activated during hRSV infection, intracellular 480 levels of nitric oxide (NO) were quantified as a marker for astrocyte activation (50).479481 Importantly, the production of NO increased in hRSV-infected astrocytes 24, 48 and 72 h 482 p.i., as compared to UV-hRSV-treated cells ( Figure 8D ).", [["astrocytes", "ANATOMY", 200, 210], ["cell", "ANATOMY", 247, 251], ["astrocytes", "ANATOMY", 294, 304], ["intracellular", "ANATOMY", 345, 358], ["astrocyte", "ANATOMY", 423, 432], ["astrocytes", "ANATOMY", 517, 527], ["cells", "ANATOMY", 585, 590], ["infection", "DISEASE", 334, 343], ["nitric oxide", "CHEMICAL", 373, 385], ["NO", "CHEMICAL", 387, 389], ["NO", "CHEMICAL", 487, 489], ["UV-hRSV", "CHEMICAL", 569, 576], ["nitric oxide", "CHEMICAL", 373, 385], ["NO", "CHEMICAL", 387, 389], ["NO", "CHEMICAL", 487, 489], ["F-hRSV", "GENE_OR_GENE_PRODUCT", 51, 57], ["hRSV", "GENE_OR_GENE_PRODUCT", 182, 186], ["astrocytes", "CELL", 200, 210], ["cell", "CELL", 247, 251], ["astrocytes", "CELL", 294, 304], ["hRSV", "GENE_OR_GENE_PRODUCT", 329, 333], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 345, 358], ["nitric oxide", "SIMPLE_CHEMICAL", 373, 385], ["NO", "SIMPLE_CHEMICAL", 387, 389], ["astrocyte", "CELL", 423, 432], ["NO", "GENE_OR_GENE_PRODUCT", 487, 489], ["hRSV", "SIMPLE_CHEMICAL", 503, 507], ["astrocytes", "CELL", 517, 527], ["cells", "CELL", 585, 590], ["F-hRSV", "PROTEIN", 51, 57], ["viral protein", "PROTEIN", 87, 100], ["hRSV-infected 466 astrocytes", "CELL_LINE", 182, 210], ["astrocytes", "CELL_TYPE", 294, 304], ["hRSV", "CELL_LINE", 503, 507], ["infected astrocytes", "CELL_TYPE", 508, 527], ["UV-hRSV-treated cells", "CELL_LINE", 569, 590], ["hRSV", "SPECIES", 182, 186], ["hRSV", "SPECIES", 329, 333], ["hRSV", "SPECIES", 503, 507], ["F-hRSV", "TEST", 51, 57], ["the viral protein", "TEST", 83, 100], ["hRSV", "PROBLEM", 182, 186], ["infected 466 astrocytes", "PROBLEM", 187, 210], ["astrocytes", "PROBLEM", 294, 304], ["hRSV infection", "PROBLEM", 329, 343], ["nitric oxide", "TREATMENT", 373, 385], ["increased in hRSV", "PROBLEM", 490, 507], ["infected astrocytes", "TEST", 508, 527], ["UV", "TEST", 569, 571], ["NO", "UNCERTAINTY", 487, 489], ["increased", "OBSERVATION_MODIFIER", 490, 499], ["hRSV", "OBSERVATION", 503, 507]]], ["These data further support the 483 notion that hRSV activates astrocytes and that this virus is likely that could induce an 484 inflammatory response in the CNS.", [["astrocytes", "ANATOMY", 62, 72], ["CNS", "ANATOMY", 157, 160], ["hRSV", "GENE_OR_GENE_PRODUCT", 47, 51], ["astrocytes", "CELL", 62, 72], ["CNS", "ANATOMICAL_SYSTEM", 157, 160], ["hRSV", "PROTEIN", 47, 51], ["astrocytes", "CELL_TYPE", 62, 72], ["hRSV", "SPECIES", 47, 51], ["hRSV activates astrocytes", "PROBLEM", 47, 72], ["this virus", "PROBLEM", 82, 92], ["an 484 inflammatory response in the CNS", "PROBLEM", 121, 160], ["inflammatory", "OBSERVATION_MODIFIER", 128, 140], ["CNS", "ANATOMY", 157, 160]]], ["Therefore, we also measured the secretion of cytokines 485 associated with inflammation, such as IL-4, IL-10, TNF-\u03b1 and IL-6 in the supernatants of 496 DISCUSSION497Neurological complications in patients with severe bronchiolitis due to infection with 498 hRSV have been increasingly reported in the past years (4, 7, 8, 10-12) .", [["supernatants", "ANATOMY", 132, 144], ["Neurological", "ANATOMY", 165, 177], ["inflammation", "DISEASE", 75, 87], ["Neurological complications", "DISEASE", 165, 191], ["bronchiolitis", "DISEASE", 216, 229], ["infection", "DISEASE", 237, 246], ["IL-4", "GENE_OR_GENE_PRODUCT", 97, 101], ["IL-10", "GENE_OR_GENE_PRODUCT", 103, 108], ["TNF-\u03b1", "GENE_OR_GENE_PRODUCT", 110, 115], ["IL-6", "GENE_OR_GENE_PRODUCT", 120, 124], ["patients", "ORGANISM", 195, 203], ["cytokines 485", "PROTEIN", 45, 58], ["IL-4, IL-10", "PROTEIN", 97, 108], ["TNF", "PROTEIN", 110, 113], ["IL-6", "PROTEIN", 120, 124], ["patients", "SPECIES", 195, 203], ["the secretion of cytokines", "PROBLEM", 28, 54], ["inflammation", "PROBLEM", 75, 87], ["IL", "TEST", 97, 99], ["IL", "TEST", 103, 105], ["TNF", "TEST", 110, 113], ["IL", "TEST", 120, 122], ["Neurological complications", "PROBLEM", 165, 191], ["severe bronchiolitis", "PROBLEM", 209, 229], ["infection", "PROBLEM", 237, 246], ["hRSV", "PROBLEM", 256, 260], ["inflammation", "OBSERVATION", 75, 87], ["complications", "OBSERVATION", 178, 191], ["severe", "OBSERVATION_MODIFIER", 209, 215], ["bronchiolitis", "OBSERVATION", 216, 229], ["infection", "OBSERVATION", 237, 246]]], ["Importantly, viral 499 mRNA has been detected in CSF samples of patients with neurological alterations, 500 suggesting that hRSV can reach the CNS (5, 6, 11, 70) .", [["CSF samples", "ANATOMY", 49, 60], ["neurological", "ANATOMY", 78, 90], ["CNS", "ANATOMY", 143, 146], ["neurological alterations", "DISEASE", 78, 102], ["CSF samples", "ORGANISM_SUBSTANCE", 49, 60], ["patients", "ORGANISM", 64, 72], ["hRSV", "GENE_OR_GENE_PRODUCT", 124, 128], ["CNS", "ANATOMICAL_SYSTEM", 143, 146], ["viral 499 mRNA", "RNA", 13, 27], ["patients", "SPECIES", 64, 72], ["hRSV", "SPECIES", 124, 128], ["viral 499 mRNA", "TEST", 13, 27], ["CSF samples", "TEST", 49, 60], ["neurological alterations", "PROBLEM", 78, 102], ["hRSV", "PROBLEM", 124, 128], ["hRSV", "OBSERVATION", 124, 128], ["CNS", "ANATOMY", 143, 146]]], ["Furthermore, an increased cytokine 501 level detected in the CSF of hRSV-infected patients suggests that CNS infection could be 502 accompanied by encephalitis (7, 8, 10, 20, 70, 71 ).", [["CNS", "ANATOMY", 105, 108], ["hRSV-infected", "DISEASE", 68, 81], ["CNS infection", "DISEASE", 105, 118], ["encephalitis", "DISEASE", 147, 159], ["cytokine 501", "GENE_OR_GENE_PRODUCT", 26, 38], ["CSF", "GENE_OR_GENE_PRODUCT", 61, 64], ["hRSV", "GENE_OR_GENE_PRODUCT", 68, 72], ["patients", "ORGANISM", 82, 90], ["CNS", "ANATOMICAL_SYSTEM", 105, 108], ["cytokine 501", "PROTEIN", 26, 38], ["patients", "SPECIES", 82, 90], ["hRSV", "SPECIES", 68, 72], ["an increased cytokine 501 level", "PROBLEM", 13, 44], ["hRSV", "PROBLEM", 68, 72], ["CNS infection", "PROBLEM", 105, 118], ["encephalitis", "PROBLEM", 147, 159], ["increased", "OBSERVATION_MODIFIER", 16, 25], ["hRSV", "OBSERVATION", 68, 72], ["infected", "OBSERVATION", 73, 81], ["CNS", "ANATOMY", 105, 108], ["infection", "OBSERVATION", 109, 118], ["encephalitis", "OBSERVATION", 147, 159]]], ["Consistently these important observations 503 in hRSV-infected patients, in this study we reported that neurological symptoms could also 504 take place in animal models.", [["neurological", "ANATOMY", 104, 116], ["hRSV-infected", "DISEASE", 49, 62], ["neurological symptoms", "DISEASE", 104, 125], ["hRSV", "ORGANISM", 49, 53], ["patients", "ORGANISM", 63, 71], ["patients", "SPECIES", 63, 71], ["hRSV", "SPECIES", 49, 53], ["this study", "TEST", 76, 86], ["neurological symptoms", "PROBLEM", 104, 125]]], ["These data further support the notion that hRSV can access to 505 the CNS, in particular by infecting astrocytes.", [["CNS", "ANATOMY", 70, 73], ["astrocytes", "ANATOMY", 102, 112], ["hRSV", "CHEMICAL", 43, 47], ["hRSV", "ORGANISM", 43, 47], ["CNS", "ANATOMICAL_SYSTEM", 70, 73], ["astrocytes", "CELL", 102, 112], ["astrocytes", "CELL_TYPE", 102, 112], ["hRSV", "SPECIES", 43, 47], ["hRSV", "PROBLEM", 43, 47]]], ["However, clinical signs associated with the 506 encephalopathy described in humans by hRSV, such as seizures (11, 12) were not observed 507 in the murine model.", [["encephalopathy", "DISEASE", 48, 62], ["seizures", "DISEASE", 100, 108], ["humans", "ORGANISM", 76, 82], ["murine", "ORGANISM", 147, 153], ["humans", "SPECIES", 76, 82], ["murine", "SPECIES", 147, 153], ["humans", "SPECIES", 76, 82], ["clinical signs", "PROBLEM", 9, 23], ["the 506 encephalopathy", "PROBLEM", 40, 62], ["seizures", "PROBLEM", 100, 108]]], ["Importantly, our findings are in agreement with previous data 508 suggesting that hRSV may enter the CNS by a \"Trojan horse\" mechanism, by infecting Figure 6 ).", [["CNS", "ANATOMY", 101, 104], ["hRSV", "GENE_OR_GENE_PRODUCT", 82, 86], ["CNS", "ANATOMICAL_SYSTEM", 101, 104], ["horse", "ORGANISM_SUBDIVISION", 118, 123], ["horse", "SPECIES", 118, 123], ["hRSV", "SPECIES", 82, 86], ["previous data", "TEST", 48, 61], ["hRSV", "PROBLEM", 82, 86]]], ["These results 565 somewhat suggest that the increase in the expression of these pro-inflammatory cytokines 566 may be due to the activation of microglia and astrocytes, which could be enough to cause a 567 behavioral alteration in mice (55).568As mentioned above, both CD200 and CX3CL1 are immunomodulatory molecules 569 that are mainly expressed by neurons allowing their interaction with microglia, which express 570 the receptor for these molecules in the resting state (84-86).", [["microglia", "ANATOMY", 143, 152], ["astrocytes", "ANATOMY", 157, 167], ["neurons", "ANATOMY", 350, 357], ["microglia", "ANATOMY", 390, 399], ["microglia", "CELL", 143, 152], ["astrocytes", "CELL", 157, 167], ["mice", "ORGANISM", 231, 235], ["CD200", "GENE_OR_GENE_PRODUCT", 269, 274], ["CX3CL1", "GENE_OR_GENE_PRODUCT", 279, 285], ["neurons", "CELL", 350, 357], ["microglia", "CELL", 390, 399], ["pro-inflammatory cytokines 566", "PROTEIN", 80, 110], ["microglia", "CELL_TYPE", 143, 152], ["astrocytes", "CELL_TYPE", 157, 167], ["CD200", "PROTEIN", 269, 274], ["CX3CL1", "PROTEIN", 279, 285], ["immunomodulatory molecules 569", "PROTEIN", 290, 320], ["microglia", "CELL_TYPE", 390, 399], ["mice", "SPECIES", 231, 235], ["mice", "SPECIES", 231, 235], ["these pro-inflammatory cytokines", "TEST", 74, 106], ["the activation of microglia and astrocytes", "PROBLEM", 125, 167], ["immunomodulatory molecules", "TEST", 290, 316], ["increase", "OBSERVATION_MODIFIER", 44, 52]]], ["Also, it is known that CD200-571 deficient mice display cognitive impairment, suggesting that this molecule plays a significant 572 role in cognition processes (86).", [["cognitive impairment", "DISEASE", 56, 76], ["CD200-571", "GENE_OR_GENE_PRODUCT", 23, 32], ["mice", "ORGANISM", 43, 47], ["CD200", "PROTEIN", 23, 28], ["mice", "SPECIES", 43, 47], ["CD200", "TEST", 23, 28], ["cognitive impairment", "PROBLEM", 56, 76]]], ["Similar to what was observed in the brains of influenza-573 infected mice, we found that CD200 expression was decreased starting day 1 p.i. in hRSV-574 infected mice, while in the study with influenza, this expression was only evaluated on day 575 7 p.i.", [["brains", "ANATOMY", 36, 42], ["hRSV-574", "CHEMICAL", 143, 151], ["influenza", "DISEASE", 191, 200], ["influenza-573", "ORGANISM", 46, 59], ["mice", "ORGANISM", 69, 73], ["CD200", "GENE_OR_GENE_PRODUCT", 89, 94], ["hRSV-574", "ORGANISM", 143, 151], ["mice", "ORGANISM", 161, 165], ["CD200", "PROTEIN", 89, 94], ["mice", "SPECIES", 69, 73], ["mice", "SPECIES", 161, 165], ["influenza-573", "SPECIES", 46, 59], ["mice", "SPECIES", 69, 73], ["hRSV-574", "SPECIES", 143, 151], ["mice", "SPECIES", 161, 165], ["influenza", "PROBLEM", 46, 55], ["CD200 expression", "PROBLEM", 89, 105], ["hRSV", "TEST", 143, 147], ["the study", "TEST", 176, 185], ["influenza", "PROBLEM", 191, 200], ["CD200 expression", "OBSERVATION", 89, 105], ["influenza", "OBSERVATION", 191, 200]]], ["Furthermore, we found a decrease in CX3CL1 mRNA expression in hRSV-576 infected mice at 3 days p.i. suggesting that the alteration of the normal expression of CD200 577 and CX3CL1, mainly on day 3 p.i., could be due to the activation of microglia with 578 subsequent astrocytes activation and an inflammatory immune response.579Previously, it has been shown that CCL2 attracts inflammatory immune cells to sites 580 of injury, mainly monocytes (59).", [["microglia", "ANATOMY", 237, 246], ["astrocytes", "ANATOMY", 267, 277], ["inflammatory immune cells", "ANATOMY", 377, 402], ["monocytes", "ANATOMY", 434, 443], ["hRSV-576", "CHEMICAL", 62, 70], ["CX3CL1", "GENE_OR_GENE_PRODUCT", 36, 42], ["hRSV-576", "CELL", 62, 70], ["mice", "ORGANISM", 80, 84], ["CD200 577", "GENE_OR_GENE_PRODUCT", 159, 168], ["CX3CL1", "GENE_OR_GENE_PRODUCT", 173, 179], ["microglia", "CELL", 237, 246], ["astrocytes", "CELL", 267, 277], ["CCL2", "GENE_OR_GENE_PRODUCT", 363, 367], ["inflammatory immune cells", "CELL", 377, 402], ["monocytes", "CELL", 434, 443], ["CX3CL1 mRNA", "RNA", 36, 47], ["CD200 577", "PROTEIN", 159, 168], ["CX3CL1", "PROTEIN", 173, 179], ["microglia", "CELL_TYPE", 237, 246], ["astrocytes", "CELL_TYPE", 267, 277], ["CCL2", "PROTEIN", 363, 367], ["inflammatory immune cells", "CELL_TYPE", 377, 402], ["monocytes", "CELL_TYPE", 434, 443], ["mice", "SPECIES", 80, 84], ["hRSV-576", "SPECIES", 62, 70], ["mice", "SPECIES", 80, 84], ["a decrease in CX3CL1 mRNA expression", "PROBLEM", 22, 58], ["hRSV", "TEST", 62, 66], ["CX3CL1", "TEST", 173, 179], ["microglia", "PROBLEM", 237, 246], ["subsequent astrocytes activation", "PROBLEM", 256, 288], ["an inflammatory immune response", "PROBLEM", 293, 324], ["inflammatory immune cells", "PROBLEM", 377, 402], ["injury", "PROBLEM", 419, 425], ["monocytes", "TEST", 434, 443], ["decrease", "OBSERVATION_MODIFIER", 24, 32], ["CX3CL1 mRNA", "OBSERVATION", 36, 47], ["could be due to", "UNCERTAINTY", 203, 218], ["microglia", "ANATOMY", 237, 246], ["inflammatory immune response", "OBSERVATION", 296, 324]]], ["In the brain, CCL2 is constitutively expressed by neurons 581 yet, its levels increase in astrocytes and microglia under pathologic conditions (87).", [["brain", "ANATOMY", 7, 12], ["neurons", "ANATOMY", 50, 57], ["astrocytes", "ANATOMY", 90, 100], ["microglia", "ANATOMY", 105, 114], ["brain", "ORGAN", 7, 12], ["CCL2", "GENE_OR_GENE_PRODUCT", 14, 18], ["neurons 581", "CELL", 50, 61], ["astrocytes", "CELL", 90, 100], ["microglia", "CELL", 105, 114], ["CCL2", "PROTEIN", 14, 18], ["astrocytes", "CELL_TYPE", 90, 100], ["microglia", "CELL_TYPE", 105, 114], ["brain", "ANATOMY", 7, 12], ["CCL2", "ANATOMY", 14, 18], ["increase", "OBSERVATION_MODIFIER", 78, 86], ["astrocytes", "ANATOMY", 90, 100], ["microglia", "ANATOMY", 105, 114]]], ["In line 582 with the findings of inflammatory monocytes in the brain of hRSV-infected mice, we found 583 that the CCL2 expression was elevated in this tissue.", [["monocytes", "ANATOMY", 46, 55], ["brain", "ANATOMY", 63, 68], ["tissue", "ANATOMY", 151, 157], ["monocytes", "CELL", 46, 55], ["brain", "ORGAN", 63, 68], ["hRSV", "GENE_OR_GENE_PRODUCT", 72, 76], ["mice", "ORGANISM", 86, 90], ["CCL2", "GENE_OR_GENE_PRODUCT", 114, 118], ["tissue", "TISSUE", 151, 157], ["inflammatory monocytes", "CELL_TYPE", 33, 55], ["CCL2", "PROTEIN", 114, 118], ["mice", "SPECIES", 86, 90], ["hRSV", "SPECIES", 72, 76], ["mice", "SPECIES", 86, 90], ["inflammatory monocytes in the brain", "PROBLEM", 33, 68], ["the CCL2 expression", "TEST", 110, 129], ["inflammatory monocytes", "OBSERVATION", 33, 55], ["brain", "ANATOMY", 63, 68], ["hRSV", "ANATOMY", 72, 76], ["elevated", "OBSERVATION_MODIFIER", 134, 142]]]], "01b4ece4d56e503d6e1f47a5ad8bc357c1c7def6": [["Dear Editor, We would like to share our ideas on \"The COVID-19 Pandemic: Clinical Information for Ophthalmologists\".", [["Pandemic", "DISEASE", 63, 71]]], ["1 Bozkurt et al. 1 discussed several issues related to COVID-19 and ophthalmologists.", [["several issues", "PROBLEM", 29, 43]]], ["The general ophthalmologic practice during the COVID-19 pandemic is similar worldwide.", [["the COVID", "TEST", 43, 52]]], ["In our country, Thailand, the second country to which the disease spread, the postponement of unnecessary ophthalmic procedures is set.", [["the disease spread", "PROBLEM", 54, 72], ["unnecessary ophthalmic procedures", "TREATMENT", 94, 127], ["disease", "OBSERVATION", 58, 65]]], ["2 We agree that ophthalmologists are at risk to get COVID-19 infection from occupational work.", [["infection", "DISEASE", 61, 70], ["COVID", "TEST", 52, 57], ["infection", "PROBLEM", 61, 70]]], ["The use of full protective equipment is necessary and the universal precautions must be used for all patients.", [["patients", "ORGANISM", 101, 109], ["patients", "SPECIES", 101, 109], ["full protective equipment", "TREATMENT", 11, 36], ["the universal precautions", "TREATMENT", 54, 79]]], ["3 Finally, there is limited mention that patients can also get COVID-19 from medical personnel.", [["patients", "ORGANISM", 41, 49], ["patients", "SPECIES", 41, 49]]], ["The holistic prevention system should be applied in ophthalmology wards.", [["The holistic prevention system", "TREATMENT", 0, 30]]]], "a96248cf1294da3df963e485be31d581fe4722e0": [["IntroductionThe novel coronavirus disease (COVID-19) outbreak started in December 2019 in Wuhan, China, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) [1, 2] .", [["coronavirus disease", "DISEASE", 22, 41], ["acute respiratory syndrome coronavirus", "DISEASE", 121, 159], ["coronavirus", "ORGANISM", 22, 33], ["severe acute respiratory syndrome coronavirus", "SPECIES", 114, 159], ["SARS-CoV-2", "SPECIES", 163, 173], ["The novel coronavirus disease", "PROBLEM", 12, 41], ["COVID", "TEST", 43, 48], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 114, 159], ["coronavirus disease", "OBSERVATION", 22, 41], ["severe", "OBSERVATION_MODIFIER", 114, 120], ["acute", "OBSERVATION_MODIFIER", 121, 126], ["respiratory syndrome", "OBSERVATION", 127, 147]]], ["The Huanan seafood wholesale market in Wuhan, where is highly suspected as the source place of COVID-19 [3] .", [["COVID-19", "CHEMICAL", 95, 103]]], ["It has spread rapidly in China and multiple other countries [1, 4] .", [["spread", "OBSERVATION_MODIFIER", 7, 13], ["rapidly", "OBSERVATION_MODIFIER", 14, 21], ["multiple", "OBSERVATION_MODIFIER", 35, 43]]], ["Over 70,000 COVID-19 cases had been confirmed until Feb 18.", [["COVID", "TEST", 12, 17]]], ["The CT image is used to assess the disease progress, whereas the continued two times of negative results from SARS-CoV-2 nucleic acid detection had been considered as a criterion for ending antiviral treatment.", [["SARS-CoV-2 nucleic acid", "CHEMICAL", 110, 133], ["The CT image", "TEST", 0, 12], ["SARS", "TEST", 110, 114], ["CoV", "TEST", 115, 118], ["nucleic acid detection", "TEST", 121, 143], ["ending antiviral treatment", "TREATMENT", 183, 209]]], ["We compared the two COVID-19 cases with similar backgrounds and CT image repeated intervals under treatment.", [["CT image", "TEST", 64, 72], ["treatment", "TREATMENT", 98, 107]]], ["Our report highlighted the unsynchronized expression in the changes of CT image and nucleic acid detection in COVID-19, and showed the suspected SARS-CoV-2 carrier.", [["nucleic acid", "CHEMICAL", 84, 96], ["CT image", "TEST", 71, 79], ["nucleic acid detection", "TEST", 84, 106], ["COVID", "TEST", 110, 115], ["the suspected SARS", "PROBLEM", 131, 149]]], ["It may be contributed to recognize the disease and improve prevention.Case 1 descriptionA 24-year-old man enrolled in his hometown hospital on Jan 22.", [["man", "ORGANISM", 102, 105], ["man", "SPECIES", 102, 105], ["the disease", "PROBLEM", 35, 46], ["disease", "OBSERVATION", 39, 46]]], ["2020 (about 1260 km far from Wuhan), China, due to a 7-day history of mild fever, dry coughs, and weakness of unknown cause.", [["fever", "DISEASE", 75, 80], ["dry coughs", "DISEASE", 82, 92], ["weakness", "DISEASE", 98, 106], ["mild fever", "PROBLEM", 70, 80], ["dry coughs", "PROBLEM", 82, 92], ["weakness", "PROBLEM", 98, 106], ["mild", "OBSERVATION_MODIFIER", 70, 74], ["fever", "OBSERVATION", 75, 80], ["dry coughs", "OBSERVATION", 82, 92], ["weakness", "OBSERVATION", 98, 106]]], ["Fourteen days before his clinical symptom appeared, he had visited the seafood wholesale market in Wuhan.", [["his clinical symptom", "PROBLEM", 21, 41]]], ["Also, he reported that he contacted with other respiratory patients with fever in Wuhan.", [["fever", "DISEASE", 73, 78], ["patients", "ORGANISM", 59, 67], ["patients", "SPECIES", 59, 67], ["fever", "PROBLEM", 73, 78]]], ["At admission (day 1), the patient reported his symptom was very mild, and his body temperature was 37.6\u00b0C (99.7\u00b0F), whereas coarse breath sounds of both lungs were heard at auscultation.", [["body", "ANATOMY", 78, 82], ["lungs", "ANATOMY", 153, 158], ["patient", "ORGANISM", 26, 33], ["body", "ORGANISM_SUBDIVISION", 78, 82], ["lungs", "ORGAN", 153, 158], ["patient", "SPECIES", 26, 33], ["his symptom", "PROBLEM", 43, 54], ["very mild", "PROBLEM", 59, 68], ["his body temperature", "TEST", 74, 94], ["C", "TEST", 104, 105], ["coarse breath sounds", "TEST", 124, 144], ["auscultation", "TEST", 173, 185], ["mild", "OBSERVATION_MODIFIER", 64, 68], ["both", "ANATOMY_MODIFIER", 148, 152], ["lungs", "ANATOMY", 153, 158]]], ["The results of laboratory tests indicated normal white blood cell count: 5.24 \u00d7 10 9 /L. The neutrophils count declined to 46.7%, whereas C-reactive protein (CRP) was up to 11.8 mg/L. Unenhanced chest computed tomography (CT) showed multiple patchy shadows in the lower lobe of both lungs (Fig. 1) .", [["white blood cell", "ANATOMY", 49, 65], ["neutrophils", "ANATOMY", 93, 104], ["lower lobe", "ANATOMY", 264, 274], ["lungs", "ANATOMY", 283, 288], ["white blood cell", "CELL", 49, 65], ["neutrophils", "CELL", 93, 104], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 138, 156], ["CRP", "GENE_OR_GENE_PRODUCT", 158, 161], ["lower lobe", "ORGAN", 264, 274], ["lungs", "ORGAN", 283, 288], ["neutrophils", "CELL_TYPE", 93, 104], ["C-reactive protein", "PROTEIN", 138, 156], ["CRP", "PROTEIN", 158, 161], ["laboratory tests", "TEST", 15, 31], ["white blood cell count", "TEST", 49, 71], ["The neutrophils count", "TEST", 89, 110], ["C-reactive protein", "TEST", 138, 156], ["CRP", "TEST", 158, 161], ["Unenhanced chest computed tomography", "TEST", 184, 220], ["CT)", "TEST", 222, 225], ["multiple patchy shadows in the lower lobe of both lungs", "PROBLEM", 233, 288], ["chest", "ANATOMY", 195, 200], ["multiple", "OBSERVATION_MODIFIER", 233, 241], ["patchy", "OBSERVATION_MODIFIER", 242, 248], ["shadows", "OBSERVATION", 249, 256], ["lower lobe", "ANATOMY", 264, 274], ["both", "ANATOMY_MODIFIER", 278, 282], ["lungs", "ANATOMY", 283, 288], ["Fig", "OBSERVATION_MODIFIER", 290, 293]]], ["The SARS-CoV-2 nucleic acid detection of the patient's throat swab was positive (Fig. 1) .", [["throat swab", "ANATOMY", 55, 66], ["SARS-CoV-2 nucleic acid", "CHEMICAL", 4, 27], ["patient", "ORGANISM", 45, 52], ["throat", "ORGANISM", 55, 61], ["swab", "ORGANISM_SUBSTANCE", 62, 66], ["patient", "SPECIES", 45, 52], ["The SARS", "TEST", 0, 8], ["CoV", "TEST", 9, 12], ["nucleic acid detection", "TEST", 15, 37], ["the patient's throat swab", "TEST", 41, 66], ["throat", "ANATOMY", 55, 61]]], ["Thus, the patient was diagnosed as COVID-19.", [["patient", "ORGANISM", 10, 17], ["patient", "SPECIES", 10, 17], ["COVID", "TEST", 35, 40]]], ["After received a day treatment with interferon inhalation (1,000, 000 IU, 3/day) and azithromycin (0.5 g, 1/day), his body temperature was declined to normal 36.7\u00b0C (98.1\u00b0F).", [["body", "ANATOMY", 118, 122], ["interferon", "CHEMICAL", 36, 46], ["azithromycin", "CHEMICAL", 85, 97], ["azithromycin", "CHEMICAL", 85, 97], ["azithromycin", "SIMPLE_CHEMICAL", 85, 97], ["body", "ORGANISM_SUBDIVISION", 118, 122], ["interferon", "PROTEIN", 36, 46], ["a day treatment", "TREATMENT", 15, 30], ["interferon inhalation", "TREATMENT", 36, 57], ["azithromycin", "TREATMENT", 85, 97], ["his body temperature", "TEST", 114, 134]]], ["On day 3 from admission (day 3), the 1st repeated chest CT showed the infection range was slightly reduced in the medial segment of the right middle lobe and the dorsal segment of the left lower lobe (Fig. 1 ).", [["medial segment", "ANATOMY", 114, 128], ["right middle lobe", "ANATOMY", 136, 153], ["dorsal segment", "ANATOMY", 162, 176], ["left lower lobe", "ANATOMY", 184, 199], ["infection", "DISEASE", 70, 79], ["medial segment", "MULTI-TISSUE_STRUCTURE", 114, 128], ["middle lobe", "MULTI-TISSUE_STRUCTURE", 142, 153], ["dorsal segment", "MULTI-TISSUE_STRUCTURE", 162, 176], ["lower lobe", "MULTI-TISSUE_STRUCTURE", 189, 199], ["the 1st repeated chest CT", "TEST", 33, 58], ["the infection range", "PROBLEM", 66, 85], ["chest", "ANATOMY", 50, 55], ["infection", "OBSERVATION", 70, 79], ["slightly", "OBSERVATION_MODIFIER", 90, 98], ["reduced", "OBSERVATION_MODIFIER", 99, 106], ["medial", "ANATOMY_MODIFIER", 114, 120], ["segment", "ANATOMY_MODIFIER", 121, 128], ["right middle lobe", "ANATOMY", 136, 153], ["dorsal", "ANATOMY_MODIFIER", 162, 168], ["segment", "ANATOMY_MODIFIER", 169, 176], ["left lower lobe", "ANATOMY", 184, 199]]], ["On day 8, the 2nd repeated chest CT image showed the infection range was reduced when compared to the previous one ( Fig. 1 ), and CRP levels was reduced to 1.3 mg/L. On day 10, the patient had less cough, and body temperature has slighter increased, but still in normal range, whereas the 2nd nucleic acid in throat swab was still positive.", [["body", "ANATOMY", 210, 214], ["throat swab", "ANATOMY", 310, 321], ["infection", "DISEASE", 53, 62], ["cough", "DISEASE", 199, 204], ["nucleic acid", "CHEMICAL", 294, 306], ["CRP", "GENE_OR_GENE_PRODUCT", 131, 134], ["patient", "ORGANISM", 182, 189], ["body", "ORGANISM_SUBDIVISION", 210, 214], ["throat swab", "ORGAN", 310, 321], ["CRP", "PROTEIN", 131, 134], ["patient", "SPECIES", 182, 189], ["the 2nd repeated chest CT image", "TEST", 10, 41], ["the infection range", "PROBLEM", 49, 68], ["CRP levels", "TEST", 131, 141], ["less cough", "PROBLEM", 194, 204], ["body temperature", "TEST", 210, 226], ["the 2nd nucleic acid in throat swab", "TEST", 286, 321], ["still positive", "PROBLEM", 326, 340], ["chest", "ANATOMY", 27, 32], ["infection", "OBSERVATION", 53, 62], ["less", "OBSERVATION_MODIFIER", 194, 198], ["cough", "OBSERVATION", 199, 204], ["increased", "OBSERVATION_MODIFIER", 240, 249], ["normal range", "OBSERVATION_MODIFIER", 264, 276]]], ["Thus, it's added another antiviral medicine as lopinavir (50 mg)/ritonavir (200 mg) (2 tablets, 2 times/day) and stopped to use azithromycin from day 10 in the treatment.", [["lopinavir", "CHEMICAL", 47, 56], ["ritonavir", "CHEMICAL", 65, 74], ["azithromycin", "CHEMICAL", 128, 140], ["lopinavir", "CHEMICAL", 47, 56], ["ritonavir", "CHEMICAL", 65, 74], ["azithromycin", "CHEMICAL", 128, 140], ["lopinavir", "SIMPLE_CHEMICAL", 47, 56], ["ritonavir", "SIMPLE_CHEMICAL", 65, 74], ["azithromycin", "SIMPLE_CHEMICAL", 128, 140], ["another antiviral medicine", "TREATMENT", 17, 43], ["lopinavir", "TREATMENT", 47, 56], ["ritonavir", "TREATMENT", 65, 74], ["azithromycin", "TREATMENT", 128, 140]]], ["On day 12, the patient reported no clinical symptom, and the repeated chest CT image showed no infection in the lung (Fig. 1 ).", [["lung", "ANATOMY", 112, 116], ["infection", "DISEASE", 95, 104], ["patient", "ORGANISM", 15, 22], ["lung", "ORGAN", 112, 116], ["patient", "SPECIES", 15, 22], ["clinical symptom", "PROBLEM", 35, 51], ["the repeated chest CT image", "TEST", 57, 84], ["infection in the lung", "PROBLEM", 95, 116], ["chest", "ANATOMY", 70, 75], ["no", "UNCERTAINTY", 92, 94], ["infection", "OBSERVATION", 95, 104], ["lung", "ANATOMY", 112, 116]]], ["On day 15, patients received the 3rd detection of nucleic acid in throat swab, it was still positive (Fig. 1) .", [["throat swab", "ANATOMY", 66, 77], ["nucleic acid", "CHEMICAL", 50, 62], ["patients", "ORGANISM", 11, 19], ["nucleic acid", "SIMPLE_CHEMICAL", 50, 62], ["throat swab", "ORGANISM_SUBSTANCE", 66, 77], ["patients", "SPECIES", 11, 19], ["the 3rd detection", "TEST", 29, 46], ["nucleic acid in throat swab", "PROBLEM", 50, 77]]], ["On day 16, the 4th result of nucleic acid in throat swab changed to negative, whereas it was positive in sputum ( Fig. 1) , thus continued the antiviral treatment with interferon inhalation and lopinavir/ ritonavir.", [["throat swab", "ANATOMY", 45, 56], ["sputum", "ANATOMY", 105, 111], ["nucleic acid", "CHEMICAL", 29, 41], ["lopinavir/ ritonavir", "CHEMICAL", 194, 214], ["lopinavir", "CHEMICAL", 194, 203], ["ritonavir", "CHEMICAL", 205, 214], ["nucleic acid", "SIMPLE_CHEMICAL", 29, 41], ["throat swab", "ORGANISM_SUBSTANCE", 45, 56], ["sputum", "ORGANISM_SUBSTANCE", 105, 111], ["lopinavir", "SIMPLE_CHEMICAL", 194, 203], ["ritonavir", "SIMPLE_CHEMICAL", 205, 214], ["interferon", "PROTEIN", 168, 178], ["nucleic acid in throat swab", "TEST", 29, 56], ["sputum", "TEST", 105, 111], ["the antiviral treatment", "TREATMENT", 139, 162], ["interferon inhalation", "TREATMENT", 168, 189], ["lopinavir", "TREATMENT", 194, 203], ["ritonavir", "TREATMENT", 205, 214]]], ["On day 19, the 5th result of nucleic acid in sputum was still positive (Fig. 1) .", [["sputum", "ANATOMY", 45, 51], ["nucleic acid", "CHEMICAL", 29, 41], ["nucleic acid", "SIMPLE_CHEMICAL", 29, 41], ["sputum", "ORGANISM_SUBSTANCE", 45, 51], ["nucleic acid in sputum", "TEST", 29, 51], ["still positive", "PROBLEM", 56, 70]]], ["On day 22, the nucleic acid in sputum changed to negative, whereas the result back to positive on day 24 (Fig. 1) .", [["sputum", "ANATOMY", 31, 37], ["nucleic acid", "CHEMICAL", 15, 27], ["sputum", "ORGANISM_SUBSTANCE", 31, 37], ["the nucleic acid in sputum", "TEST", 11, 37]]], ["The treatment continued.", [["The treatment", "TREATMENT", 0, 13]]], ["Finally, the nucleic acid detection result was changed to negative on day 29 and day 31 (Fig. 1) .", [["nucleic acid", "CHEMICAL", 13, 25], ["the nucleic acid detection", "TEST", 9, 35]]], ["The patient was discharged from hospital on day 32.Case 2 descriptionA 29-year-old man enrolled in his hometown hospital on Jan 22, 2020 (about 1250 km far from Wuhan), due to a 3day history of very mild fever and cough of unknown cause.", [["fever", "DISEASE", 204, 209], ["cough", "DISEASE", 214, 219], ["patient", "ORGANISM", 4, 11], ["man", "ORGANISM", 83, 86], ["patient", "SPECIES", 4, 11], ["man", "SPECIES", 83, 86], ["very mild fever", "PROBLEM", 194, 209], ["cough", "PROBLEM", 214, 219], ["mild", "OBSERVATION_MODIFIER", 199, 203], ["fever", "OBSERVATION", 204, 209], ["cough", "OBSERVATION", 214, 219]]], ["He had been lived in Wuhan since March 2019, and contacted to the other patients with fever in Wuhan.", [["fever", "DISEASE", 86, 91], ["patients", "ORGANISM", 72, 80], ["patients", "SPECIES", 72, 80], ["fever", "PROBLEM", 86, 91]]], ["The patient reported mild symptoms at admission, since his body temperature was 37.4\u00b0C (99.3\u00b0F), whereas coarse breath sounds of both lungs were heard at auscultation.", [["body", "ANATOMY", 59, 63], ["lungs", "ANATOMY", 134, 139], ["patient", "ORGANISM", 4, 11], ["body", "ORGANISM_SUBDIVISION", 59, 63], ["lungs", "ORGAN", 134, 139], ["patient", "SPECIES", 4, 11], ["mild symptoms", "PROBLEM", 21, 34], ["his body temperature", "TEST", 55, 75], ["coarse breath sounds of both lungs", "PROBLEM", 105, 139], ["auscultation", "TEST", 154, 166], ["mild", "OBSERVATION_MODIFIER", 21, 25], ["symptoms", "OBSERVATION", 26, 34], ["both", "ANATOMY_MODIFIER", 129, 133], ["lungs", "ANATOMY", 134, 139]]], ["Laboratory tests indicated leucopenia as white blood cell count was declined to 3.38 \u00d7 10 9 /L. The white blood cell differential count showed 72.8% as neutrophils, whereas CRP and erythrocyte sedimentation rate (ESR) was elevated to 9.8 mg/L and 15 mm/h, respectively.", [["white blood cell", "ANATOMY", 41, 57], ["white blood cell", "ANATOMY", 100, 116], ["neutrophils", "ANATOMY", 152, 163], ["erythrocyte", "ANATOMY", 181, 192], ["leucopenia", "DISEASE", 27, 37], ["blood cell", "CELL", 47, 57], ["blood cell", "CELL", 106, 116], ["neutrophils", "CELL", 152, 163], ["CRP", "GENE_OR_GENE_PRODUCT", 173, 176], ["erythrocyte", "CELL", 181, 192], ["neutrophils", "CELL_TYPE", 152, 163], ["CRP", "PROTEIN", 173, 176], ["Laboratory tests", "TEST", 0, 16], ["leucopenia", "PROBLEM", 27, 37], ["white blood cell count", "TEST", 41, 63], ["The white blood cell differential count", "TEST", 96, 135], ["neutrophils", "TEST", 152, 163], ["CRP", "TEST", 173, 176], ["erythrocyte sedimentation rate", "TEST", 181, 211], ["ESR", "TEST", 213, 216], ["elevated", "PROBLEM", 222, 230], ["leucopenia", "OBSERVATION", 27, 37]]], ["The unenhanced chest CT image showed multiple patchy shadows in lower lobe of both lungs (Fig. 1) .", [["chest", "ANATOMY", 15, 20], ["lower lobe", "ANATOMY", 64, 74], ["lungs", "ANATOMY", 83, 88], ["lower lobe", "MULTI-TISSUE_STRUCTURE", 64, 74], ["lungs", "ORGAN", 83, 88], ["The unenhanced chest CT image", "TEST", 0, 29], ["multiple patchy shadows in lower lobe of both lungs", "PROBLEM", 37, 88], ["chest", "ANATOMY", 15, 20], ["multiple", "OBSERVATION_MODIFIER", 37, 45], ["patchy", "OBSERVATION_MODIFIER", 46, 52], ["shadows", "OBSERVATION", 53, 60], ["lower lobe", "ANATOMY", 64, 74], ["both", "ANATOMY_MODIFIER", 78, 82], ["lungs", "ANATOMY", 83, 88], ["Fig", "OBSERVATION_MODIFIER", 90, 93]]], ["The SARS-CoV-2 nucleic acid in throat swab was detected as positive.", [["throat swab", "ANATOMY", 31, 42], ["SARS-CoV-2 nucleic acid", "CHEMICAL", 4, 27], ["throat swab", "ORGANISM_SUBSTANCE", 31, 42], ["The SARS", "TEST", 0, 8], ["CoV", "TEST", 9, 12], ["nucleic acid in throat swab", "TEST", 15, 42]]], ["Thus, the patient was diagnosed as of COVID-19 pneumonia.", [["pneumonia", "DISEASE", 47, 56], ["patient", "ORGANISM", 10, 17], ["patient", "SPECIES", 10, 17], ["COVID", "TEST", 38, 43], ["pneumonia", "PROBLEM", 47, 56], ["pneumonia", "OBSERVATION", 47, 56]]], ["Since Fig. 1 The summary of two COVID-19 cases admission (day 1), the patients received the antiviral treatment with interferon inhalation (5,000,000 IU, 2 times/day) and lopinavir (50 mg)/ritonavir (200 mg) (2 tablets, 2 times/ day), the antibacterial treatment with ceftazidime (2.0 g, 2 times/day), and the anti-inflammation treatment with prednisone (30 mg, 1time/day).", [["interferon", "CHEMICAL", 117, 127], ["lopinavir", "CHEMICAL", 171, 180], ["ritonavir", "CHEMICAL", 189, 198], ["ceftazidime", "CHEMICAL", 268, 279], ["prednisone", "CHEMICAL", 343, 353], ["lopinavir", "CHEMICAL", 171, 180], ["ritonavir", "CHEMICAL", 189, 198], ["ceftazidime", "CHEMICAL", 268, 279], ["prednisone", "CHEMICAL", 343, 353], ["patients", "ORGANISM", 70, 78], ["lopinavir", "SIMPLE_CHEMICAL", 171, 180], ["ritonavir", "SIMPLE_CHEMICAL", 189, 198], ["ceftazidime", "SIMPLE_CHEMICAL", 268, 279], ["prednisone", "SIMPLE_CHEMICAL", 343, 353], ["interferon", "PROTEIN", 117, 127], ["patients", "SPECIES", 70, 78], ["the antiviral treatment", "TREATMENT", 88, 111], ["interferon inhalation", "TREATMENT", 117, 138], ["lopinavir", "TREATMENT", 171, 180], ["ritonavir", "TREATMENT", 189, 198], ["the antibacterial treatment", "TREATMENT", 235, 262], ["ceftazidime", "TREATMENT", 268, 279], ["the anti-inflammation treatment", "TREATMENT", 306, 337], ["prednisone", "TREATMENT", 343, 353]]], ["On day 3, the body temperature declined to normal 36.3\u00b0C (97.3\u00b0F) and no cough.", [["body", "ANATOMY", 14, 18], ["cough", "DISEASE", 73, 78], ["body", "ORGANISM_SUBDIVISION", 14, 18], ["the body temperature", "TEST", 10, 30], ["C", "TEST", 55, 56], ["cough", "PROBLEM", 73, 78], ["no", "UNCERTAINTY", 70, 72], ["cough", "OBSERVATION", 73, 78]]], ["On day 8 and day 10, SARS-CoV-2 nucleic acid in throat swab were shown the negative at that two time, and the repeated chest CT image showed that the infection range was declined a lot (Fig. 1) .", [["throat swab", "ANATOMY", 48, 59], ["nucleic acid", "CHEMICAL", 32, 44], ["infection", "DISEASE", 150, 159], ["throat swab", "ORGAN", 48, 59], ["SARS", "TEST", 21, 25], ["CoV", "TEST", 26, 29], ["nucleic acid in throat swab", "TEST", 32, 59], ["the repeated chest CT image", "TEST", 106, 133], ["the infection range", "PROBLEM", 146, 165], ["throat", "ANATOMY", 48, 54], ["chest", "ANATOMY", 119, 124], ["infection", "OBSERVATION", 150, 159]]], ["On day 12, the infection still showed in peripheral lung, but very little (Fig. 1) , thus the patient was discharged from hospital.", [["peripheral lung", "ANATOMY", 41, 56], ["infection", "DISEASE", 15, 24], ["lung", "ORGAN", 52, 56], ["patient", "ORGANISM", 94, 101], ["patient", "SPECIES", 94, 101], ["the infection", "PROBLEM", 11, 24], ["infection", "OBSERVATION", 15, 24], ["peripheral", "ANATOMY_MODIFIER", 41, 51], ["lung", "ANATOMY", 52, 56]]], ["At Feb 18, the CT image of 1st follow-up showed that no infection in his lung (Fig. 1 ).DiscussionThe main finding is the unsynchronized changes in the CT image and SARS-CoV-2 nucleic acid detection in the two imported COVID-19 cases.", [["lung", "ANATOMY", 73, 77], ["infection", "DISEASE", 56, 65], ["nucleic acid", "CHEMICAL", 176, 188], ["lung", "ORGAN", 73, 77], ["the CT image", "TEST", 11, 23], ["infection in his lung", "PROBLEM", 56, 77], ["the unsynchronized changes", "PROBLEM", 118, 144], ["the CT image", "TEST", 148, 160], ["SARS", "TEST", 165, 169], ["CoV", "TEST", 170, 173], ["nucleic acid detection", "TEST", 176, 198], ["no", "UNCERTAINTY", 53, 55], ["infection", "OBSERVATION", 56, 65], ["lung", "ANATOMY", 73, 77], ["main", "OBSERVATION_MODIFIER", 102, 106]]], ["Importantly, we highlight the need for evaluating the suspected virus carriers even after the recovery from pneumonia, who may be asymptomatic with no positive result in laboratory test.", [["pneumonia", "DISEASE", 108, 117], ["the suspected virus carriers", "PROBLEM", 50, 78], ["pneumonia", "PROBLEM", 108, 117], ["laboratory test", "TEST", 170, 185], ["pneumonia", "OBSERVATION", 108, 117]]], ["The PCR positive result in the 1st young male patient lasted nearly 20 days after his pneumonia recovery, suggested a proportion of recovered patients still may be asymptomatic virus carriers.", [["pneumonia", "DISEASE", 86, 95], ["patient", "ORGANISM", 46, 53], ["patients", "ORGANISM", 142, 150], ["patient", "SPECIES", 46, 53], ["patients", "SPECIES", 142, 150], ["The PCR", "TEST", 0, 7], ["his pneumonia recovery", "PROBLEM", 82, 104], ["asymptomatic virus carriers", "PROBLEM", 164, 191], ["pneumonia", "OBSERVATION", 86, 95]]], ["When SARS-CoV-2 enters humans, the interplay between virus and host antiviral defence is a governed factor for outcome of infection.", [["SARS", "DISEASE", 5, 9], ["infection", "DISEASE", 122, 131], ["SARS-CoV-2", "ORGANISM", 5, 15], ["humans", "ORGANISM", 23, 29], ["humans", "SPECIES", 23, 29], ["SARS-CoV", "SPECIES", 5, 13], ["humans", "SPECIES", 23, 29], ["SARS", "PROBLEM", 5, 9], ["virus", "TREATMENT", 53, 58], ["host antiviral defence", "TREATMENT", 63, 85], ["infection", "PROBLEM", 122, 131], ["host antiviral", "OBSERVATION", 63, 77], ["infection", "OBSERVATION", 122, 131]]], ["Asymptomatic carriers might arise when host antiviral defence is either strong or decoupled, thus asymptomatic shedding might occur when the immune response effectively limits but could not enough to completely block SARS-CoV-2 replication [6] .", [["SARS", "DISEASE", 217, 221], ["CoV-2", "ORGANISM", 222, 227], ["Asymptomatic carriers", "PROBLEM", 0, 21], ["asymptomatic shedding", "PROBLEM", 98, 119]]], ["Thus, the continued treatment and isolated is needed, since the risk of transmitting to others still exist.", [["the continued treatment", "TREATMENT", 6, 29]]], ["On the other hand, it is the need to evaluation the effect of the long-time antiviral treatment and side effect, especially for positive SARS-CoV-2 nucleic acid patient without any pneumonia.", [["SARS-CoV-2 nucleic acid", "CHEMICAL", 137, 160], ["pneumonia", "DISEASE", 181, 190], ["patient", "ORGANISM", 161, 168], ["patient", "SPECIES", 161, 168], ["SARS-CoV", "SPECIES", 137, 145], ["evaluation", "TEST", 37, 47], ["the long-time antiviral treatment", "TREATMENT", 62, 95], ["side effect", "PROBLEM", 100, 111], ["positive SARS", "PROBLEM", 128, 141], ["CoV", "TEST", 142, 145], ["nucleic acid", "TEST", 148, 160], ["any pneumonia", "PROBLEM", 177, 190], ["pneumonia", "OBSERVATION", 181, 190]]], ["The unsynchronized result of nucleic acid detection between throat and sputum sample were shown in the 1st patient in our study.", [["throat", "ANATOMY", 60, 66], ["sputum sample", "ANATOMY", 71, 84], ["nucleic acid", "CHEMICAL", 29, 41], ["throat", "ORGANISM_SUBDIVISION", 60, 66], ["patient", "ORGANISM", 107, 114], ["patient", "SPECIES", 107, 114], ["nucleic acid detection", "TEST", 29, 51], ["throat and sputum sample", "TEST", 60, 84], ["our study", "TEST", 118, 127], ["nucleic acid", "OBSERVATION", 29, 41]]], ["First patient showed the virus PCRnegative throat swab on day 16, whereas the result in sputum was continued to be positive until day 24.", [["throat swab", "ANATOMY", 43, 54], ["sputum", "ANATOMY", 88, 94], ["patient", "ORGANISM", 6, 13], ["sputum", "ORGANISM_SUBSTANCE", 88, 94], ["patient", "SPECIES", 6, 13], ["the virus PCRnegative throat swab", "PROBLEM", 21, 54], ["sputum", "TEST", 88, 94]]], ["Thus, we supposed that the different viral load shown between lower respiratory tract than upper respiratory tract.DiscussionHase. et al. study reported that a COVID-19 case diagnosed by PCR-positive lower respiratory specimen, but with PCR-negative throat swabs [7] .", [["lower respiratory tract", "ANATOMY", 62, 85], ["upper respiratory tract", "ANATOMY", 91, 114], ["lower respiratory specimen", "ANATOMY", 200, 226], ["lower", "ORGANISM_SUBDIVISION", 62, 67], ["respiratory tract", "ORGANISM_SUBDIVISION", 68, 85], ["upper respiratory", "ORGANISM_SUBDIVISION", 91, 108], ["tract", "ORGANISM_SUBDIVISION", 109, 114], ["the different viral load", "PROBLEM", 23, 47], ["lower respiratory tract than upper respiratory tract", "PROBLEM", 62, 114], ["a COVID", "TEST", 158, 165], ["PCR", "TEST", 187, 190], ["positive lower respiratory specimen", "PROBLEM", 191, 226], ["PCR", "TEST", 237, 240], ["throat swabs", "TEST", 250, 262], ["viral load", "OBSERVATION", 37, 47], ["lower", "ANATOMY_MODIFIER", 62, 67], ["respiratory tract", "ANATOMY", 68, 85], ["upper", "ANATOMY_MODIFIER", 91, 96], ["respiratory tract", "ANATOMY", 97, 114], ["respiratory specimen", "OBSERVATION", 206, 226]]], ["Although the knowledge of viral loads in COVID-19 is limited, the high viral loads of lower respiratory tract specimens had been reported in severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS) [8, 9] .", [["lower respiratory tract specimens", "ANATOMY", 86, 119], ["acute respiratory syndrome", "DISEASE", 148, 174], ["SARS", "DISEASE", 176, 180], ["Middle East respiratory syndrome", "DISEASE", 186, 218], ["COVID-19", "CELL", 41, 49], ["Middle East respiratory syndrome (MERS)", "SPECIES", 186, 225], ["viral loads in COVID", "TEST", 26, 46], ["the high viral loads of lower respiratory tract specimens", "PROBLEM", 62, 119], ["severe acute respiratory syndrome", "PROBLEM", 141, 174], ["SARS)", "PROBLEM", 176, 181], ["Middle East respiratory syndrome", "PROBLEM", 186, 218], ["viral loads", "OBSERVATION", 26, 37], ["viral loads", "OBSERVATION", 71, 82], ["lower", "ANATOMY_MODIFIER", 86, 91], ["respiratory tract", "ANATOMY", 92, 109], ["severe", "OBSERVATION_MODIFIER", 141, 147], ["acute", "OBSERVATION_MODIFIER", 148, 153], ["respiratory syndrome", "OBSERVATION", 154, 174], ["Middle", "ANATOMY_MODIFIER", 186, 192], ["respiratory syndrome", "OBSERVATION", 198, 218]]], ["Our results not only confirmed the necessary of multiple times test in COVID-19, but also highly recommended to use multitype samples for the disease evaluation, especially lower airway.", [["samples", "ANATOMY", 126, 133], ["lower airway", "ANATOMY", 173, 185], ["airway", "MULTI-TISSUE_STRUCTURE", 179, 185], ["multiple times test", "TEST", 48, 67], ["COVID", "TEST", 71, 76], ["multitype samples", "TREATMENT", 116, 133], ["the disease evaluation", "TEST", 138, 160], ["lower", "ANATOMY_MODIFIER", 173, 178], ["airway", "ANATOMY", 179, 185]]], ["To collect the induced sputum may be recommended for the patients with dry cough or no symptom.", [["sputum", "ANATOMY", 23, 29], ["dry cough", "DISEASE", 71, 80], ["sputum", "ORGANISM_SUBSTANCE", 23, 29], ["patients", "ORGANISM", 57, 65], ["patients", "SPECIES", 57, 65], ["the induced sputum", "TEST", 11, 29], ["dry cough", "PROBLEM", 71, 80], ["symptom", "PROBLEM", 87, 94], ["sputum", "OBSERVATION", 23, 29]]], ["In our cases, the patient had very less symptom, whereas the CT image showed a clearly infection.", [["infection", "DISEASE", 87, 96], ["patient", "ORGANISM", 18, 25], ["patient", "SPECIES", 18, 25], ["very less symptom", "PROBLEM", 30, 47], ["the CT image", "TEST", 57, 69], ["a clearly infection", "PROBLEM", 77, 96], ["infection", "OBSERVATION", 87, 96]]], ["This unsynchronized expression may help clinician to arrange the examination plan for suspected COVID-19 patient.", [["COVID", "DISEASE", 96, 101], ["patient", "ORGANISM", 105, 112], ["patient", "SPECIES", 105, 112], ["the examination", "TEST", 61, 76]]], ["The choice of antiviral medicine for COVID-19 is still controversial, especially no specific anti-SARS-CoV-2 medicine is available.", [["COVID-19", "CHEMICAL", 37, 45], ["COVID-19", "CHEMICAL", 37, 45], ["antiviral medicine", "TREATMENT", 14, 32], ["COVID", "TEST", 37, 42]]], ["However, we noticed that the 2nd patient got quicker recovery compared to the 1st patient, which may relate to the use of double antiviral medicines at early stage.", [["patient", "ORGANISM", 33, 40], ["patient", "ORGANISM", 82, 89], ["patient", "SPECIES", 33, 40], ["patient", "SPECIES", 82, 89], ["double antiviral medicines", "TREATMENT", 122, 148]]], ["Olfactory disturbance or taste disorder was reported in COVID-19 patients [10] , and these symptoms did not been reported by our patients at hospital or follow-up.", [["Olfactory", "ANATOMY", 0, 9], ["Olfactory disturbance", "DISEASE", 0, 21], ["taste disorder", "DISEASE", 25, 39], ["Olfactory", "ORGAN", 0, 9], ["patients", "ORGANISM", 65, 73], ["patients", "ORGANISM", 129, 137], ["patients", "SPECIES", 65, 73], ["patients", "SPECIES", 129, 137], ["Olfactory disturbance", "PROBLEM", 0, 21], ["taste disorder", "PROBLEM", 25, 39], ["these symptoms", "PROBLEM", 85, 99]]], ["The study was limited to a small number of patients, which could not identify the representative and generalizable in COVID-19.ConclusionThe unsynchronized changes in the CT image and SARS-CoV-2 nucleic acid detection in the two imported COVID-19 cases.", [["nucleic acid", "CHEMICAL", 195, 207], ["patients", "ORGANISM", 43, 51], ["patients", "SPECIES", 43, 51], ["The study", "TEST", 0, 9], ["COVID", "TEST", 118, 123], ["The unsynchronized changes", "PROBLEM", 137, 163], ["the CT image", "TEST", 167, 179], ["SARS", "TEST", 184, 188], ["CoV", "TEST", 189, 192], ["nucleic acid detection", "TEST", 195, 217], ["small", "OBSERVATION_MODIFIER", 27, 32]]], ["Lasting positive nucleic acid test result shown in patients recovered from COVID-19.", [["nucleic acid", "CHEMICAL", 17, 29], ["COVID-19", "CHEMICAL", 75, 83], ["patients", "ORGANISM", 51, 59], ["patients", "SPECIES", 51, 59], ["nucleic acid test", "TEST", 17, 34], ["COVID", "TEST", 75, 80]]], ["Our report would be contributed to aid clinicians in a more personalized management.", [["a more personalized management", "TREATMENT", 53, 83]]]], "edf41ca7468dd75ba6a77b909aa1dc7e1202519e": [["A REVIEW OF THE 2003-2004 INFLUENZA SEASONThe news of a vaccine shortage and rampant bird flu came on the heels of an annual epidemic in 2003-2004 that was moderately severe, especially among children.", [["children", "ORGANISM", 192, 200], ["children", "SPECIES", 192, 200], ["a vaccine shortage", "TREATMENT", 54, 72], ["moderately severe", "PROBLEM", 156, 173], ["heels", "ANATOMY", 106, 111], ["moderately severe", "OBSERVATION_MODIFIER", 156, 173]]], ["It began earlier than usual (October) and continued into January 2004, with widespread disease occurring in 45 states.", [["widespread disease", "PROBLEM", 76, 94], ["widespread", "OBSERVATION_MODIFIER", 76, 86], ["disease", "OBSERVATION", 87, 94]]], ["The CDC prospectively monitored mortality rates in U.S. children for the first time during this outbreak, and 152 deaths among U.S. residents <18 years of age were attributed to influenza and its known complications (particularly secondary bacterial infections).", [["deaths", "DISEASE", 114, 120], ["influenza", "DISEASE", 178, 187], ["bacterial infections", "DISEASE", 240, 260], ["children", "ORGANISM", 56, 64], ["children", "SPECIES", 56, 64], ["influenza", "PROBLEM", 178, 187], ["its known complications", "PROBLEM", 192, 215], ["bacterial infections", "PROBLEM", 240, 260], ["bacterial", "OBSERVATION_MODIFIER", 240, 249], ["infections", "OBSERVATION", 250, 260]]], ["10 Additionally, 50 children met the case definition for influenza-related encephalopathy (altered mental status lasting >1 day with onset of neurologic symptoms within 5 days of fever onset), with more than 40% having severe outcomes (death or neurologic sequelae).", [["neurologic", "ANATOMY", 142, 152], ["neurologic", "ANATOMY", 245, 255], ["influenza", "DISEASE", 57, 66], ["encephalopathy", "DISEASE", 75, 89], ["neurologic symptoms", "DISEASE", 142, 161], ["fever", "DISEASE", 179, 184], ["death", "DISEASE", 236, 241], ["neurologic sequelae", "DISEASE", 245, 264], ["children", "ORGANISM", 20, 28], ["children", "SPECIES", 20, 28], ["influenza", "PROBLEM", 57, 66], ["related encephalopathy", "PROBLEM", 67, 89], ["altered mental status", "PROBLEM", 91, 112], ["neurologic symptoms", "PROBLEM", 142, 161], ["fever onset", "PROBLEM", 179, 190], ["severe outcomes (death", "PROBLEM", 219, 241], ["neurologic sequelae", "PROBLEM", 245, 264], ["encephalopathy", "OBSERVATION", 75, 89]]], ["11 Influenza A viruses accounted for 99.0% of cases in the United States in 2003-2004.", [["Influenza A viruses", "DISEASE", 3, 22], ["Influenza A viruses", "ORGANISM", 3, 22], ["Influenza A viruses", "SPECIES", 3, 22], ["Influenza A viruses", "PROBLEM", 3, 22]]], ["H3N2 strains accounted for 99.9% of the influenza A viruses, and 89% of these were antigenically similar to the drift variant A/Fujian/411/2002.", [["influenza A viruses", "DISEASE", 40, 59], ["H3N2", "ORGANISM", 0, 4], ["influenza A viruses", "ORGANISM", 40, 59], ["influenza A viruses", "SPECIES", 40, 59], ["Fujian/411/2002", "SPECIES", 128, 143], ["H3N2 strains", "PROBLEM", 0, 12], ["the influenza A viruses", "PROBLEM", 36, 59]]], ["Compared with the A/Panama/2007/99 H3N2 strain (which accounted for 11% of influenza cases) that was included in the 2003-2004 vaccine, A/Fujian has 13 amino acid changes involving several antigenic sites.", [["influenza", "DISEASE", 75, 84], ["amino acid", "CHEMICAL", 152, 162], ["amino acid", "CHEMICAL", 152, 162], ["Panama/2007/99 H3N2 strain", "ORGANISM", 20, 46], ["amino acid", "AMINO_ACID", 152, 162], ["A/Panama/2007/99 H3N2 strain", "SPECIES", 18, 46], ["H3N2 strain", "PROBLEM", 35, 46], ["influenza cases", "PROBLEM", 75, 90], ["13 amino acid changes", "PROBLEM", 149, 170], ["amino acid", "OBSERVATION", 152, 162], ["several", "OBSERVATION_MODIFIER", 181, 188], ["antigenic sites", "OBSERVATION", 189, 204]]], ["10, 12 Although early reports raised concerns that the 2003-2004 vaccine provided minimal, if any, effectiveness against the predominant A/Fujian strain, there was some protection: vaccine efficacy was estimated to be 25% and 49%, respectively, in 2 analyses among children, and 38% and 52%, respectively, among adults with and without an underlying high-risk condition in a case-control study.", [["children", "ORGANISM", 265, 273], ["children", "SPECIES", 265, 273], ["the predominant A/Fujian strain", "PROBLEM", 121, 152], ["vaccine efficacy", "TREATMENT", 181, 197], ["an underlying high-risk condition", "PROBLEM", 336, 369]]], ["13 The CDC conducted a convenience survey of 221 hospitals throughout the U.S. and found that the following types of shortages occurred during the 2003-2004 influenza season: (1) 40% had inadequate vaccine supply, (2) 58% ran out of diagnostic influenza test kits, (3) 28% and 43% had too few general inpatient and intensive care beds, respectively, (4) 35% had insufficient numbers of health care workers (HCWs), and (5) 9% needed to divert patients because of bed or HCW shortages.", [["influenza", "DISEASE", 157, 166], ["patients", "ORGANISM", 442, 450], ["patients", "SPECIES", 442, 450], ["inadequate vaccine supply", "TREATMENT", 187, 212], ["diagnostic influenza test kits", "TEST", 233, 263]]], ["14 This survey did not ask about shortages of antiinfluenza drugs or hospital supplies (eg, masks), but these types of shortages occurred at our hospital, as well as other health care centers.PANDEMIC PREPARATIONSThe severity of the 2003-2004 flu season will pale in comparison with that of the next pandemic.", [["antiinfluenza drugs", "TREATMENT", 46, 65]]], ["There were 3 pandemics in the last century: the 1918 Spanish A/H1N1 influenza strain that killed at least 20 million and perhaps more than 50 million people worldwide, including many young adults, the 1957 Asian A/H2N2 influenza strain where ;70,000 persons died in the U.S. over a 2-year period, and the 1968 Hong Kong A/H3N2 influenza strain that caused the death of ;34,000 people in the U.S. in the first year.", [["influenza", "DISEASE", 68, 77], ["influenza", "DISEASE", 219, 228], ["influenza", "DISEASE", 327, 336], ["death", "DISEASE", 360, 365], ["A/H1N1 influenza", "ORGANISM", 61, 77], ["people", "ORGANISM", 150, 156], ["A/H2N2 influenza strain", "ORGANISM", 212, 235], ["persons", "ORGANISM", 250, 257], ["Hong Kong A/H3N2 influenza", "ORGANISM", 310, 336], ["people", "ORGANISM", 377, 383], ["H1N1 influenza", "SPECIES", 63, 77], ["people", "SPECIES", 150, 156], ["H2N2 influenza", "SPECIES", 214, 228], ["persons", "SPECIES", 250, 257], ["H3N2 influenza", "SPECIES", 322, 336], ["people", "SPECIES", 377, 383], ["A/H1N1 influenza strain", "SPECIES", 61, 84], ["Asian A/H2N2 influenza strain", "SPECIES", 206, 235], ["Hong Kong A/H3N2 influenza strain", "SPECIES", 310, 343], ["H1N1 influenza strain", "PROBLEM", 63, 84], ["A/H2N2 influenza strain", "PROBLEM", 212, 235], ["H3N2 influenza strain", "PROBLEM", 322, 343]]], ["[15] [16] [17] The potential impact of the next influenza pandemic in the U.S. was modeled in 1999 by the CDC.", [["influenza pandemic", "DISEASE", 48, 66], ["the next influenza pandemic", "PROBLEM", 39, 66]]], ["18 These estimates projected 89,000 to 207,000 deaths, 314,000 to 734,000 hospitalizations, 18,000,000 to 42,000,000 outpatient visits, and 20,000,000 to 47,000,000 additional illnesses.", [["deaths", "DISEASE", 47, 53]]], ["Estimates of medical costs, in 1999 dollars, ranged from $71 billion to $167 billion and did not include the indirect costs associated with disruptions to commerce and society.PANDEMIC PREPARATIONSOn August 26, 2004, the U.S. Department of Health and Human Services, via the National Vaccine Program Office, put forth the first public draft of the National Pandemic Influenza Preparedness Plan (N-PIPP) for the beginning of a 60-day public comment period.", [["Influenza", "DISEASE", 366, 375], ["Human", "ORGANISM", 251, 256], ["Human", "SPECIES", 251, 256], ["the indirect costs", "PROBLEM", 105, 123], ["PIPP", "TREATMENT", 397, 401]]], ["16, 20, 21 This document, when finalized, will not be the completion of preparation (and was never intended to be such) but rather a major step forward in the process of (1) identifying issues that must be addressed at federal, state, and local levels-in both the public and private sectors and (2) providing guidance for planning and response to a pandemic.PANDEMIC PREPARATIONSThe need for federal, state, and local public health preparation and involvement is well recognized, but public health planning efforts in the past few years, especially at the local level, have been distracted by issues surrounding bioterrorism (eg, smallpox) and emerging infections (eg, severe acute respiratory syndrome [SARS] ).", [["smallpox", "DISEASE", 630, 638], ["infections", "DISEASE", 653, 663], ["acute respiratory syndrome", "DISEASE", 676, 702], ["SARS", "DISEASE", 704, 708], ["a pandemic", "PROBLEM", 347, 357], ["emerging infections (eg", "PROBLEM", 644, 667], ["severe acute respiratory syndrome", "PROBLEM", 669, 702], ["infections", "OBSERVATION", 653, 663], ["severe", "OBSERVATION_MODIFIER", 669, 675], ["acute", "OBSERVATION_MODIFIER", 676, 681], ["respiratory syndrome", "OBSERVATION", 682, 702]]], ["The N-PIPP recognizes that it is time to refocus public health efforts toward preparation for pandemic influenza and in some circumstances even to merge these efforts with those for bioterrorism and emerging infections.", [["influenza", "DISEASE", 103, 112], ["infections", "DISEASE", 208, 218], ["N-PIPP", "PROTEIN", 4, 10], ["pandemic influenza", "PROBLEM", 94, 112], ["bioterrorism", "PROBLEM", 182, 194], ["emerging infections", "PROBLEM", 199, 218], ["infections", "OBSERVATION", 208, 218]]], ["At the local level particularly, individuals from the multiple public agencies that will need to work together in response to each of these types of events are largely the same, and the types of issues they will be facing are highly similar, and in many instances identical (Figure) .", [["multiple", "OBSERVATION_MODIFIER", 54, 62]]], ["[21] [22] [23] [24] WHAT ABOUT PANDEMIC PLANS FOR CHILDREN?PANDEMIC PREPARATIONSThe various problems that need to be addressed before arrival of a pandemic are broad in scope.", [["[21] [22] [23] [24", "SIMPLE_CHEMICAL", 0, 18]]], ["The draft of the N-PIPP begins to address many of these issues, but as welcome and detailed as it is, there is little discussion or guidance for addressing the varying needs of infants and young children (or the very elderly).", [["infants", "ORGANISM", 177, 184], ["children", "ORGANISM", 195, 203], ["infants", "SPECIES", 177, 184], ["children", "SPECIES", 195, 203]]], ["Table I provides a selected list of problems that are important for the care of children (and for adults in some cases) and potential solutions.PANDEMIC PREPARATIONSIn terms of children's care issues, the N-PIPP does list the development of ''regional surge capacity in providing care for children and adults including facilities and personnel, both in the hospital and in the community'' as a priority area for upgrading the nation's health care system ''to respond to bioterrorist and naturally occurring outbreaks of infectious diseases.''", [["infectious diseases", "DISEASE", 520, 539], ["children", "ORGANISM", 80, 88], ["children", "ORGANISM", 177, 185], ["children", "ORGANISM", 289, 297], ["children", "SPECIES", 80, 88], ["children", "SPECIES", 177, 185], ["children", "SPECIES", 289, 297], ["infectious diseases", "PROBLEM", 520, 539], ["infectious", "OBSERVATION", 520, 530]]], ["Communities also are urged to develop real-time tracking of the number of available intensive care unit beds and medical beds for adults and children.", [["children", "ORGANISM", 141, 149], ["children", "SPECIES", 141, 149]]], ["Health care systems are encouraged to offer or expand hospital-sponsored sick care services for children of hospital staff to reduce absenteeism during pandemic conditions.", [["children", "ORGANISM", 96, 104], ["children", "SPECIES", 96, 104]]], ["25 The planning for specific needs of children currently is largely left to the local level.", [["children", "ORGANISM", 38, 46], ["children", "SPECIES", 38, 46], ["left", "ANATOMY_MODIFIER", 68, 72]]], ["The CDC has developed 2 simple computer software modules for use as planning tools at local levels: FluAid 2.0 and FluSurge.", [["FluAid", "TEST", 100, 106]]], ["FluAid uses population estimates for 0-18 years, 19-64 years, and 651 years along with estimates of the percentage of high-risk patients in each age group and estimates of expected death, hospitalization, outpatient visit, and attack rates to estimate impact of influenza on a local health care system.", [["death", "DISEASE", 181, 186], ["influenza", "DISEASE", 262, 271], ["patients", "ORGANISM", 128, 136], ["patients", "SPECIES", 128, 136], ["influenza", "PROBLEM", 262, 271]]], ["26 FluSurge uses population estimates for 0-17 years, 18-64 years, and 651 years along with the number of staffed hospital beds, staffed ICU beds, and number of ventilators available to estimate total hospital demand and total deaths for specified attack rates and duration in weeks of the pandemic period.", [["deaths", "DISEASE", 227, 233], ["ventilators", "TREATMENT", 161, 172]]], ["27 These tools are works in progress but likely need to be refined at least in terms of the pediatric age ranges used (e.g., <2 yrs, 2-5 years, 5-12 yrs, and 13-18 years).PANDEMIC PREPARATIONSEven with ''pediatric improvements'' in these tools, it is not clear that many localities will have the necessary public health expertise to plan for or respond adequately to the variety of health and social needs of young children that will arise during a pandemic, and expectations of such likely are unfair, given the relative paucity of resources in many small communities.", [["children", "ORGANISM", 415, 423], ["children", "SPECIES", 415, 423], ["small", "OBSERVATION_MODIFIER", 551, 556], ["communities", "OBSERVATION", 557, 568]]], ["It may be more appropriate to work on pediatric pandemic planning and response issues at regional and state levels in conjunction with pediatric hospitals and referral centers (Figure) .PANDEMIC PREPARATIONSUnder pandemic conditions, even with good planning, it will be more difficult to increase surge capacity for infants and young children than for adolescents and adults.", [["infants", "ORGANISM", 316, 323], ["children", "ORGANISM", 334, 342], ["infants", "SPECIES", 316, 323], ["children", "SPECIES", 334, 342], ["adolescents", "SPECIES", 352, 363], ["pediatric pandemic planning", "TREATMENT", 38, 65], ["response issues", "PROBLEM", 70, 85]]], ["The very young may require the presence of parents or other adults at all times, and especially when heart and pulse oximetry monitors (as well as the health care workers to respond to alarms) may be in short supply.", [["heart", "ANATOMY", 101, 106], ["heart", "ORGAN", 101, 106], ["heart and pulse oximetry monitors", "TEST", 101, 134], ["heart", "ANATOMY", 101, 106]]], ["This translates into more floor space rather than less for young patients.", [["patients", "ORGANISM", 65, 73], ["patients", "SPECIES", 65, 73]]], ["Also, there is likely far less available ''surge capacity'' in terms of personnel able to care for young children than older children and adults.", [["children", "ORGANISM", 105, 113], ["children", "ORGANISM", 125, 133], ["children", "SPECIES", 105, 113], ["children", "SPECIES", 125, 133], ["likely", "UNCERTAINTY", 15, 21]]], ["There also will be frequent occurrences where children have a parent(s) or guardian(s) too ill to provide care or oversight for them.", [["children", "ORGANISM", 46, 54], ["children", "SPECIES", 46, 54]]], ["In the current social structures of many families, extended family members often are not readily available to take over these responsibilities for either well or sick children.PANDEMIC PREPARATIONSThe N-PIPP is hopeful that home health care programs may be able to fill in the gap for many ''less ill'' patients.", [["children", "ORGANISM", 167, 175], ["patients", "ORGANISM", 303, 311], ["children", "SPECIES", 167, 175], ["patients", "SPECIES", 303, 311]]], ["19 This may or may not be true for adults in terms of sustainable capacity at many local areas but is likely not true for infants and young children, where such resources often are minimal even under nonepidemic conditions.", [["infants", "ORGANISM", 122, 129], ["children", "ORGANISM", 140, 148], ["infants", "SPECIES", 122, 129], ["children", "SPECIES", 140, 148], ["sustainable capacity", "PROBLEM", 54, 74], ["likely not", "UNCERTAINTY", 102, 112]]], ["Many HCWs are not comfortable or lack the training or skills needed to provide basic care to young children (placing intravenous lines, assessing degree of illness, etc).PANDEMIC PREPARATIONSEarlier pandemic planning documents such as the ''Nature's Terrorist Attack, Pandemic Influenza.", [["intravenous lines", "ANATOMY", 117, 134], ["illness", "DISEASE", 156, 163], ["Influenza", "DISEASE", 277, 286], ["HCWs", "ORGANISM", 5, 9], ["children", "ORGANISM", 99, 107], ["children", "SPECIES", 99, 107], ["intravenous lines", "TREATMENT", 117, 134], ["illness", "PROBLEM", 156, 163], ["Pandemic Influenza", "PROBLEM", 268, 286]]], ["Initial state-level plans likely will mirror this and the N-PIPP, often as a matter of practicality.", [["PIPP", "TREATMENT", 60, 64]]], ["Indeed, the only references to children in the otherwise detailed North Carolina Pandemic Influenza Response Plan of the Division of Public Health of the North Carolina Department of Health and Human Services, released in October 2004, were those referring to determination of projections of case numbers (using FluAid 2.0) and need for hospital beds and ventilators (using FluSurge).", [["Influenza", "DISEASE", 90, 99], ["children", "ORGANISM", 31, 39], ["Human", "ORGANISM", 194, 199], ["children", "SPECIES", 31, 39], ["Human", "SPECIES", 194, 199], ["hospital beds", "TREATMENT", 337, 350], ["ventilators", "TREATMENT", 355, 366]]], ["28 Lastly, the medical literature also provides little guidance on influenza pandemic planning efforts for children.", [["children", "ORGANISM", 107, 115], ["children", "SPECIES", 107, 115], ["influenza pandemic planning", "TREATMENT", 67, 94]]], ["Only 3 English-language articles published since 1990 have any information relevant to pandemic planning efforts for children.", [["children", "ORGANISM", 117, 125], ["children", "SPECIES", 117, 125]]], ["Two provide information about potential attack rates of among various age groups, 29, 30 and one modeled effectiveness of antiviral agents by age groups.", [["antiviral agents", "TREATMENT", 122, 138]]], ["31 The above issues are in addition to the need for (1) more studies of vaccine efficacy in young children and perhaps development of additional influenza vaccine products (and producers of vaccine products-now standing at only 1 for children <4 years old), and (2) more studies of antiviral agents for infants.", [["children", "ORGANISM", 98, 106], ["children", "ORGANISM", 234, 242], ["infants", "ORGANISM", 303, 310], ["children", "SPECIES", 98, 106], ["children", "SPECIES", 234, 242], ["infants", "SPECIES", 303, 310], ["vaccine efficacy", "TREATMENT", 72, 88], ["additional influenza vaccine products", "TREATMENT", 134, 171], ["vaccine products", "TREATMENT", 190, 206], ["antiviral agents", "TREATMENT", 282, 298]]], ["Neither the amantadine nor neuraminidase inhibitors are approved for use in infants by the Food and Drug Administration (FDA).", [["amantadine", "CHEMICAL", 12, 22], ["amantadine", "CHEMICAL", 12, 22], ["amantadine", "SIMPLE_CHEMICAL", 12, 22], ["neuraminidase inhibitors", "SIMPLE_CHEMICAL", 27, 51], ["infants", "ORGANISM", 76, 83], ["infants", "SPECIES", 76, 83], ["the amantadine", "TREATMENT", 8, 22], ["neuraminidase inhibitors", "TREATMENT", 27, 51], ["amantadine", "OBSERVATION", 12, 22]]], ["It is past time for the pediatric community to begin to consider the needs that will likely arise and to advocate for the resources that will be required to address each of these issues (Table I) .GENERAL ISSUES RELATED TO PANDEMIC PREPAREDNESSA substantial further increase in funding is needed for the research and infrastructure required for an effective response to the next pandemic (Table I, 9) .", [["increase", "OBSERVATION_MODIFIER", 266, 274]]], ["If insufficient new federal dollars are available to deal with influenza, then serious consideration should be given to reprioritizing the large infusions of dollars designated for other potential bioterrorism agents, where the risk of disease occurrence is far less certain.", [["influenza", "DISEASE", 63, 72], ["influenza", "PROBLEM", 63, 72], ["the large infusions of dollars", "TREATMENT", 135, 165], ["bioterrorism agents", "TREATMENT", 197, 216], ["disease occurrence", "PROBLEM", 236, 254], ["disease", "OBSERVATION", 236, 243]]], ["Indeed, many of the issues that must be addressed for influenza are relevant to responses to other potentially widespread emerging infections (eg, SARS) and bioterrorism agents (eg, smallpox virus).", [["influenza", "DISEASE", 54, 63], ["infections", "DISEASE", 131, 141], ["SARS", "DISEASE", 147, 151], ["smallpox virus", "ORGANISM", 182, 196], ["smallpox virus", "SPECIES", 182, 196], ["influenza", "PROBLEM", 54, 63], ["bioterrorism agents (eg, smallpox virus", "TREATMENT", 157, 196], ["infections", "OBSERVATION", 131, 141]]], ["Configuration of working groups charged with planning for and oversight of responses to (1) bioterrorism events, (2) emerging infections such as SARS, and (3) pandemic influenza will, and likely must, vary from federal to state to local areas.", [["infections", "DISEASE", 126, 136], ["SARS", "DISEASE", 145, 149], ["influenza", "DISEASE", 168, 177], ["bioterrorism events", "PROBLEM", 92, 111], ["emerging infections", "PROBLEM", 117, 136], ["SARS", "PROBLEM", 145, 149], ["pandemic influenza", "PROBLEM", 159, 177], ["infections", "OBSERVATION", 126, 136]]], ["At federal level, alignment of expertise and resources into dedicated groups that collaborate and have some overlap in membership at key agencies is likely most effective approach at this time.", [["likely", "UNCERTAINTY", 149, 155], ["most effective", "OBSERVATION_MODIFIER", 156, 170]]], ["Configuration of state and large urban area working groups may vary depending on their specific population size and geographic characteristics, as well as expertise available in public and private sectors.", [["large", "OBSERVATION_MODIFIER", 27, 32], ["urban", "OBSERVATION_MODIFIER", 33, 38], ["size", "OBSERVATION_MODIFIER", 107, 111]]], ["Expertise in planning for and providing of care to children may not be readily available in many localities and may be unevenly distributed among states.", [["children", "ORGANISM", 51, 59], ["children", "SPECIES", 51, 59]]], ["Use of the precautionary principle with regard to the public health obligation to protect populations against foreseeable threats, 34 even under conditions of uncertainty, will be necessary.", [["the precautionary principle", "TREATMENT", 7, 34], ["the public health obligation", "TREATMENT", 50, 78]]], ["Studies that assess the impact of school children on spread of influenza in the community are underway in the U.S. Additional epidemiologic studies assessing impact of other more crowded situations such as child care centers, shopping malls, and sports venues would be helpful.", [["influenza", "DISEASE", 63, 72], ["children", "ORGANISM", 41, 49], ["children", "SPECIES", 41, 49], ["Studies", "TEST", 0, 7], ["influenza", "PROBLEM", 63, 72], ["epidemiologic studies", "TEST", 126, 147]]], ["B. Prioritization plan to determine who should be the first to receive the vaccine because of the likelihood that only limited vaccine supplies will be available initially.GENERAL ISSUES RELATED TO PANDEMIC PREPAREDNESSRationale for vaccination prioritization plan that is transparent (eg, HCW and first responders receive high priority so that they can care for patients) Completion of a logistical plan for vaccine distribution, from sites of manufacture to sites of administration.GENERAL ISSUES RELATED TO PANDEMIC PREPAREDNESSFederal legislation may be necessary to allow such prioritization plans to proceed unimpeded by legal challenges that might arise during the early stages of a pandemic with limited vaccine supply.", [["patients", "ORGANISM", 363, 371], ["patients", "SPECIES", 363, 371], ["the vaccine", "TREATMENT", 71, 82], ["limited vaccine supplies", "TREATMENT", 119, 143], ["vaccination prioritization plan", "TREATMENT", 233, 264], ["a logistical plan", "TREATMENT", 387, 404], ["vaccine distribution", "TREATMENT", 409, 429], ["PANDEMIC PREPAREDNESSFederal legislation", "TREATMENT", 510, 550], ["limited vaccine supply", "TREATMENT", 704, 726]]], ["Issues of children vs the elderly could arise and should be discussed.", [["children", "ORGANISM", 10, 18], ["children", "SPECIES", 10, 18]]], ["Legal provisions should be enacted before arrival of a pandemic to reduce appearances of favoritism during peak times of irrationality.", [["appearances of favoritism", "PROBLEM", 74, 99], ["irrationality", "PROBLEM", 121, 134]]], ["Use of tissue culture methods and other technology that allow for more rapid production of large quantities of influenza vaccine.", [["tissue culture", "ANATOMY", 7, 21], ["influenza", "DISEASE", 111, 120], ["tissue", "TISSUE", 7, 13], ["tissue culture methods", "TEST", 7, 29], ["influenza vaccine", "TREATMENT", 111, 128]]], ["Streamlining of the FDA process for influenza vaccine licensing and manufacturing.GENERAL ISSUES RELATED TO PANDEMIC PREPAREDNESSResearch funding also should be provided for efforts toward (1) improved efficacy in young children, (2) vaccination of children ,6 months old, and (3) new vaccines that do not need to be given on a yearly basis.", [["children", "ORGANISM", 220, 228], ["children", "ORGANISM", 249, 257], ["children", "SPECIES", 220, 228], ["children", "SPECIES", 249, 257], ["influenza vaccine", "TREATMENT", 36, 53], ["new vaccines", "TREATMENT", 281, 293]]], ["This change would also help with other emerging infections with epidemic potential, such as the SARS coronavirus.", [["infections", "DISEASE", 48, 58], ["SARS coronavirus", "DISEASE", 96, 112], ["SARS coronavirus", "ORGANISM", 96, 112], ["SARS coronavirus", "SPECIES", 96, 112], ["the SARS coronavirus", "PROBLEM", 92, 112], ["infections", "OBSERVATION", 48, 58]]], ["This venture likely will require federal subsidization (eg, reimbursement for unused product) with collaboration from vaccine manufacturers and the academic medical community.", [["federal subsidization (eg", "TREATMENT", 33, 58]]], ["The United Kingdom has drafted a business plan for a facility that can make vaccines rapidly.", [["vaccines", "TREATMENT", 76, 84]]], ["Canada has contracted with its private sector for capacity to produce 32 million doses in 4 months by 2006.", [["contracted", "OBSERVATION", 11, 21]]], ["19 B. Inadequate production capacity for pandemic needs.GENERAL ISSUES RELATED TO PANDEMIC PREPAREDNESSDesign and building of additional dedicated facilities.GENERAL ISSUES RELATED TO PANDEMIC PREPAREDNESSC.", [["pandemic needs", "TREATMENT", 41, 55]]], ["Concerns for potential risk to researchers working with virus strains to which they have no protective antibody.Development of new BiosafetyLevel 31 vaccine production facilities.Vaccination use and distributionA.", [["protective antibody", "PROTEIN", 92, 111], ["virus strains", "PROBLEM", 56, 69], ["protective antibody", "PROBLEM", 92, 111], ["new BiosafetyLevel 31 vaccine production facilities", "TREATMENT", 127, 178], ["distributionA", "PROBLEM", 199, 212], ["new", "OBSERVATION_MODIFIER", 127, 130]]], ["Logistical issues associated with attempting universal vaccination of everyone .6 mos of age.Vaccination use and distributionMovement toward routine annual universal vaccination in the U.S.Vaccination use and distributionRoutine annual universal vaccination would provide a foundation to ensure that adequate manufacturing capacity exists to make the needed number of vaccine doses and that the logistics needed to vaccinate the entire population are in place.", [["Logistical issues", "PROBLEM", 0, 17], ["universal vaccination", "TREATMENT", 45, 66], ["Vaccination use", "TREATMENT", 93, 108], ["routine annual universal vaccination", "TREATMENT", 141, 177], ["Routine annual universal vaccination", "TREATMENT", 221, 257], ["vaccine doses", "TREATMENT", 368, 381], ["the logistics", "TREATMENT", 391, 404]]], ["Further studies of ''half-doses'' for healthy adults, as well as high-risk groups as a means of extending supplies and increasing capacity should be initiated.", [["Further studies", "TEST", 0, 15], ["increasing capacity", "PROBLEM", 119, 138]]], ["Requirement for mandatory vaccination of everyone .6 mos of age during a pandemic.Vaccination use and distributionA mandatory vaccination policy to be instituted during a pandemic will likely require federal legislation because of likely legal challenges and should be undertaken before the pandemic.", [["mandatory vaccination", "TREATMENT", 16, 37], ["a pandemic", "PROBLEM", 71, 81], ["Vaccination use", "TREATMENT", 82, 97], ["distributionA mandatory vaccination policy", "TREATMENT", 102, 144], ["federal legislation", "TREATMENT", 200, 219]]], ["Issues surrounding the swine flu vaccine effort in 1976 will need to be revisited and thought through.", [["swine flu vaccine", "SPECIES", 23, 40], ["the swine flu vaccine", "TREATMENT", 19, 40]]], ["37 B. Potential need for 2 doses for effective immunity against a pandemic strain.Vaccination use and distributionAdditional clinical studies of influenza vaccines in young children.Vaccination use and distributionMuch more needs to be learned about this issue.", [["influenza", "DISEASE", 145, 154], ["children", "ORGANISM", 173, 181], ["children", "SPECIES", 173, 181], ["a pandemic strain", "PROBLEM", 64, 81], ["Vaccination use", "TREATMENT", 82, 97], ["influenza vaccines", "TREATMENT", 145, 163], ["Vaccination use", "TREATMENT", 182, 197]]], ["A second dose would be even more costly and logistically more difficult to accomplish.Rapid diagnosis of influenzaShortage of diagnostic kits.", [["A second dose", "TREATMENT", 0, 13]]], ["Stockpiling and increased production capacity for diagnostic kits.Rapid diagnosis of influenzaShelf-life issues may require rotation of stocks.", [["Stockpiling", "PROBLEM", 0, 11], ["increased production capacity", "PROBLEM", 16, 45], ["diagnostic kits", "TEST", 50, 65], ["influenzaShelf-life issues", "PROBLEM", 85, 111], ["rotation of stocks", "TREATMENT", 124, 142], ["increased", "OBSERVATION_MODIFIER", 16, 25], ["production capacity", "OBSERVATION", 26, 45]]], ["Stockpiling may require federal subsidy for manufacturers and reimbursement for expired products.", [["expired products", "TREATMENT", 80, 96]]], ["Government-funded studies to determine pharmacokinetics, safety, and efficacy of antiinfluenza agents in infants.Rapid diagnosis of influenzaEfficacy of antiviral agents against potential pandemic strains should be ascertained, and new drugs may need to be developed.", [["antiinfluenza agents", "SIMPLE_CHEMICAL", 81, 101], ["infants", "ORGANISM", 105, 112], ["infants", "SPECIES", 105, 112], ["funded studies", "TEST", 11, 25], ["antiinfluenza agents", "TREATMENT", 81, 101], ["influenzaEfficacy", "PROBLEM", 132, 149], ["antiviral agents", "TREATMENT", 153, 169], ["potential pandemic strains", "PROBLEM", 178, 204], ["new drugs", "TREATMENT", 232, 241]]], ["Under pandemic conditions, use of antibacterial agents for suspected or real secondary bacterial infections could lead to unanticipated shortages of some agents.", [["bacterial infections", "DISEASE", 87, 107], ["antibacterial agents", "TREATMENT", 34, 54], ["real secondary bacterial infections", "PROBLEM", 72, 107], ["some agents", "TREATMENT", 149, 160], ["infections", "OBSERVATION", 97, 107]]], ["Rapid production and stockpiling issues also may need to be considered for selected antibacterial agents.", [["Rapid production and stockpiling issues", "PROBLEM", 0, 39], ["selected antibacterial agents", "TREATMENT", 75, 104]]], ["Plan for off-site care (eg, schools) for people requiring minimal intervention (eg, oxygen, fluids etc).", [["oxygen", "CHEMICAL", 84, 90], ["oxygen", "CHEMICAL", 84, 90], ["people", "ORGANISM", 41, 47], ["oxygen", "SIMPLE_CHEMICAL", 84, 90], ["people", "SPECIES", 41, 47], ["off-site care", "TREATMENT", 9, 22], ["minimal intervention", "TREATMENT", 58, 78], ["oxygen", "TREATMENT", 84, 90], ["fluids etc", "TREATMENT", 92, 102]]], ["Postpone elective admissions.Rapid diagnosis of influenzaThe national pandemic plan prefers use of nontraditional hospital beds and home health care first, but these resources could quickly be exhausted for adults and may not exist for young children.", [["influenza", "DISEASE", 48, 57], ["influenza", "ORGANISM", 48, 57], ["children", "ORGANISM", 242, 250], ["children", "SPECIES", 242, 250], ["influenza", "PROBLEM", 48, 57], ["nontraditional hospital beds", "TREATMENT", 99, 127], ["influenza", "OBSERVATION", 48, 57]]], ["Protocols for temporary ''wards'' still need to be developed that address needs of young children, as well as adults and that include basic infection control procedures and mechanisms of handling medical waste.", [["infection", "DISEASE", 140, 149], ["children", "ORGANISM", 89, 97], ["children", "SPECIES", 89, 97], ["basic infection control procedures", "TREATMENT", 134, 168], ["handling medical waste", "TREATMENT", 187, 209], ["infection", "OBSERVATION", 140, 149]]], ["B. Shortage of supplies and equipmentRapid diagnosis of influenzaStockpile of supplies (eg, masks, oxygen delivery materials, IV fluids) and equipment (ventilators, IV pumps).Rapid diagnosis of influenzaPrograms to store ''retired'' ventilators and other equipment in central locations would be helpful.", [["oxygen", "CHEMICAL", 99, 105], ["oxygen", "CHEMICAL", 99, 105], ["oxygen", "SIMPLE_CHEMICAL", 99, 105], ["influenzaStockpile of supplies", "TREATMENT", 56, 86], ["masks", "TREATMENT", 92, 97], ["oxygen delivery materials", "TREATMENT", 99, 124], ["IV fluids)", "TREATMENT", 126, 136], ["equipment (ventilators", "TREATMENT", 141, 163], ["IV pumps", "TREATMENT", 165, 173], ["influenzaPrograms", "PROBLEM", 194, 211], ["ventilators", "TREATMENT", 233, 244]]], ["Protocols for sterilization/reuse of normally disposed items such as face masks and plastic tubing may need to be developed.", [["face", "ANATOMY", 69, 73], ["sterilization", "TREATMENT", 14, 27], ["face masks", "TREATMENT", 69, 79], ["plastic tubing", "TREATMENT", 84, 98], ["plastic tubing", "OBSERVATION", 84, 98]]], ["Pediatric ventilators likely would be in very short supply.", [["Pediatric ventilators", "TREATMENT", 0, 21]]], ["C. Long waiting periods in emergency departments and difficulties in triage.Rapid diagnosis of influenzaDevelop protocols that facilitate collaboration between local health care providers and news media to provide instructions to the public as to when and where to seek help for varying degrees of illness.", [["illness", "DISEASE", 298, 305], ["influenzaDevelop protocols", "TREATMENT", 95, 121], ["illness", "PROBLEM", 298, 305]]], ["Those for children will differ from those for adults.Rapid diagnosis of influenzaInvolvement of institutional public relations and marketing personnel may be useful in development and implementation of local and regional triage plans.", [["children", "ORGANISM", 10, 18], ["children", "SPECIES", 10, 18], ["influenzaInvolvement", "PROBLEM", 72, 92]]], ["Points of triage may need to be moved to other sites (eg, private offices) in some communities, with expertise required for both pediatric and adult patients.D. Nosocomial outbreaksScreening protocols for HCWs, family members and other visitors should be developed to help prevent nosocomial infections.D. Nosocomial outbreaksHospital visitation policies have been greatly liberalized in recent years.", [["infections", "DISEASE", 292, 302], ["patients", "ORGANISM", 149, 157], ["patients", "SPECIES", 149, 157], ["nosocomial infections", "PROBLEM", 281, 302], ["Nosocomial outbreaks", "OBSERVATION", 161, 181], ["infections", "OBSERVATION", 292, 302], ["Nosocomial outbreaks", "OBSERVATION", 306, 326]]], ["Involvement of local news media may be essential to deal effectively with potential restrictions.D. Nosocomial outbreaks9.", [["Nosocomial outbreaks9", "OBSERVATION", 100, 121]]], ["Public and private health care systems A. Communication, coordination and collaboration between local and regional health care systems or institutions (even those competing in normal circumstances) z Establish or improve collaborations to coordinate private/public and private/private efforts, including plans to manage hospital beds and critical supplies in a collective manner.D. Nosocomial outbreaksCollaborative efforts in working with news media and responding to the public also will be critical in lessening impacts on societal functions.", [["Nosocomial", "OBSERVATION_MODIFIER", 382, 392]]], ["Tabletop exercises similar to those used in preparation for bioterrorism events may be useful planning exercises for pandemic influenza.", [["influenza", "DISEASE", 126, 135], ["Tabletop exercises", "TREATMENT", 0, 18], ["bioterrorism events", "PROBLEM", 60, 79], ["pandemic influenza", "PROBLEM", 117, 135]]], ["38, 39 N-PIPP provides excellent initial guidance in this area.D. Nosocomial outbreaksB.", [["PIPP", "TREATMENT", 9, 13], ["Nosocomial outbreaksB", "OBSERVATION", 66, 87]]], ["Shortage of staff to meet increased patient demands for health care Development of strategies to call up retired or part-time health care workers and expand hours of care provided by existing staff.", [["patient", "ORGANISM", 36, 43], ["patient", "SPECIES", 36, 43]]], ["Development of mechanisms for sharing of employees across systems or from outpatient to inpatient facilities at the local level (which may need to be done at the regional or state level for children).D. Nosocomial outbreaksLegislation or other administrative procedures may be required to allow for temporary circumvention of licensing requirements of various professional boards during emergency conditions.", [["children", "ORGANISM", 190, 198], ["children", "SPECIES", 190, 198], ["administrative procedures", "TREATMENT", 244, 269]]], ["Off-service clinical faculty in medical schools, medical students, residents on nonessential rotations, nursing students, and students in other health care profession training programs represent an additional HCW resource pool.D. Nosocomial outbreaksMany of the influenza-induced deaths in children and adults occur in people for whom the vaccine is not routinely recommended, and this has led the Advisory Committee on Immunization Practices to begin consideration of a universal annual vaccination recommendation for everyone >6 months of age.", [["influenza", "DISEASE", 262, 271], ["deaths", "DISEASE", 280, 286], ["children", "ORGANISM", 290, 298], ["people", "ORGANISM", 319, 325], ["children", "SPECIES", 290, 298], ["people", "SPECIES", 319, 325], ["the influenza-induced deaths", "PROBLEM", 258, 286], ["the vaccine", "TREATMENT", 335, 346], ["Immunization Practices", "TREATMENT", 420, 442], ["a universal annual vaccination recommendation", "TREATMENT", 469, 514], ["Nosocomial outbreaks", "OBSERVATION", 230, 250]]], ["14 For a universal vaccination recommendation to be feasible, multiple obstacles will need to be overcome, including markedly enhancing the manufacturing infrastructure to increase the number of available vaccine doses, logistical issues related to mass vaccination within a few-month period each year, and acceptance of universal influenza vaccination by practitioners and the public (Table I , Categories 4 and 5).D. Nosocomial outbreaksOur ability to predict which strains of influenza virus will cause widespread severe disease needs improvement (Table I, category 1 ).", [["influenza virus", "DISEASE", 479, 494], ["influenza virus", "ORGANISM", 479, 494], ["influenza virus", "SPECIES", 479, 494], ["influenza virus", "SPECIES", 479, 494], ["a universal vaccination", "TREATMENT", 7, 30], ["available vaccine doses", "TREATMENT", 195, 218], ["logistical issues", "PROBLEM", 220, 237], ["mass vaccination", "TREATMENT", 249, 265], ["universal influenza vaccination", "TREATMENT", 321, 352], ["influenza virus", "PROBLEM", 479, 494], ["widespread severe disease", "PROBLEM", 506, 531], ["mass", "OBSERVATION", 249, 253], ["severe", "OBSERVATION_MODIFIER", 517, 523], ["disease", "OBSERVATION", 524, 531]]], ["There had been substantial debate about whether to include the Fujian or Panama strain in the 2003-2004 vaccine.", [["Panama strain", "PROBLEM", 73, 86], ["substantial", "OBSERVATION_MODIFIER", 15, 26]]], ["The expert committee making recommendation to the FDA suggested that the Panama strain, rather than the Fujian strain, be included in the vaccine, mainly because of the uncertainty about which strain would predominate and whether the Fujian strain could be grown in time to be included in the vaccine.", [["the Panama strain", "PROBLEM", 69, 86], ["the Fujian strain", "PROBLEM", 100, 117], ["the Fujian strain", "PROBLEM", 230, 247]]], ["14 Predicting whether an epizootic strain will cross the species barrier into human beings and initiate the next pandemic is even more difficult.", [["human", "ORGANISM", 78, 83], ["human", "SPECIES", 78, 83], ["human", "SPECIES", 78, 83], ["an epizootic strain", "PROBLEM", 22, 41], ["epizootic", "OBSERVATION_MODIFIER", 25, 34]]], ["33 Genetic motifs that are associated with avian and mammalian virulence for some influenza strains are absent from other strains that cause severe human disease, such that inference of human virulence from animal models is not straightforward.", [["influenza", "DISEASE", 82, 91], ["human", "ORGANISM", 148, 153], ["human", "ORGANISM", 186, 191], ["human", "SPECIES", 148, 153], ["human", "SPECIES", 186, 191], ["human", "SPECIES", 148, 153], ["human", "SPECIES", 186, 191], ["Genetic motifs", "TEST", 3, 17], ["avian and mammalian virulence", "PROBLEM", 43, 72], ["some influenza strains", "PROBLEM", 77, 99], ["other strains", "PROBLEM", 116, 129], ["severe human disease", "PROBLEM", 141, 161], ["human virulence", "PROBLEM", 186, 201], ["severe", "OBSERVATION_MODIFIER", 141, 147], ["human disease", "OBSERVATION", 148, 161]]], ["An additional vaccine-related concern is that influenza A viruses of the H5 and H7 subtypes cannot be grown in eggs, the current standard method of vaccine production, because of the rapid lethality of these strains to chick embryos (Table I, problem 4A).", [["eggs", "ANATOMY", 111, 115], ["embryos", "ANATOMY", 225, 232], ["influenza A viruses", "ORGANISM", 46, 65], ["H7 subtypes", "ORGANISM", 80, 91], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 111, 115], ["chick", "ORGANISM", 219, 224], ["embryos", "DEVELOPING_ANATOMICAL_STRUCTURE", 225, 232], ["An additional vaccine", "TREATMENT", 0, 21], ["influenza", "PROBLEM", 46, 55], ["the H5 and H7 subtypes", "PROBLEM", 69, 91], ["vaccine production", "TREATMENT", 148, 166], ["the rapid lethality", "PROBLEM", 179, 198], ["these strains", "PROBLEM", 202, 215], ["chick embryos", "PROBLEM", 219, 232], ["influenza", "OBSERVATION", 46, 55]]], ["33 A substantial international infrastructure to detect and hopefully interdict pandemic influenza has been put in place over the past 50 years.", [["influenza", "DISEASE", 89, 98], ["A substantial international infrastructure", "PROBLEM", 3, 45], ["hopefully interdict pandemic influenza", "PROBLEM", 60, 98], ["substantial", "OBSERVATION_MODIFIER", 5, 16], ["international infrastructure", "OBSERVATION", 17, 45]]], ["The network of 110 National Influenza Centers in 83 countries allows for extensive monitoring capabilities that should provide at least several months warning of an impending influenza pandemic.", [["Influenza", "DISEASE", 28, 37], ["influenza", "DISEASE", 175, 184], ["extensive monitoring capabilities", "TEST", 73, 106], ["an impending influenza pandemic", "PROBLEM", 162, 193]]], ["The National Institute of Health has provided funding for a network of research laboratories for the study of emerging and reemerging infectious diseases.", [["infectious diseases", "DISEASE", 134, 153], ["the study", "TEST", 97, 106], ["infectious", "OBSERVATION", 134, 144]]], ["34 It is hoped this will improve our understanding of the genetic factors and virulence characteristics of influenza viruses that will lead to improved vaccines for yearly epidemics and the next pandemic.D. Nosocomial outbreaksIn the absence of a program capable of rapidly making vaccines that include the pandemic strain, the public health response will have to shift emphasis from prevention to treatment.", [["influenza viruses", "DISEASE", 107, 124], ["influenza viruses", "ORGANISM", 107, 124], ["the genetic factors", "PROBLEM", 54, 73], ["influenza viruses", "PROBLEM", 107, 124], ["yearly epidemics", "PROBLEM", 165, 181], ["vaccines", "TREATMENT", 281, 289], ["the pandemic strain", "PROBLEM", 303, 322], ["treatment", "TREATMENT", 398, 407], ["Nosocomial outbreaks", "OBSERVATION", 207, 227]]], ["Shortages of health care facilities, HCWs and supplies will put a tremendous strain on the ability to care for patients (Table I , Categories 6 -9).", [["patients", "ORGANISM", 111, 119], ["patients", "SPECIES", 111, 119]]], ["Although stockpiling of supplies, including antiviral agents, would be helpful, it is unlikely that supply would meet the demand.", [["antiviral agents", "TREATMENT", 44, 60]]], ["Furthermore, amantadine and rimantadine are not active against some of the potential pandemic strains (eg, H5N1).", [["amantadine", "CHEMICAL", 13, 23], ["rimantadine", "CHEMICAL", 28, 39], ["amantadine", "CHEMICAL", 13, 23], ["rimantadine", "CHEMICAL", 28, 39], ["amantadine", "SIMPLE_CHEMICAL", 13, 23], ["rimantadine", "SIMPLE_CHEMICAL", 28, 39], ["amantadine", "TREATMENT", 13, 23], ["rimantadine", "TREATMENT", 28, 39], ["the potential pandemic strains", "PROBLEM", 71, 101]]], ["This could leave us with only 1 antiviral class of drugs (ie, neuraminidase inhibitors) and no treatment option for infants, because oseltamivir is contraindicated in children less than 1 year of age based on a study, done by the manufacturer, showing increased central nervous system drug concentrations in a juvenile animal model.CONCLUSIONIn the U.S. and elsewhere, we are not yet ready to respond in the ways necessary to provide medical care for the large numbers of children (and adults) who would have severe disease under pandemic conditions.", [["central nervous system", "ANATOMY", 262, 284], ["oseltamivir", "CHEMICAL", 133, 144], ["oseltamivir", "CHEMICAL", 133, 144], ["infants", "ORGANISM", 116, 123], ["oseltamivir", "SIMPLE_CHEMICAL", 133, 144], ["children", "ORGANISM", 167, 175], ["central nervous system", "ANATOMICAL_SYSTEM", 262, 284], ["children", "ORGANISM", 472, 480], ["infants", "SPECIES", 116, 123], ["children", "SPECIES", 167, 175], ["children", "SPECIES", 472, 480], ["drugs", "TREATMENT", 51, 56], ["neuraminidase inhibitors", "TREATMENT", 62, 86], ["treatment option", "TREATMENT", 95, 111], ["oseltamivir", "TREATMENT", 133, 144], ["a study", "TEST", 209, 216], ["increased central nervous system drug concentrations", "PROBLEM", 252, 304], ["medical care", "TREATMENT", 434, 446], ["severe disease under pandemic conditions", "PROBLEM", 509, 549], ["increased", "OBSERVATION_MODIFIER", 252, 261], ["central nervous system", "OBSERVATION", 262, 284], ["drug concentrations", "OBSERVATION", 285, 304], ["severe", "OBSERVATION_MODIFIER", 509, 515], ["disease", "OBSERVATION", 516, 523]]], ["Others have been under discussion since at least the era of the swine flu scare in 1976 (eg, Table I , problems 4A-C, 5A-B).", [["swine", "SPECIES", 64, 69]]], ["Some of these we have finally recognized, or at least have had forced higher into our consciousness, by the A/Fujian epidemic of 2003-2004 (eg , Table I , problems 6, 7A-B, 8B-C, 9A).CONCLUSIONWe do have a plan on paper now, the N-PIPP, but it is a good beginning that needs to be expanded to better meet the needs of children.", [["children", "ORGANISM", 318, 326], ["children", "SPECIES", 318, 326], ["PIPP", "TREATMENT", 231, 235]]], ["Do we also have the collective will to put the necessary scientific, logistical, medical, and legal preparations in place to minimize death and other individual and societal consequences of pandemic influenza when it comes?", [["death", "DISEASE", 134, 139], ["influenza", "DISEASE", 199, 208], ["legal preparations", "TREATMENT", 94, 112], ["death", "PROBLEM", 134, 139], ["pandemic influenza", "PROBLEM", 190, 208]]], ["We fight a war on terrorism in part to diminish the risk of mass casualties from potential weapons of mass destruction.", [["mass casualties", "PROBLEM", 60, 75], ["mass destruction", "PROBLEM", 102, 118], ["mass", "OBSERVATION", 60, 64], ["mass", "OBSERVATION", 102, 106]]], ["Pandemic influenza, poorly planned for and therefore poorly fought, would be a mass-casualty event worldwide.", [["influenza", "DISEASE", 9, 18], ["Pandemic influenza", "PROBLEM", 0, 18], ["a mass", "PROBLEM", 77, 83], ["mass", "OBSERVATION", 79, 83]]], ["The key to effective intervention during a pandemic ultimately will be preparation at the local level, built on public and private sector collaboration, coordinated and supported by state and federal working groups.", [["effective intervention", "TREATMENT", 11, 33], ["effective", "OBSERVATION_MODIFIER", 11, 20]]], ["A wide range of pediatric expertise also must be brought to bear at the national and state levels in an effort to support response efforts for children at the local level.", [["children", "ORGANISM", 143, 151], ["children", "SPECIES", 143, 151], ["wide", "OBSERVATION_MODIFIER", 2, 6]]], ["These planning efforts also will be useful for more effective management of other potential infectious and noninfectious scenarios causing serious widespread impact.", [["other potential infectious and noninfectious scenarios", "PROBLEM", 76, 130], ["infectious", "OBSERVATION", 92, 102], ["noninfectious", "OBSERVATION_MODIFIER", 107, 120], ["serious", "OBSERVATION_MODIFIER", 139, 146], ["widespread", "OBSERVATION_MODIFIER", 147, 157], ["impact", "OBSERVATION", 158, 164]]], ["Our time to prepare for the next influenza pandemic may well be short, for current events suggest that the pandemic clock is already ticking down.", [["influenza", "DISEASE", 33, 42], ["the next influenza pandemic", "PROBLEM", 24, 51], ["the pandemic clock", "PROBLEM", 103, 121]]]], "db2f92a0fb72b7ad5821547641453678c6dad90f": [["IntroductionThe physical, chemical, and biological behavior of macromolecules in biological tissues depends on the content and binding energy with water molecules.", [["tissues", "ANATOMY", 92, 99], ["tissues", "TISSUE", 92, 99], ["biological tissues", "OBSERVATION", 81, 99]]], ["Proteins and other macromolecules in living tissue are functional provided that they contain water molecules as an integral part.", [["tissue", "ANATOMY", 44, 50], ["tissue", "TISSUE", 44, 50], ["Proteins and other macromolecules in living tissue", "PROBLEM", 0, 50], ["macromolecules", "OBSERVATION", 19, 33], ["living tissue", "OBSERVATION", 37, 50]]], ["Biological macromolecules are inactive in the absence of bound water.", [["water", "SIMPLE_CHEMICAL", 63, 68], ["Biological macromolecules", "PROBLEM", 0, 25], ["macromolecules", "OBSERVATION", 11, 25], ["inactive", "OBSERVATION_MODIFIER", 30, 38]]], ["The changes in bound water and free water ratios have been associated with age-related and protein-conformational diseases and have an important role in time-dependent processes in biological tissues [1] [2] [3] .", [["tissues", "ANATOMY", 192, 199], ["water", "SIMPLE_CHEMICAL", 21, 26], ["tissues", "TISSUE", 192, 199], ["The changes in bound water and free water ratios", "PROBLEM", 0, 48], ["conformational diseases", "PROBLEM", 99, 122]]], ["The content of tightly bound water in biological tissues decreases with advanced age [1, 2] .", [["tissues", "ANATOMY", 49, 56], ["water", "SIMPLE_CHEMICAL", 29, 34], ["tissues", "TISSUE", 49, 56], ["tightly bound water in biological tissues", "PROBLEM", 15, 56], ["tightly", "OBSERVATION_MODIFIER", 15, 22], ["bound", "OBSERVATION_MODIFIER", 23, 28], ["water", "OBSERVATION_MODIFIER", 29, 34]]], ["Nuclear magnetic resonance (NMR) and differential scanning calorimetry (DSC) are methods that can determine the state of water.", [["water", "SIMPLE_CHEMICAL", 121, 126], ["Nuclear magnetic resonance", "TEST", 0, 26], ["NMR", "TEST", 28, 31], ["differential scanning calorimetry", "TEST", 37, 70]]], ["NMR and differential thermal analysis (DTA) studies demonstrated variation in water binding energy from tightly bound water molecules to loosely bound water molecules depending on the changes of moisture content in a polymer material.", [["water", "SIMPLE_CHEMICAL", 78, 83], ["NMR", "TEST", 0, 3], ["differential thermal analysis", "TEST", 8, 37], ["DTA) studies", "TEST", 39, 51], ["variation in water binding energy", "PROBLEM", 65, 98], ["loosely bound water molecules", "PROBLEM", 137, 166], ["a polymer material", "TREATMENT", 215, 233], ["variation", "OBSERVATION_MODIFIER", 65, 74], ["water binding", "OBSERVATION", 78, 91], ["moisture content", "OBSERVATION", 195, 211]]], ["Commonly, three regions of proton molecular mobility represented by relaxation times can be observed using NMR.", [["proton molecular mobility", "PROBLEM", 27, 52], ["NMR", "TEST", 107, 110], ["proton molecular mobility", "OBSERVATION", 27, 52]]], ["The relaxation time of free water is much higher if compared with the relaxation time of tightly bound water molecules.", [["tightly bound water molecules", "PROTEIN", 89, 118], ["The relaxation time of free water", "TREATMENT", 0, 33], ["relaxation", "OBSERVATION_MODIFIER", 4, 14]]], ["Otsuka and co-authors [4] suggested the application of near-infrared spectroscopy to study states of water.", [["Otsuka", "ORGANISM", 0, 6]]], ["Absorbance spectra in the frequency range of 4500-5500 cm \u22121 were resolved into three peaks, which correspond to water molecules with different hydrogen bond states.IntroductionThe behavior of unfrozen water below the equilibrium free water freezing temperature has been discussed by Wolfe and co-authors [5] .", [["hydrogen", "CHEMICAL", 144, 152], ["Absorbance spectra", "TEST", 0, 18], ["different hydrogen bond states", "PROBLEM", 134, 164], ["unfrozen water", "TREATMENT", 193, 207], ["the equilibrium free water freezing temperature", "TREATMENT", 214, 261], ["5500 cm", "OBSERVATION_MODIFIER", 50, 57], ["water molecules", "OBSERVATION", 113, 128], ["hydrogen bond", "OBSERVATION", 144, 157]]], ["Free water freezes at 0 \u2022 C, but freezing point depression can be observed for loosely bound water molecules absorbed by polymers.", [["depression", "DISEASE", 48, 58], ["Free water freezes", "TREATMENT", 0, 18], ["freezing point depression", "PROBLEM", 33, 58], ["loosely bound water molecules", "PROBLEM", 79, 108]]], ["Wolfe et al. suggested that the binding energy of water molecules depends on the distance from the hydrophilic surface or hydrophilic functional groups of macromolecules, and higher water freezing point depression is related to higher energy of interaction with the surface or macromolecule.", [["surface", "ANATOMY", 111, 118], ["surface", "ANATOMY", 266, 273], ["depression", "DISEASE", 203, 213], ["surface", "CELLULAR_COMPONENT", 266, 273], ["the binding energy of water molecules", "PROBLEM", 28, 65], ["hydrophilic functional groups of macromolecules", "PROBLEM", 122, 169], ["higher water freezing point depression", "PROBLEM", 175, 213], ["higher", "OBSERVATION_MODIFIER", 175, 181], ["water freezing", "OBSERVATION_MODIFIER", 182, 196]]], ["The tightly bound unfreezable water molecules in the first and second molecular layers next to the surface are less mobile than the water molecules that are at a higher distance from the surface [5] [6] [7] .IntroductionIt has been concluded that water in close contact with macromolecules is no longer liquid but somewhat structured [8] .", [["surface", "ANATOMY", 99, 106], ["surface", "CELLULAR_COMPONENT", 99, 106], ["water", "SIMPLE_CHEMICAL", 247, 252], ["unfreezable water molecules", "PROTEIN", 18, 45], ["The tightly bound unfreezable water molecules", "PROBLEM", 0, 45], ["Introduction", "TREATMENT", 208, 220], ["tightly", "OBSERVATION_MODIFIER", 4, 11], ["bound", "OBSERVATION_MODIFIER", 12, 17], ["unfreezable", "OBSERVATION_MODIFIER", 18, 29], ["water molecules", "OBSERVATION", 30, 45], ["second molecular", "ANATOMY_MODIFIER", 63, 79], ["layers", "OBSERVATION_MODIFIER", 80, 86], ["surface", "OBSERVATION_MODIFIER", 99, 106], ["less", "OBSERVATION_MODIFIER", 111, 115], ["mobile", "OBSERVATION_MODIFIER", 116, 122], ["no longer", "UNCERTAINTY", 293, 302]]], ["Bound water also controls the conformational changes in biological macromolecules.IntroductionThe effect of living tissue plasticization by water on tissue stiffness is typically neglected in the current state of the art.", [["tissue", "ANATOMY", 115, 121], ["tissue", "ANATOMY", 149, 155], ["tissue", "TISSUE", 115, 121], ["water", "SIMPLE_CHEMICAL", 140, 145], ["tissue", "TISSUE", 149, 155], ["the conformational changes in biological macromolecules", "PROBLEM", 26, 81], ["living tissue plasticization", "TREATMENT", 108, 136], ["tissue stiffness", "PROBLEM", 149, 165], ["water on tissue", "OBSERVATION_MODIFIER", 140, 155], ["stiffness", "OBSERVATION", 156, 165]]], ["The aim of this paper is to review mechanisms that demonstrate how changes in bound water content can lead to changes in tissue stiffness, promoting the aging process and triggering related pathologies.Tissue StiffnessDischer and co-authors reported in 2005 that cells respond to the rigidity of their planar substrate [9] .", [["tissue", "ANATOMY", 121, 127], ["Tissue", "ANATOMY", 202, 208], ["cells", "ANATOMY", 263, 268], ["rigidity", "DISEASE", 284, 292], ["water", "SIMPLE_CHEMICAL", 84, 89], ["tissue", "TISSUE", 121, 127], ["Tissue", "TISSUE", 202, 208], ["cells", "CELL", 263, 268], ["how changes in bound water content", "PROBLEM", 63, 97], ["changes in tissue stiffness", "PROBLEM", 110, 137], ["triggering related pathologies", "PROBLEM", 171, 201], ["Tissue StiffnessDischer", "PROBLEM", 202, 225], ["tissue", "ANATOMY", 121, 127], ["stiffness", "OBSERVATION", 128, 137], ["Stiffness", "OBSERVATION", 209, 218]]], ["It has been further demonstrated that cellular processes in the three-dimensional matrix respond differently to microenvironment stiffness and, for example, in hyaluronic acid hydrogels, the differentiation behavior of human mesenchymal stem cells (hMSCs) depends on cellular traction.", [["cellular", "ANATOMY", 38, 46], ["mesenchymal stem cells", "ANATOMY", 225, 247], ["hMSCs", "ANATOMY", 249, 254], ["cellular", "ANATOMY", 267, 275], ["hyaluronic acid", "CHEMICAL", 160, 175], ["cellular", "CELL", 38, 46], ["matrix", "CELLULAR_COMPONENT", 82, 88], ["hyaluronic acid", "SIMPLE_CHEMICAL", 160, 175], ["human", "ORGANISM", 219, 224], ["mesenchymal stem cells", "CELL", 225, 247], ["hMSCs", "CELL", 249, 254], ["cellular", "CELL", 267, 275], ["human mesenchymal stem cells", "CELL_TYPE", 219, 247], ["hMSCs", "CELL_TYPE", 249, 254], ["human", "SPECIES", 219, 224], ["human", "SPECIES", 219, 224], ["cellular processes", "PROBLEM", 38, 56], ["microenvironment stiffness", "PROBLEM", 112, 138], ["hyaluronic acid hydrogels", "TREATMENT", 160, 185], ["cellular traction", "TREATMENT", 267, 284], ["cellular processes", "OBSERVATION", 38, 56], ["microenvironment stiffness", "OBSERVATION", 112, 138], ["mesenchymal stem cells", "OBSERVATION", 225, 247], ["cellular traction", "OBSERVATION", 267, 284]]], ["High degrees of cell spreading on stiffer surfaces favored osteogenesis, and lower degrees of cell spreading on softer surfaces favored adipogenesis [10] .", [["cell", "ANATOMY", 16, 20], ["cell", "ANATOMY", 94, 98], ["cell", "CELL", 16, 20], ["cell", "CELL", 94, 98], ["High degrees of cell spreading on stiffer surfaces", "PROBLEM", 0, 50], ["osteogenesis", "PROBLEM", 59, 71], ["lower degrees of cell spreading", "PROBLEM", 77, 108], ["adipogenesis", "PROBLEM", 136, 148], ["cell", "OBSERVATION", 16, 20], ["spreading", "OBSERVATION_MODIFIER", 21, 30], ["stiffer surfaces", "OBSERVATION_MODIFIER", 34, 50], ["osteogenesis", "OBSERVATION", 59, 71], ["lower degrees", "OBSERVATION_MODIFIER", 77, 90], ["cell", "OBSERVATION", 94, 98], ["spreading", "OBSERVATION_MODIFIER", 99, 108], ["softer surfaces", "OBSERVATION_MODIFIER", 112, 127]]], ["Protein-conformational diseases and age-related diseases are associated with increasing tissue stiffness with increasing age [1, 11, 12] .", [["tissue", "ANATOMY", 88, 94], ["tissue", "TISSUE", 88, 94], ["Protein", "TEST", 0, 7], ["conformational diseases", "PROBLEM", 8, 31], ["age-related diseases", "PROBLEM", 36, 56], ["increasing tissue stiffness", "PROBLEM", 77, 104], ["conformational diseases", "OBSERVATION", 8, 31], ["increasing tissue", "OBSERVATION_MODIFIER", 77, 94], ["stiffness", "OBSERVATION", 95, 104], ["increasing", "OBSERVATION_MODIFIER", 110, 120]]], ["Arterial stiffness was associated, not only with cardiovascular diseases, but also with neurodegenerative diseases, cognitive impairment, and vascular dementia [13] [14] [15] .", [["Arterial", "ANATOMY", 0, 8], ["cardiovascular", "ANATOMY", 49, 63], ["vascular", "ANATOMY", 142, 150], ["Arterial stiffness", "DISEASE", 0, 18], ["cardiovascular diseases", "DISEASE", 49, 72], ["neurodegenerative diseases", "DISEASE", 88, 114], ["cognitive impairment", "DISEASE", 116, 136], ["dementia", "DISEASE", 151, 159], ["Arterial", "MULTI-TISSUE_STRUCTURE", 0, 8], ["vascular", "MULTI-TISSUE_STRUCTURE", 142, 150], ["[13] [14] [15]", "SIMPLE_CHEMICAL", 160, 174], ["Arterial stiffness", "PROBLEM", 0, 18], ["cardiovascular diseases", "PROBLEM", 49, 72], ["neurodegenerative diseases", "PROBLEM", 88, 114], ["cognitive impairment", "PROBLEM", 116, 136], ["vascular dementia", "PROBLEM", 142, 159], ["stiffness", "OBSERVATION", 9, 18], ["neurodegenerative", "OBSERVATION_MODIFIER", 88, 105], ["diseases", "OBSERVATION", 106, 114], ["vascular", "ANATOMY", 142, 150], ["dementia", "OBSERVATION", 151, 159]]], ["Thus, the prevention of tissue stiffening is a therapeutic approach with the clinical potential to attenuate disease, which has been discussed in a recent review by Lampi and Reinhart-King [11] .", [["tissue", "ANATOMY", 24, 30], ["tissue stiffening", "DISEASE", 24, 41], ["tissue", "TISSUE", 24, 30], ["tissue stiffening", "PROBLEM", 24, 41], ["a therapeutic approach", "TREATMENT", 45, 67], ["attenuate disease", "PROBLEM", 99, 116], ["tissue", "ANATOMY", 24, 30], ["stiffening", "OBSERVATION", 31, 41]]], ["It has also been suggested that antihypertensive drugs can decrease vascular stiffness and reduce the occurrence of cognitive impairment [15] .", [["vascular", "ANATOMY", 68, 76], ["vascular stiffness", "DISEASE", 68, 86], ["cognitive impairment", "DISEASE", 116, 136], ["vascular", "MULTI-TISSUE_STRUCTURE", 68, 76], ["antihypertensive drugs", "TREATMENT", 32, 54], ["vascular stiffness", "PROBLEM", 68, 86], ["cognitive impairment", "PROBLEM", 116, 136], ["vascular", "ANATOMY", 68, 76]]], ["Increased extracellular matrix (ECM) stiffness was related to cancer, cardiovascular disease, diabetes, and other pathologies.", [["extracellular matrix", "ANATOMY", 10, 30], ["ECM", "ANATOMY", 32, 35], ["cancer", "ANATOMY", 62, 68], ["cardiovascular", "ANATOMY", 70, 84], ["cancer", "DISEASE", 62, 68], ["cardiovascular disease", "DISEASE", 70, 92], ["diabetes", "DISEASE", 94, 102], ["extracellular matrix", "CELLULAR_COMPONENT", 10, 30], ["ECM", "CELLULAR_COMPONENT", 32, 35], ["cancer", "CANCER", 62, 68], ["cardiovascular", "ANATOMICAL_SYSTEM", 70, 84], ["Increased extracellular matrix (ECM) stiffness", "PROBLEM", 0, 46], ["cancer", "PROBLEM", 62, 68], ["cardiovascular disease", "PROBLEM", 70, 92], ["diabetes", "PROBLEM", 94, 102], ["other pathologies", "PROBLEM", 108, 125], ["extracellular matrix", "OBSERVATION", 10, 30], ["cancer", "OBSERVATION", 62, 68], ["cardiovascular", "ANATOMY", 70, 84], ["disease", "OBSERVATION", 85, 92], ["diabetes", "OBSERVATION", 94, 102], ["pathologies", "OBSERVATION", 114, 125]]], ["ECM provides biomechanical cues that direct cell growth, migration, differentiation, and survival [16] .Tightly Bound WaterIt is important to take into account that mechanical properties depend on the content and state of water bound to biological macromolecules [2, 3] .", [["ECM", "ANATOMY", 0, 3], ["cell", "ANATOMY", 44, 48], ["ECM", "CELLULAR_COMPONENT", 0, 3], ["cell", "CELL", 44, 48], ["water", "SIMPLE_CHEMICAL", 222, 227], ["ECM", "PROTEIN", 0, 3], ["Bound WaterIt", "PROTEIN", 112, 125], ["direct cell growth", "PROBLEM", 37, 55], ["mechanical properties", "PROBLEM", 165, 186], ["Bound", "OBSERVATION_MODIFIER", 112, 117], ["WaterIt", "OBSERVATION", 118, 125]]], ["The binding energy of water molecules to biological macromolecules decreases with aging, and tightly bound water transforms into loosely bound and free water.", [["water", "SIMPLE_CHEMICAL", 107, 112]]], ["Tightly bound water is a plasticizer and the decrease in its content results in an increase in tissue stiffness.", [["tissue", "ANATOMY", 95, 101], ["water", "SIMPLE_CHEMICAL", 14, 19], ["tissue", "TISSUE", 95, 101], ["a plasticizer", "TREATMENT", 23, 36], ["the decrease in its content", "PROBLEM", 41, 68], ["an increase in tissue stiffness", "PROBLEM", 80, 111], ["bound", "OBSERVATION_MODIFIER", 8, 13], ["water", "OBSERVATION", 14, 19], ["decrease", "OBSERVATION_MODIFIER", 45, 53], ["increase", "OBSERVATION_MODIFIER", 83, 91], ["tissue stiffness", "OBSERVATION", 95, 111]]], ["The decrease in bound water fraction in the extracellular matrix with advanced age was correlated with the loss of mechanical properties of the cortical bone in female and male BALB/c mice [17] .", [["extracellular matrix", "ANATOMY", 44, 64], ["cortical bone", "ANATOMY", 144, 157], ["extracellular matrix", "CELLULAR_COMPONENT", 44, 64], ["cortical bone", "MULTI-TISSUE_STRUCTURE", 144, 157], ["BALB/c mice", "ORGANISM", 177, 188], ["mice", "SPECIES", 184, 188], ["The decrease in bound water fraction", "PROBLEM", 0, 36], ["the loss of mechanical properties", "PROBLEM", 103, 136], ["decrease", "OBSERVATION_MODIFIER", 4, 12], ["bound", "OBSERVATION_MODIFIER", 16, 21], ["water fraction", "OBSERVATION", 22, 36], ["extracellular matrix", "ANATOMY", 44, 64], ["mechanical properties", "OBSERVATION", 115, 136], ["cortical", "ANATOMY_MODIFIER", 144, 152], ["bone", "ANATOMY", 153, 157]]], ["Strength and toughness of hydrated human bone decreases with decrease of bound water content, indicating the risk of fracture [18] .", [["bone", "ANATOMY", 41, 45], ["fracture", "DISEASE", 117, 125], ["human", "ORGANISM", 35, 40], ["bone", "TISSUE", 41, 45], ["water", "SIMPLE_CHEMICAL", 79, 84], ["human", "SPECIES", 35, 40], ["human", "SPECIES", 35, 40], ["hydrated human bone decreases", "PROBLEM", 26, 55], ["decrease of bound water content", "PROBLEM", 61, 92], ["fracture", "PROBLEM", 117, 125], ["bone", "ANATOMY", 41, 45], ["decreases", "OBSERVATION_MODIFIER", 46, 55], ["decrease", "OBSERVATION_MODIFIER", 61, 69], ["bound water content", "OBSERVATION_MODIFIER", 73, 92], ["fracture", "OBSERVATION", 117, 125]]], ["In bone, the quantity of water bound to collagen decreases with age [19] .", [["bone", "ANATOMY", 3, 7], ["bone", "TISSUE", 3, 7], ["water", "SIMPLE_CHEMICAL", 25, 30], ["collagen", "GENE_OR_GENE_PRODUCT", 40, 48], ["collagen", "PROTEIN", 40, 48], ["bone", "ANATOMY", 3, 7], ["quantity", "OBSERVATION_MODIFIER", 13, 21]]], ["Total body water (TBW) and intracellular water (ICW) decrease with age, but elderly individuals with higher ICW content have higher muscle strength and better functional performance [20] .", [["body", "ANATOMY", 6, 10], ["intracellular", "ANATOMY", 27, 40], ["muscle", "ANATOMY", 132, 138], ["body", "ORGANISM_SUBDIVISION", 6, 10], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 27, 40], ["muscle", "ORGAN", 132, 138], ["Total body water (TBW)", "TREATMENT", 0, 22], ["intracellular water (ICW)", "TREATMENT", 27, 52], ["higher muscle strength", "PROBLEM", 125, 147], ["muscle", "ANATOMY", 132, 138]]], ["An increase in the extracellular water (ECW) to ICW ratio in the upper legs determined using segmental bioelectrical impedance spectroscopy was associated with a decrease in muscle strength in older individuals [21] .", [["extracellular", "ANATOMY", 19, 32], ["upper legs", "ANATOMY", 65, 75], ["muscle", "ANATOMY", 174, 180], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 19, 32], ["upper legs", "ORGANISM_SUBDIVISION", 65, 75], ["muscle", "ORGAN", 174, 180], ["the extracellular water (ECW)", "TREATMENT", 15, 44], ["ICW ratio", "TEST", 48, 57], ["segmental bioelectrical impedance spectroscopy", "TEST", 93, 139], ["a decrease in muscle strength", "PROBLEM", 160, 189], ["increase", "OBSERVATION_MODIFIER", 3, 11], ["extracellular", "OBSERVATION_MODIFIER", 19, 32], ["water", "OBSERVATION_MODIFIER", 33, 38], ["upper legs", "ANATOMY", 65, 75], ["decrease", "OBSERVATION_MODIFIER", 162, 170], ["muscle", "ANATOMY", 174, 180]]], ["Kim and co-authors demonstrated that high ECW/ICW ratio is a major risk indicator for all-cause mortality and cardiovascular diseases.", [["cardiovascular", "ANATOMY", 110, 124], ["cardiovascular diseases", "DISEASE", 110, 133], ["ECW", "GENE_OR_GENE_PRODUCT", 42, 45], ["cardiovascular", "ANATOMICAL_SYSTEM", 110, 124], ["ECW", "PROTEIN", 42, 45], ["high ECW/ICW ratio", "PROBLEM", 37, 55], ["cardiovascular diseases", "PROBLEM", 110, 133], ["cardiovascular", "ANATOMY", 110, 124], ["diseases", "OBSERVATION", 125, 133]]], ["A correlation between ECW/ICW with inflammation and pulse wave velocity was reported [22] .", [["inflammation", "DISEASE", 35, 47], ["ECW", "PROTEIN", 22, 25], ["ECW/ICW", "TREATMENT", 22, 29], ["inflammation", "PROBLEM", 35, 47], ["pulse wave velocity", "TEST", 52, 71], ["inflammation", "OBSERVATION", 35, 47]]], ["ECW/ICW also has been reported as a prognostic factor for survival in metastatic cancer [23] .", [["metastatic cancer", "ANATOMY", 70, 87], ["cancer", "DISEASE", 81, 87], ["ECW", "GENE_OR_GENE_PRODUCT", 0, 3], ["metastatic cancer", "CANCER", 70, 87], ["ECW", "PROTEIN", 0, 3], ["ICW", "PROTEIN", 4, 7], ["ICW", "PROBLEM", 4, 7], ["metastatic cancer", "PROBLEM", 70, 87], ["metastatic", "OBSERVATION_MODIFIER", 70, 80], ["cancer", "OBSERVATION", 81, 87]]], ["A decrease in the ICW content with age proceeds with a higher rate than in the ECW content.", [["ICW", "SIMPLE_CHEMICAL", 18, 21], ["ECW", "SIMPLE_CHEMICAL", 79, 82], ["ECW", "PROTEIN", 79, 82], ["A decrease in the ICW content", "PROBLEM", 0, 29], ["decrease", "OBSERVATION_MODIFIER", 2, 10]]], ["Increase in ECW/ICW ratio accelerates after the age of 70 years [24] .Tightly Bound WaterThus, it is very important to prevent or retard the transformation of intracellular tightly bound water into extracellular loosely bound and free water in order to mitigate an increase in tissue stiffness.Advanced Glycation End ProductsIt has been shown that tissue stiffness increases as a result of tissue crosslinking by advanced glycation end products (AGEs).", [["intracellular", "ANATOMY", 159, 172], ["extracellular", "ANATOMY", 198, 211], ["tissue", "ANATOMY", 277, 283], ["tissue", "ANATOMY", 348, 354], ["tissue", "ANATOMY", 390, 396], ["ECW", "GENE_OR_GENE_PRODUCT", 12, 15], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 159, 172], ["water", "SIMPLE_CHEMICAL", 187, 192], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 198, 211], ["tissue", "TISSUE", 277, 283], ["tissue", "TISSUE", 348, 354], ["tissue", "TISSUE", 390, 396], ["advanced glycation end products", "SIMPLE_CHEMICAL", 413, 444], ["AGEs", "SIMPLE_CHEMICAL", 446, 450], ["ECW", "PROTEIN", 12, 15], ["advanced glycation end products", "PROTEIN", 413, 444], ["AGEs", "PROTEIN", 446, 450], ["an increase in tissue stiffness", "PROBLEM", 262, 293], ["Advanced Glycation End Products", "TREATMENT", 294, 325], ["tissue stiffness", "PROBLEM", 348, 364], ["tissue crosslinking", "TREATMENT", 390, 409], ["advanced glycation end products", "TREATMENT", 413, 444], ["Bound", "OBSERVATION_MODIFIER", 78, 83], ["WaterThus", "OBSERVATION", 84, 93], ["increase", "OBSERVATION_MODIFIER", 265, 273], ["tissue stiffness", "OBSERVATION", 277, 293], ["Glycation", "OBSERVATION", 303, 312], ["tissue", "OBSERVATION_MODIFIER", 348, 354], ["stiffness", "OBSERVATION_MODIFIER", 355, 364], ["increases", "OBSERVATION_MODIFIER", 365, 374]]], ["Dehydration and glycation may be considered as subsequent steps during the aging process [3, 25] .", [["Dehydration", "DISEASE", 0, 11], ["Dehydration", "PROBLEM", 0, 11], ["glycation", "TREATMENT", 16, 25], ["glycation", "OBSERVATION", 16, 25], ["may be considered", "UNCERTAINTY", 26, 43]]], ["A decrease in bound water content and increase in AGEs during aging were reported in the cortical bones of rats [26] .", [["cortical bones", "ANATOMY", 89, 103], ["AGEs", "CHEMICAL", 50, 54], ["water", "SIMPLE_CHEMICAL", 20, 25], ["AGEs", "SIMPLE_CHEMICAL", 50, 54], ["cortical bones", "MULTI-TISSUE_STRUCTURE", 89, 103], ["rats", "ORGANISM", 107, 111], ["AGEs", "PROTEIN", 50, 54], ["rats", "SPECIES", 107, 111], ["A decrease in bound water content", "PROBLEM", 0, 33], ["decrease", "OBSERVATION_MODIFIER", 2, 10], ["bound", "OBSERVATION_MODIFIER", 14, 19], ["water content", "OBSERVATION_MODIFIER", 20, 33], ["increase", "OBSERVATION_MODIFIER", 38, 46], ["cortical", "ANATOMY_MODIFIER", 89, 97], ["bones", "ANATOMY", 98, 103]]], ["The accumulation of AGEs and reduction of water content in the ovine intervertebral disc was also observed [27] .", [["intervertebral disc", "ANATOMY", 69, 88], ["AGEs", "CHEMICAL", 20, 24], ["AGEs", "SIMPLE_CHEMICAL", 20, 24], ["water", "SIMPLE_CHEMICAL", 42, 47], ["ovine", "ORGANISM", 63, 68], ["intervertebral disc", "MULTI-TISSUE_STRUCTURE", 69, 88], ["The accumulation of AGEs", "PROBLEM", 0, 24], ["reduction of water content in the ovine intervertebral disc", "PROBLEM", 29, 88], ["accumulation", "OBSERVATION_MODIFIER", 4, 16], ["AGEs", "OBSERVATION_MODIFIER", 20, 24], ["reduction", "OBSERVATION_MODIFIER", 29, 38], ["water content", "OBSERVATION", 42, 55], ["ovine", "ANATOMY_MODIFIER", 63, 68], ["intervertebral disc", "ANATOMY", 69, 88]]], ["Crosslinking of elastin and collagen by AGEs was associated with stiffening of the arterial wall with aging [12, 16] and AGE cross-link breakers can be suggested as \"de-stiffening\" drugs [28, 29] .Advanced Glycation End ProductsA number of AGE inhibitors that are effective in decreasing AGE accumulation in tissues have been proposed, such as aminoguanidine, pyridoxamine, aspirin, ALT-711 (alagebrium), thiamine, tenilsetam (antidementia drug), and others [30] [31] [32] [33] [34] [35] [36] .PolyphenolsPolyphenols have been suggested as inhibitors of AGEs [37] [38] [39] [40] [41] [42] .", [["arterial wall", "ANATOMY", 83, 96], ["tissues", "ANATOMY", 308, 315], ["AGEs", "CHEMICAL", 40, 44], ["AGE", "CHEMICAL", 240, 243], ["AGE", "CHEMICAL", 288, 291], ["aminoguanidine", "CHEMICAL", 344, 358], ["pyridoxamine", "CHEMICAL", 360, 372], ["aspirin", "CHEMICAL", 374, 381], ["ALT-711", "CHEMICAL", 383, 390], ["alagebrium", "CHEMICAL", 392, 402], ["thiamine", "CHEMICAL", 405, 413], ["tenilsetam", "CHEMICAL", 415, 425], ["antidementia", "CHEMICAL", 427, 439], ["Polyphenols", "CHEMICAL", 505, 516], ["AGEs [37] [38] [39] [40] [41", "CHEMICAL", 554, 582], ["aminoguanidine", "CHEMICAL", 344, 358], ["pyridoxamine", "CHEMICAL", 360, 372], ["aspirin", "CHEMICAL", 374, 381], ["ALT-711", "CHEMICAL", 383, 390], ["alagebrium", "CHEMICAL", 392, 402], ["thiamine", "CHEMICAL", 405, 413], ["tenilsetam", "CHEMICAL", 415, 425], ["antidementia", "CHEMICAL", 427, 439], ["Polyphenols", "CHEMICAL", 494, 505], ["Polyphenols", "CHEMICAL", 505, 516], ["elastin", "GENE_OR_GENE_PRODUCT", 16, 23], ["collagen", "GENE_OR_GENE_PRODUCT", 28, 36], ["AGEs", "SIMPLE_CHEMICAL", 40, 44], ["arterial wall", "MULTI-TISSUE_STRUCTURE", 83, 96], ["AGE", "SIMPLE_CHEMICAL", 121, 124], ["AGE", "SIMPLE_CHEMICAL", 240, 243], ["AGE", "SIMPLE_CHEMICAL", 288, 291], ["tissues", "TISSUE", 308, 315], ["aminoguanidine", "SIMPLE_CHEMICAL", 344, 358], ["pyridoxamine", "SIMPLE_CHEMICAL", 360, 372], ["aspirin", "SIMPLE_CHEMICAL", 374, 381], ["ALT-711", "SIMPLE_CHEMICAL", 383, 390], ["alagebrium", "SIMPLE_CHEMICAL", 392, 402], ["thiamine", "SIMPLE_CHEMICAL", 405, 413], ["tenilsetam", "SIMPLE_CHEMICAL", 415, 425], ["antidementia", "SIMPLE_CHEMICAL", 427, 439], ["[30] [31] [32] [33] [34] [35] [36]", "SIMPLE_CHEMICAL", 458, 492], ["Polyphenols", "SIMPLE_CHEMICAL", 494, 505], ["Polyphenols", "SIMPLE_CHEMICAL", 505, 516], ["AGEs", "SIMPLE_CHEMICAL", 554, 558], ["[37] [38] [39] [40] [41] [42]", "SIMPLE_CHEMICAL", 559, 588], ["elastin", "PROTEIN", 16, 23], ["collagen", "PROTEIN", 28, 36], ["AGE", "PROTEIN", 288, 291], ["Advanced Glycation End ProductsA number of AGE inhibitors", "TREATMENT", 197, 254], ["decreasing AGE accumulation in tissues", "PROBLEM", 277, 315], ["aminoguanidine", "TREATMENT", 344, 358], ["pyridoxamine", "TREATMENT", 360, 372], ["aspirin", "TREATMENT", 374, 381], ["ALT", "TEST", 383, 386], ["thiamine", "TREATMENT", 405, 413], ["PolyphenolsPolyphenols", "TREATMENT", 494, 516], ["elastin", "OBSERVATION", 16, 23], ["collagen", "OBSERVATION_MODIFIER", 28, 36], ["stiffening", "OBSERVATION", 65, 75], ["arterial wall", "ANATOMY", 83, 96]]], ["Diabetes leads to glycocalyx degradation, and the maintenance or restoration of the integrity of the glycocalyx is an important therapeutic target.", [["glycocalyx", "ANATOMY", 18, 28], ["glycocalyx", "ANATOMY", 101, 111], ["Diabetes", "DISEASE", 0, 8], ["glycocalyx", "CELLULAR_COMPONENT", 18, 28], ["glycocalyx", "CELLULAR_COMPONENT", 101, 111], ["Diabetes", "PROBLEM", 0, 8], ["glycocalyx degradation", "PROBLEM", 18, 40], ["glycocalyx degradation", "OBSERVATION", 18, 40], ["integrity", "OBSERVATION_MODIFIER", 84, 93]]], ["Polyphenols, such as resveratrol, quercetin, and (\u2212)-epicatechin, can promote the swelling of the highly hydrated endothelial glycocalyx, increasing its thickness and decreasing stiffness, as a result of cystic fibrosis transmembrane conductance regulator (CFTR) activation [40] .", [["endothelial glycocalyx", "ANATOMY", 114, 136], ["Polyphenols", "CHEMICAL", 0, 11], ["resveratrol", "CHEMICAL", 21, 32], ["quercetin", "CHEMICAL", 34, 43], ["(\u2212)-epicatechin", "CHEMICAL", 49, 64], ["fibrosis", "DISEASE", 211, 219], ["Polyphenols", "CHEMICAL", 0, 11], ["resveratrol", "CHEMICAL", 21, 32], ["quercetin", "CHEMICAL", 34, 43], ["(\u2212)-epicatechin", "CHEMICAL", 49, 64], ["Polyphenols", "SIMPLE_CHEMICAL", 0, 11], ["resveratrol", "SIMPLE_CHEMICAL", 21, 32], ["quercetin", "SIMPLE_CHEMICAL", 34, 43], ["(\u2212)-epicatechin", "SIMPLE_CHEMICAL", 49, 64], ["endothelial glycocalyx", "TISSUE", 114, 136], ["cystic fibrosis transmembrane conductance regulator", "GENE_OR_GENE_PRODUCT", 204, 255], ["CFTR", "GENE_OR_GENE_PRODUCT", 257, 261], ["cystic fibrosis transmembrane conductance regulator", "PROTEIN", 204, 255], ["CFTR", "PROTEIN", 257, 261], ["Polyphenols", "TREATMENT", 0, 11], ["resveratrol", "TREATMENT", 21, 32], ["quercetin", "TREATMENT", 34, 43], ["epicatechin", "TREATMENT", 53, 64], ["the swelling", "PROBLEM", 78, 90], ["the highly hydrated endothelial glycocalyx", "PROBLEM", 94, 136], ["decreasing stiffness", "PROBLEM", 167, 187], ["cystic fibrosis transmembrane conductance regulator", "PROBLEM", 204, 255], ["swelling", "OBSERVATION", 82, 90], ["highly", "OBSERVATION_MODIFIER", 98, 104], ["hydrated", "OBSERVATION", 105, 113], ["endothelial glycocalyx", "OBSERVATION", 114, 136], ["decreasing", "OBSERVATION_MODIFIER", 167, 177], ["stiffness", "OBSERVATION_MODIFIER", 178, 187], ["cystic", "OBSERVATION_MODIFIER", 204, 210], ["fibrosis", "OBSERVATION", 211, 219]]], ["CFTR regulates the transport of ions and water across the epithelial barrier.", [["epithelial barrier", "ANATOMY", 58, 76], ["CFTR", "GENE_OR_GENE_PRODUCT", 0, 4], ["ions", "SIMPLE_CHEMICAL", 32, 36], ["water", "SIMPLE_CHEMICAL", 41, 46], ["epithelial barrier", "TISSUE", 58, 76], ["CFTR", "PROTEIN", 0, 4], ["ions", "TREATMENT", 32, 36], ["the epithelial barrier", "TREATMENT", 54, 76], ["epithelial barrier", "OBSERVATION", 58, 76]]], ["Therefore, it can be concluded that polyphenols decrease stiffness and increase hydration.PolyphenolsHigher flavonoid consumption has been associated with a lower arterial stiffness.", [["arterial", "ANATOMY", 163, 171], ["polyphenols", "CHEMICAL", 36, 47], ["flavonoid", "CHEMICAL", 108, 117], ["polyphenols", "CHEMICAL", 36, 47], ["Polyphenols", "CHEMICAL", 90, 101], ["flavonoid", "CHEMICAL", 108, 117], ["polyphenols", "SIMPLE_CHEMICAL", 36, 47], ["Polyphenols", "SIMPLE_CHEMICAL", 90, 101], ["flavonoid", "SIMPLE_CHEMICAL", 108, 117], ["arterial", "MULTI-TISSUE_STRUCTURE", 163, 171], ["polyphenols decrease stiffness", "PROBLEM", 36, 66], ["increase hydration", "TREATMENT", 71, 89], ["PolyphenolsHigher flavonoid consumption", "PROBLEM", 90, 129], ["a lower arterial stiffness", "PROBLEM", 155, 181], ["increase", "OBSERVATION_MODIFIER", 71, 79], ["hydration", "OBSERVATION_MODIFIER", 80, 89], ["Higher", "OBSERVATION_MODIFIER", 101, 107], ["flavonoid consumption", "OBSERVATION", 108, 129], ["lower", "ANATOMY_MODIFIER", 157, 162], ["arterial", "ANATOMY", 163, 171], ["stiffness", "OBSERVATION", 172, 181]]], ["Isoflavones and anthocyanins have been recommended as the most efficient for the improvement of vascular health [34] .", [["vascular", "ANATOMY", 96, 104], ["Isoflavones", "CHEMICAL", 0, 11], ["anthocyanins", "CHEMICAL", 16, 28], ["Isoflavones", "CHEMICAL", 0, 11], ["anthocyanins", "CHEMICAL", 16, 28], ["Isoflavones", "SIMPLE_CHEMICAL", 0, 11], ["anthocyanins", "SIMPLE_CHEMICAL", 16, 28], ["vascular", "MULTI-TISSUE_STRUCTURE", 96, 104], ["Isoflavones", "TREATMENT", 0, 11], ["anthocyanins", "TREATMENT", 16, 28], ["vascular", "ANATOMY", 96, 104]]], ["Polyphenols activate endothelial nitric oxide synthase and increase endothelial synthesis and the production of nitric oxide [42] , in such a way regulating arterial stiffness and preventing cardiovascular diseases.", [["endothelial", "ANATOMY", 68, 79], ["arterial", "ANATOMY", 157, 165], ["cardiovascular", "ANATOMY", 191, 205], ["nitric oxide", "CHEMICAL", 33, 45], ["nitric oxide", "CHEMICAL", 112, 124], ["arterial stiffness", "DISEASE", 157, 175], ["cardiovascular diseases", "DISEASE", 191, 214], ["Polyphenols", "CHEMICAL", 0, 11], ["nitric oxide", "CHEMICAL", 33, 45], ["nitric oxide", "CHEMICAL", 112, 124], ["Polyphenols", "SIMPLE_CHEMICAL", 0, 11], ["endothelial nitric oxide synthase", "GENE_OR_GENE_PRODUCT", 21, 54], ["endothelial", "CELL", 68, 79], ["nitric oxide", "SIMPLE_CHEMICAL", 112, 124], ["arterial", "MULTI-TISSUE_STRUCTURE", 157, 165], ["cardiovascular", "ANATOMICAL_SYSTEM", 191, 205], ["endothelial nitric oxide synthase", "PROTEIN", 21, 54], ["Polyphenols", "TREATMENT", 0, 11], ["endothelial nitric oxide synthase", "TREATMENT", 21, 54], ["increase endothelial synthesis", "TREATMENT", 59, 89], ["the production of nitric oxide", "TREATMENT", 94, 124], ["arterial stiffness", "PROBLEM", 157, 175], ["cardiovascular diseases", "PROBLEM", 191, 214], ["arterial", "ANATOMY", 157, 165], ["stiffness", "OBSERVATION", 166, 175], ["cardiovascular", "ANATOMY", 191, 205], ["diseases", "OBSERVATION", 206, 214]]], ["Anthocyanins are not only effective in the improvement of vascular health but also have antiviral properties.", [["vascular", "ANATOMY", 58, 66], ["Anthocyanins", "CHEMICAL", 0, 12], ["Anthocyanins", "CHEMICAL", 0, 12], ["Anthocyanins", "SIMPLE_CHEMICAL", 0, 12], ["vascular", "MULTI-TISSUE_STRUCTURE", 58, 66], ["Anthocyanins", "TREATMENT", 0, 12], ["antiviral properties", "TREATMENT", 88, 108], ["not only", "UNCERTAINTY", 17, 25], ["effective", "OBSERVATION_MODIFIER", 26, 35], ["vascular", "ANATOMY", 58, 66], ["antiviral properties", "OBSERVATION", 88, 108]]], ["Inhibitory effects of anthocyanins [43] on different pathways involved in the virus life cycle have also been recently reviewed.PolyphenolsIn an in-vitro study, it was shown that bovine coronavirus infections can be neutralized by theaflavins extracted from black tea [44] .", [["anthocyanins", "CHEMICAL", 22, 34], ["coronavirus infections", "DISEASE", 186, 208], ["theaflavins", "CHEMICAL", 231, 242], ["anthocyanins", "CHEMICAL", 22, 34], ["Polyphenols", "CHEMICAL", 128, 139], ["theaflavins", "CHEMICAL", 231, 242], ["anthocyanins [43]", "SIMPLE_CHEMICAL", 22, 39], ["Polyphenols", "SIMPLE_CHEMICAL", 128, 139], ["bovine", "ORGANISM", 179, 185], ["coronavirus", "ORGANISM", 186, 197], ["theaflavins", "SIMPLE_CHEMICAL", 231, 242], ["bovine", "SPECIES", 179, 185], ["black tea", "SPECIES", 258, 267], ["bovine coronavirus", "SPECIES", 179, 197], ["black tea", "SPECIES", 258, 267], ["anthocyanins", "TREATMENT", 22, 34], ["the virus life cycle", "TREATMENT", 74, 94], ["Polyphenols", "TREATMENT", 128, 139], ["an in-vitro study", "TEST", 142, 159], ["bovine coronavirus infections", "PROBLEM", 179, 208], ["coronavirus", "OBSERVATION_MODIFIER", 186, 197], ["infections", "OBSERVATION", 198, 208]]], ["Ueda et al. [45] reported that tannins decreased viral infectivity against 12 different viruses, which were both enveloped and non-enveloped.", [["tannins", "CHEMICAL", 31, 38], ["tannins", "SIMPLE_CHEMICAL", 31, 38], ["tannins decreased viral infectivity", "PROBLEM", 31, 66], ["12 different viruses", "PROBLEM", 75, 95], ["viral infectivity", "OBSERVATION", 49, 66], ["non-enveloped", "OBSERVATION_MODIFIER", 127, 140]]], ["Extracts from persimmon (Diospyros kaki), which contains 22% of a food supplement persimmon tannin, demonstrated the highest antiviral effect.", [["Extracts", "ANATOMY", 0, 8], ["persimmon", "CHEMICAL", 14, 23], ["Diospyros kaki", "CHEMICAL", 25, 39], ["persimmon tannin", "CHEMICAL", 82, 98], ["Extracts", "ORGANISM_SUBSTANCE", 0, 8], ["persimmon", "SIMPLE_CHEMICAL", 14, 23], ["Diospyros kaki", "ORGANISM", 25, 39], ["tannin", "SIMPLE_CHEMICAL", 92, 98], ["Diospyros kaki", "SPECIES", 25, 39], ["Diospyros kaki", "SPECIES", 25, 39], ["persimmon (Diospyros kaki)", "TREATMENT", 14, 40], ["a food supplement persimmon tannin", "TREATMENT", 64, 98], ["the highest antiviral effect", "PROBLEM", 113, 141], ["antiviral effect", "OBSERVATION", 125, 141]]], ["The authors demonstrated that extracts from persimmon inhibited attachment of the virus to cells.", [["extracts", "ANATOMY", 30, 38], ["cells", "ANATOMY", 91, 96], ["persimmon", "CHEMICAL", 44, 53], ["extracts", "ORGANISM_SUBSTANCE", 30, 38], ["persimmon", "SIMPLE_CHEMICAL", 44, 53], ["cells", "CELL", 91, 96], ["the virus to cells", "PROBLEM", 78, 96]]], ["Pretreatment or posttreatment of cells with the persimmon extracts before or after virus infection did not inhibit virus replication.", [["cells", "ANATOMY", 33, 38], ["extracts", "ANATOMY", 58, 66], ["infection", "DISEASE", 89, 98], ["cells", "CELL", 33, 38], ["persimmon extracts", "ORGANISM_SUBSTANCE", 48, 66], ["Pretreatment", "TREATMENT", 0, 12], ["posttreatment of cells", "TREATMENT", 16, 38], ["the persimmon extracts", "TREATMENT", 44, 66], ["virus infection", "PROBLEM", 83, 98], ["virus replication", "TREATMENT", 115, 132]]], ["It was suggested that the antiviral effect of persimmon tannin can be explained by possible influenza virus protein aggregation.", [["persimmon tannin", "CHEMICAL", 46, 62], ["persimmon tannin", "CHEMICAL", 46, 62], ["persimmon tannin", "SIMPLE_CHEMICAL", 46, 62], ["influenza virus", "ORGANISM", 92, 107], ["influenza virus", "SPECIES", 92, 107], ["persimmon tannin", "TREATMENT", 46, 62], ["influenza virus protein aggregation", "PROBLEM", 92, 127]]], ["However, inhibited attachment of the virus to cells can also be explained by relative cell de-stiffening by persimmon extract due to changes in the ratio of virus and cell stiffnesses.", [["cells", "ANATOMY", 46, 51], ["cell", "ANATOMY", 86, 90], ["cell", "ANATOMY", 167, 171], ["persimmon extract", "CHEMICAL", 108, 125], ["cells", "CELL", 46, 51], ["cell", "CELL", 86, 90], ["cell", "CELL", 167, 171], ["the virus to cells", "PROBLEM", 33, 51], ["persimmon extract", "PROBLEM", 108, 125], ["changes in the ratio of virus", "PROBLEM", 133, 162], ["cell stiffnesses", "PROBLEM", 167, 183], ["virus", "OBSERVATION", 37, 42], ["virus", "OBSERVATION", 157, 162], ["cell stiffnesses", "OBSERVATION", 167, 183]]], ["Similarly, virus de-stiffening decreases platelet adhesion and prevents thrombus formation [7] .", [["platelet", "ANATOMY", 41, 49], ["thrombus", "ANATOMY", 72, 80], ["thrombus", "DISEASE", 72, 80], ["platelet", "CELL", 41, 49], ["thrombus", "PATHOLOGICAL_FORMATION", 72, 80], ["virus de-stiffening", "TREATMENT", 11, 30], ["platelet adhesion", "TREATMENT", 41, 58], ["thrombus formation", "PROBLEM", 72, 90], ["virus", "OBSERVATION", 11, 16], ["platelet adhesion", "OBSERVATION", 41, 58], ["prevents", "UNCERTAINTY", 63, 71], ["thrombus", "OBSERVATION", 72, 80]]], ["It has been shown that polyphenols can act as plasticizers; for example, tea-polyphenol-treated skin collagen demonstrated resistance to dehydration [46] .Omega-3 Fatty AcidsA more hydrated and intact intervertebral disc tissue has been observed in rats who consumed an omega-3 fatty acids diet [47] .", [["skin", "ANATOMY", 96, 100], ["intervertebral disc tissue", "ANATOMY", 201, 227], ["polyphenols", "CHEMICAL", 23, 34], ["tea-polyphenol", "CHEMICAL", 73, 87], ["dehydration", "DISEASE", 137, 148], ["omega-3 fatty acids", "CHEMICAL", 270, 289], ["polyphenols", "CHEMICAL", 23, 34], ["tea-polyphenol", "CHEMICAL", 73, 87], ["omega-3 fatty acids", "CHEMICAL", 270, 289], ["polyphenols", "SIMPLE_CHEMICAL", 23, 34], ["tea-polyphenol", "SIMPLE_CHEMICAL", 73, 87], ["skin", "ORGAN", 96, 100], ["collagen", "GENE_OR_GENE_PRODUCT", 101, 109], ["Omega-3", "GENE_OR_GENE_PRODUCT", 155, 162], ["intervertebral disc tissue", "TISSUE", 201, 227], ["rats", "ORGANISM", 249, 253], ["omega-3 fatty acids", "SIMPLE_CHEMICAL", 270, 289], ["rats", "SPECIES", 249, 253], ["polyphenols", "TREATMENT", 23, 34], ["tea-polyphenol-treated skin collagen", "TREATMENT", 73, 109], ["dehydration", "PROBLEM", 137, 148], ["Omega-3 Fatty AcidsA", "TREATMENT", 155, 175], ["intact intervertebral disc tissue", "PROBLEM", 194, 227], ["an omega-3 fatty acids diet", "TREATMENT", 267, 294], ["skin", "ANATOMY", 96, 100], ["intervertebral disc", "ANATOMY", 201, 220]]], ["At the same time, omega-3 fatty acids have been reported to be a de-stiffening agent; long-term omega-3 fatty acid (fish oil) supplementation in a diet decreases arterial stiffness [48] .", [["arterial", "ANATOMY", 162, 170], ["omega-3 fatty acids", "CHEMICAL", 18, 37], ["omega-3 fatty acid", "CHEMICAL", 96, 114], ["omega-3 fatty acids", "CHEMICAL", 18, 37], ["omega-3 fatty acid", "CHEMICAL", 96, 114], ["omega-3 fatty acids", "SIMPLE_CHEMICAL", 18, 37], ["omega-3 fatty acid", "SIMPLE_CHEMICAL", 96, 114], ["fish", "ORGANISM", 116, 120], ["oil", "ORGANISM_SUBSTANCE", 121, 124], ["arterial", "MULTI-TISSUE_STRUCTURE", 162, 170], ["omega-3 fatty acids", "TREATMENT", 18, 37], ["a de-stiffening agent", "TREATMENT", 63, 84], ["long-term omega-3 fatty acid (fish oil) supplementation", "TREATMENT", 86, 141]]], ["Fish oil supplementation decreases large arterial stiffness in overweight hypertensive patients [49] .", [["oil", "ANATOMY", 5, 8], ["arterial", "ANATOMY", 41, 49], ["arterial stiffness", "DISEASE", 41, 59], ["hypertensive", "DISEASE", 74, 86], ["oil", "ORGANISM_SUBSTANCE", 5, 8], ["arterial", "MULTI-TISSUE_STRUCTURE", 41, 49], ["patients", "ORGANISM", 87, 95], ["patients", "SPECIES", 87, 95], ["Fish oil supplementation", "TREATMENT", 0, 24], ["large arterial stiffness", "PROBLEM", 35, 59], ["overweight hypertensive patients", "PROBLEM", 63, 95], ["arterial stiffness", "OBSERVATION_MODIFIER", 41, 59]]], ["Schmidt et al. analyzed the effect of omega-3 polyunsaturated fatty acids on the cytoskeleton and concluded that n-3 PUFAs regulated cytoskeleton-associated gene expression [50] .Omega-3 Fatty AcidsIt has also been reported that Rho GTPase inhibited the metastatic ability of human prostate cancer cell line PC-3 by omega-3 polyunsaturated fatty acids [51] .", [["cytoskeleton", "ANATOMY", 81, 93], ["cytoskeleton", "ANATOMY", 133, 145], ["prostate cancer cell line PC-3", "ANATOMY", 282, 312], ["omega-3 polyunsaturated fatty acids", "CHEMICAL", 38, 73], ["n-3 PUFAs", "CHEMICAL", 113, 122], ["Omega-3 Fatty Acids", "CHEMICAL", 179, 198], ["prostate cancer", "DISEASE", 282, 297], ["omega-3 polyunsaturated fatty acids", "CHEMICAL", 316, 351], ["omega-3 polyunsaturated fatty acids", "CHEMICAL", 38, 73], ["PUFAs", "CHEMICAL", 117, 122], ["Omega-3 Fatty Acids", "CHEMICAL", 179, 198], ["omega-3 polyunsaturated fatty acids", "CHEMICAL", 316, 351], ["omega-3 polyunsaturated fatty acids", "SIMPLE_CHEMICAL", 38, 73], ["cytoskeleton", "CELLULAR_COMPONENT", 81, 93], ["n-3 PUFAs", "SIMPLE_CHEMICAL", 113, 122], ["cytoskeleton", "CELLULAR_COMPONENT", 133, 145], ["Omega-3 Fatty Acids", "SIMPLE_CHEMICAL", 179, 198], ["Rho", "GENE_OR_GENE_PRODUCT", 229, 232], ["human", "ORGANISM", 276, 281], ["prostate cancer cell line PC-3", "CELL", 282, 312], ["omega-3 polyunsaturated fatty acids", "SIMPLE_CHEMICAL", 316, 351], ["Rho GTPase", "PROTEIN", 229, 239], ["human prostate cancer cell line PC-3", "CELL_LINE", 276, 312], ["human", "SPECIES", 276, 281], ["human", "SPECIES", 276, 281], ["omega-3 polyunsaturated fatty acids", "TREATMENT", 38, 73], ["Omega", "TEST", 179, 184], ["Fatty Acids", "TREATMENT", 187, 198], ["Rho GTPase", "PROBLEM", 229, 239], ["the metastatic ability of human prostate cancer", "PROBLEM", 250, 297], ["cell line PC", "TEST", 298, 310], ["omega", "TEST", 316, 321], ["polyunsaturated fatty acids", "TEST", 324, 351], ["metastatic", "OBSERVATION_MODIFIER", 254, 264], ["prostate", "ANATOMY", 282, 290], ["cancer", "OBSERVATION", 291, 297]]], ["It was also recently suggested that arachidonic acid, eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA) are able to inactivate enveloped viruses and increase resistance and recovery from SARS-CoV-2, SARS, and Middle East respiratory syndrome (MERS) infections [52] .", [["arachidonic acid", "CHEMICAL", 36, 52], ["eicosapentaenoic acid", "CHEMICAL", 54, 75], ["EPA", "CHEMICAL", 77, 80], ["docosahexaenoic acid", "CHEMICAL", 87, 107], ["DHA", "CHEMICAL", 109, 112], ["SARS", "DISEASE", 197, 201], ["SARS", "DISEASE", 209, 213], ["Middle East respiratory syndrome (MERS) infections", "DISEASE", 219, 269], ["arachidonic acid", "CHEMICAL", 36, 52], ["eicosapentaenoic acid", "CHEMICAL", 54, 75], ["EPA", "CHEMICAL", 77, 80], ["docosahexaenoic acid", "CHEMICAL", 87, 107], ["DHA", "CHEMICAL", 109, 112], ["arachidonic acid", "SIMPLE_CHEMICAL", 36, 52], ["eicosapentaenoic acid", "SIMPLE_CHEMICAL", 54, 75], ["EPA", "SIMPLE_CHEMICAL", 77, 80], ["docosahexaenoic acid", "SIMPLE_CHEMICAL", 87, 107], ["DHA", "SIMPLE_CHEMICAL", 109, 112], ["SARS-CoV-2", "ORGANISM", 197, 207], ["Middle East respiratory", "ORGANISM", 219, 242], ["SARS-CoV", "SPECIES", 197, 205], ["Middle East respiratory syndrome (MERS)", "SPECIES", 219, 258], ["arachidonic acid", "TREATMENT", 36, 52], ["eicosapentaenoic acid (EPA)", "TREATMENT", 54, 81], ["docosahexaenoic acid (DHA)", "TREATMENT", 87, 113], ["enveloped viruses", "PROBLEM", 137, 154], ["increase resistance", "PROBLEM", 159, 178], ["SARS", "PROBLEM", 197, 201], ["CoV", "TEST", 202, 205], ["SARS", "PROBLEM", 209, 213], ["Middle East respiratory syndrome (MERS) infections", "PROBLEM", 219, 269], ["viruses", "OBSERVATION", 147, 154], ["Middle", "ANATOMY_MODIFIER", 219, 225], ["respiratory syndrome", "OBSERVATION", 231, 251]]], ["Very low blood levels of the sum of eicosapentaenoic acid and docosahexaenoic acid were observed in USA, Italy, UK, and Brazil [53] .", [["blood", "ANATOMY", 9, 14], ["eicosapentaenoic acid", "CHEMICAL", 36, 57], ["docosahexaenoic acid", "CHEMICAL", 62, 82], ["eicosapentaenoic acid", "CHEMICAL", 36, 57], ["docosahexaenoic acid", "CHEMICAL", 62, 82], ["blood", "ORGANISM_SUBSTANCE", 9, 14], ["eicosapentaenoic acid", "SIMPLE_CHEMICAL", 36, 57], ["docosahexaenoic acid", "SIMPLE_CHEMICAL", 62, 82], ["Very low blood levels", "PROBLEM", 0, 21], ["eicosapentaenoic acid", "TREATMENT", 36, 57], ["docosahexaenoic acid", "TREATMENT", 62, 82], ["low", "OBSERVATION", 5, 8]]], ["A high number of COVID-19 patients were reported in these countries.DrugsArterial wall stiffness is related to cardiovascular diseases [54] .", [["wall", "ANATOMY", 82, 86], ["cardiovascular", "ANATOMY", 111, 125], ["cardiovascular diseases", "DISEASE", 111, 134], ["patients", "ORGANISM", 26, 34], ["DrugsArterial wall", "TISSUE", 68, 86], ["patients", "SPECIES", 26, 34], ["COVID", "TEST", 17, 22], ["DrugsArterial wall stiffness", "PROBLEM", 68, 96], ["cardiovascular diseases", "PROBLEM", 111, 134], ["high", "OBSERVATION_MODIFIER", 2, 6], ["number", "OBSERVATION_MODIFIER", 7, 13], ["wall", "ANATOMY_MODIFIER", 82, 86], ["stiffness", "OBSERVATION", 87, 96], ["cardiovascular diseases", "OBSERVATION", 111, 134]]], ["For example, platelet adhesion and thrombus formation depend on arterial wall stiffness and hydration [7, 55] , Figure 1 .", [["platelet", "ANATOMY", 13, 21], ["thrombus", "ANATOMY", 35, 43], ["arterial wall", "ANATOMY", 64, 77], ["thrombus", "DISEASE", 35, 43], ["platelet", "CELL", 13, 21], ["thrombus", "PATHOLOGICAL_FORMATION", 35, 43], ["arterial wall", "MULTI-TISSUE_STRUCTURE", 64, 77], ["platelet adhesion", "PROBLEM", 13, 30], ["thrombus formation", "PROBLEM", 35, 53], ["arterial wall stiffness", "PROBLEM", 64, 87], ["hydration", "TEST", 92, 101], ["platelet adhesion", "OBSERVATION", 13, 30], ["thrombus", "OBSERVATION", 35, 43], ["arterial", "ANATOMY_MODIFIER", 64, 72], ["wall", "ANATOMY_MODIFIER", 73, 77], ["stiffness", "OBSERVATION_MODIFIER", 78, 87]]], ["An increase in substrate stiffness leads to endothelial monolayer disruption by increased cellular traction stresses and to increased endothelium permeability by leukocytes resulting in the development of atherosclerosis.", [["endothelial monolayer", "ANATOMY", 44, 65], ["cellular", "ANATOMY", 90, 98], ["endothelium", "ANATOMY", 134, 145], ["leukocytes", "ANATOMY", 162, 172], ["atherosclerosis", "DISEASE", 205, 220], ["endothelial monolayer", "CELL", 44, 65], ["cellular", "CELL", 90, 98], ["endothelium", "TISSUE", 134, 145], ["leukocytes", "CELL", 162, 172], ["leukocytes", "CELL_TYPE", 162, 172], ["An increase in substrate stiffness", "PROBLEM", 0, 34], ["endothelial monolayer disruption", "PROBLEM", 44, 76], ["increased cellular traction stresses", "PROBLEM", 80, 116], ["increased endothelium permeability", "PROBLEM", 124, 158], ["leukocytes", "PROBLEM", 162, 172], ["atherosclerosis", "PROBLEM", 205, 220], ["increase", "OBSERVATION_MODIFIER", 3, 11], ["substrate stiffness", "OBSERVATION", 15, 34], ["endothelial", "ANATOMY", 44, 55], ["monolayer disruption", "OBSERVATION", 56, 76], ["increased", "OBSERVATION_MODIFIER", 80, 89], ["cellular traction stresses", "OBSERVATION", 90, 116], ["increased", "OBSERVATION_MODIFIER", 124, 133], ["endothelium", "OBSERVATION", 134, 145], ["permeability", "OBSERVATION_MODIFIER", 146, 158], ["leukocytes", "OBSERVATION_MODIFIER", 162, 172], ["atherosclerosis", "OBSERVATION", 205, 220]]], ["It has been suggested that simvastatin can reduce matrix stiffness due to the decrease in RhoA activity in regulating contractility of the actin cytoskeleton and decrease in cellular traction forces.", [["matrix", "ANATOMY", 50, 56], ["cytoskeleton", "ANATOMY", 145, 157], ["cellular", "ANATOMY", 174, 182], ["simvastatin", "CHEMICAL", 27, 38], ["simvastatin", "CHEMICAL", 27, 38], ["simvastatin", "SIMPLE_CHEMICAL", 27, 38], ["matrix", "CELLULAR_COMPONENT", 50, 56], ["RhoA", "GENE_OR_GENE_PRODUCT", 90, 94], ["actin", "GENE_OR_GENE_PRODUCT", 139, 144], ["cytoskeleton", "CELLULAR_COMPONENT", 145, 157], ["cellular", "CELL", 174, 182], ["RhoA", "PROTEIN", 90, 94], ["actin", "PROTEIN", 139, 144], ["simvastatin", "TREATMENT", 27, 38], ["matrix stiffness", "PROBLEM", 50, 66], ["the decrease in RhoA activity", "PROBLEM", 74, 103], ["decrease in cellular traction forces", "PROBLEM", 162, 198], ["decrease", "OBSERVATION_MODIFIER", 78, 86], ["RhoA activity", "OBSERVATION", 90, 103], ["contractility", "OBSERVATION_MODIFIER", 118, 131], ["actin cytoskeleton", "OBSERVATION", 139, 157], ["decrease", "OBSERVATION_MODIFIER", 162, 170], ["cellular traction forces", "OBSERVATION", 174, 198]]], ["Simvastatin treatment resulted in improved endothelial barrier integrity and decreased endothelium permeability by decreasing cell-cell junction size in endothelial monolayers.", [["endothelial barrier", "ANATOMY", 43, 62], ["endothelium", "ANATOMY", 87, 98], ["cell-cell junction", "ANATOMY", 126, 144], ["endothelial monolayers", "ANATOMY", 153, 175], ["Simvastatin", "CHEMICAL", 0, 11], ["Simvastatin", "CHEMICAL", 0, 11], ["Simvastatin", "SIMPLE_CHEMICAL", 0, 11], ["endothelial barrier", "TISSUE", 43, 62], ["endothelium", "TISSUE", 87, 98], ["cell", "CELL", 126, 130], ["cell junction", "CELLULAR_COMPONENT", 131, 144], ["endothelial monolayers", "CELL", 153, 175], ["endothelial monolayers", "CELL_TYPE", 153, 175], ["Simvastatin treatment", "TREATMENT", 0, 21], ["improved endothelial barrier integrity", "TREATMENT", 34, 72], ["decreased endothelium permeability", "PROBLEM", 77, 111], ["improved endothelial", "OBSERVATION", 34, 54], ["barrier integrity", "OBSERVATION", 55, 72], ["decreased endothelium", "OBSERVATION", 77, 98], ["permeability", "OBSERVATION_MODIFIER", 99, 111], ["decreasing", "OBSERVATION_MODIFIER", 115, 125], ["cell", "OBSERVATION", 126, 130], ["cell junction", "OBSERVATION", 131, 144], ["size", "OBSERVATION_MODIFIER", 145, 149], ["endothelial monolayers", "OBSERVATION", 153, 175]]], ["It has been suggested that statins are able to maintain endothelial barrier integrity and prevent the development of atherosclerosis as a result of leukocyte penetration through endothelial monolayer damaged by tissue stiffness [56] .", [["endothelial barrier", "ANATOMY", 56, 75], ["leukocyte", "ANATOMY", 148, 157], ["endothelial monolayer", "ANATOMY", 178, 199], ["tissue", "ANATOMY", 211, 217], ["statins", "CHEMICAL", 27, 34], ["atherosclerosis", "DISEASE", 117, 132], ["statins", "CHEMICAL", 27, 34], ["statins", "SIMPLE_CHEMICAL", 27, 34], ["endothelial barrier", "TISSUE", 56, 75], ["leukocyte", "CELL", 148, 157], ["endothelial monolayer", "CELL", 178, 199], ["tissue", "TISSUE", 211, 217], ["statins", "TREATMENT", 27, 34], ["endothelial barrier integrity", "TREATMENT", 56, 85], ["atherosclerosis", "PROBLEM", 117, 132], ["leukocyte penetration", "PROBLEM", 148, 169], ["atherosclerosis", "OBSERVATION", 117, 132], ["leukocyte penetration", "OBSERVATION", 148, 169]]], ["Similarly, it is possible that coronavirus penetration in novel COVID-19 disease can be increased for older patients due to increased age-related tissue stiffness.", [["tissue", "ANATOMY", 146, 152], ["coronavirus", "ORGANISM", 31, 42], ["patients", "ORGANISM", 108, 116], ["tissue", "TISSUE", 146, 152], ["patients", "SPECIES", 108, 116], ["coronavirus penetration", "PROBLEM", 31, 54], ["novel COVID-19 disease", "PROBLEM", 58, 80], ["increased age", "PROBLEM", 124, 137], ["related tissue stiffness", "PROBLEM", 138, 162], ["is possible", "UNCERTAINTY", 14, 25], ["coronavirus penetration", "OBSERVATION", 31, 54], ["related tissue", "OBSERVATION_MODIFIER", 138, 152], ["stiffness", "OBSERVATION", 153, 162]]], ["It was already reported that statins may decrease the fatality rate of MERS infection [57] and may be used in the treatment of COVID-19 [58] .", [["statins", "CHEMICAL", 29, 36], ["infection", "DISEASE", 76, 85], ["statins", "CHEMICAL", 29, 36], ["COVID-19", "CHEMICAL", 127, 135], ["statins", "SIMPLE_CHEMICAL", 29, 36], ["statins", "TREATMENT", 29, 36], ["MERS infection", "PROBLEM", 71, 85], ["COVID", "TEST", 127, 132]]], ["The activities of various statins-simvastatin, atorvastatin, rusovastatin, simvastatin, lovastatin, mevastatin-and the possibility to use statins in treatment of COVID-19 was recently suggested [59] .DrugsPolymers 2020, 12, x FOR PEER REVIEW 4 of 15 cell line PC-3 by omega-3 polyunsaturated fatty acids [51] .", [["cell line", "ANATOMY", 250, 259], ["statins", "CHEMICAL", 26, 33], ["simvastatin", "CHEMICAL", 34, 45], ["atorvastatin", "CHEMICAL", 47, 59], ["rusovastatin", "CHEMICAL", 61, 73], ["simvastatin", "CHEMICAL", 75, 86], ["lovastatin", "CHEMICAL", 88, 98], ["mevastatin", "CHEMICAL", 100, 110], ["statins", "CHEMICAL", 138, 145], ["COVID-19", "CHEMICAL", 162, 170], ["omega-3 polyunsaturated fatty acids", "CHEMICAL", 268, 303], ["statins", "CHEMICAL", 26, 33], ["simvastatin", "CHEMICAL", 34, 45], ["atorvastatin", "CHEMICAL", 47, 59], ["rusovastatin", "CHEMICAL", 61, 73], ["simvastatin", "CHEMICAL", 75, 86], ["lovastatin", "CHEMICAL", 88, 98], ["mevastatin", "CHEMICAL", 100, 110], ["statins", "CHEMICAL", 138, 145], ["COVID-19", "CHEMICAL", 162, 170], ["omega-3 polyunsaturated fatty acids", "CHEMICAL", 268, 303], ["statins", "SIMPLE_CHEMICAL", 26, 33], ["simvastatin", "SIMPLE_CHEMICAL", 34, 45], ["atorvastatin", "SIMPLE_CHEMICAL", 47, 59], ["rusovastatin", "SIMPLE_CHEMICAL", 61, 73], ["simvastatin", "SIMPLE_CHEMICAL", 75, 86], ["lovastatin", "SIMPLE_CHEMICAL", 88, 98], ["mevastatin", "SIMPLE_CHEMICAL", 100, 110], ["cell line PC-3", "CELL", 250, 264], ["omega-3 polyunsaturated fatty acids", "SIMPLE_CHEMICAL", 268, 303], ["various statins", "TREATMENT", 18, 33], ["simvastatin", "TREATMENT", 34, 45], ["atorvastatin", "TREATMENT", 47, 59], ["rusovastatin", "TREATMENT", 61, 73], ["simvastatin", "TREATMENT", 75, 86], ["lovastatin", "TREATMENT", 88, 98], ["mevastatin", "TREATMENT", 100, 110], ["statins", "TREATMENT", 138, 145], ["COVID", "TEST", 162, 167], ["cell line PC", "TEST", 250, 262], ["polyunsaturated fatty acids", "TEST", 276, 303]]], ["It was also recently suggested that arachidonic acid, eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA) are able to inactivate enveloped viruses and increase resistance and recovery from SARS-CoV-2, SARS, and Middle East respiratory syndrome (MERS) infections [52] .", [["arachidonic acid", "CHEMICAL", 36, 52], ["eicosapentaenoic acid", "CHEMICAL", 54, 75], ["EPA", "CHEMICAL", 77, 80], ["docosahexaenoic acid", "CHEMICAL", 87, 107], ["DHA", "CHEMICAL", 109, 112], ["SARS", "DISEASE", 197, 201], ["SARS", "DISEASE", 209, 213], ["Middle East respiratory syndrome (MERS) infections", "DISEASE", 219, 269], ["arachidonic acid", "CHEMICAL", 36, 52], ["eicosapentaenoic acid", "CHEMICAL", 54, 75], ["EPA", "CHEMICAL", 77, 80], ["docosahexaenoic acid", "CHEMICAL", 87, 107], ["DHA", "CHEMICAL", 109, 112], ["arachidonic acid", "SIMPLE_CHEMICAL", 36, 52], ["eicosapentaenoic acid", "SIMPLE_CHEMICAL", 54, 75], ["EPA", "SIMPLE_CHEMICAL", 77, 80], ["docosahexaenoic acid", "SIMPLE_CHEMICAL", 87, 107], ["DHA", "SIMPLE_CHEMICAL", 109, 112], ["SARS-CoV-2", "ORGANISM", 197, 207], ["Middle East respiratory", "ORGANISM", 219, 242], ["SARS-CoV", "SPECIES", 197, 205], ["Middle East respiratory syndrome (MERS)", "SPECIES", 219, 258], ["arachidonic acid", "TREATMENT", 36, 52], ["eicosapentaenoic acid (EPA)", "TREATMENT", 54, 81], ["docosahexaenoic acid (DHA)", "TREATMENT", 87, 113], ["enveloped viruses", "PROBLEM", 137, 154], ["increase resistance", "PROBLEM", 159, 178], ["SARS", "PROBLEM", 197, 201], ["CoV", "TEST", 202, 205], ["SARS", "PROBLEM", 209, 213], ["Middle East respiratory syndrome (MERS) infections", "PROBLEM", 219, 269], ["viruses", "OBSERVATION", 147, 154], ["Middle", "ANATOMY_MODIFIER", 219, 225], ["respiratory syndrome", "OBSERVATION", 231, 251]]], ["Very low blood levels of the sum of eicosapentaenoic acid and docosahexaenoic acid were observed in USA, Italy, UK, and Brazil [53] .", [["blood", "ANATOMY", 9, 14], ["eicosapentaenoic acid", "CHEMICAL", 36, 57], ["docosahexaenoic acid", "CHEMICAL", 62, 82], ["eicosapentaenoic acid", "CHEMICAL", 36, 57], ["docosahexaenoic acid", "CHEMICAL", 62, 82], ["blood", "ORGANISM_SUBSTANCE", 9, 14], ["eicosapentaenoic acid", "SIMPLE_CHEMICAL", 36, 57], ["docosahexaenoic acid", "SIMPLE_CHEMICAL", 62, 82], ["Very low blood levels", "PROBLEM", 0, 21], ["eicosapentaenoic acid", "TREATMENT", 36, 57], ["docosahexaenoic acid", "TREATMENT", 62, 82], ["low", "OBSERVATION", 5, 8]]], ["A high number of COVID-19 patients were reported in these countries.DrugsArterial wall stiffness is related to cardiovascular diseases [54] .", [["wall", "ANATOMY", 82, 86], ["cardiovascular", "ANATOMY", 111, 125], ["cardiovascular diseases", "DISEASE", 111, 134], ["patients", "ORGANISM", 26, 34], ["DrugsArterial wall", "TISSUE", 68, 86], ["patients", "SPECIES", 26, 34], ["COVID", "TEST", 17, 22], ["DrugsArterial wall stiffness", "PROBLEM", 68, 96], ["cardiovascular diseases", "PROBLEM", 111, 134], ["high", "OBSERVATION_MODIFIER", 2, 6], ["number", "OBSERVATION_MODIFIER", 7, 13], ["wall", "ANATOMY_MODIFIER", 82, 86], ["stiffness", "OBSERVATION", 87, 96], ["cardiovascular diseases", "OBSERVATION", 111, 134]]], ["For example, platelet adhesion and thrombus formation depend on arterial wall stiffness and hydration [7, 55] , Figure 1 .", [["platelet", "ANATOMY", 13, 21], ["thrombus", "ANATOMY", 35, 43], ["arterial wall", "ANATOMY", 64, 77], ["thrombus", "DISEASE", 35, 43], ["platelet", "CELL", 13, 21], ["thrombus", "PATHOLOGICAL_FORMATION", 35, 43], ["arterial wall", "MULTI-TISSUE_STRUCTURE", 64, 77], ["platelet adhesion", "PROBLEM", 13, 30], ["thrombus formation", "PROBLEM", 35, 53], ["arterial wall stiffness", "PROBLEM", 64, 87], ["hydration", "TEST", 92, 101], ["platelet adhesion", "OBSERVATION", 13, 30], ["thrombus", "OBSERVATION", 35, 43], ["arterial", "ANATOMY_MODIFIER", 64, 72], ["wall", "ANATOMY_MODIFIER", 73, 77], ["stiffness", "OBSERVATION_MODIFIER", 78, 87]]], ["An increase in substrate stiffness leads to endothelial monolayer disruption by increased cellular traction stresses and to increased endothelium permeability by leukocytes resulting in the development of atherosclerosis.", [["endothelial monolayer", "ANATOMY", 44, 65], ["cellular", "ANATOMY", 90, 98], ["endothelium", "ANATOMY", 134, 145], ["leukocytes", "ANATOMY", 162, 172], ["atherosclerosis", "DISEASE", 205, 220], ["endothelial monolayer", "CELL", 44, 65], ["cellular", "CELL", 90, 98], ["endothelium", "TISSUE", 134, 145], ["leukocytes", "CELL", 162, 172], ["leukocytes", "CELL_TYPE", 162, 172], ["An increase in substrate stiffness", "PROBLEM", 0, 34], ["endothelial monolayer disruption", "PROBLEM", 44, 76], ["increased cellular traction stresses", "PROBLEM", 80, 116], ["increased endothelium permeability", "PROBLEM", 124, 158], ["leukocytes", "PROBLEM", 162, 172], ["atherosclerosis", "PROBLEM", 205, 220], ["increase", "OBSERVATION_MODIFIER", 3, 11], ["substrate stiffness", "OBSERVATION", 15, 34], ["endothelial", "ANATOMY", 44, 55], ["monolayer disruption", "OBSERVATION", 56, 76], ["increased", "OBSERVATION_MODIFIER", 80, 89], ["cellular traction stresses", "OBSERVATION", 90, 116], ["increased", "OBSERVATION_MODIFIER", 124, 133], ["endothelium", "OBSERVATION", 134, 145], ["permeability", "OBSERVATION_MODIFIER", 146, 158], ["leukocytes", "OBSERVATION_MODIFIER", 162, 172], ["atherosclerosis", "OBSERVATION", 205, 220]]], ["It has been suggested that simvastatin can reduce matrix stiffness due to the decrease in RhoA activity in regulating contractility of the actin cytoskeleton and decrease in cellular traction forces.", [["matrix", "ANATOMY", 50, 56], ["cytoskeleton", "ANATOMY", 145, 157], ["cellular", "ANATOMY", 174, 182], ["simvastatin", "CHEMICAL", 27, 38], ["simvastatin", "CHEMICAL", 27, 38], ["simvastatin", "SIMPLE_CHEMICAL", 27, 38], ["matrix", "CELLULAR_COMPONENT", 50, 56], ["RhoA", "GENE_OR_GENE_PRODUCT", 90, 94], ["actin", "GENE_OR_GENE_PRODUCT", 139, 144], ["cytoskeleton", "CELLULAR_COMPONENT", 145, 157], ["cellular", "CELL", 174, 182], ["RhoA", "PROTEIN", 90, 94], ["actin", "PROTEIN", 139, 144], ["simvastatin", "TREATMENT", 27, 38], ["matrix stiffness", "PROBLEM", 50, 66], ["the decrease in RhoA activity", "PROBLEM", 74, 103], ["decrease in cellular traction forces", "PROBLEM", 162, 198], ["decrease", "OBSERVATION_MODIFIER", 78, 86], ["RhoA activity", "OBSERVATION", 90, 103], ["contractility", "OBSERVATION_MODIFIER", 118, 131], ["actin cytoskeleton", "OBSERVATION", 139, 157], ["decrease", "OBSERVATION_MODIFIER", 162, 170], ["cellular traction forces", "OBSERVATION", 174, 198]]], ["Simvastatin treatment resulted in improved endothelial barrier integrity and decreased endothelium permeability by decreasing cell-cell junction size in endothelial monolayers.", [["endothelial barrier", "ANATOMY", 43, 62], ["endothelium", "ANATOMY", 87, 98], ["cell-cell junction", "ANATOMY", 126, 144], ["endothelial monolayers", "ANATOMY", 153, 175], ["Simvastatin", "CHEMICAL", 0, 11], ["Simvastatin", "CHEMICAL", 0, 11], ["Simvastatin", "SIMPLE_CHEMICAL", 0, 11], ["endothelial barrier", "TISSUE", 43, 62], ["endothelium", "TISSUE", 87, 98], ["cell", "CELL", 126, 130], ["cell junction", "CELLULAR_COMPONENT", 131, 144], ["endothelial monolayers", "CELL", 153, 175], ["endothelial monolayers", "CELL_TYPE", 153, 175], ["Simvastatin treatment", "TREATMENT", 0, 21], ["improved endothelial barrier integrity", "TREATMENT", 34, 72], ["decreased endothelium permeability", "PROBLEM", 77, 111], ["improved endothelial", "OBSERVATION", 34, 54], ["barrier integrity", "OBSERVATION", 55, 72], ["decreased endothelium", "OBSERVATION", 77, 98], ["permeability", "OBSERVATION_MODIFIER", 99, 111], ["decreasing", "OBSERVATION_MODIFIER", 115, 125], ["cell", "OBSERVATION", 126, 130], ["cell junction", "OBSERVATION", 131, 144], ["size", "OBSERVATION_MODIFIER", 145, 149], ["endothelial monolayers", "OBSERVATION", 153, 175]]], ["It has been suggested that statins are able to maintain endothelial barrier integrity and prevent the development of atherosclerosis as a result of leukocyte penetration through endothelial monolayer damaged by tissue stiffness [56] .", [["endothelial barrier", "ANATOMY", 56, 75], ["leukocyte", "ANATOMY", 148, 157], ["endothelial monolayer", "ANATOMY", 178, 199], ["tissue", "ANATOMY", 211, 217], ["statins", "CHEMICAL", 27, 34], ["atherosclerosis", "DISEASE", 117, 132], ["statins", "CHEMICAL", 27, 34], ["statins", "SIMPLE_CHEMICAL", 27, 34], ["endothelial barrier", "TISSUE", 56, 75], ["leukocyte", "CELL", 148, 157], ["endothelial monolayer", "CELL", 178, 199], ["tissue", "TISSUE", 211, 217], ["statins", "TREATMENT", 27, 34], ["endothelial barrier integrity", "TREATMENT", 56, 85], ["atherosclerosis", "PROBLEM", 117, 132], ["leukocyte penetration", "PROBLEM", 148, 169], ["atherosclerosis", "OBSERVATION", 117, 132], ["leukocyte penetration", "OBSERVATION", 148, 169]]], ["Similarly, it is possible that coronavirus penetration in novel COVID-19 disease can be increased for older patients due to increased age-related tissue stiffness.", [["tissue", "ANATOMY", 146, 152], ["coronavirus", "ORGANISM", 31, 42], ["patients", "ORGANISM", 108, 116], ["tissue", "TISSUE", 146, 152], ["patients", "SPECIES", 108, 116], ["coronavirus penetration", "PROBLEM", 31, 54], ["novel COVID-19 disease", "PROBLEM", 58, 80], ["increased age", "PROBLEM", 124, 137], ["related tissue stiffness", "PROBLEM", 138, 162], ["is possible", "UNCERTAINTY", 14, 25], ["coronavirus penetration", "OBSERVATION", 31, 54], ["related tissue", "OBSERVATION_MODIFIER", 138, 152], ["stiffness", "OBSERVATION", 153, 162]]], ["It was already reported that statins may decrease the fatality rate of MERS infection [57] and may be used in the treatment of COVID-19 [58] .", [["statins", "CHEMICAL", 29, 36], ["infection", "DISEASE", 76, 85], ["statins", "CHEMICAL", 29, 36], ["COVID-19", "CHEMICAL", 127, 135], ["statins", "SIMPLE_CHEMICAL", 29, 36], ["statins", "TREATMENT", 29, 36], ["MERS infection", "PROBLEM", 71, 85], ["COVID", "TEST", 127, 132]]], ["The activities of various statins-simvastatin, atorvastatin, rusovastatin, simvastatin, lovastatin, mevastatin-and the possibility to use statins in treatment of COVID-19 was recently suggested [59] .", [["statins", "CHEMICAL", 26, 33], ["simvastatin", "CHEMICAL", 34, 45], ["atorvastatin", "CHEMICAL", 47, 59], ["rusovastatin", "CHEMICAL", 61, 73], ["simvastatin", "CHEMICAL", 75, 86], ["lovastatin", "CHEMICAL", 88, 98], ["mevastatin", "CHEMICAL", 100, 110], ["statins", "CHEMICAL", 138, 145], ["COVID-19", "CHEMICAL", 162, 170], ["statins", "CHEMICAL", 26, 33], ["simvastatin", "CHEMICAL", 34, 45], ["atorvastatin", "CHEMICAL", 47, 59], ["rusovastatin", "CHEMICAL", 61, 73], ["simvastatin", "CHEMICAL", 75, 86], ["lovastatin", "CHEMICAL", 88, 98], ["mevastatin", "CHEMICAL", 100, 110], ["statins", "CHEMICAL", 138, 145], ["COVID-19", "CHEMICAL", 162, 170], ["statins", "SIMPLE_CHEMICAL", 26, 33], ["simvastatin", "SIMPLE_CHEMICAL", 34, 45], ["atorvastatin", "SIMPLE_CHEMICAL", 47, 59], ["rusovastatin", "SIMPLE_CHEMICAL", 61, 73], ["simvastatin", "SIMPLE_CHEMICAL", 75, 86], ["lovastatin", "SIMPLE_CHEMICAL", 88, 98], ["mevastatin", "SIMPLE_CHEMICAL", 100, 110], ["various statins", "TREATMENT", 18, 33], ["simvastatin", "TREATMENT", 34, 45], ["atorvastatin", "TREATMENT", 47, 59], ["rusovastatin", "TREATMENT", 61, 73], ["simvastatin", "TREATMENT", 75, 86], ["lovastatin", "TREATMENT", 88, 98], ["mevastatin", "TREATMENT", 100, 110], ["statins", "TREATMENT", 138, 145], ["COVID", "TEST", 162, 167]]], ["Antihypertensive drugs, such as angiotensin-converting enzyme inhibitors, have been suggested to decrease arterial stiffness [60, 61] .", [["Antihypertensive", "ANATOMY", 0, 16], ["arterial", "ANATOMY", 106, 114], ["angiotensin", "CHEMICAL", 32, 43], ["arterial stiffness", "DISEASE", 106, 124], ["angiotensin-converting enzyme", "GENE_OR_GENE_PRODUCT", 32, 61], ["arterial", "MULTI-TISSUE_STRUCTURE", 106, 114], ["Antihypertensive drugs", "TREATMENT", 0, 22], ["angiotensin", "TREATMENT", 32, 43], ["converting enzyme inhibitors", "TREATMENT", 44, 72], ["arterial stiffness", "TEST", 106, 124]]], ["The possibility of using angiotensin-converting enzyme inhibitors in COVID-19 treatment must be investigated in more detail.", [["angiotensin", "CHEMICAL", 25, 36], ["COVID-19", "CHEMICAL", 69, 77], ["COVID-19", "CHEMICAL", 69, 77], ["angiotensin-converting enzyme", "GENE_OR_GENE_PRODUCT", 25, 54], ["COVID-19", "SIMPLE_CHEMICAL", 69, 77], ["angiotensin-converting enzyme inhibitors", "TREATMENT", 25, 65], ["COVID-19 treatment", "TREATMENT", 69, 87]]], ["Antihypertensive drugs, such as angiotensin-converting enzyme inhibitors, have been suggested to decrease arterial stiffness [60, 61] .", [["Antihypertensive", "ANATOMY", 0, 16], ["arterial", "ANATOMY", 106, 114], ["angiotensin", "CHEMICAL", 32, 43], ["arterial stiffness", "DISEASE", 106, 124], ["angiotensin-converting enzyme", "GENE_OR_GENE_PRODUCT", 32, 61], ["arterial", "MULTI-TISSUE_STRUCTURE", 106, 114], ["Antihypertensive drugs", "TREATMENT", 0, 22], ["angiotensin", "TREATMENT", 32, 43], ["converting enzyme inhibitors", "TREATMENT", 44, 72], ["arterial stiffness", "TEST", 106, 124]]], ["The possibility of using angiotensin-converting enzyme inhibitors in COVID-19 treatment must be investigated in more detail.Chitosan and Its DerivativesIt can be expected that AGE content will increase in the presence of high-molecular-weight chitosan [62] .", [["angiotensin", "CHEMICAL", 25, 36], ["COVID-19", "CHEMICAL", 69, 77], ["Chitosan", "CHEMICAL", 124, 132], ["AGE", "CHEMICAL", 176, 179], ["chitosan", "CHEMICAL", 243, 251], ["COVID-19", "CHEMICAL", 69, 77], ["angiotensin-converting enzyme", "GENE_OR_GENE_PRODUCT", 25, 54], ["COVID-19", "SIMPLE_CHEMICAL", 69, 77], ["Chitosan", "SIMPLE_CHEMICAL", 124, 132], ["Its Derivatives", "SIMPLE_CHEMICAL", 137, 152], ["AGE", "SIMPLE_CHEMICAL", 176, 179], ["angiotensin-converting enzyme inhibitors", "TREATMENT", 25, 65], ["COVID-19 treatment", "TREATMENT", 69, 87], ["Chitosan", "TREATMENT", 124, 132], ["Its Derivatives", "TREATMENT", 137, 152], ["AGE content", "PROBLEM", 176, 187]]], ["However, chitosan oligosaccharides demonstrated angiotensin-converting enzyme inhibition activity [63] .", [["chitosan oligosaccharides", "CHEMICAL", 9, 34], ["angiotensin", "CHEMICAL", 48, 59], ["chitosan oligosaccharides", "SIMPLE_CHEMICAL", 9, 34], ["angiotensin-converting enzyme", "GENE_OR_GENE_PRODUCT", 48, 77], ["angiotensin-converting enzyme", "PROTEIN", 48, 77], ["chitosan oligosaccharides", "TEST", 9, 34], ["angiotensin", "TEST", 48, 59]]], ["It has also been reported that substitution of the hydrogen atom at the C-6 position of pyranose residue by the aminoethyl group promotes angiotensin-converting enzyme inhibitory effects of chitooligosaccharides [64] .", [["hydrogen", "CHEMICAL", 51, 59], ["C-6", "CHEMICAL", 72, 75], ["pyranose", "CHEMICAL", 88, 96], ["aminoethyl", "CHEMICAL", 112, 122], ["angiotensin", "CHEMICAL", 138, 149], ["chitooligosaccharides", "CHEMICAL", 190, 211], ["hydrogen", "CHEMICAL", 51, 59], ["pyranose", "CHEMICAL", 88, 96], ["aminoethyl", "CHEMICAL", 112, 122], ["chitooligosaccharides", "CHEMICAL", 190, 211], ["hydrogen atom", "SIMPLE_CHEMICAL", 51, 64], ["pyranose", "SIMPLE_CHEMICAL", 88, 96], ["aminoethyl", "SIMPLE_CHEMICAL", 112, 122], ["angiotensin-converting enzyme", "GENE_OR_GENE_PRODUCT", 138, 167], ["chitooligosaccharides", "SIMPLE_CHEMICAL", 190, 211], ["C-6 position", "PROTEIN", 72, 84], ["angiotensin-converting enzyme", "PROTEIN", 138, 167], ["the hydrogen atom", "PROBLEM", 47, 64], ["pyranose residue", "PROBLEM", 88, 104], ["the aminoethyl group promotes angiotensin", "TREATMENT", 108, 149], ["converting enzyme inhibitory effects of chitooligosaccharides", "TREATMENT", 150, 211], ["pyranose residue", "OBSERVATION", 88, 104]]], ["It is known that angiotensin-converting enzyme inhibition dilates the blood vessels and decreases high blood pressure.", [["blood vessels", "ANATOMY", 70, 83], ["blood", "ANATOMY", 103, 108], ["angiotensin", "CHEMICAL", 17, 28], ["angiotensin-converting enzyme", "GENE_OR_GENE_PRODUCT", 17, 46], ["blood vessels", "MULTI-TISSUE_STRUCTURE", 70, 83], ["blood", "ORGANISM_SUBSTANCE", 103, 108], ["angiotensin-converting enzyme", "PROTEIN", 17, 46], ["angiotensin-converting enzyme inhibition", "TREATMENT", 17, 57], ["the blood vessels", "PROBLEM", 66, 83], ["high blood pressure", "PROBLEM", 98, 117], ["angiotensin", "OBSERVATION", 17, 28], ["blood vessels", "ANATOMY", 70, 83], ["decreases", "OBSERVATION_MODIFIER", 88, 97], ["high blood pressure", "OBSERVATION", 98, 117]]], ["Angiotensin-converting enzyme inhibitors can also be used to decrease arterial stiffness.", [["arterial", "ANATOMY", 70, 78], ["Angiotensin", "CHEMICAL", 0, 11], ["arterial stiffness", "DISEASE", 70, 88], ["Angiotensin-converting enzyme", "GENE_OR_GENE_PRODUCT", 0, 29], ["arterial", "MULTI-TISSUE_STRUCTURE", 70, 78], ["Angiotensin", "TREATMENT", 0, 11], ["converting enzyme inhibitors", "TREATMENT", 12, 40], ["arterial stiffness", "PROBLEM", 70, 88], ["arterial", "ANATOMY", 70, 78], ["stiffness", "OBSERVATION", 79, 88]]], ["Aminoethyl-chitooligosaccharide also suppresses proliferation of human lung A549 cancer cells [65] .", [["lung A549 cancer cells", "ANATOMY", 71, 93], ["Aminoethyl-chitooligosaccharide", "CHEMICAL", 0, 31], ["cancer", "DISEASE", 81, 87], ["Aminoethyl-chitooligosaccharide", "CHEMICAL", 0, 31], ["Aminoethyl-chitooligosaccharide", "SIMPLE_CHEMICAL", 0, 31], ["human", "ORGANISM", 65, 70], ["lung A549 cancer cells", "CELL", 71, 93], ["human lung A549 cancer cells", "CELL_LINE", 65, 93], ["human", "SPECIES", 65, 70], ["human", "SPECIES", 65, 70], ["Aminoethyl", "TREATMENT", 0, 10], ["chitooligosaccharide", "TREATMENT", 11, 31], ["human lung A549 cancer cells", "PROBLEM", 65, 93], ["lung", "ANATOMY", 71, 75], ["A549 cancer", "OBSERVATION", 76, 87]]], ["Chitosan oligosaccharides suppress pathogenic microorganisms' adhesion to cells and in such a way can be considered inhibitors of initial stages of infection processes [66] .", [["cells", "ANATOMY", 74, 79], ["Chitosan", "CHEMICAL", 0, 8], ["infection", "DISEASE", 148, 157], ["Chitosan oligosaccharides", "SIMPLE_CHEMICAL", 0, 25], ["cells", "CELL", 74, 79], ["Chitosan oligosaccharides", "TREATMENT", 0, 25], ["pathogenic microorganisms' adhesion to cells", "PROBLEM", 35, 79], ["infection processes", "PROBLEM", 148, 167], ["infection", "OBSERVATION", 148, 157]]], ["Chitosan oligosaccharides are also able to penetrate inside pathogenic organisms and prevent their reproduction.Chitosan and Its DerivativesN-(2-hydroxypropyl)-3-trimethylammonium chitosan chloride (HTCC) was proposed as an inhibitor of human coronavirus HCoV-NL63.", [["Chitosan", "CHEMICAL", 0, 8], ["Chitosan", "CHEMICAL", 112, 120], ["DerivativesN-(2-hydroxypropyl)-3-trimethylammonium chitosan chloride", "CHEMICAL", 129, 197], ["HTCC", "CHEMICAL", 199, 203], ["DerivativesN-(2-hydroxypropyl)-3-trimethylammonium chitosan chloride", "CHEMICAL", 129, 197], ["HTCC", "CHEMICAL", 199, 203], ["Chitosan oligosaccharides", "SIMPLE_CHEMICAL", 0, 25], ["Chitosan", "SIMPLE_CHEMICAL", 112, 120], ["Its DerivativesN-(2-hydroxypropyl)-3-trimethylammonium chitosan chloride", "SIMPLE_CHEMICAL", 125, 197], ["HTCC", "SIMPLE_CHEMICAL", 199, 203], ["human", "ORGANISM", 237, 242], ["coronavirus HCoV-NL63", "ORGANISM", 243, 264], ["human", "SPECIES", 237, 242], ["coronavirus", "SPECIES", 243, 254], ["human coronavirus HCoV-NL63", "SPECIES", 237, 264], ["Chitosan oligosaccharides", "TREATMENT", 0, 25], ["Chitosan", "TREATMENT", 112, 120], ["Its DerivativesN", "TREATMENT", 125, 141], ["hydroxypropyl)", "TREATMENT", 145, 159], ["3-trimethylammonium chitosan chloride (HTCC)", "TREATMENT", 160, 204], ["human coronavirus HCoV", "TREATMENT", 237, 259]]], ["It was suggested that HTCC blocks human coronavirus interaction with the cellular receptor, angiotensin-converting enzyme type 2 (ACE2) proteins [67] .VitaminsAssociation between vitamin D deficiency and arterial stiffness determined from pulse wave velocity measurements was reported in a number of publications.", [["cellular", "ANATOMY", 73, 81], ["arterial", "ANATOMY", 204, 212], ["HTCC", "CHEMICAL", 22, 26], ["angiotensin", "CHEMICAL", 92, 103], ["vitamin D", "CHEMICAL", 179, 188], ["arterial stiffness", "DISEASE", 204, 222], ["vitamin D", "CHEMICAL", 179, 188], ["HTCC", "SIMPLE_CHEMICAL", 22, 26], ["human", "ORGANISM", 34, 39], ["coronavirus", "ORGANISM", 40, 51], ["cellular", "CELL", 73, 81], ["angiotensin-converting enzyme type 2", "GENE_OR_GENE_PRODUCT", 92, 128], ["ACE2", "GENE_OR_GENE_PRODUCT", 130, 134], ["vitamin D", "SIMPLE_CHEMICAL", 179, 188], ["arterial", "MULTI-TISSUE_STRUCTURE", 204, 212], ["cellular receptor", "PROTEIN", 73, 90], ["angiotensin-converting enzyme type 2 (ACE2) proteins", "PROTEIN", 92, 144], ["human", "SPECIES", 34, 39], ["human coronavirus", "SPECIES", 34, 51], ["HTCC blocks human coronavirus interaction", "PROBLEM", 22, 63], ["the cellular receptor", "TEST", 69, 90], ["angiotensin", "TEST", 92, 103], ["VitaminsAssociation", "TREATMENT", 151, 170], ["vitamin D deficiency", "PROBLEM", 179, 199], ["arterial stiffness", "PROBLEM", 204, 222], ["pulse wave velocity measurements", "TEST", 239, 271], ["arterial", "ANATOMY", 204, 212], ["stiffness", "OBSERVATION", 213, 222]]], ["Vitamin D deficiency was associated with the increase in arterial stiffness in children with type 1 and type 2 diabetes and with chronical kidney disease as well as in the elderly population [68] [69] [70] [71] [72] [73] [74] [75] .VitaminsGenerally, the results from randomized controlled trials have been inconsistent and more large population studies should be conducted.", [["arterial", "ANATOMY", 57, 65], ["kidney", "ANATOMY", 139, 145], ["Vitamin D", "CHEMICAL", 0, 9], ["increase in arterial stiffness", "DISEASE", 45, 75], ["type 1 and type 2 diabetes", "DISEASE", 93, 119], ["chronical kidney disease", "DISEASE", 129, 153], ["Vitamin D", "CHEMICAL", 0, 9], ["[68] [69] [70] [71] [72] [73] [74]", "CHEMICAL", 191, 225], ["Vitamins", "CHEMICAL", 232, 240], ["Vitamin D", "SIMPLE_CHEMICAL", 0, 9], ["arterial", "MULTI-TISSUE_STRUCTURE", 57, 65], ["children", "ORGANISM", 79, 87], ["kidney", "ORGAN", 139, 145], ["Vitamins", "SIMPLE_CHEMICAL", 232, 240], ["children", "SPECIES", 79, 87], ["Vitamin D deficiency", "PROBLEM", 0, 20], ["arterial stiffness", "PROBLEM", 57, 75], ["type 1 and type 2 diabetes", "PROBLEM", 93, 119], ["chronical kidney disease", "PROBLEM", 129, 153], ["Vitamins", "TREATMENT", 232, 240], ["randomized controlled trials", "TREATMENT", 268, 296], ["deficiency", "OBSERVATION", 10, 20], ["increase", "OBSERVATION_MODIFIER", 45, 53], ["arterial", "ANATOMY", 57, 65], ["stiffness", "OBSERVATION", 66, 75], ["diabetes", "OBSERVATION", 111, 119], ["kidney", "ANATOMY", 139, 145], ["disease", "OBSERVATION", 146, 153]]], ["It was reported that high-dose-but not low-dose-vitamin D supplementation was able to decrease arterial stiffness [74] .", [["arterial", "ANATOMY", 95, 103], ["vitamin D", "CHEMICAL", 48, 57], ["vitamin D", "CHEMICAL", 48, 57], ["low-dose-vitamin D", "SIMPLE_CHEMICAL", 39, 57], ["arterial", "MULTI-TISSUE_STRUCTURE", 95, 103], ["vitamin D supplementation", "TREATMENT", 48, 73], ["arterial stiffness", "PROBLEM", 95, 113]]], ["The decrease in arterial stiffness was related to the suggestion that 25-hydroxyvitamin D inhibits macrophage stimulation [76] and with the suppression of endothelin-induced vascular smooth muscle cell proliferation [77] .VitaminsIt has been recently reported that vitamin D supplementation could reduce the risk of death from the current COVID-19 epidemic.", [["arterial", "ANATOMY", 16, 24], ["macrophage", "ANATOMY", 99, 109], ["vascular smooth muscle cell", "ANATOMY", 174, 201], ["arterial stiffness", "DISEASE", 16, 34], ["25-hydroxyvitamin D", "CHEMICAL", 70, 89], ["Vitamins", "CHEMICAL", 222, 230], ["vitamin D", "CHEMICAL", 265, 274], ["death", "DISEASE", 316, 321], ["25-hydroxyvitamin D", "CHEMICAL", 70, 89], ["Vitamins", "CHEMICAL", 222, 230], ["vitamin D", "CHEMICAL", 265, 274], ["arterial", "MULTI-TISSUE_STRUCTURE", 16, 24], ["25-hydroxyvitamin D", "SIMPLE_CHEMICAL", 70, 89], ["macrophage", "CELL", 99, 109], ["endothelin", "GENE_OR_GENE_PRODUCT", 155, 165], ["vascular smooth muscle cell", "CELL", 174, 201], ["Vitamins", "SIMPLE_CHEMICAL", 222, 230], ["vitamin D", "SIMPLE_CHEMICAL", 265, 274], ["vascular smooth muscle cell", "CELL_TYPE", 174, 201], ["The decrease in arterial stiffness", "PROBLEM", 0, 34], ["hydroxyvitamin D inhibits macrophage stimulation", "TREATMENT", 73, 121], ["endothelin", "TREATMENT", 155, 165], ["induced vascular smooth muscle cell proliferation", "PROBLEM", 166, 215], ["Vitamins", "TREATMENT", 222, 230], ["vitamin D supplementation", "TREATMENT", 265, 290], ["death", "PROBLEM", 316, 321], ["the current COVID", "TEST", 327, 344], ["epidemic", "PROBLEM", 348, 356], ["decrease", "OBSERVATION_MODIFIER", 4, 12], ["arterial", "ANATOMY", 16, 24], ["stiffness", "OBSERVATION", 25, 34], ["vascular", "ANATOMY", 174, 182], ["smooth muscle cell proliferation", "OBSERVATION", 183, 215]]], ["It is commonly accepted that vitamin D deficiency weakens the immune system.", [["immune system", "ANATOMY", 62, 75], ["vitamin D", "CHEMICAL", 29, 38], ["vitamin D", "CHEMICAL", 29, 38], ["vitamin D", "SIMPLE_CHEMICAL", 29, 38], ["vitamin D deficiency", "PROBLEM", 29, 49]]], ["Vitamin D deficiency also increases tissue stiffness, and maintaining tight junctions was mentioned as one of mechanisms of vitamin D function [78] .", [["tissue", "ANATOMY", 36, 42], ["tight junctions", "ANATOMY", 70, 85], ["Vitamin D", "CHEMICAL", 0, 9], ["vitamin D", "CHEMICAL", 124, 133], ["Vitamin D", "CHEMICAL", 0, 9], ["vitamin D", "CHEMICAL", 124, 133], ["Vitamin D", "SIMPLE_CHEMICAL", 0, 9], ["tissue", "TISSUE", 36, 42], ["tight junctions", "CELLULAR_COMPONENT", 70, 85], ["vitamin D", "SIMPLE_CHEMICAL", 124, 133], ["Vitamin D deficiency", "PROBLEM", 0, 20], ["tissue stiffness", "PROBLEM", 36, 52], ["vitamin D function", "TEST", 124, 142], ["deficiency", "OBSERVATION", 10, 20], ["increases tissue", "OBSERVATION_MODIFIER", 26, 42], ["stiffness", "OBSERVATION_MODIFIER", 43, 52], ["tight junctions", "OBSERVATION", 70, 85]]], ["Maintaining tight junctions prevents coronavirus infection by preventing tissue permeability.VitaminsVitamin D intake is very low in Italy, Spain and France [79] .", [["tight junctions", "ANATOMY", 12, 27], ["tissue", "ANATOMY", 73, 79], ["coronavirus infection", "DISEASE", 37, 58], ["Vitamins", "CHEMICAL", 93, 101], ["Vitamin D", "CHEMICAL", 101, 110], ["Vitamins", "CHEMICAL", 93, 101], ["Vitamin D", "CHEMICAL", 101, 110], ["tight junctions", "CELLULAR_COMPONENT", 12, 27], ["coronavirus", "ORGANISM", 37, 48], ["tissue", "TISSUE", 73, 79], ["VitaminsVitamin D", "SIMPLE_CHEMICAL", 93, 110], ["coronavirus", "SPECIES", 37, 48], ["coronavirus infection", "PROBLEM", 37, 58], ["tissue permeability", "PROBLEM", 73, 92], ["Vitamins", "TREATMENT", 93, 101], ["Vitamin D intake", "TREATMENT", 101, 117], ["tight junctions", "OBSERVATION", 12, 27], ["prevents", "UNCERTAINTY", 28, 36], ["coronavirus", "OBSERVATION_MODIFIER", 37, 48], ["infection", "OBSERVATION", 49, 58], ["tissue permeability", "OBSERVATION", 73, 92]]], ["The most severe COVID-19 epidemic was observed in these countries, although, at present, there are not enough data confirming the link between vitamin D and COVID-19.VitaminsVitamin E prevented an increase in femoral artery stiffness in diabetic Wistar rats [80] .", [["femoral artery", "ANATOMY", 209, 223], ["vitamin D", "CHEMICAL", 143, 152], ["VitaminsVitamin E", "CHEMICAL", 166, 183], ["increase in femoral artery stiffness", "DISEASE", 197, 233], ["diabetic", "DISEASE", 237, 245], ["vitamin D", "CHEMICAL", 143, 152], ["COVID-19", "CHEMICAL", 157, 165], ["VitaminsVitamin E", "CHEMICAL", 166, 183], ["vitamin D", "SIMPLE_CHEMICAL", 143, 152], ["VitaminsVitamin E", "SIMPLE_CHEMICAL", 166, 183], ["femoral artery", "MULTI-TISSUE_STRUCTURE", 209, 223], ["Wistar rats", "ORGANISM", 246, 257], ["rats", "SPECIES", 253, 257], ["The most severe COVID", "PROBLEM", 0, 21], ["epidemic", "PROBLEM", 25, 33], ["vitamin D", "TREATMENT", 143, 152], ["COVID", "TEST", 157, 162], ["VitaminsVitamin E", "TREATMENT", 166, 183], ["femoral artery stiffness", "PROBLEM", 209, 233], ["most", "OBSERVATION_MODIFIER", 4, 8], ["severe", "OBSERVATION_MODIFIER", 9, 15], ["increase", "OBSERVATION_MODIFIER", 197, 205], ["femoral artery", "ANATOMY", 209, 223], ["stiffness", "OBSERVATION_MODIFIER", 224, 233]]], ["It was reported that consumption of vitamin E for 2 months resulted in a decrease in carotid femoral pulse wave velocity and augmentation index in a group of 36 healthy men [81] .", [["carotid femoral", "ANATOMY", 85, 100], ["vitamin E", "CHEMICAL", 36, 45], ["vitamin E", "CHEMICAL", 36, 45], ["vitamin E", "SIMPLE_CHEMICAL", 36, 45], ["carotid femoral", "MULTI-TISSUE_STRUCTURE", 85, 100], ["men", "ORGANISM", 169, 172], ["men", "SPECIES", 169, 172], ["vitamin E", "TREATMENT", 36, 45], ["a decrease in carotid femoral pulse wave velocity", "PROBLEM", 71, 120], ["augmentation index", "TEST", 125, 143], ["decrease", "OBSERVATION_MODIFIER", 73, 81], ["carotid femoral", "ANATOMY", 85, 100], ["augmentation", "OBSERVATION_MODIFIER", 125, 137], ["index", "OBSERVATION_MODIFIER", 138, 143]]], ["Arterial stiffness decreased as a result of long-term treatment with vitamin E in combination with vitamin C, coenzyme Q10, and selenium [82] .", [["Arterial", "ANATOMY", 0, 8], ["Arterial stiffness", "DISEASE", 0, 18], ["vitamin E", "CHEMICAL", 69, 78], ["vitamin C", "CHEMICAL", 99, 108], ["coenzyme Q10", "CHEMICAL", 110, 122], ["selenium", "CHEMICAL", 128, 136], ["vitamin E", "CHEMICAL", 69, 78], ["vitamin C", "CHEMICAL", 99, 108], ["coenzyme Q10", "CHEMICAL", 110, 122], ["selenium", "CHEMICAL", 128, 136], ["Arterial", "MULTI-TISSUE_STRUCTURE", 0, 8], ["vitamin E", "SIMPLE_CHEMICAL", 69, 78], ["vitamin C", "SIMPLE_CHEMICAL", 99, 108], ["coenzyme Q10", "SIMPLE_CHEMICAL", 110, 122], ["selenium [82]", "SIMPLE_CHEMICAL", 128, 141], ["Arterial stiffness", "PROBLEM", 0, 18], ["long-term treatment", "TREATMENT", 44, 63], ["vitamin E", "TREATMENT", 69, 78], ["vitamin C", "TREATMENT", 99, 108], ["coenzyme Q10", "TREATMENT", 110, 122], ["stiffness", "OBSERVATION_MODIFIER", 9, 18], ["decreased", "OBSERVATION", 19, 28]]], ["The effect of vitamin E in combination with pravastatin and hymocysteine on arterial stiffness was studied with the aim to reduce increased aortic and carotid artery stiffness in patients with end-stage renal disease [83] .VitaminsIt was suggested that supplementation with vitamin D and vitamin E may increase resistance to novel coronavirus SARS-CoV-2 [84] .VitaminsVitamin C decreases arterial stiffness [85, 86] .", [["arterial", "ANATOMY", 76, 84], ["aortic", "ANATOMY", 140, 146], ["carotid artery", "ANATOMY", 151, 165], ["renal", "ANATOMY", 203, 208], ["arterial", "ANATOMY", 388, 396], ["vitamin E", "CHEMICAL", 14, 23], ["pravastatin", "CHEMICAL", 44, 55], ["hymocysteine", "CHEMICAL", 60, 72], ["aortic and carotid artery stiffness", "DISEASE", 140, 175], ["end-stage renal disease", "DISEASE", 193, 216], ["Vitamins", "CHEMICAL", 223, 231], ["vitamin D", "CHEMICAL", 274, 283], ["vitamin E", "CHEMICAL", 288, 297], ["VitaminsVitamin C", "CHEMICAL", 360, 377], ["arterial stiffness", "DISEASE", 388, 406], ["vitamin E", "CHEMICAL", 14, 23], ["pravastatin", "CHEMICAL", 44, 55], ["hymocysteine", "CHEMICAL", 60, 72], ["Vitamins", "CHEMICAL", 223, 231], ["vitamin D", "CHEMICAL", 274, 283], ["vitamin E", "CHEMICAL", 288, 297], ["VitaminsVitamin C", "CHEMICAL", 360, 377], ["vitamin E", "SIMPLE_CHEMICAL", 14, 23], ["pravastatin", "SIMPLE_CHEMICAL", 44, 55], ["hymocysteine", "SIMPLE_CHEMICAL", 60, 72], ["arterial", "MULTI-TISSUE_STRUCTURE", 76, 84], ["aortic", "MULTI-TISSUE_STRUCTURE", 140, 146], ["carotid artery", "MULTI-TISSUE_STRUCTURE", 151, 165], ["patients", "ORGANISM", 179, 187], ["renal", "ORGAN", 203, 208], ["Vitamins", "SIMPLE_CHEMICAL", 223, 231], ["vitamin D", "SIMPLE_CHEMICAL", 274, 283], ["vitamin E", "SIMPLE_CHEMICAL", 288, 297], ["coronavirus SARS-CoV-2", "ORGANISM", 331, 353], ["VitaminsVitamin C", "SIMPLE_CHEMICAL", 360, 377], ["arterial", "MULTI-TISSUE_STRUCTURE", 388, 396], ["patients", "SPECIES", 179, 187], ["vitamin E", "TREATMENT", 14, 23], ["pravastatin", "TREATMENT", 44, 55], ["hymocysteine", "TREATMENT", 60, 72], ["arterial stiffness", "TREATMENT", 76, 94], ["increased aortic and carotid artery stiffness", "PROBLEM", 130, 175], ["end-stage renal disease", "PROBLEM", 193, 216], ["Vitamins", "TREATMENT", 223, 231], ["vitamin D", "TREATMENT", 274, 283], ["vitamin E", "TREATMENT", 288, 297], ["novel coronavirus SARS", "TEST", 325, 347], ["CoV", "TEST", 348, 351], ["VitaminsVitamin", "TREATMENT", 360, 375], ["arterial stiffness", "TEST", 388, 406], ["arterial", "ANATOMY", 76, 84], ["increased", "OBSERVATION", 130, 139], ["aortic", "ANATOMY", 140, 146], ["carotid artery", "ANATOMY", 151, 165], ["stiffness", "OBSERVATION", 166, 175], ["stage", "OBSERVATION_MODIFIER", 197, 202], ["renal", "ANATOMY", 203, 208], ["disease", "OBSERVATION", 209, 216], ["arterial stiffness", "OBSERVATION_MODIFIER", 388, 406]]], ["A combination of vitamin C with various other drugs could be beneficial for COVID-19 patients [87] .VitaminsVitamin K2 decreases arterial stiffness by preventing and reversing calcification of arteries and inhibition of inflammation in the vascular wall [72, [88] [89] [90] .VitaminsIt was reported that chitosan oligosaccharide ascorbate corrected deficiency in vitamin A, E, C and B groups [66] .Salt RestrictionIt was observed that salt consumption increases arterial stiffness and the risk of cardiovascular diseases [91] [92] [93] [94] [95] , and salt also increases tightly bound water mobility due to the decrease in binding energy in pork meat [96] .", [["arterial", "ANATOMY", 129, 137], ["arteries", "ANATOMY", 193, 201], ["vascular wall", "ANATOMY", 240, 253], ["arterial", "ANATOMY", 462, 470], ["cardiovascular", "ANATOMY", 497, 511], ["pork meat", "ANATOMY", 642, 651], ["vitamin C", "CHEMICAL", 17, 26], ["Vitamins", "CHEMICAL", 100, 108], ["Vitamin K2", "CHEMICAL", 108, 118], ["arterial stiffness", "DISEASE", 129, 147], ["calcification", "DISEASE", 176, 189], ["inflammation", "DISEASE", 220, 232], ["Vitamins", "CHEMICAL", 275, 283], ["chitosan oligosaccharide", "CHEMICAL", 304, 328], ["ascorbate", "CHEMICAL", 329, 338], ["vitamin A, E, C and B", "CHEMICAL", 363, 384], ["salt", "CHEMICAL", 435, 439], ["arterial stiffness", "DISEASE", 462, 480], ["cardiovascular diseases", "DISEASE", 497, 520], ["91] [92] [93] [94] [95]", "CHEMICAL", 522, 545], ["salt", "CHEMICAL", 552, 556], ["vitamin C", "CHEMICAL", 17, 26], ["Vitamins", "CHEMICAL", 100, 108], ["Vitamin K2", "CHEMICAL", 108, 118], ["Vitamins", "CHEMICAL", 275, 283], ["ascorbate", "CHEMICAL", 329, 338], ["vitamin A, E, C and B", "CHEMICAL", 363, 384], ["[91] [92] [93] [94] [95]", "CHEMICAL", 521, 545], ["vitamin C", "SIMPLE_CHEMICAL", 17, 26], ["patients", "ORGANISM", 85, 93], ["VitaminsVitamin K2", "SIMPLE_CHEMICAL", 100, 118], ["arterial", "MULTI-TISSUE_STRUCTURE", 129, 137], ["arteries", "MULTI-TISSUE_STRUCTURE", 193, 201], ["vascular wall", "MULTI-TISSUE_STRUCTURE", 240, 253], ["Vitamins", "SIMPLE_CHEMICAL", 275, 283], ["chitosan oligosaccharide", "SIMPLE_CHEMICAL", 304, 328], ["ascorbate", "SIMPLE_CHEMICAL", 329, 338], ["vitamin A", "SIMPLE_CHEMICAL", 363, 372], ["E", "SIMPLE_CHEMICAL", 374, 375], ["C", "SIMPLE_CHEMICAL", 377, 378], ["B", "SIMPLE_CHEMICAL", 383, 384], ["salt", "SIMPLE_CHEMICAL", 435, 439], ["arterial", "MULTI-TISSUE_STRUCTURE", 462, 470], ["cardiovascular", "ANATOMICAL_SYSTEM", 497, 511], ["92] [93] [94] [95]", "SIMPLE_CHEMICAL", 527, 545], ["salt", "SIMPLE_CHEMICAL", 552, 556], ["patients", "SPECIES", 85, 93], ["pork", "SPECIES", 642, 646], ["vitamin C", "TREATMENT", 17, 26], ["various other drugs", "TREATMENT", 32, 51], ["COVID", "TEST", 76, 81], ["Vitamins", "TREATMENT", 100, 108], ["Vitamin K2", "TREATMENT", 108, 118], ["arterial stiffness", "PROBLEM", 129, 147], ["reversing calcification of arteries", "PROBLEM", 166, 201], ["inflammation in the vascular wall", "PROBLEM", 220, 253], ["Vitamins", "TREATMENT", 275, 283], ["chitosan oligosaccharide ascorbate", "PROBLEM", 304, 338], ["corrected deficiency", "PROBLEM", 339, 359], ["vitamin A", "TREATMENT", 363, 372], ["Salt Restriction", "TREATMENT", 398, 414], ["salt consumption", "PROBLEM", 435, 451], ["arterial stiffness", "PROBLEM", 462, 480], ["cardiovascular diseases", "PROBLEM", 497, 520], ["the decrease in binding energy", "PROBLEM", 608, 638], ["calcification", "OBSERVATION", 176, 189], ["arteries", "ANATOMY", 193, 201], ["inflammation", "OBSERVATION", 220, 232], ["vascular wall", "ANATOMY", 240, 253]]], ["Therefore, it is possible to suggest a correlation between arterial stiffness and increased tightly bound water relaxation time (increased protein mobility) measured by low field nuclear magnetic resonance.Salt RestrictionOptimal hydration retards development of age-related diseases [97] .", [["arterial", "ANATOMY", 59, 67], ["arterial stiffness", "DISEASE", 59, 77], ["arterial", "MULTI-TISSUE_STRUCTURE", 59, 67], ["arterial stiffness", "PROBLEM", 59, 77], ["increased tightly bound water relaxation time", "TREATMENT", 82, 127], ["increased protein mobility", "PROBLEM", 129, 155], ["Salt RestrictionOptimal hydration retards", "TREATMENT", 206, 247], ["related diseases", "PROBLEM", 267, 283], ["arterial", "ANATOMY", 59, 67], ["stiffness", "OBSERVATION", 68, 77], ["increased", "OBSERVATION_MODIFIER", 82, 91], ["tightly", "OBSERVATION_MODIFIER", 92, 99], ["bound", "OBSERVATION_MODIFIER", 100, 105], ["water relaxation", "OBSERVATION", 106, 122]]], ["Increase in extracellular sodium concentration results in vascular endothelial cells' activation and leads to shrinking and increased stiffness of glycocalyx [98] [99] [100] .", [["extracellular", "ANATOMY", 12, 25], ["vascular endothelial cells", "ANATOMY", 58, 84], ["sodium", "CHEMICAL", 26, 32], ["sodium", "CHEMICAL", 26, 32], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 12, 25], ["sodium", "SIMPLE_CHEMICAL", 26, 32], ["vascular endothelial cells", "CELL", 58, 84], ["vascular endothelial cells", "CELL_TYPE", 58, 84], ["extracellular sodium concentration", "TEST", 12, 46], ["vascular endothelial cells' activation", "PROBLEM", 58, 96], ["increased stiffness of glycocalyx", "PROBLEM", 124, 157], ["sodium concentration", "OBSERVATION", 26, 46], ["vascular", "ANATOMY", 58, 66], ["endothelial cells", "OBSERVATION", 67, 84], ["increased", "OBSERVATION_MODIFIER", 124, 133], ["stiffness", "OBSERVATION_MODIFIER", 134, 143]]], ["Dehydration and related increases in sodium concentration also lead to the expression of inflammation mediators vascular cell adhesion molecule 1 (VCAM-1), endothelial-leukocyte adhesion molecule 1 (E-selectin), and monocyte chemoattractant protein 1 (MCP-1) [101, 102] .", [["Dehydration", "DISEASE", 0, 11], ["sodium", "CHEMICAL", 37, 43], ["sodium", "CHEMICAL", 37, 43], ["sodium", "SIMPLE_CHEMICAL", 37, 43], ["vascular cell adhesion molecule 1", "GENE_OR_GENE_PRODUCT", 112, 145], ["VCAM-1", "GENE_OR_GENE_PRODUCT", 147, 153], ["endothelial-leukocyte adhesion molecule 1", "GENE_OR_GENE_PRODUCT", 156, 197], ["E-selectin", "GENE_OR_GENE_PRODUCT", 199, 209], ["monocyte chemoattractant protein 1", "GENE_OR_GENE_PRODUCT", 216, 250], ["MCP-1", "GENE_OR_GENE_PRODUCT", 252, 257], ["inflammation mediators", "PROTEIN", 89, 111], ["vascular cell adhesion molecule 1", "PROTEIN", 112, 145], ["VCAM", "PROTEIN", 147, 151], ["endothelial-leukocyte adhesion molecule 1", "PROTEIN", 156, 197], ["E", "PROTEIN", 199, 200], ["selectin", "PROTEIN", 201, 209], ["monocyte chemoattractant protein 1", "PROTEIN", 216, 250], ["MCP", "PROTEIN", 252, 255], ["Dehydration", "PROBLEM", 0, 11], ["related increases in sodium concentration", "PROBLEM", 16, 57], ["inflammation mediators", "PROBLEM", 89, 111], ["vascular cell adhesion molecule", "TEST", 112, 143], ["VCAM", "TEST", 147, 151], ["endothelial-leukocyte adhesion molecule", "TEST", 156, 195], ["monocyte chemoattractant protein", "TEST", 216, 248], ["MCP", "TEST", 252, 255], ["increases", "OBSERVATION_MODIFIER", 24, 33], ["sodium concentration", "OBSERVATION_MODIFIER", 37, 57], ["inflammation", "OBSERVATION", 89, 101], ["vascular", "ANATOMY", 112, 120], ["cell adhesion", "OBSERVATION", 121, 134], ["endothelial", "ANATOMY", 156, 167], ["leukocyte", "ANATOMY", 168, 177]]], ["High sodium concentration decreases NO release and promotes endothelial release of the pro-inflammatory cytokines IL-1\u00df and TNF\u03b1 [103] .", [["endothelial", "ANATOMY", 60, 71], ["sodium", "CHEMICAL", 5, 11], ["NO", "CHEMICAL", 36, 38], ["sodium", "CHEMICAL", 5, 11], ["NO", "CHEMICAL", 36, 38], ["sodium", "SIMPLE_CHEMICAL", 5, 11], ["NO", "SIMPLE_CHEMICAL", 36, 38], ["endothelial", "CELL", 60, 71], ["IL-1\u00df", "GENE_OR_GENE_PRODUCT", 114, 119], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 124, 128], ["pro-inflammatory cytokines", "PROTEIN", 87, 113], ["IL-1\u00df", "PROTEIN", 114, 119], ["TNF", "PROTEIN", 124, 127], ["High sodium concentration", "PROBLEM", 0, 25], ["the pro-inflammatory cytokines IL", "TEST", 83, 116], ["TNF", "TEST", 124, 127]]], ["Increased endothelial stiffening and diminished glycocalyx coverage were observed in diabetic mice if compared with control.", [["endothelial", "ANATOMY", 10, 21], ["glycocalyx", "ANATOMY", 48, 58], ["diabetic", "DISEASE", 85, 93], ["endothelial", "TISSUE", 10, 21], ["glycocalyx", "TISSUE", 48, 58], ["mice", "ORGANISM", 94, 98], ["mice", "SPECIES", 94, 98], ["mice", "SPECIES", 94, 98], ["Increased endothelial stiffening", "PROBLEM", 0, 32], ["diminished glycocalyx coverage", "TREATMENT", 37, 67], ["endothelial stiffening", "OBSERVATION", 10, 32], ["diminished", "OBSERVATION_MODIFIER", 37, 47], ["glycocalyx coverage", "OBSERVATION", 48, 67]]], ["Glycocalyx coverage decreases in advanced age with diabetes progression [104] .Dehydration, Stiffness and NF-\u03baB ActivationDehydration activates NF-\u03baB [105] .", [["diabetes", "DISEASE", 51, 59], ["Dehydration", "DISEASE", 79, 90], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 106, 111], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 144, 149], ["NF-\u03baB", "PROTEIN", 144, 149], ["Glycocalyx coverage", "TREATMENT", 0, 19], ["diabetes progression", "PROBLEM", 51, 71], ["Dehydration", "PROBLEM", 79, 90], ["Stiffness", "PROBLEM", 92, 101], ["NF", "PROBLEM", 106, 108], ["Dehydration", "PROBLEM", 122, 133], ["coverage", "OBSERVATION_MODIFIER", 11, 19], ["decreases", "OBSERVATION_MODIFIER", 20, 29], ["Stiffness", "OBSERVATION_MODIFIER", 92, 101]]], ["Dehydration also results in enhanced tissue stiffness.", [["tissue", "ANATOMY", 37, 43], ["Dehydration", "DISEASE", 0, 11], ["tissue", "TISSUE", 37, 43], ["Dehydration", "PROBLEM", 0, 11], ["enhanced tissue stiffness", "PROBLEM", 28, 53], ["enhanced tissue stiffness", "OBSERVATION", 28, 53]]], ["Ishihara et al. reported that increased substrate stiffness leads to expression of inflammatory genes via NF-\u03baB activation and results in actomyosin contractions, which triggers NF-\u03baB activation [106] .", [["actomyosin", "ANATOMY", 138, 148], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 106, 111], ["actomyosin", "CELLULAR_COMPONENT", 138, 148], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 178, 183], ["inflammatory genes", "DNA", 83, 101], ["NF-\u03baB", "PROTEIN", 106, 111], ["NF-\u03baB", "PROTEIN", 178, 183], ["increased substrate stiffness", "PROBLEM", 30, 59], ["inflammatory genes", "PROBLEM", 83, 101], ["actomyosin contractions", "PROBLEM", 138, 161], ["increased", "OBSERVATION_MODIFIER", 30, 39], ["substrate stiffness", "OBSERVATION", 40, 59], ["inflammatory", "OBSERVATION_MODIFIER", 83, 95], ["actomyosin contractions", "OBSERVATION", 138, 161]]], ["The actomyosin contractions are induced by phosphorylation of myosin regulatory light chain (MRLC).", [["actomyosin", "ANATOMY", 4, 14], ["myosin regulatory light chain", "GENE_OR_GENE_PRODUCT", 62, 91], ["MRLC", "GENE_OR_GENE_PRODUCT", 93, 97], ["myosin regulatory light chain", "PROTEIN", 62, 91], ["MRLC", "PROTEIN", 93, 97], ["The actomyosin contractions", "TREATMENT", 0, 27], ["actomyosin contractions", "OBSERVATION", 4, 27]]], ["The inhibition of MRLC phosphorylation by Rho kinase inhibitor Y27632 reduced the activity of NF-Kb.", [["Y27632", "CHEMICAL", 63, 69], ["Y27632", "CHEMICAL", 63, 69], ["MRLC", "GENE_OR_GENE_PRODUCT", 18, 22], ["Rho kinase", "GENE_OR_GENE_PRODUCT", 42, 52], ["Y27632", "SIMPLE_CHEMICAL", 63, 69], ["NF-Kb.", "GENE_OR_GENE_PRODUCT", 94, 100], ["MRLC", "PROTEIN", 18, 22], ["Rho kinase", "PROTEIN", 42, 52], ["NF", "PROTEIN", 94, 96], ["MRLC phosphorylation", "TREATMENT", 18, 38], ["Rho kinase inhibitor", "TREATMENT", 42, 62]]], ["NF-\u03baB activation may be associated with numerous diseases, including cancer and fibrosis development.Dehydration, Stiffness and NF-\u03baB ActivationMatrix stiffening promotes F-actin polymerization regulated by small GTPase RhoA, Figure 2 , and \u03b1 smooth muscle actin (\u03b1-SMA)-containing stress-fiber formation.", [["cancer", "ANATOMY", 69, 75], ["stress-fiber", "ANATOMY", 282, 294], ["cancer", "DISEASE", 69, 75], ["fibrosis", "DISEASE", 80, 88], ["Dehydration", "DISEASE", 101, 112], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 0, 5], ["cancer", "CANCER", 69, 75], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 128, 133], ["F-actin", "GENE_OR_GENE_PRODUCT", 171, 178], ["RhoA", "GENE_OR_GENE_PRODUCT", 220, 224], ["Figure 2", "GENE_OR_GENE_PRODUCT", 226, 234], ["\u03b1 smooth muscle actin", "GENE_OR_GENE_PRODUCT", 241, 262], ["\u03b1-SMA", "GENE_OR_GENE_PRODUCT", 264, 269], ["stress-fiber", "CELLULAR_COMPONENT", 282, 294], ["NF-\u03baB", "PROTEIN", 0, 5], ["F-actin", "PROTEIN", 171, 178], ["small GTPase", "PROTEIN", 207, 219], ["RhoA", "PROTEIN", 220, 224], ["Figure 2", "PROTEIN", 226, 234], ["\u03b1 smooth muscle actin", "PROTEIN", 241, 262], ["SMA", "PROTEIN", 266, 269], ["numerous diseases", "PROBLEM", 40, 57], ["cancer", "PROBLEM", 69, 75], ["fibrosis development", "PROBLEM", 80, 100], ["Dehydration", "PROBLEM", 101, 112], ["Stiffness", "PROBLEM", 114, 123], ["NF", "PROBLEM", 128, 130], ["\u03baB ActivationMatrix stiffening", "TREATMENT", 131, 161], ["F-actin polymerization", "TREATMENT", 171, 193], ["stress-fiber formation", "TREATMENT", 282, 304], ["may be associated with", "UNCERTAINTY", 17, 39], ["numerous", "OBSERVATION_MODIFIER", 40, 48], ["diseases", "OBSERVATION", 49, 57], ["cancer", "OBSERVATION", 69, 75], ["fibrosis", "OBSERVATION", 80, 88], ["Stiffness", "OBSERVATION_MODIFIER", 114, 123], ["F-actin polymerization", "OBSERVATION", 171, 193], ["small", "OBSERVATION_MODIFIER", 207, 212], ["GTPase RhoA", "OBSERVATION", 213, 224], ["smooth muscle", "ANATOMY", 243, 256], ["SMA", "ANATOMY", 266, 269]]], ["Inhibition of RhoA inhibits stress-fiber formation.", [["stress-fiber", "ANATOMY", 28, 40], ["RhoA", "GENE_OR_GENE_PRODUCT", 14, 18], ["stress-fiber", "CELLULAR_COMPONENT", 28, 40], ["RhoA", "PROTEIN", 14, 18], ["RhoA", "OBSERVATION_MODIFIER", 14, 18], ["fiber formation", "OBSERVATION", 35, 50]]], ["Water molecules have an important role in F-actin polymerization, and it was shown that fewer water molecules were associated with actin when it polymerized [107] .", [["F-actin", "SIMPLE_CHEMICAL", 42, 49], ["actin", "GENE_OR_GENE_PRODUCT", 131, 136], ["F-actin", "PROTEIN", 42, 49], ["actin", "PROTEIN", 131, 136], ["Water molecules", "PROBLEM", 0, 15], ["F-actin polymerization", "TREATMENT", 42, 64], ["fewer water molecules", "PROBLEM", 88, 109], ["F-actin polymerization", "OBSERVATION", 42, 64]]], ["Thus, the polymerization of actin and dehydration can be associated with an increase in tissue stiffness.", [["tissue", "ANATOMY", 88, 94], ["dehydration", "DISEASE", 38, 49], ["actin", "GENE_OR_GENE_PRODUCT", 28, 33], ["tissue", "TISSUE", 88, 94], ["actin", "PROTEIN", 28, 33], ["dehydration", "PROBLEM", 38, 49], ["an increase in tissue stiffness", "PROBLEM", 73, 104], ["increase", "OBSERVATION_MODIFIER", 76, 84], ["tissue stiffness", "OBSERVATION", 88, 104]]], ["The mechanical properties of actin can be regulated using various agents.", [["actin", "GENE_OR_GENE_PRODUCT", 29, 34], ["actin", "PROTEIN", 29, 34], ["The mechanical properties of actin", "TREATMENT", 0, 34], ["various agents", "TREATMENT", 58, 72], ["mechanical properties", "OBSERVATION", 4, 25]]], ["For example, jasplakinolide, cytochalasin D, and latrunculin A were used to directly modulate actin polymerization of cultured rat airway smooth muscle cells [108] .Dehydration, Stiffness and NF-\u03baB ActivationPolymers 2020, 12, x FOR PEER REVIEW 6 of 15 energy in pork meat [96] .", [["airway smooth muscle cells", "ANATOMY", 131, 157], ["pork meat", "ANATOMY", 263, 272], ["jasplakinolide", "CHEMICAL", 13, 27], ["cytochalasin D", "CHEMICAL", 29, 43], ["latrunculin A", "CHEMICAL", 49, 62], ["Dehydration", "DISEASE", 165, 176], ["jasplakinolide", "CHEMICAL", 13, 27], ["cytochalasin D", "CHEMICAL", 29, 43], ["latrunculin A", "CHEMICAL", 49, 62], ["jasplakinolide", "SIMPLE_CHEMICAL", 13, 27], ["cytochalasin D", "SIMPLE_CHEMICAL", 29, 43], ["latrunculin A", "SIMPLE_CHEMICAL", 49, 62], ["actin", "GENE_OR_GENE_PRODUCT", 94, 99], ["rat", "ORGANISM", 127, 130], ["airway smooth muscle cells [108]", "CELL", 131, 163], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 192, 197], ["actin", "PROTEIN", 94, 99], ["cultured rat airway smooth muscle cells", "CELL_LINE", 118, 157], ["rat", "SPECIES", 127, 130], ["rat", "SPECIES", 127, 130], ["pork", "SPECIES", 263, 267], ["jasplakinolide", "TREATMENT", 13, 27], ["cytochalasin D", "TREATMENT", 29, 43], ["latrunculin A", "TREATMENT", 49, 62], ["Dehydration", "PROBLEM", 165, 176], ["Stiffness", "PROBLEM", 178, 187], ["actin polymerization", "OBSERVATION", 94, 114], ["Stiffness", "OBSERVATION_MODIFIER", 178, 187]]], ["Therefore, it is possible to suggest a correlation between arterial stiffness and increased tightly bound water relaxation time (increased protein mobility) measured by low field nuclear magnetic resonance.", [["arterial", "ANATOMY", 59, 67], ["arterial stiffness", "DISEASE", 59, 77], ["arterial", "MULTI-TISSUE_STRUCTURE", 59, 67], ["arterial stiffness", "PROBLEM", 59, 77], ["increased tightly bound water relaxation time", "TREATMENT", 82, 127], ["increased protein mobility", "PROBLEM", 129, 155], ["arterial", "ANATOMY", 59, 67], ["stiffness", "OBSERVATION", 68, 77], ["increased", "OBSERVATION_MODIFIER", 82, 91], ["tightly", "OBSERVATION_MODIFIER", 92, 99], ["bound", "OBSERVATION_MODIFIER", 100, 105], ["water relaxation", "OBSERVATION", 106, 122]]], ["Optimal hydration retards development of age-related diseases [97] .", [["Optimal hydration retards", "TREATMENT", 0, 25], ["related diseases", "PROBLEM", 45, 61]]], ["Increase in extracellular sodium concentration results in vascular endothelial cells' activation and leads to shrinking and increased stiffness of glycocalyx [98] [99] [100] .", [["extracellular", "ANATOMY", 12, 25], ["vascular endothelial cells", "ANATOMY", 58, 84], ["sodium", "CHEMICAL", 26, 32], ["sodium", "CHEMICAL", 26, 32], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 12, 25], ["sodium", "SIMPLE_CHEMICAL", 26, 32], ["vascular endothelial cells", "CELL", 58, 84], ["vascular endothelial cells", "CELL_TYPE", 58, 84], ["extracellular sodium concentration", "TEST", 12, 46], ["vascular endothelial cells' activation", "PROBLEM", 58, 96], ["increased stiffness of glycocalyx", "PROBLEM", 124, 157], ["sodium concentration", "OBSERVATION", 26, 46], ["vascular", "ANATOMY", 58, 66], ["endothelial cells", "OBSERVATION", 67, 84], ["increased", "OBSERVATION_MODIFIER", 124, 133], ["stiffness", "OBSERVATION_MODIFIER", 134, 143]]], ["Dehydration and related increases in sodium concentration also lead to the expression of inflammation mediators vascular cell adhesion molecule 1 (VCAM-1), endothelial-leukocyte adhesion molecule 1 (E-selectin), and monocyte chemoattractant protein 1 (MCP-1) [101, 102] .", [["Dehydration", "DISEASE", 0, 11], ["sodium", "CHEMICAL", 37, 43], ["sodium", "CHEMICAL", 37, 43], ["sodium", "SIMPLE_CHEMICAL", 37, 43], ["vascular cell adhesion molecule 1", "GENE_OR_GENE_PRODUCT", 112, 145], ["VCAM-1", "GENE_OR_GENE_PRODUCT", 147, 153], ["endothelial-leukocyte adhesion molecule 1", "GENE_OR_GENE_PRODUCT", 156, 197], ["E-selectin", "GENE_OR_GENE_PRODUCT", 199, 209], ["monocyte chemoattractant protein 1", "GENE_OR_GENE_PRODUCT", 216, 250], ["MCP-1", "GENE_OR_GENE_PRODUCT", 252, 257], ["inflammation mediators", "PROTEIN", 89, 111], ["vascular cell adhesion molecule 1", "PROTEIN", 112, 145], ["VCAM", "PROTEIN", 147, 151], ["endothelial-leukocyte adhesion molecule 1", "PROTEIN", 156, 197], ["E", "PROTEIN", 199, 200], ["selectin", "PROTEIN", 201, 209], ["monocyte chemoattractant protein 1", "PROTEIN", 216, 250], ["MCP", "PROTEIN", 252, 255], ["Dehydration", "PROBLEM", 0, 11], ["related increases in sodium concentration", "PROBLEM", 16, 57], ["inflammation mediators", "PROBLEM", 89, 111], ["vascular cell adhesion molecule", "TEST", 112, 143], ["VCAM", "TEST", 147, 151], ["endothelial-leukocyte adhesion molecule", "TEST", 156, 195], ["monocyte chemoattractant protein", "TEST", 216, 248], ["MCP", "TEST", 252, 255], ["increases", "OBSERVATION_MODIFIER", 24, 33], ["sodium concentration", "OBSERVATION_MODIFIER", 37, 57], ["inflammation", "OBSERVATION", 89, 101], ["vascular", "ANATOMY", 112, 120], ["cell adhesion", "OBSERVATION", 121, 134], ["endothelial", "ANATOMY", 156, 167], ["leukocyte", "ANATOMY", 168, 177]]], ["High sodium concentration decreases NO release and promotes endothelial release of the pro-inflammatory cytokines IL-1\u00df and TNF\u03b1 [103] .", [["endothelial", "ANATOMY", 60, 71], ["sodium", "CHEMICAL", 5, 11], ["NO", "CHEMICAL", 36, 38], ["sodium", "CHEMICAL", 5, 11], ["NO", "CHEMICAL", 36, 38], ["sodium", "SIMPLE_CHEMICAL", 5, 11], ["NO", "SIMPLE_CHEMICAL", 36, 38], ["endothelial", "CELL", 60, 71], ["IL-1\u00df", "GENE_OR_GENE_PRODUCT", 114, 119], ["TNF\u03b1", "GENE_OR_GENE_PRODUCT", 124, 128], ["pro-inflammatory cytokines", "PROTEIN", 87, 113], ["IL-1\u00df", "PROTEIN", 114, 119], ["TNF", "PROTEIN", 124, 127], ["High sodium concentration", "PROBLEM", 0, 25], ["the pro-inflammatory cytokines IL", "TEST", 83, 116], ["TNF", "TEST", 124, 127]]], ["Increased endothelial stiffening and diminished glycocalyx coverage were observed in diabetic mice if compared with control.", [["endothelial", "ANATOMY", 10, 21], ["glycocalyx", "ANATOMY", 48, 58], ["diabetic", "DISEASE", 85, 93], ["endothelial", "TISSUE", 10, 21], ["glycocalyx", "TISSUE", 48, 58], ["mice", "ORGANISM", 94, 98], ["mice", "SPECIES", 94, 98], ["mice", "SPECIES", 94, 98], ["Increased endothelial stiffening", "PROBLEM", 0, 32], ["diminished glycocalyx coverage", "TREATMENT", 37, 67], ["endothelial stiffening", "OBSERVATION", 10, 32], ["diminished", "OBSERVATION_MODIFIER", 37, 47], ["glycocalyx coverage", "OBSERVATION", 48, 67]]], ["Glycocalyx coverage decreases in advanced age with diabetes progression [104] .Dehydration, Stiffness and NF-\u03baB ActivationDehydration activates NF-\u03baB [105] .", [["diabetes", "DISEASE", 51, 59], ["Dehydration", "DISEASE", 79, 90], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 106, 111], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 144, 149], ["NF-\u03baB", "PROTEIN", 144, 149], ["Glycocalyx coverage", "TREATMENT", 0, 19], ["diabetes progression", "PROBLEM", 51, 71], ["Dehydration", "PROBLEM", 79, 90], ["Stiffness", "PROBLEM", 92, 101], ["NF", "PROBLEM", 106, 108], ["Dehydration", "PROBLEM", 122, 133], ["coverage", "OBSERVATION_MODIFIER", 11, 19], ["decreases", "OBSERVATION_MODIFIER", 20, 29], ["Stiffness", "OBSERVATION_MODIFIER", 92, 101]]], ["Dehydration also results in enhanced tissue stiffness.", [["tissue", "ANATOMY", 37, 43], ["Dehydration", "DISEASE", 0, 11], ["tissue", "TISSUE", 37, 43], ["Dehydration", "PROBLEM", 0, 11], ["enhanced tissue stiffness", "PROBLEM", 28, 53], ["enhanced tissue stiffness", "OBSERVATION", 28, 53]]], ["Ishihara et al. reported that increased substrate stiffness leads to expression of inflammatory genes via NF-\u03baB activation and results in actomyosin contractions, which triggers NF-\u03baB activation [106] .", [["actomyosin", "ANATOMY", 138, 148], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 106, 111], ["actomyosin", "CELLULAR_COMPONENT", 138, 148], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 178, 183], ["inflammatory genes", "DNA", 83, 101], ["NF-\u03baB", "PROTEIN", 106, 111], ["NF-\u03baB", "PROTEIN", 178, 183], ["increased substrate stiffness", "PROBLEM", 30, 59], ["inflammatory genes", "PROBLEM", 83, 101], ["actomyosin contractions", "PROBLEM", 138, 161], ["increased", "OBSERVATION_MODIFIER", 30, 39], ["substrate stiffness", "OBSERVATION", 40, 59], ["inflammatory", "OBSERVATION_MODIFIER", 83, 95], ["actomyosin contractions", "OBSERVATION", 138, 161]]], ["The actomyosin contractions are induced by phosphorylation of myosin regulatory light chain (MRLC).", [["actomyosin", "ANATOMY", 4, 14], ["myosin regulatory light chain", "GENE_OR_GENE_PRODUCT", 62, 91], ["MRLC", "GENE_OR_GENE_PRODUCT", 93, 97], ["myosin regulatory light chain", "PROTEIN", 62, 91], ["MRLC", "PROTEIN", 93, 97], ["The actomyosin contractions", "TREATMENT", 0, 27], ["actomyosin contractions", "OBSERVATION", 4, 27]]], ["The inhibition of MRLC phosphorylation by Rho kinase inhibitor Y27632 reduced the activity of NF-\u039ab.", [["Y27632", "CHEMICAL", 63, 69], ["Y27632", "CHEMICAL", 63, 69], ["MRLC", "GENE_OR_GENE_PRODUCT", 18, 22], ["Rho kinase", "GENE_OR_GENE_PRODUCT", 42, 52], ["Y27632", "SIMPLE_CHEMICAL", 63, 69], ["NF-\u039ab.", "GENE_OR_GENE_PRODUCT", 94, 100], ["MRLC", "PROTEIN", 18, 22], ["Rho kinase", "PROTEIN", 42, 52], ["NF", "PROTEIN", 94, 96], ["MRLC phosphorylation", "TREATMENT", 18, 38], ["Rho kinase inhibitor", "TREATMENT", 42, 62]]], ["NF-\u03baB activation may be associated with numerous diseases, including cancer and fibrosis development.Dehydration, Stiffness and NF-\u03baB ActivationMatrix stiffening promotes F-actin polymerization regulated by small GTPase RhoA, Figure 2 , and \u03b1 smooth muscle actin (\u03b1-SMA)-containing stress-fiber formation.", [["cancer", "ANATOMY", 69, 75], ["stress-fiber", "ANATOMY", 282, 294], ["cancer", "DISEASE", 69, 75], ["fibrosis", "DISEASE", 80, 88], ["Dehydration", "DISEASE", 101, 112], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 0, 5], ["cancer", "CANCER", 69, 75], ["NF-\u03baB", "GENE_OR_GENE_PRODUCT", 128, 133], ["F-actin", "GENE_OR_GENE_PRODUCT", 171, 178], ["RhoA", "GENE_OR_GENE_PRODUCT", 220, 224], ["Figure 2", "GENE_OR_GENE_PRODUCT", 226, 234], ["\u03b1 smooth muscle actin", "GENE_OR_GENE_PRODUCT", 241, 262], ["\u03b1-SMA", "GENE_OR_GENE_PRODUCT", 264, 269], ["stress-fiber", "CELLULAR_COMPONENT", 282, 294], ["NF-\u03baB", "PROTEIN", 0, 5], ["F-actin", "PROTEIN", 171, 178], ["small GTPase", "PROTEIN", 207, 219], ["RhoA", "PROTEIN", 220, 224], ["Figure 2", "PROTEIN", 226, 234], ["\u03b1 smooth muscle actin", "PROTEIN", 241, 262], ["SMA", "PROTEIN", 266, 269], ["numerous diseases", "PROBLEM", 40, 57], ["cancer", "PROBLEM", 69, 75], ["fibrosis development", "PROBLEM", 80, 100], ["Dehydration", "PROBLEM", 101, 112], ["Stiffness", "PROBLEM", 114, 123], ["NF", "PROBLEM", 128, 130], ["\u03baB ActivationMatrix stiffening", "TREATMENT", 131, 161], ["F-actin polymerization", "TREATMENT", 171, 193], ["stress-fiber formation", "TREATMENT", 282, 304], ["may be associated with", "UNCERTAINTY", 17, 39], ["numerous", "OBSERVATION_MODIFIER", 40, 48], ["diseases", "OBSERVATION", 49, 57], ["cancer", "OBSERVATION", 69, 75], ["fibrosis", "OBSERVATION", 80, 88], ["Stiffness", "OBSERVATION_MODIFIER", 114, 123], ["F-actin polymerization", "OBSERVATION", 171, 193], ["small", "OBSERVATION_MODIFIER", 207, 212], ["GTPase RhoA", "OBSERVATION", 213, 224], ["smooth muscle", "ANATOMY", 243, 256], ["SMA", "ANATOMY", 266, 269]]], ["Inhibition of RhoA inhibits stress-fiber formation.", [["stress-fiber", "ANATOMY", 28, 40], ["RhoA", "GENE_OR_GENE_PRODUCT", 14, 18], ["stress-fiber", "CELLULAR_COMPONENT", 28, 40], ["RhoA", "PROTEIN", 14, 18], ["RhoA", "OBSERVATION_MODIFIER", 14, 18], ["fiber formation", "OBSERVATION", 35, 50]]], ["Water molecules have an important role in F-actin polymerization, and it was shown that fewer water molecules were associated with actin when it polymerized [107] .", [["F-actin", "SIMPLE_CHEMICAL", 42, 49], ["actin", "GENE_OR_GENE_PRODUCT", 131, 136], ["F-actin", "PROTEIN", 42, 49], ["actin", "PROTEIN", 131, 136], ["Water molecules", "PROBLEM", 0, 15], ["F-actin polymerization", "TREATMENT", 42, 64], ["fewer water molecules", "PROBLEM", 88, 109], ["F-actin polymerization", "OBSERVATION", 42, 64]]], ["Thus, the polymerization of actin and dehydration can be associated with an increase in tissue stiffness.", [["tissue", "ANATOMY", 88, 94], ["dehydration", "DISEASE", 38, 49], ["actin", "GENE_OR_GENE_PRODUCT", 28, 33], ["tissue", "TISSUE", 88, 94], ["actin", "PROTEIN", 28, 33], ["dehydration", "PROBLEM", 38, 49], ["an increase in tissue stiffness", "PROBLEM", 73, 104], ["increase", "OBSERVATION_MODIFIER", 76, 84], ["tissue stiffness", "OBSERVATION", 88, 104]]], ["The mechanical properties of actin can be regulated using various agents.", [["actin", "GENE_OR_GENE_PRODUCT", 29, 34], ["actin", "PROTEIN", 29, 34], ["The mechanical properties of actin", "TREATMENT", 0, 34], ["various agents", "TREATMENT", 58, 72], ["mechanical properties", "OBSERVATION", 4, 25]]], ["For example, jasplakinolide, cytochalasin D, and latrunculin A were used to directly modulate actin polymerization of cultured rat airway smooth muscle cells [108] .", [["airway smooth muscle cells", "ANATOMY", 131, 157], ["jasplakinolide", "CHEMICAL", 13, 27], ["cytochalasin D", "CHEMICAL", 29, 43], ["latrunculin A", "CHEMICAL", 49, 62], ["jasplakinolide", "CHEMICAL", 13, 27], ["cytochalasin D", "CHEMICAL", 29, 43], ["latrunculin A", "CHEMICAL", 49, 62], ["jasplakinolide", "SIMPLE_CHEMICAL", 13, 27], ["cytochalasin D", "SIMPLE_CHEMICAL", 29, 43], ["latrunculin A", "SIMPLE_CHEMICAL", 49, 62], ["actin", "GENE_OR_GENE_PRODUCT", 94, 99], ["rat", "ORGANISM", 127, 130], ["airway smooth muscle cells [108]", "CELL", 131, 163], ["actin", "PROTEIN", 94, 99], ["cultured rat airway smooth muscle cells", "CELL_LINE", 118, 157], ["rat", "SPECIES", 127, 130], ["rat", "SPECIES", 127, 130], ["jasplakinolide", "TREATMENT", 13, 27], ["cytochalasin D", "TREATMENT", 29, 43], ["latrunculin A", "TREATMENT", 49, 62], ["actin polymerization", "OBSERVATION", 94, 114]]], ["Rho GTPases control cell proliferation and cytoskeleton remodeling and they are commonly hyper-expressed in tumors.", [["cell", "ANATOMY", 20, 24], ["cytoskeleton", "ANATOMY", 43, 55], ["tumors", "ANATOMY", 108, 114], ["tumors", "DISEASE", 108, 114], ["Rho", "GENE_OR_GENE_PRODUCT", 0, 3], ["cell", "CELL", 20, 24], ["cytoskeleton", "CELLULAR_COMPONENT", 43, 55], ["tumors", "CANCER", 108, 114], ["Rho GTPases", "PROTEIN", 0, 11], ["Rho GTPases control cell proliferation", "PROBLEM", 0, 38], ["cytoskeleton remodeling", "PROBLEM", 43, 66], ["tumors", "PROBLEM", 108, 114], ["GTPases", "OBSERVATION_MODIFIER", 4, 11], ["control cell proliferation", "OBSERVATION", 12, 38], ["cytoskeleton remodeling", "OBSERVATION", 43, 66], ["tumors", "OBSERVATION", 108, 114]]], ["Y-27632 also suppresses formation of stress fibers in cultured cells and decreases hypertension in several hypertensive rat models [109] [110] [111] .", [["stress fibers", "ANATOMY", 37, 50], ["cells", "ANATOMY", 63, 68], ["Y-27632", "CHEMICAL", 0, 7], ["hypertension", "DISEASE", 83, 95], ["hypertensive", "DISEASE", 107, 119], ["Y-27632", "CHEMICAL", 0, 7], ["Y-27632", "SIMPLE_CHEMICAL", 0, 7], ["stress fibers", "CELLULAR_COMPONENT", 37, 50], ["cells", "CELL", 63, 68], ["rat", "ORGANISM", 120, 123], ["cultured cells", "CELL_LINE", 54, 68], ["rat", "SPECIES", 120, 123], ["Y-27632", "SPECIES", 0, 7], ["stress fibers in cultured cells", "PROBLEM", 37, 68], ["decreases hypertension", "PROBLEM", 73, 95], ["several hypertensive rat models", "PROBLEM", 99, 130], ["stress fibers", "OBSERVATION", 37, 50], ["decreases", "OBSERVATION_MODIFIER", 73, 82], ["hypertension", "OBSERVATION", 83, 95]]], ["Pretreatment with ibuprofen was reported to prevent F-actin upregulation in articular chondrocytes from New Zealand White rabbits due to inhibition of RhoA pathway [112] .", [["articular chondrocytes", "ANATOMY", 76, 98], ["ibuprofen", "CHEMICAL", 18, 27], ["ibuprofen", "CHEMICAL", 18, 27], ["ibuprofen", "SIMPLE_CHEMICAL", 18, 27], ["F-actin", "GENE_OR_GENE_PRODUCT", 52, 59], ["articular chondrocytes", "TISSUE", 76, 98], ["rabbits", "ORGANISM", 122, 129], ["RhoA", "GENE_OR_GENE_PRODUCT", 151, 155], ["F-actin", "PROTEIN", 52, 59], ["articular chondrocytes", "CELL_TYPE", 76, 98], ["RhoA", "PROTEIN", 151, 155], ["rabbits", "SPECIES", 122, 129], ["ibuprofen", "TREATMENT", 18, 27], ["F-actin upregulation in articular chondrocytes", "PROBLEM", 52, 98], ["New Zealand White rabbits", "TREATMENT", 104, 129], ["RhoA pathway", "TEST", 151, 163], ["F-actin upregulation", "OBSERVATION", 52, 72], ["articular chondrocytes", "ANATOMY", 76, 98], ["New", "OBSERVATION_MODIFIER", 104, 107]]], ["In the treatment of COVID-19, a number of doctors recommend using paracetamol rather than ibuprofen [113] .", [["paracetamol", "CHEMICAL", 66, 77], ["ibuprofen", "CHEMICAL", 90, 99], ["paracetamol", "CHEMICAL", 66, 77], ["ibuprofen", "CHEMICAL", 90, 99], ["paracetamol", "SIMPLE_CHEMICAL", 66, 77], ["ibuprofen", "SIMPLE_CHEMICAL", 90, 99], ["COVID", "TEST", 20, 25], ["paracetamol", "TREATMENT", 66, 77], ["ibuprofen", "TREATMENT", 90, 99]]], ["ROCK has been suggested as a potential target for the treatment of a number of diseases, such as cancer, neuronal degeneration, vascular diseases, kidney failure, asthma, acute lung injury, glaucoma, osteoporosis, erectile dysfunction, and insulin resistance [114] [115] [116] [117] [118] [119] .", [["cancer", "ANATOMY", 97, 103], ["neuronal", "ANATOMY", 105, 113], ["vascular", "ANATOMY", 128, 136], ["kidney", "ANATOMY", 147, 153], ["lung", "ANATOMY", 177, 181], ["glaucoma", "ANATOMY", 190, 198], ["erectile", "ANATOMY", 214, 222], ["cancer", "DISEASE", 97, 103], ["neuronal degeneration", "DISEASE", 105, 126], ["vascular diseases", "DISEASE", 128, 145], ["kidney failure", "DISEASE", 147, 161], ["asthma", "DISEASE", 163, 169], ["acute lung injury", "DISEASE", 171, 188], ["glaucoma", "DISEASE", 190, 198], ["osteoporosis", "DISEASE", 200, 212], ["erectile dysfunction", "DISEASE", 214, 234], ["ROCK", "GENE_OR_GENE_PRODUCT", 0, 4], ["cancer", "CANCER", 97, 103], ["neuronal", "CELL", 105, 113], ["vascular", "MULTI-TISSUE_STRUCTURE", 128, 136], ["kidney", "ORGAN", 147, 153], ["lung", "ORGAN", 177, 181], ["insulin", "GENE_OR_GENE_PRODUCT", 240, 247], ["[114] [115] [116] [117] [118] [119]", "SIMPLE_CHEMICAL", 259, 294], ["ROCK", "PROTEIN", 0, 4], ["diseases", "PROBLEM", 79, 87], ["cancer", "PROBLEM", 97, 103], ["neuronal degeneration", "PROBLEM", 105, 126], ["vascular diseases", "PROBLEM", 128, 145], ["kidney failure", "PROBLEM", 147, 161], ["asthma", "PROBLEM", 163, 169], ["acute lung injury", "PROBLEM", 171, 188], ["glaucoma", "PROBLEM", 190, 198], ["osteoporosis", "PROBLEM", 200, 212], ["erectile dysfunction", "PROBLEM", 214, 234], ["insulin resistance", "PROBLEM", 240, 258], ["diseases", "OBSERVATION", 79, 87], ["cancer", "OBSERVATION", 97, 103], ["neuronal degeneration", "OBSERVATION", 105, 126], ["vascular", "ANATOMY", 128, 136], ["diseases", "OBSERVATION", 137, 145], ["kidney", "ANATOMY", 147, 153], ["failure", "OBSERVATION", 154, 161], ["asthma", "OBSERVATION", 163, 169], ["acute", "OBSERVATION_MODIFIER", 171, 176], ["lung", "ANATOMY", 177, 181], ["injury", "OBSERVATION", 182, 188], ["glaucoma", "OBSERVATION", 190, 198], ["osteoporosis", "OBSERVATION", 200, 212], ["erectile dysfunction", "OBSERVATION", 214, 234], ["insulin resistance", "OBSERVATION", 240, 258]]], ["For example, it has been recently reported that, in the treatment of acute lung injury, the Rho kinase inhibitor decreases inflammation, immune cell migration, apoptosis, coagulation, contraction, and cell adhesion in pulmonary endothelial cells.", [["lung", "ANATOMY", 75, 79], ["immune cell", "ANATOMY", 137, 148], ["cell", "ANATOMY", 201, 205], ["pulmonary endothelial cells", "ANATOMY", 218, 245], ["lung injury", "DISEASE", 75, 86], ["inflammation", "DISEASE", 123, 135], ["lung", "ORGAN", 75, 79], ["Rho", "GENE_OR_GENE_PRODUCT", 92, 95], ["immune cell", "CELL", 137, 148], ["cell", "CELL", 201, 205], ["pulmonary endothelial cells", "CELL", 218, 245], ["Rho kinase", "PROTEIN", 92, 102], ["pulmonary endothelial cells", "CELL_TYPE", 218, 245], ["acute lung injury", "PROBLEM", 69, 86], ["the Rho kinase inhibitor", "TREATMENT", 88, 112], ["inflammation", "PROBLEM", 123, 135], ["immune cell migration", "PROBLEM", 137, 158], ["apoptosis", "PROBLEM", 160, 169], ["coagulation", "TEST", 171, 182], ["contraction", "PROBLEM", 184, 195], ["cell adhesion in pulmonary endothelial cells", "PROBLEM", 201, 245], ["acute", "OBSERVATION_MODIFIER", 69, 74], ["lung", "ANATOMY", 75, 79], ["injury", "OBSERVATION", 80, 86], ["immune cell migration", "OBSERVATION", 137, 158], ["cell adhesion", "OBSERVATION", 201, 214], ["pulmonary endothelial cells", "OBSERVATION", 218, 245]]], ["It means that all the above-mentioned diseases may be dependent on tissue stiffness related to time-dependent interaction of water molecules and tissue macromolecules.", [["tissue", "ANATOMY", 67, 73], ["tissue macromolecules", "ANATOMY", 145, 166], ["tissue", "TISSUE", 67, 73], ["tissue macromolecules", "CELLULAR_COMPONENT", 145, 166], ["water molecules", "PROTEIN", 125, 140], ["dependent on tissue stiffness", "PROBLEM", 54, 83], ["diseases", "OBSERVATION", 38, 46], ["may be", "UNCERTAINTY", 47, 53], ["dependent", "OBSERVATION_MODIFIER", 54, 63], ["on tissue", "OBSERVATION_MODIFIER", 64, 73], ["stiffness", "OBSERVATION", 74, 83]]], ["F-Actin reorganization is related to lung inflammation via increased blood neutrophil adhesion and migration.", [["lung", "ANATOMY", 37, 41], ["blood neutrophil", "ANATOMY", 69, 85], ["inflammation", "DISEASE", 42, 54], ["F-Actin", "GENE_OR_GENE_PRODUCT", 0, 7], ["lung", "ORGAN", 37, 41], ["blood", "ORGANISM_SUBSTANCE", 69, 74], ["neutrophil", "CELL", 75, 85], ["Actin", "PROTEIN", 2, 7], ["Actin reorganization", "TREATMENT", 2, 22], ["lung inflammation", "PROBLEM", 37, 54], ["increased blood neutrophil adhesion", "PROBLEM", 59, 94], ["Actin reorganization", "OBSERVATION", 2, 22], ["is related to", "UNCERTAINTY", 23, 36], ["lung", "ANATOMY", 37, 41], ["inflammation", "OBSERVATION", 42, 54], ["increased", "OBSERVATION_MODIFIER", 59, 68], ["blood neutrophil adhesion", "OBSERVATION", 69, 94], ["migration", "OBSERVATION_MODIFIER", 99, 108]]], ["Pretreatment by cytochalasin B (CB) can block F-actin reorganization [120] .", [["cytochalasin B", "CHEMICAL", 16, 30], ["CB", "CHEMICAL", 32, 34], ["cytochalasin B", "CHEMICAL", 16, 30], ["cytochalasin B", "SIMPLE_CHEMICAL", 16, 30], ["CB", "SIMPLE_CHEMICAL", 32, 34], ["F-actin", "GENE_OR_GENE_PRODUCT", 46, 53], ["F-actin", "PROTEIN", 46, 53], ["Pretreatment", "TREATMENT", 0, 12], ["cytochalasin B (CB) can block F-actin reorganization", "TREATMENT", 16, 68]]], ["Currently, it is generally recognized that many questions remain to be investigated in order to understand Rho GTPase function, and it would be beneficial if tissue stiffness and the content of bound water were taken into account.COVID-19 Age DependenceIt is very important that children have an extremely low rate of hospitalization presented by the U.S. Department of Health and Human Services in Figure 3 .", [["tissue", "ANATOMY", 158, 164], ["Rho", "GENE_OR_GENE_PRODUCT", 107, 110], ["tissue", "TISSUE", 158, 164], ["children", "ORGANISM", 279, 287], ["Human", "ORGANISM", 381, 386], ["Rho", "PROTEIN", 107, 110], ["GTPase", "PROTEIN", 111, 117], ["children", "SPECIES", 279, 287], ["Human", "SPECIES", 381, 386], ["tissue stiffness", "PROBLEM", 158, 174]]], ["This fact demonstrates that people with soft tissues have a low chance of becoming ill with both age-related diseases and COVID-19.", [["soft tissues", "ANATOMY", 40, 52], ["people", "ORGANISM", 28, 34], ["soft tissues", "TISSUE", 40, 52], ["people", "SPECIES", 28, 34], ["soft tissues", "PROBLEM", 40, 52], ["related diseases", "PROBLEM", 101, 117], ["COVID", "TEST", 122, 127], ["soft tissues", "ANATOMY", 40, 52], ["low chance", "OBSERVATION_MODIFIER", 60, 70]]], ["Rho GTPases control cell proliferation and cytoskeleton remodeling and they are commonly hyper-expressed in tumors.", [["cell", "ANATOMY", 20, 24], ["cytoskeleton", "ANATOMY", 43, 55], ["tumors", "ANATOMY", 108, 114], ["tumors", "DISEASE", 108, 114], ["Rho", "GENE_OR_GENE_PRODUCT", 0, 3], ["cell", "CELL", 20, 24], ["cytoskeleton", "CELLULAR_COMPONENT", 43, 55], ["tumors", "CANCER", 108, 114], ["Rho GTPases", "PROTEIN", 0, 11], ["Rho GTPases control cell proliferation", "PROBLEM", 0, 38], ["cytoskeleton remodeling", "PROBLEM", 43, 66], ["tumors", "PROBLEM", 108, 114], ["GTPases", "OBSERVATION_MODIFIER", 4, 11], ["control cell proliferation", "OBSERVATION", 12, 38], ["cytoskeleton remodeling", "OBSERVATION", 43, 66], ["tumors", "OBSERVATION", 108, 114]]], ["Y-27632 also suppresses formation of stress fibers in cultured cells and decreases hypertension in several hypertensive rat models [109] [110] [111] .", [["stress fibers", "ANATOMY", 37, 50], ["cells", "ANATOMY", 63, 68], ["Y-27632", "CHEMICAL", 0, 7], ["hypertension", "DISEASE", 83, 95], ["hypertensive", "DISEASE", 107, 119], ["Y-27632", "CHEMICAL", 0, 7], ["Y-27632", "SIMPLE_CHEMICAL", 0, 7], ["stress fibers", "CELLULAR_COMPONENT", 37, 50], ["cells", "CELL", 63, 68], ["rat", "ORGANISM", 120, 123], ["cultured cells", "CELL_LINE", 54, 68], ["rat", "SPECIES", 120, 123], ["Y-27632", "SPECIES", 0, 7], ["stress fibers in cultured cells", "PROBLEM", 37, 68], ["decreases hypertension", "PROBLEM", 73, 95], ["several hypertensive rat models", "PROBLEM", 99, 130], ["stress fibers", "OBSERVATION", 37, 50], ["decreases", "OBSERVATION_MODIFIER", 73, 82], ["hypertension", "OBSERVATION", 83, 95]]], ["Pretreatment with ibuprofen was reported to prevent F-actin upregulation in articular chondrocytes from New Zealand White rabbits due to inhibition of RhoA pathway [112] .", [["articular chondrocytes", "ANATOMY", 76, 98], ["ibuprofen", "CHEMICAL", 18, 27], ["ibuprofen", "CHEMICAL", 18, 27], ["ibuprofen", "SIMPLE_CHEMICAL", 18, 27], ["F-actin", "GENE_OR_GENE_PRODUCT", 52, 59], ["articular chondrocytes", "TISSUE", 76, 98], ["rabbits", "ORGANISM", 122, 129], ["RhoA", "GENE_OR_GENE_PRODUCT", 151, 155], ["F-actin", "PROTEIN", 52, 59], ["articular chondrocytes", "CELL_TYPE", 76, 98], ["RhoA", "PROTEIN", 151, 155], ["rabbits", "SPECIES", 122, 129], ["ibuprofen", "TREATMENT", 18, 27], ["F-actin upregulation in articular chondrocytes", "PROBLEM", 52, 98], ["New Zealand White rabbits", "TREATMENT", 104, 129], ["RhoA pathway", "TEST", 151, 163], ["F-actin upregulation", "OBSERVATION", 52, 72], ["articular chondrocytes", "ANATOMY", 76, 98], ["New", "OBSERVATION_MODIFIER", 104, 107]]], ["In the treatment of COVID-19, a number of doctors recommend using paracetamol rather than ibuprofen [113] .", [["paracetamol", "CHEMICAL", 66, 77], ["ibuprofen", "CHEMICAL", 90, 99], ["paracetamol", "CHEMICAL", 66, 77], ["ibuprofen", "CHEMICAL", 90, 99], ["paracetamol", "SIMPLE_CHEMICAL", 66, 77], ["ibuprofen", "SIMPLE_CHEMICAL", 90, 99], ["COVID", "TEST", 20, 25], ["paracetamol", "TREATMENT", 66, 77], ["ibuprofen", "TREATMENT", 90, 99]]], ["ROCK has been suggested as a potential target for the treatment of a number of diseases, such as cancer, neuronal degeneration, vascular diseases, kidney failure, asthma, acute lung injury, glaucoma, osteoporosis, erectile dysfunction, and insulin resistance [114] [115] [116] [117] [118] [119] .", [["cancer", "ANATOMY", 97, 103], ["neuronal", "ANATOMY", 105, 113], ["vascular", "ANATOMY", 128, 136], ["kidney", "ANATOMY", 147, 153], ["lung", "ANATOMY", 177, 181], ["glaucoma", "ANATOMY", 190, 198], ["erectile", "ANATOMY", 214, 222], ["cancer", "DISEASE", 97, 103], ["neuronal degeneration", "DISEASE", 105, 126], ["vascular diseases", "DISEASE", 128, 145], ["kidney failure", "DISEASE", 147, 161], ["asthma", "DISEASE", 163, 169], ["acute lung injury", "DISEASE", 171, 188], ["glaucoma", "DISEASE", 190, 198], ["osteoporosis", "DISEASE", 200, 212], ["erectile dysfunction", "DISEASE", 214, 234], ["ROCK", "GENE_OR_GENE_PRODUCT", 0, 4], ["cancer", "CANCER", 97, 103], ["neuronal", "CELL", 105, 113], ["vascular", "MULTI-TISSUE_STRUCTURE", 128, 136], ["kidney", "ORGAN", 147, 153], ["lung", "ORGAN", 177, 181], ["insulin", "GENE_OR_GENE_PRODUCT", 240, 247], ["[114] [115] [116] [117] [118] [119]", "SIMPLE_CHEMICAL", 259, 294], ["ROCK", "PROTEIN", 0, 4], ["diseases", "PROBLEM", 79, 87], ["cancer", "PROBLEM", 97, 103], ["neuronal degeneration", "PROBLEM", 105, 126], ["vascular diseases", "PROBLEM", 128, 145], ["kidney failure", "PROBLEM", 147, 161], ["asthma", "PROBLEM", 163, 169], ["acute lung injury", "PROBLEM", 171, 188], ["glaucoma", "PROBLEM", 190, 198], ["osteoporosis", "PROBLEM", 200, 212], ["erectile dysfunction", "PROBLEM", 214, 234], ["insulin resistance", "PROBLEM", 240, 258], ["diseases", "OBSERVATION", 79, 87], ["cancer", "OBSERVATION", 97, 103], ["neuronal degeneration", "OBSERVATION", 105, 126], ["vascular", "ANATOMY", 128, 136], ["diseases", "OBSERVATION", 137, 145], ["kidney", "ANATOMY", 147, 153], ["failure", "OBSERVATION", 154, 161], ["asthma", "OBSERVATION", 163, 169], ["acute", "OBSERVATION_MODIFIER", 171, 176], ["lung", "ANATOMY", 177, 181], ["injury", "OBSERVATION", 182, 188], ["glaucoma", "OBSERVATION", 190, 198], ["osteoporosis", "OBSERVATION", 200, 212], ["erectile dysfunction", "OBSERVATION", 214, 234], ["insulin resistance", "OBSERVATION", 240, 258]]], ["For example, it has been recently reported that, in the treatment of acute lung injury, the Rho kinase inhibitor decreases inflammation, immune cell migration, apoptosis, coagulation, contraction, and cell adhesion in pulmonary endothelial cells.", [["lung", "ANATOMY", 75, 79], ["immune cell", "ANATOMY", 137, 148], ["cell", "ANATOMY", 201, 205], ["pulmonary endothelial cells", "ANATOMY", 218, 245], ["lung injury", "DISEASE", 75, 86], ["inflammation", "DISEASE", 123, 135], ["lung", "ORGAN", 75, 79], ["Rho", "GENE_OR_GENE_PRODUCT", 92, 95], ["immune cell", "CELL", 137, 148], ["cell", "CELL", 201, 205], ["pulmonary endothelial cells", "CELL", 218, 245], ["Rho kinase", "PROTEIN", 92, 102], ["pulmonary endothelial cells", "CELL_TYPE", 218, 245], ["acute lung injury", "PROBLEM", 69, 86], ["the Rho kinase inhibitor", "TREATMENT", 88, 112], ["inflammation", "PROBLEM", 123, 135], ["immune cell migration", "PROBLEM", 137, 158], ["apoptosis", "PROBLEM", 160, 169], ["coagulation", "TEST", 171, 182], ["contraction", "PROBLEM", 184, 195], ["cell adhesion in pulmonary endothelial cells", "PROBLEM", 201, 245], ["acute", "OBSERVATION_MODIFIER", 69, 74], ["lung", "ANATOMY", 75, 79], ["injury", "OBSERVATION", 80, 86], ["immune cell migration", "OBSERVATION", 137, 158], ["cell adhesion", "OBSERVATION", 201, 214], ["pulmonary endothelial cells", "OBSERVATION", 218, 245]]], ["It means that all the abovementioned diseases may be dependent on tissue stiffness related to time-dependent interaction of water molecules and tissue macromolecules.", [["tissue", "ANATOMY", 66, 72], ["tissue macromolecules", "ANATOMY", 144, 165], ["tissue", "TISSUE", 66, 72], ["tissue macromolecules", "CELLULAR_COMPONENT", 144, 165], ["water molecules", "PROTEIN", 124, 139], ["all the abovementioned diseases", "PROBLEM", 14, 45], ["dependent on tissue stiffness", "PROBLEM", 53, 82], ["diseases", "OBSERVATION", 37, 45], ["may be", "UNCERTAINTY", 46, 52], ["dependent", "OBSERVATION_MODIFIER", 53, 62], ["on tissue", "OBSERVATION_MODIFIER", 63, 72], ["stiffness", "OBSERVATION", 73, 82]]], ["F-Actin reorganization is related to lung inflammation via increased blood neutrophil adhesion and migration.", [["lung", "ANATOMY", 37, 41], ["blood neutrophil", "ANATOMY", 69, 85], ["inflammation", "DISEASE", 42, 54], ["F-Actin", "GENE_OR_GENE_PRODUCT", 0, 7], ["lung", "ORGAN", 37, 41], ["blood", "ORGANISM_SUBSTANCE", 69, 74], ["neutrophil", "CELL", 75, 85], ["Actin", "PROTEIN", 2, 7], ["Actin reorganization", "TREATMENT", 2, 22], ["lung inflammation", "PROBLEM", 37, 54], ["increased blood neutrophil adhesion", "PROBLEM", 59, 94], ["Actin reorganization", "OBSERVATION", 2, 22], ["is related to", "UNCERTAINTY", 23, 36], ["lung", "ANATOMY", 37, 41], ["inflammation", "OBSERVATION", 42, 54], ["increased", "OBSERVATION_MODIFIER", 59, 68], ["blood neutrophil adhesion", "OBSERVATION", 69, 94], ["migration", "OBSERVATION_MODIFIER", 99, 108]]], ["Pretreatment by cytochalasin B (CB) can block F-actin reorganization [120] .", [["cytochalasin B", "CHEMICAL", 16, 30], ["CB", "CHEMICAL", 32, 34], ["cytochalasin B", "CHEMICAL", 16, 30], ["cytochalasin B", "SIMPLE_CHEMICAL", 16, 30], ["CB", "SIMPLE_CHEMICAL", 32, 34], ["F-actin", "GENE_OR_GENE_PRODUCT", 46, 53], ["F-actin", "PROTEIN", 46, 53], ["Pretreatment", "TREATMENT", 0, 12], ["cytochalasin B (CB) can block F-actin reorganization", "TREATMENT", 16, 68]]], ["Currently, it is generally recognized that many questions remain to be investigated in order to understand Rho GTPase function, and it would be beneficial if tissue stiffness and the content of bound water were taken into account.COVID-19 Age DependenceIt is very important that children have an extremely low rate of hospitalization presented by the U.S. Department of Health and Human Services in Figure 3 .", [["tissue", "ANATOMY", 158, 164], ["Rho", "GENE_OR_GENE_PRODUCT", 107, 110], ["tissue", "TISSUE", 158, 164], ["children", "ORGANISM", 279, 287], ["Human", "ORGANISM", 381, 386], ["Rho", "PROTEIN", 107, 110], ["GTPase", "PROTEIN", 111, 117], ["children", "SPECIES", 279, 287], ["Human", "SPECIES", 381, 386], ["tissue stiffness", "PROBLEM", 158, 174]]], ["This fact demonstrates that people with soft tissues have a low chance of becoming ill with both age-related diseases and COVID-19.", [["soft tissues", "ANATOMY", 40, 52], ["people", "ORGANISM", 28, 34], ["soft tissues", "TISSUE", 40, 52], ["people", "SPECIES", 28, 34], ["soft tissues", "PROBLEM", 40, 52], ["related diseases", "PROBLEM", 101, 117], ["COVID", "TEST", 122, 127], ["soft tissues", "ANATOMY", 40, 52], ["low chance", "OBSERVATION_MODIFIER", 60, 70]]], ["It has been also reported that obesity as an underlying condition was observed in 48.3% COVID-19 patients.", [["obesity", "DISEASE", 31, 38], ["patients", "ORGANISM", 97, 105], ["patients", "SPECIES", 97, 105], ["obesity", "PROBLEM", 31, 38], ["an underlying condition", "PROBLEM", 42, 65], ["obesity", "OBSERVATION", 31, 38]]], ["It was earlier demonstrated that obesity results in increased arterial stiffness [121] .", [["arterial", "ANATOMY", 62, 70], ["obesity", "DISEASE", 33, 40], ["increased arterial stiffness", "DISEASE", 52, 80], ["arterial", "MULTI-TISSUE_STRUCTURE", 62, 70], ["obesity", "PROBLEM", 33, 40], ["increased arterial stiffness", "PROBLEM", 52, 80], ["obesity", "OBSERVATION", 33, 40], ["increased", "OBSERVATION_MODIFIER", 52, 61], ["arterial stiffness", "OBSERVATION", 62, 80]]], ["It has been also reported that obesity as an underlying condition was observed in 48.3% COVID-19 patients.", [["obesity", "DISEASE", 31, 38], ["patients", "ORGANISM", 97, 105], ["patients", "SPECIES", 97, 105], ["obesity", "PROBLEM", 31, 38], ["an underlying condition", "PROBLEM", 42, 65], ["obesity", "OBSERVATION", 31, 38]]], ["It was earlier demonstrated that obesity results in increased arterial stiffness [121] .Conclusions and Future PerspectivesStrong dependence on a patient's age allows us to conclude that current methods of treatment of age-related diseases have to be verified, as well for application in the treatment of COVID-19.", [["arterial", "ANATOMY", 62, 70], ["obesity", "DISEASE", 33, 40], ["increased arterial stiffness", "DISEASE", 52, 80], ["arterial", "MULTI-TISSUE_STRUCTURE", 62, 70], ["patient", "ORGANISM", 146, 153], ["patient", "SPECIES", 146, 153], ["obesity", "PROBLEM", 33, 40], ["increased arterial stiffness", "PROBLEM", 52, 80], ["age-related diseases", "PROBLEM", 219, 239], ["COVID", "TEST", 305, 310], ["obesity", "OBSERVATION", 33, 40], ["increased", "OBSERVATION_MODIFIER", 52, 61], ["arterial stiffness", "OBSERVATION", 62, 80]]], ["Thus, COVID-19 is unique and differs from previous epidemics by the fact that children are very rarely infected by novel coronavirus (Figure 3 ).", [["children", "ORGANISM", 78, 86], ["coronavirus", "ORGANISM", 121, 132], ["COVID", "PROTEIN", 6, 11], ["children", "SPECIES", 78, 86], ["COVID", "TEST", 6, 11]]], ["COVID-19 virus particles interact with stiffer cell surfaces in old people, and, in cardiovascular diseases, platelets interact with stiffer arterial wall surfaces in old people.", [["cell surfaces", "ANATOMY", 47, 60], ["cardiovascular", "ANATOMY", 84, 98], ["platelets", "ANATOMY", 109, 118], ["arterial wall surfaces", "ANATOMY", 141, 163], ["cardiovascular diseases", "DISEASE", 84, 107], ["COVID-19 virus", "ORGANISM", 0, 14], ["people", "ORGANISM", 68, 74], ["cardiovascular", "ANATOMICAL_SYSTEM", 84, 98], ["platelets", "CELL", 109, 118], ["arterial wall", "MULTI-TISSUE_STRUCTURE", 141, 154], ["people", "ORGANISM", 171, 177], ["platelets", "CELL_TYPE", 109, 118], ["people", "SPECIES", 68, 74], ["people", "SPECIES", 171, 177], ["COVID-19 virus", "SPECIES", 0, 14], ["COVID", "TEST", 0, 5], ["stiffer cell surfaces", "TREATMENT", 39, 60], ["cardiovascular diseases", "PROBLEM", 84, 107], ["platelets", "TEST", 109, 118], ["stiffer arterial wall surfaces", "TREATMENT", 133, 163], ["stiffer cell", "OBSERVATION_MODIFIER", 39, 51], ["surfaces", "OBSERVATION_MODIFIER", 52, 60], ["cardiovascular", "ANATOMY", 84, 98], ["diseases", "OBSERVATION", 99, 107], ["wall", "ANATOMY_MODIFIER", 150, 154], ["surfaces", "OBSERVATION_MODIFIER", 155, 163]]], ["In both cases, stiffer substrate leads to a much more severe disease because, in both cases, the tissue surface adhesion and permeability increases.", [["tissue surface", "ANATOMY", 97, 111], ["tissue", "TISSUE", 97, 103], ["a much more severe disease", "PROBLEM", 42, 68], ["the tissue surface adhesion", "PROBLEM", 93, 120], ["much more", "OBSERVATION_MODIFIER", 44, 53], ["severe", "OBSERVATION_MODIFIER", 54, 60], ["disease", "OBSERVATION", 61, 68], ["tissue", "ANATOMY", 97, 103], ["surface", "OBSERVATION_MODIFIER", 104, 111], ["adhesion", "OBSERVATION", 112, 120], ["permeability", "OBSERVATION_MODIFIER", 125, 137], ["increases", "OBSERVATION_MODIFIER", 138, 147]]], ["It is well known that children have the highest level of tissue hydration that decreases with advanced age and that tissue stiffness increases with aging.", [["tissue", "ANATOMY", 57, 63], ["tissue", "ANATOMY", 116, 122], ["children", "ORGANISM", 22, 30], ["tissue", "TISSUE", 57, 63], ["tissue", "TISSUE", 116, 122], ["children", "SPECIES", 22, 30], ["tissue hydration", "TREATMENT", 57, 73], ["tissue stiffness", "PROBLEM", 116, 132], ["tissue", "ANATOMY", 116, 122], ["stiffness", "OBSERVATION", 123, 132]]], ["The hospitalization rate is very low for children having soft tissue and the hospitalization rate is high for the older population with hard tissue.", [["soft tissue", "ANATOMY", 57, 68], ["tissue", "ANATOMY", 141, 147], ["children", "ORGANISM", 41, 49], ["soft tissue", "TISSUE", 57, 68], ["tissue", "TISSUE", 141, 147], ["children", "SPECIES", 41, 49], ["The hospitalization rate", "TEST", 0, 24], ["soft tissue", "PROBLEM", 57, 68], ["the hospitalization rate", "TEST", 73, 97], ["hard tissue", "PROBLEM", 136, 147], ["soft tissue", "OBSERVATION_MODIFIER", 57, 68], ["hard tissue", "OBSERVATION_MODIFIER", 136, 147]]], ["Hence, there is an urgent need for the development of de-stiffening therapies.Conclusions and Future PerspectivesChanges in water status lead to the change in extracellular matrix stiffness.", [["extracellular matrix", "ANATOMY", 159, 179], ["extracellular matrix", "CELLULAR_COMPONENT", 159, 179], ["de-stiffening therapies", "TREATMENT", 54, 77], ["Changes in water status", "PROBLEM", 113, 136], ["the change in extracellular matrix stiffness", "PROBLEM", 145, 189], ["change", "OBSERVATION_MODIFIER", 149, 155], ["extracellular matrix stiffness", "OBSERVATION", 159, 189]]], ["The age-related decrease in tightly bound water content due to reduction of binding forces between water molecules and biological macromolecules results in the development of age-related and protein-conformational diseases due to an increase in tissue stiffness and permeability.", [["tissue", "ANATOMY", 245, 251], ["water", "SIMPLE_CHEMICAL", 42, 47], ["tissue", "TISSUE", 245, 251], ["tightly bound water content", "PROBLEM", 28, 55], ["binding forces between water molecules", "PROBLEM", 76, 114], ["biological macromolecules", "TEST", 119, 144], ["protein-conformational diseases", "PROBLEM", 191, 222], ["an increase in tissue stiffness", "PROBLEM", 230, 261], ["decrease", "OBSERVATION_MODIFIER", 16, 24], ["tightly bound", "OBSERVATION_MODIFIER", 28, 41], ["water content", "OBSERVATION", 42, 55], ["binding forces", "OBSERVATION", 76, 90], ["conformational diseases", "OBSERVATION", 199, 222], ["increase", "OBSERVATION_MODIFIER", 233, 241], ["tissue stiffness", "OBSERVATION", 245, 261], ["permeability", "OBSERVATION_MODIFIER", 266, 278]]], ["It has been recently demonstrated that the ratio of extracellular water/intracellular water increases with advanced age and especially accelerates after the age of 70 years; a high value of this ratio is a major risk indicator for all-cause mortality.Conclusions and Future PerspectivesThe role of bound water in biological processes is underestimated in the current state of the art.", [["extracellular", "ANATOMY", 52, 65], ["intracellular", "ANATOMY", 72, 85], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 52, 65], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 72, 85], ["water", "SIMPLE_CHEMICAL", 304, 309], ["extracellular water/intracellular water", "TREATMENT", 52, 91]]], ["It is evident that taking into account the effect of bound water on protein conformations and stability can facilitate understanding mechanisms of biophysical processes in age-related diseases and protein-conformational diseases.", [["water", "SIMPLE_CHEMICAL", 59, 64], ["bound water on protein conformations", "TREATMENT", 53, 89], ["related diseases", "PROBLEM", 176, 192], ["protein-conformational diseases", "PROBLEM", 197, 228], ["conformational diseases", "OBSERVATION", 205, 228]]], ["It is more correct to say that bound water is essential to life than to say that liquid water is essential to life.Conclusions and Future PerspectivesRelease of tightly bound water triggers glycation reactions that have a very important role in the aging process.", [["water", "SIMPLE_CHEMICAL", 175, 180], ["glycation reactions", "PROBLEM", 190, 209]]], ["Correlation between arterial stiffness and tightly bound water mobility can be expected.", [["arterial", "ANATOMY", 20, 28], ["arterial", "MULTI-TISSUE_STRUCTURE", 20, 28], ["arterial stiffness", "PROBLEM", 20, 38], ["tightly bound water mobility", "PROBLEM", 43, 71], ["arterial", "ANATOMY", 20, 28], ["stiffness", "OBSERVATION", 29, 38]]], ["An increase in arterial stiffness is commonly accompanied by a decrease in glycocalyx coverage.Conclusions and Future PerspectivesThe relationship of bound water with tissue stiffness has scarcely been studied for the time being and can be suggested for in-depth study in future.Conclusions and Future PerspectivesBiochemical glycation reactions and biophysical changes in hydration status are equally important in the development of physiological processes during aging.", [["arterial", "ANATOMY", 15, 23], ["glycocalyx", "ANATOMY", 75, 85], ["tissue", "ANATOMY", 167, 173], ["increase in arterial stiffness", "DISEASE", 3, 33], ["arterial", "MULTI-TISSUE_STRUCTURE", 15, 23], ["glycocalyx", "TISSUE", 75, 85], ["tissue", "TISSUE", 167, 173], ["An increase in arterial stiffness", "PROBLEM", 0, 33], ["glycocalyx coverage", "TREATMENT", 75, 94], ["tissue stiffness", "PROBLEM", 167, 183], ["Biochemical glycation reactions", "TREATMENT", 314, 345], ["biophysical changes in hydration status", "PROBLEM", 350, 389], ["increase", "OBSERVATION_MODIFIER", 3, 11], ["arterial", "ANATOMY", 15, 23], ["stiffness", "OBSERVATION", 24, 33], ["decrease", "OBSERVATION_MODIFIER", 63, 71], ["glycocalyx coverage", "OBSERVATION", 75, 94]]], ["The possibility to regulate the hydration status of extracellular matrix could help in the development of new, more effective therapeutics for treatment of age-related and protein-conformational diseases.Conclusions and Future PerspectivesNF-\u03baB activation was associated with matrix stiffening and the development of age-related diseases.", [["extracellular matrix", "ANATOMY", 52, 72], ["matrix", "ANATOMY", 276, 282], ["extracellular matrix", "CELLULAR_COMPONENT", 52, 72], ["PerspectivesNF-\u03baB", "GENE_OR_GENE_PRODUCT", 227, 244], ["matrix", "CELLULAR_COMPONENT", 276, 282], ["-\u03baB", "PROTEIN", 241, 244], ["the hydration status of extracellular matrix", "TREATMENT", 28, 72], ["treatment", "TREATMENT", 143, 152], ["age-related and protein-conformational diseases", "PROBLEM", 156, 203], ["matrix stiffening", "PROBLEM", 276, 293], ["age-related diseases", "PROBLEM", 317, 337], ["new", "OBSERVATION_MODIFIER", 106, 109], ["conformational diseases", "OBSERVATION", 180, 203]]], ["Rho GTPases control cell proliferation and cytoskeleton remodeling, and the inhibition of RhoA/ROCK inhibits stress fiber formation and has the potential to decrease the stiffness of extracellular matrix and, in such a way, to treat a wide number of pathologies.", [["cell", "ANATOMY", 20, 24], ["cytoskeleton", "ANATOMY", 43, 55], ["stress fiber", "ANATOMY", 109, 121], ["extracellular matrix", "ANATOMY", 183, 203], ["Rho", "GENE_OR_GENE_PRODUCT", 0, 3], ["cell", "CELL", 20, 24], ["cytoskeleton", "CELLULAR_COMPONENT", 43, 55], ["RhoA", "GENE_OR_GENE_PRODUCT", 90, 94], ["ROCK", "GENE_OR_GENE_PRODUCT", 95, 99], ["stress fiber", "CELLULAR_COMPONENT", 109, 121], ["extracellular matrix", "CELLULAR_COMPONENT", 183, 203], ["Rho GTPases", "PROTEIN", 0, 11], ["RhoA", "PROTEIN", 90, 94], ["ROCK", "PROTEIN", 95, 99], ["Rho GTPases control cell proliferation", "PROBLEM", 0, 38], ["cytoskeleton remodeling", "PROBLEM", 43, 66], ["RhoA/ROCK", "TREATMENT", 90, 99], ["stress fiber formation", "PROBLEM", 109, 131], ["the stiffness of extracellular matrix", "PROBLEM", 166, 203], ["pathologies", "PROBLEM", 250, 261], ["GTPases", "OBSERVATION_MODIFIER", 4, 11], ["control cell proliferation", "OBSERVATION", 12, 38], ["cytoskeleton remodeling", "OBSERVATION", 43, 66], ["stiffness", "OBSERVATION", 170, 179], ["extracellular matrix", "OBSERVATION", 183, 203], ["pathologies", "OBSERVATION", 250, 261]]], ["In order to understand Rho GTPase inhibitors' functional properties more clearly, it would be reasonable-in parallel with tissue stiffness-to study changes in the content of tightly bound water using nuclear magnetic resonance.Conclusions and Future PerspectivesPolyphenols, omega-3 fatty acids, vitamins D, E, C and K2, and statins have been suggested as de-stiffening agents.", [["tissue", "ANATOMY", 122, 128], ["omega-3 fatty acids", "CHEMICAL", 275, 294], ["vitamins D", "CHEMICAL", 296, 306], ["statins", "CHEMICAL", 325, 332], ["Polyphenols", "CHEMICAL", 262, 273], ["omega-3 fatty acids", "CHEMICAL", 275, 294], ["vitamins D, E, C and K2", "CHEMICAL", 296, 319], ["statins", "CHEMICAL", 325, 332], ["Rho", "GENE_OR_GENE_PRODUCT", 23, 26], ["tissue", "TISSUE", 122, 128], ["water", "SIMPLE_CHEMICAL", 188, 193], ["Polyphenols", "SIMPLE_CHEMICAL", 262, 273], ["omega-3 fatty acids", "SIMPLE_CHEMICAL", 275, 294], ["vitamins D", "SIMPLE_CHEMICAL", 296, 306], ["E", "SIMPLE_CHEMICAL", 308, 309], ["C", "SIMPLE_CHEMICAL", 311, 312], ["K2", "SIMPLE_CHEMICAL", 317, 319], ["statins", "SIMPLE_CHEMICAL", 325, 332], ["Rho GTPase", "PROTEIN", 23, 33], ["Rho GTPase inhibitors", "TREATMENT", 23, 44], ["tissue stiffness", "PROBLEM", 122, 138], ["nuclear magnetic resonance", "TEST", 200, 226], ["Polyphenols", "TEST", 262, 273], ["omega-3 fatty acids", "TREATMENT", 275, 294], ["vitamins D, E, C and K2", "TREATMENT", 296, 319], ["statins", "TREATMENT", 325, 332], ["de-stiffening agents", "TREATMENT", 356, 376]]], ["This review is focused on the role of dehydration and stiffness development in aging tissues.", [["tissues", "ANATOMY", 85, 92], ["dehydration", "DISEASE", 38, 49], ["tissues", "TISSUE", 85, 92], ["dehydration", "PROBLEM", 38, 49], ["stiffness development in aging tissues", "PROBLEM", 54, 92], ["dehydration", "OBSERVATION", 38, 49], ["stiffness", "OBSERVATION", 54, 63]]], ["Evidently, other processes-for example, those involved in water-salt metabolism-have an important role in aging, and they could be discussed in special reviews.Conclusions and Future PerspectivesFunding: This research received no external funding.Conflicts of Interest:The author declares no conflict of interest.", [["water", "SIMPLE_CHEMICAL", 58, 63], ["salt", "SIMPLE_CHEMICAL", 64, 68], ["external funding", "TREATMENT", 230, 246], ["funding", "OBSERVATION", 239, 246]]]]}